-DOCSTART- -X- -X- O

BRCA1 NN B-NP O
is VBZ B-VP O
secreted VBN I-VP O
and CC O O
exhibits VBZ B-VP O
properties NNS B-NP O
of IN B-PP O
a DT B-NP O
granin NN I-NP O
. . O O

Germline NN B-NP O
mutations NNS I-NP O
in IN B-PP O
BRCA1 NN B-NP O
are VBP B-VP O
responsible JJ B-ADJP O
for IN B-PP O
most JJS B-NP O
cases NNS I-NP O
of IN B-PP O
inherited VBN B-NP B-Disease
breast NN I-NP I-Disease
and CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
. . O O

However RB B-ADVP O
, , O O
the DT B-NP O
function NN I-NP O
of IN B-PP O
the DT B-NP O
BRCA1 NN I-NP O
protein NN I-NP O
has VBZ B-VP O
remained VBN I-VP O
elusive JJ B-ADJP O
. . O O

We PRP B-NP O
now RB B-ADVP O
show VBP B-VP O
that IN B-SBAR O
BRCA1 NN B-NP O
encodes VBZ B-VP O
a DT B-NP O
190 CD I-NP O
- HYPH I-NP O
kD NN I-NP O
protein NN I-NP O
with IN B-PP O
sequence NN B-NP O
homology NN I-NP O
and CC O O
biochemical JJ B-NP O
analogy NN I-NP O
to TO B-PP O
the DT B-NP O
granin NN I-NP O
protein NN I-NP O
family NN I-NP O
. . O O

Interestingly RB B-ADVP O
, , O O
BRCA2 NN B-NP O
also RB B-ADVP O
includes VBZ B-VP O
a DT B-NP O
motif NN I-NP O
similar JJ B-ADJP O
to TO B-PP O
the DT B-NP O
granin NN I-NP O
consensus NN I-NP O
at IN B-PP O
the DT B-NP O
C NN I-NP O
terminus NN I-NP O
of IN B-PP O
the DT B-NP O
protein NN I-NP O
. . O O

Both CC O O
BRCA1 NN B-NP O
and CC O O
the DT B-NP O
granins NNS I-NP O
localize VBP B-VP O
to TO B-PP O
secretory JJ B-NP O
vesicles NNS I-NP O
, , O O
are VBP B-VP O
secreted VBN I-VP O
by IN B-PP O
a DT B-NP O
regulated VBN I-NP O
pathway NN I-NP O
, , O O
are VBP B-VP O
post AFX B-ADVP O
- HYPH B-NP O
translationally RB B-VP O
glycosylated VBN I-VP O
and CC O O
are VBP B-VP O
responsive JJ B-ADJP O
to TO B-PP O
hormones NNS B-NP O
. . O O

As IN B-PP O
a DT B-NP O
regulated VBN I-NP O
secretory JJ I-NP O
protein NN I-NP O
, , O O
BRCA1 NN B-NP O
appears VBZ B-VP O
to TO I-VP O
function VB I-VP O
by IN B-PP O
a DT B-NP O
mechanism NN I-NP O
not RB O O
previously RB B-VP O
described VBN I-VP O
for IN B-PP O
tumour NN B-NP B-Disease
suppressor NN I-NP O
gene NN I-NP O
products NNS I-NP O
. . O O

. . O O

Ovarian JJ B-NP B-Disease
cancer NN I-NP I-Disease
risk NN I-NP O
in IN B-PP O
BRCA1 NN B-NP O
carriers NNS I-NP O
is VBZ B-VP O
modified VBN I-VP O
by IN B-PP O
the DT B-NP O
HRAS1 NN I-NP O
variable JJ I-NP O
number NN I-NP O
of IN B-PP O
tandem JJ B-NP O
repeat NN I-NP O
( ( O O
VNTR NN B-NP O
) ) O O
locus NN B-NP O
. . O O

Women NNS B-NP O
who WP B-NP O
carry VBP B-VP O
a DT B-NP O
mutation NN I-NP O
in IN B-PP O
the DT B-NP O
BRCA1 NN I-NP O
gene NN I-NP O
( ( O O
on IN B-PP O
chromosome NN B-NP O
17q21 NN I-NP O
) ) O O
, , O O
have VBP B-VP O
an DT B-NP O
80 CD I-NP O
% NN I-NP O
risk NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
and CC O O
a DT B-NP O
40 CD I-NP O
% NN I-NP O
risk NN I-NP O
of IN B-PP O
ovarian JJ B-NP B-Disease
cancer NN I-NP I-Disease
by IN B-PP O
the DT B-NP O
age NN I-NP O
of IN B-PP O
70 CD B-NP O
( ( O O
ref NN B-NP O
. . I-NP O

1 CD I-NP O
) ) O O
. . O O

The DT B-NP O
variable JJ I-NP O
penetrance NN I-NP O
of IN B-PP O
BRCA1 NN B-NP O
suggests VBZ B-VP O
that IN B-SBAR O
other JJ B-NP O
genetic JJ I-NP O
and CC I-NP O
non AFX I-NP O
- HYPH I-NP O
genetic JJ B-NP O
factors NNS I-NP O
play VBP B-VP O
a DT B-NP O
role NN I-NP O
in IN B-PP O
tumourigenesis NN B-NP O
in IN B-PP O
these DT B-NP O
individuals NNS I-NP O
. . O O

The DT B-NP O
HRAS1 NN I-NP O
variable JJ I-NP O
number NN I-NP O
of IN B-PP O
tandem JJ B-NP O
repeats NNS I-NP O
( ( O O
VNTR NN B-NP O
) ) O O
polymorphism NN B-NP O
, , O O
located JJ B-NP O
1 CD I-NP O
kilobase NN I-NP O
( ( O O
kb NN B-NP O
) ) O O
downstream RB B-ADVP O
of IN B-PP O
the DT B-NP O
HRAS1 NN I-NP O
proto AFX O O
- HYPH O O
oncogene NN B-NP O
( ( O O
chromosome NN B-NP O
11p15 CD I-NP O
. . I-NP O

5 CD I-NP O
) ) O O
is VBZ B-VP O
one CD B-NP O
possible JJ I-NP O
genetic JJ I-NP O
modifier NN I-NP O
of IN B-PP O
cancer NN B-NP B-Disease
penetrance NN I-NP O
. . O O

Individuals NNS B-NP O
who WP B-NP O
have VBP B-VP O
rare JJ B-NP O
alleles NNS I-NP O
of IN B-PP O
the DT B-NP O
VNTR NN I-NP O
have VBP B-VP O
an DT B-NP O
increased VBN I-NP O
risk NN I-NP O
of IN B-PP O
certain JJ B-NP O
types NNS I-NP O
of IN B-PP O
cancers NNS B-NP B-Disease
, , O O
including VBG B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
( ( O O
2 CD B-NP O
- HYPH I-NP O
4 CD I-NP O
) ) O O
. . O O

To TO B-VP O
investigate VB I-VP O
whether IN B-SBAR O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
rare JJ B-NP O
HRAS1 NN I-NP O
alleles NNS I-NP O
increases VBZ B-VP O
susceptibility NN B-NP O
to TO B-PP O
hereditary JJ B-NP B-Disease
breast NN I-NP I-Disease
and CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
, , O O
we PRP B-NP O
have VBP B-VP O
typed VBN I-VP O
a DT B-NP O
panel NN I-NP O
of IN B-PP O
307 CD B-NP O
female JJ I-NP O
BRCA1 NN I-NP O
carriers NNS I-NP O
at IN B-PP O
this DT B-NP O
locus NN I-NP O
using VBG B-VP O
a DT B-NP O
PCR NN I-NP O
- HYPH O O
based VBN B-NP O
technique NN I-NP O
. . O O

The DT B-NP O
risk NN I-NP O
for IN B-PP O
ovarian JJ B-NP B-Disease
cancer NN I-NP I-Disease
was VBD B-VP O
2 CD B-NP O
. . O O

11 CD B-NP O
times NNS I-NP O
greater JJR I-NP O
for IN B-PP O
BRCA1 NN B-NP O
carriers NNS I-NP O
harbouring VBG B-VP O
one CD B-NP O
or CC I-NP O
two CD I-NP O
rare JJ I-NP O
HRAS1 NN I-NP O
alleles NNS I-NP O
, , O O
compared VBN B-PP O
to TO B-PP O
carriers NNS B-NP O
with IN B-PP O
only RB B-NP O
common JJ I-NP O
alleles NNS I-NP O
( ( O O
P NN B-NP O
= SYM B-VP O
0 CD B-NP O
. SYM I-NP O

015 CD I-NP O
) ) O O
. . O O

The DT B-NP O
magnitude NN I-NP O
of IN B-PP O
the DT B-NP O
relative JJ I-NP O
risk NN I-NP O
associated VBN B-VP O
with IN B-PP O
a DT B-NP O
rare JJ I-NP O
HRAS1 NN I-NP O
allele NN I-NP O
was VBD B-VP O
not RB I-VP O
altered VBN I-VP O
by IN B-PP O
adjusting VBG B-VP O
for IN B-PP O
the DT B-NP O
other JJ I-NP O
known VBN I-NP O
risk NN I-NP O
factors NNS I-NP O
for IN B-PP O
hereditary JJ B-NP B-Disease
ovarian JJ I-NP I-Disease
cancer NN I-NP I-Disease
( ( O O
5 CD B-NP O
) ) O O
. . O O

Susceptibility NN B-NP O
to TO B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
did VBD B-VP O
not RB I-VP O
appear VB I-VP O
to TO I-VP O
be VB I-VP O
affected VBN I-VP O
by IN B-PP O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
rare JJ B-NP O
HRAS1 NN I-NP O
alleles NNS I-NP O
. . O O

This DT B-NP O
study NN I-NP O
is VBZ B-VP O
the DT B-NP O
first JJ I-NP O
to TO B-VP O
show VB I-VP O
the DT B-NP O
effect NN I-NP O
of IN B-PP O
a DT B-NP O
modifying NN I-NP O
gene NN I-NP O
on IN B-PP O
the DT B-NP O
penetrance NN I-NP O
of IN B-PP O
an DT B-NP O
inherited VBN I-NP B-Disease
cancer NN I-NP I-Disease
syndrome NN I-NP I-Disease
A DT B-NP O
novel JJ I-NP O
homeodomain NN I-NP O
- HYPH O O
encoding VBG B-VP O
gene NN B-NP O
is VBZ B-VP O
associated VBN I-VP O
with IN B-PP O
a DT B-NP O
large JJ I-NP O
CpG NN I-NP O
island NN I-NP O
interrupted VBN B-VP O
by IN B-PP O
the DT B-NP O
myotonic JJ I-NP B-Disease
dystrophy NN I-NP I-Disease
unstable JJ B-ADJP O
( ( O O
CTG NN B-NP O
) ) O O
n NN B-NP O
repeat NN I-NP O
. . O O

Myotonic JJ B-NP B-Disease
dystrophy NN I-NP I-Disease
( ( O O
DM NN B-NP B-Disease
) ) O O
is VBZ B-VP O
associated VBN I-VP O
with IN B-PP O
a DT B-NP O
( ( O O
CTG NN O O
) ) O O
n NN B-NP O
trinucleotide NN I-NP O
repeat NN I-NP O
expansion NN I-NP O
in IN B-PP O
the DT B-NP O
3 CD I-NP O
- HYPH I-NP O
untranslated JJ I-NP O
region NN I-NP O
of IN B-PP O
a DT B-NP O
protein NN I-NP O
kinase NN I-NP O
- HYPH O O
encoding VBG B-VP O
gene NN B-NP O
, , O O
DMPK NN B-NP O
, , O O
which WDT B-NP O
maps VBZ B-VP O
to TO B-PP O
chromosome NN B-NP O
19q13 CD I-NP O
. . O O

3 LS B-LST O
. . O O

Characterisation NN B-NP O
of IN B-PP O
the DT B-NP O
expression NN I-NP O
of IN B-PP O
this DT B-NP O
gene NN I-NP O
in IN B-PP O
patient NN B-NP O
tissues NNS I-NP O
has VBZ B-VP O
thus RB I-VP O
far RB I-VP O
generated VBN I-VP O
conflicting VBG B-VP O
data NNS B-NP O
on IN B-PP O
alterations NNS B-NP O
in IN B-PP O
the DT B-NP O
steady JJ I-NP O
state NN I-NP O
levels NNS I-NP O
of IN B-PP O
DMPK NN B-NP O
mRNA NN I-NP O
, , O O
and CC O O
on IN B-PP O
the DT B-NP O
final JJ I-NP O
DMPK NN I-NP O
protein NN I-NP O
levels NNS I-NP O
in IN B-PP O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
the DT B-NP O
expansion NN I-NP O
. . O O

The DT B-NP O
DM NN I-NP B-Disease
region NN I-NP O
of IN B-PP O
chromosome NN B-NP O
19 CD I-NP O
is VBZ B-VP O
gene NN B-NP O
rich JJ I-NP O
, , O O
and CC O O
it PRP B-NP O
is VBZ B-VP O
possible JJ B-ADJP O
that IN B-SBAR O
the DT B-NP O
repeat NN I-NP O
expansion NN I-NP O
may MD B-VP O
lead VB I-VP O
to TO B-PP O
dysfunction NN B-NP O
of IN B-PP O
a DT B-NP O
number NN I-NP O
of IN B-PP O
transcription NN B-NP O
units NNS I-NP O
in IN B-PP O
the DT B-NP O
vicinity NN I-NP O
, , O O
perhaps RB B-ADVP O
as IN B-PP O
a DT B-NP O
consequence NN I-NP O
of IN B-PP O
chromatin NN B-NP O
disruption NN I-NP O
. . O O

We PRP B-NP O
have VBP B-VP O
searched VBN I-VP O
for IN B-PP O
genes NNS B-NP O
associated VBN B-VP O
with IN B-PP O
a DT B-NP O
CpG NN I-NP O
island NN I-NP O
at IN B-PP O
the DT B-NP O
3 CD I-NP O
end NN I-NP O
of IN B-PP O
DMPK NN B-NP O
. . O O

Sequencing NN B-NP O
of IN B-PP O
this DT B-NP O
region NN I-NP O
shows VBZ B-VP O
that IN B-SBAR O
the DT B-NP O
island NN I-NP O
extends VBZ B-VP O
over IN B-NP O
3 CD I-NP O
. . O O

5 CD B-NP O
kb NN I-NP O
and CC O O
is VBZ B-VP O
interrupted VBN I-VP O
by IN B-PP O
the DT B-NP O
( ( O O
CTG NN O O
) ) O O
n NN B-NP O
repeat NN I-NP O
. . O O

Comparison NN B-NP O
of IN B-PP O
genomic JJ B-NP O
sequences NNS I-NP O
downstream JJ B-ADJP O
( ( O O
centromeric JJ B-ADJP O
) ) O O
of IN B-PP O
the DT B-NP O
repeat NN I-NP O
in IN B-PP O
human JJ O O
and CC O O
mouse NN B-NP O
identified VBD B-VP O
regions NNS B-NP O
of IN B-PP O
significant JJ B-NP O
homology NN I-NP O
. . O O

These DT B-NP O
correspond VBP B-VP O
to TO B-PP O
exons NNS B-NP O
of IN B-PP O
a DT B-NP O
gene NN I-NP O
predicted VBN B-VP O
to TO B-VP O
encode VB I-VP O
a DT B-NP O
homeodomain NN I-NP O
protein NN I-NP O
. . O O

RT NN B-NP O
- HYPH I-NP O
PCR NN I-NP O
analysis NN I-NP O
shows VBZ B-VP O
that IN B-SBAR O
this DT B-NP O
gene NN I-NP O
, , O O
which WDT B-NP O
we PRP B-NP O
have VBP B-VP O
called VBN I-VP O
DM NN B-NP B-Disease
locus NN I-NP O
- HYPH B-VP O
associated VBN B-NP O
homeodomain NN I-NP O
protein NN I-NP O
( ( O O
DMAHP NN B-NP O
) ) O O
, , O O
is VBZ B-VP O
expressed VBN I-VP O
in IN B-PP O
a DT B-NP O
number NN I-NP O
of IN B-PP O
human JJ B-NP O
tissues NNS I-NP O
, , O O
including VBG B-PP O
skeletal JJ B-NP O
muscle NN I-NP O
, , I-NP O
heart NN I-NP O
and CC I-NP O
brain NN I-NP O
. . O O

Germline NN B-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
RB1 NN I-NP O
gene NN I-NP O
in IN B-PP O
patients NNS B-NP O
with IN B-PP O
hereditary JJ B-NP B-Disease
retinoblastoma NN I-NP I-Disease
. . O O

We PRP B-NP O
have VBP B-VP O
analyzed VBN I-VP O
the DT B-NP O
27 CD I-NP O
exons NNS I-NP O
and CC O O
the DT B-NP O
promoter NN I-NP O
region NN I-NP O
of IN B-PP O
the DT B-NP O
RB1 NN I-NP O
gene NN I-NP O
in IN B-PP O
familial JJ B-NP B-Disease
or CC I-NP I-Disease
sporadic JJ I-NP I-Disease
bilateral JJ I-NP I-Disease
retinoblastoma NN I-NP I-Disease
by IN B-PP O
using VBG B-VP O
single JJ B-NP O
- HYPH I-NP O
strand NN I-NP O
conformation NN I-NP O
polymorphism NN I-NP O
analysis NN I-NP O
. . O O

For IN B-PP O
improvement NN B-NP O
over IN B-PP O
previous JJ B-NP O
studies NNS I-NP O
, , O O
a DT B-NP O
new JJ I-NP O
set NN I-NP O
of IN B-PP O
primers NNS B-NP O
has VBZ B-VP O
been VBN I-VP O
designed VBN I-VP O
, , O O
which WDT B-NP O
allow VBP B-VP O
for IN B-PP O
amplification NN B-NP O
of IN B-PP O
the DT B-NP O
coding NN I-NP O
and CC I-NP O
splicing NN I-NP O
sequences NNS I-NP O
only RB B-ADVP O
. . O O

The DT B-NP O
positioning NN I-NP O
of IN B-PP O
the DT B-NP O
polymerase NN I-NP O
chain NN I-NP O
reaction NN I-NP O
( ( O O
PCR NN B-NP O
) ) O O
primers NNS B-NP O
was VBD B-VP O
such JJ B-ADJP O
that IN B-SBAR O
the DT B-NP O
resulting VBG I-NP O
PCR NN I-NP O
products NNS I-NP O
were VBD B-VP O
of IN B-PP O
different JJ B-NP O
sizes NNS I-NP O
, , O O
which WDT B-NP O
enabled VBD B-VP O
us PRP B-NP O
to TO B-VP O
analyze VB I-VP O
two CD B-NP O
different JJ I-NP O
exons NNS I-NP O
simultaneously RB B-ADVP O
and CC O O
still RB B-ADJP O
distinguish JJ I-ADJP O
between IN B-PP O
the DT B-NP O
banding NN I-NP O
profiles NNS I-NP O
for IN B-PP O
both DT B-NP O
( ( O O
biplex NN B-NP O
analysis NN I-NP O
) ) O O
. . O O

By IN B-PP O
using VBG B-VP O
this DT B-NP O
approach NN I-NP O
, , O O
we PRP B-NP O
were VBD B-VP O
able JJ B-ADJP O
to TO B-VP O
identify VB I-VP O
mutation NN B-NP O
in IN B-PP O
22 CD B-NP O
new JJ I-NP O
patients NNS I-NP O
, , O O
but CC O O
the DT B-NP O
overall JJ I-NP O
efficiency NN I-NP O
of IN B-PP O
the DT B-NP O
procedure NN I-NP O
when WRB B-ADVP O
we PRP B-NP O
used VBD B-VP O
a DT B-NP O
single JJ I-NP O
- HYPH I-NP O
pass NN I-NP O
regimen NN I-NP O
was VBD B-VP O
only RB B-NP O
48 CD I-NP O
% NN I-NP O
. . O O

The DT B-NP O
mutations NNS I-NP O
were VBD B-VP O
small JJ B-NP O
insertions NNS I-NP O
and CC I-NP O
deletions NNS I-NP O
and CC O O
point NN B-NP O
mutations NNS I-NP O
in IN B-PP O
roughly RB B-NP O
equal JJ I-NP O
proportions NNS I-NP O
. . O O

. . O O

Type NN B-NP B-Disease
II CD I-NP I-Disease
human JJ I-NP I-Disease
complement NN I-NP I-Disease
C2 NN I-NP I-Disease
deficiency NN I-NP I-Disease
. . O O

Allele NN B-NP O
- HYPH I-NP O
specific JJ I-NP O
amino NN I-NP O
acid NN I-NP O
substitutions NNS I-NP O
( ( O O
Ser189 NN B-NP O
- SYM O O
- HYPH O O
> SYM O O
Phe NN B-NP O
; : O O
Gly444 NN B-NP O
- SYM B-NP O
- HYPH B-NP O
> SYM I-NP O
Arg NN I-NP O
) ) O O
cause VBP B-VP O
impaired JJ B-NP O
C2 NN I-NP O
secretion NN I-NP O
. . O O

Type NN B-NP B-Disease
II CD I-NP I-Disease
complement NN I-NP I-Disease
protein NN I-NP I-Disease
C2 NN I-NP I-Disease
deficiency NN I-NP I-Disease
is VBZ B-VP O
characterized VBN I-VP O
by IN B-PP O
a DT B-NP O
selective JJ I-NP O
block NN I-NP O
in IN B-PP O
C2 NN B-NP O
secretion NN I-NP O
. . O O

The DT B-NP O
Type NN I-NP O
II CD I-NP O
C2 NN I-NP O
allele NN I-NP O
( ( O O
C2Q0 NN B-NP O
) ) O O
is VBZ B-VP O
linked VBN I-VP O
to TO B-PP O
two CD B-NP O
major JJ I-NP O
histocompatibility NN I-NP O
haplotypes NNS I-NP O
( ( O O
MHC NN B-NP O
) ) O O
that WDT B-NP O
differ VBP B-VP O
from IN B-PP O
the DT B-NP O
MHC NN I-NP O
of IN B-PP O
the DT B-NP O
more RBR I-NP O
common JJ I-NP O
Type NN I-NP B-Disease
I CD I-NP I-Disease
C2 NN I-NP I-Disease
deficiency NN I-NP I-Disease
. . O O

To TO B-VP O
determine VB I-VP O
the DT B-NP O
molecular JJ I-NP O
basis NN I-NP O
of IN B-PP O
Type NN B-NP B-Disease
II CD I-NP I-Disease
deficiency NN I-NP I-Disease
the DT B-NP O
two CD I-NP O
Type NN I-NP O
II CD I-NP O
C2Q0 NN I-NP O
genes NNS I-NP O
were VBD B-VP O
isolated VBN I-VP O
and CC O O
transfected VBN B-VP O
separately RB B-ADVP O
into IN B-PP O
L NN B-NP O
- HYPH B-VP O
cells NNS B-NP O
. . O O

Subsequent JJ B-NP O
molecular JJ I-NP O
biology NN I-NP O
, , O O
biosynthetic JJ B-ADJP O
, , O O
and CC O O
immunofluorescence NN B-NP O
studies NNS I-NP O
demonstrated VBD B-VP O
that IN B-SBAR O
C2 NN B-NP O
secretion NN I-NP O
is VBZ B-VP O
impaired JJ B-ADJP O
in IN B-PP O
Type NN B-NP B-Disease
II CD I-NP I-Disease
C2 NN I-NP I-Disease
deficiency NN I-NP I-Disease
because IN B-PP O
of IN I-PP O
different JJ B-NP O
missense JJ I-NP O
mutations NNS I-NP O
at IN B-PP O
highly RB B-NP O
conserved VBN I-NP O
residues NNS I-NP O
in IN B-PP O
each DT B-NP O
of IN B-PP O
the DT B-NP O
C2Q0 NN I-NP O
alleles NNS I-NP O
. . O O

One CD B-NP O
is VBZ B-VP O
in IN B-PP O
exon NN B-NP O
5 CD I-NP O
( ( O O
nucleotide NN B-NP O
C566 NN I-NP O
- SYM O O
- HYPH O O
> SYM O O
T NN B-NP O
; : O O
Ser189 NN B-NP O
- SYM B-NP O
- HYPH B-NP O
> SYM I-NP O
Phe NN I-NP O
) ) O O
of IN B-PP O
the DT B-NP O
C2Q0 NN I-NP O
gene NN I-NP O
linked VBN B-VP O
to TO B-PP O
the DT B-NP O
MHC NN I-NP O
haplotype NN I-NP O
A11 NN I-NP O
, , O O
B35 NN B-NP O
, , O O
DRw1 NN B-NP O
, , O O
BFS NN B-NP O
, , O O
C4A0B1 NN B-NP O
. . O O

The DT B-NP O
other JJ I-NP O
is VBZ B-VP O
in IN B-PP O
exon NN B-NP O
11 CD I-NP O
( ( O O
G1930 NN B-NP O
- SYM O O
- HYPH B-NP O
> SYM I-NP O
A NN I-NP O
; : O O
Gly444 NN B-NP O
- SYM B-NP O
- HYPH B-NP O
> SYM I-NP O
Arg NN I-NP O
) ) O O
of IN B-PP O
the DT B-NP O
C2Q0 NN I-NP O
gene NN I-NP O
linked VBN B-VP O
to TO B-PP O
the DT B-NP O
MHC NN I-NP O
haplotype NN I-NP O
A2 NN I-NP O
, , O O
B5 NN B-NP O
, , O O
DRw4 NN B-NP O
, , O O
BFS NN B-NP O
, , O O
C4A3B1 NN B-NP O
. . O O

Each DT B-NP O
mutant JJ I-NP O
C2 NN I-NP O
gene NN I-NP O
product NN I-NP O
is VBZ B-VP O
retained VBN I-VP O
early RB B-ADVP O
in IN B-PP O
the DT B-NP O
secretory JJ I-NP O
pathway NN I-NP O
. . O O

These DT B-NP O
mutants NNS I-NP O
provide VBP B-VP O
models NNS B-NP O
for IN B-PP O
elucidating VBG B-VP O
the DT B-NP O
C2 NN I-NP O
secretory NN I-NP O
pathway NN I-NP O
. . O O

. . O O

Defective JJ B-NP O
dimerization NN I-NP O
of IN B-PP O
von NN B-NP B-Disease
Willebrand NN I-NP I-Disease
factor NN I-NP O
subunits NNS I-NP O
due JJ B-ADJP O
to TO B-PP O
a DT B-NP O
Cys NN I-NP O
- HYPH O O
> SYM B-NP O
Arg NN I-NP O
mutation NN I-NP O
in IN B-PP O
type NN B-NP B-Disease
IID NN I-NP I-Disease
von NN I-NP I-Disease
Willebrand NN I-NP I-Disease
disease NN I-NP I-Disease
. . O O

The DT B-NP O
same JJ I-NP O
heterozygous JJ I-NP O
T NN I-NP O
- HYPH B-NP O
> SYM I-NP O
C NN I-NP O
transition NN I-NP O
at IN B-PP O
nt NN B-NP O
8567 CD I-NP O
of IN B-PP O
the DT B-NP O
von NN I-NP B-Disease
Willebrand NN I-NP I-Disease
factor NN I-NP O
( ( O O
vWF NN B-NP O
) ) O O
transcript NN B-NP O
was VBD B-VP O
found VBN I-VP O
in IN B-PP O
two CD B-NP O
unrelated JJ I-NP O
patients NNS I-NP O
with IN B-PP O
type NN B-NP B-Disease
IID NN I-NP I-Disease
von NN I-NP I-Disease
Willebrand NN I-NP I-Disease
disease NN I-NP I-Disease
, , O O
with IN B-PP O
no DT B-NP O
other JJ I-NP O
apparent JJ I-NP O
abnormality NN I-NP O
. . O O

In IN B-PP O
one CD B-NP O
family NN I-NP O
, , O O
both DT B-NP O
alleles NNS I-NP O
were VBD B-VP O
normal JJ B-ADJP O
in IN B-PP O
the DT B-NP O
parents NNS I-NP O
and CC O O
one CD B-NP O
sister NN I-NP O
; : O O
thus RB B-ADVP O
, , O O
the DT B-NP O
mutation NN I-NP O
originated VBD B-VP O
de FW B-NP O
novo FW I-NP O
in IN B-PP O
the DT B-NP O
proposita NN I-NP O
. . O O

The DT B-NP O
second JJ I-NP O
patient NN I-NP O
also RB B-ADVP O
had VBD B-VP O
asymptomatic JJ B-NP O
parents NNS I-NP O
who WP B-NP O
, , O O
however RB B-ADVP O
, , O O
were VBD B-VP O
not RB O O
available JJ B-ADJP O
for IN B-PP O
study NN B-NP O
. . O O

The DT B-NP O
structural JJ I-NP O
consequences NNS I-NP O
of IN B-PP O
the DT B-NP O
identified VBN I-NP O
mutation NN I-NP O
, , O O
resulting VBG B-VP O
in IN B-PP O
the DT B-NP O
CyS2010 NN I-NP O
- HYPH O O
> SYM B-NP O
Arg NN I-NP O
substitution NN I-NP O
, , O O
were VBD B-VP O
evaluated VBN I-VP O
by IN B-PP O
expression NN B-NP O
of IN B-PP O
the DT B-NP O
vWF NN I-NP O
carboxyl NN I-NP O
- HYPH B-NP O
terminal JJ I-NP O
domain NN I-NP O
containing VBG B-VP O
residues NNS B-NP O
1366 CD B-NP O
- HYPH I-NP O
2050 CD I-NP O
. . O O

Insect NN B-NP O
cells NNS I-NP O
infected VBN B-VP O
with IN B-PP O
recombinant JJ B-NP O
baculovirus NN I-NP O
expressing VBG B-VP O
normal JJ B-NP O
vWF NN I-NP O
sequence NN I-NP O
secreted VBD B-VP O
a DT B-NP O
disulfide NN I-NP O
linked VBD B-VP O
dimeric JJ B-NP O
molecule NN I-NP O
with IN B-PP O
an DT B-NP O
apparent JJ I-NP O
molecular JJ I-NP O
mass NN I-NP O
of IN B-PP O
150 CD B-NP O
kDa NN I-NP O
before IN B-PP O
reduction NN B-NP O
, , O O
yielding VBG B-VP O
a DT B-NP O
single JJ I-NP O
band NN I-NP O
of IN B-PP O
80 CD B-NP O
kDa NN I-NP O
after IN B-PP O
disulfide NN B-NP O
bond NN I-NP O
reduction NN I-NP O
. . O O

In IN B-PP O
contrast NN B-NP O
, , O O
cells NNS B-NP O
expressing VBG B-VP O
the DT B-NP O
mutant JJ I-NP O
fragment NN I-NP O
secreted VBD B-VP O
a DT B-NP O
monomeric JJ I-NP O
molecule NN I-NP O
of IN B-PP O
apparent JJ B-NP O
molecular JJ I-NP O
mass NN I-NP O
of IN B-PP O
80 CD B-NP O
kDa NN I-NP O
, , O O
which WDT B-NP O
remained VBD B-VP O
unchanged JJ B-ADJP O
after IN B-PP O
reduction NN B-NP O
. . O O

We PRP B-NP O
conclude VBP B-VP O
that IN B-SBAR O
CyS2010 NN B-NP O
is VBZ B-VP O
essential JJ B-ADJP O
for IN B-PP O
normal JJ B-NP O
dimerization NN I-NP O
of IN B-PP O
vWF NN B-NP O
subunits NNS I-NP O
through IN B-PP O
disulfide NN B-NP O
bonding NN I-NP O
of IN B-PP O
carboxyl NN B-NP O
- HYPH B-NP O
terminal JJ I-NP O
domains NNS I-NP O
and CC O O
that IN B-SBAR O
a DT B-NP O
heterozygous JJ I-NP O
mutation NN I-NP O
in IN B-PP O
the DT B-NP O
corresponding JJ I-NP O
codon NN I-NP O
is VBZ B-VP O
responsible JJ B-ADJP O
for IN B-PP O
defective JJ B-NP O
multimer NN I-NP O
formation NN I-NP O
in IN B-PP O
type NN B-NP B-Disease
IID NN I-NP I-Disease
von NN I-NP I-Disease
Willebrand NN I-NP I-Disease
disease NN I-NP I-Disease
. . O O

. . O O

Wiskott NNP B-NP B-Disease
- HYPH I-NP I-Disease
Aldrich NNP I-NP I-Disease
syndrome NN I-NP I-Disease
protein NN I-NP O
, , O O
a DT B-NP O
novel JJ I-NP O
effector NN I-NP O
for IN B-PP O
the DT B-NP O
GTPase NN I-NP O
CDC42Hs NNS I-NP O
, , O O
is VBZ B-VP O
implicated VBN I-VP O
in IN B-PP O
actin NN B-NP O
polymerization NN I-NP O
. . O O

The DT B-NP O
Rho NN I-NP O
family NN I-NP O
of IN B-PP O
GTPases NNS B-NP O
control VBP B-VP O
diverse JJ B-NP O
biological JJ I-NP O
processes NNS I-NP O
, , O O
including VBG B-PP O
cell NN B-NP O
morphology NN I-NP O
and CC O O
mitogenesis NN B-NP O
. . O O

We PRP B-NP O
have VBP B-VP O
identified VBN I-VP O
WASP NN B-NP O
, , O O
the DT B-NP O
protein NN I-NP O
that WDT B-NP O
is VBZ B-VP O
defective JJ B-ADJP O
in IN B-PP O
Wiskott NNP B-NP B-Disease
- HYPH B-NP I-Disease
Aldrich NNP I-NP I-Disease
syndrome NN I-NP I-Disease
( ( O O
WAS NN B-NP B-Disease
) ) O O
, , O O
as IN B-PP O
a DT B-NP O
novel JJ I-NP O
effector NN I-NP O
for IN B-PP O
CDC42Hs NNS B-NP O
, , O O
but CC O O
not RB O O
for IN B-PP O
the DT B-NP O
other JJ I-NP O
Rho NN I-NP O
family NN I-NP O
members NNS I-NP O
, , O O
Rac NN B-NP O
and CC I-NP O
Rho NN I-NP O
. . O O

This DT B-NP O
interaction NN I-NP O
is VBZ B-VP O
dependent JJ B-ADJP O
on IN B-PP O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
the DT B-NP O
G NN I-NP O
protein NN I-NP O
- HYPH O O
binding VBG B-NP O
domain NN I-NP O
. . O O

Cellular JJ B-NP O
expression NN I-NP O
of IN B-PP O
epitope NN B-NP O
- HYPH B-NP O
tagged VBN I-NP O
WASP NN I-NP O
produces VBZ B-VP O
clusters NNS B-NP O
of IN B-PP O
WASP NN B-NP O
that WDT B-NP O
are VBP B-VP O
highly RB I-VP O
enriched VBN I-VP O
in IN B-PP O
polymerized JJ B-NP O
actin NN I-NP O
. . O O

This DT B-NP O
clustering NN I-NP O
is VBZ B-VP O
not RB I-VP O
observed VBN I-VP O
with IN B-PP O
a DT B-NP O
C NN I-NP O
- HYPH B-VP O
terminally RB B-NP O
deleted VBN I-NP O
WASP NN I-NP O
and CC O O
is VBZ B-VP O
inhibited VBN I-VP O
by IN B-PP O
coexpression NN B-NP O
with IN B-PP O
dominant JJ B-NP O
negative JJ I-NP O
CDC42Hs NNS I-NP O
- HYPH B-NP O
N17 NN I-NP O
, , O O
but CC O O
not RB O O
with IN B-PP O
dominant JJ B-NP O
negative JJ I-NP O
forms NNS I-NP O
of IN B-PP O
Rac NN B-NP O
or CC I-NP O
Rho NN I-NP O
. . O O

Thus RB B-ADVP O
, , O O
WASP NN B-NP O
provides VBZ B-VP O
a DT B-NP O
novel JJ I-NP O
link NN I-NP O
between IN B-PP O
CDC42Hs NNS B-NP O
and CC O O
the DT B-NP O
actin NN I-NP O
cytoskeleton NN I-NP O
, , O O
which WDT B-NP O
suggests VBZ B-VP O
a DT B-NP O
molecular JJ I-NP O
mechanism NN I-NP O
for IN B-PP O
many JJ B-NP O
of IN B-PP O
the DT B-NP O
cellular JJ I-NP O
abnormalities NNS I-NP O
in IN B-PP O
WAS NNP B-NP B-Disease
. . O O

The DT B-NP O
WASP NN I-NP O
sequence NN I-NP O
contains VBZ B-VP O
two CD B-NP O
novel JJ I-NP O
domains NNS I-NP O
that WDT B-NP O
are VBP B-VP O
homologous JJ B-ADJP O
to TO B-PP O
other JJ B-NP O
proteins NNS I-NP O
involved VBN B-VP O
in IN B-PP O
action NN B-NP O
organization NN I-NP O
. . O O

. . O O

X NN B-NP B-Disease
- HYPH B-PP I-Disease
linked VBN B-NP I-Disease
adrenoleukodystrophy NN I-NP I-Disease
is VBZ B-VP O
a DT B-NP O
frequent JJ I-NP O
cause NN I-NP O
of IN B-PP O
idiopathic JJ B-NP O
Addison NN I-NP B-Disease
' POS B-NP I-Disease
s NNS I-NP I-Disease
disease NN I-NP I-Disease
in IN B-PP O
young JJ B-NP O
adult JJ I-NP O
male JJ I-NP O
patients NNS I-NP O
. . O O

X NN B-NP B-Disease
- HYPH O I-Disease
Linked VBN B-VP I-Disease
adrenoleukodystrophy NN B-NP I-Disease
( ( O O
ALD NN B-NP B-Disease
) ) O O
is VBZ B-VP O
a DT B-NP O
genetic JJ I-NP B-Disease
disease NN I-NP I-Disease
associated VBN B-VP O
with IN B-PP O
demyelination NN B-NP B-Disease
of IN B-PP I-Disease
the DT B-NP I-Disease
central JJ I-NP I-Disease
nervous JJ I-NP I-Disease
system NN I-NP I-Disease
, , O O
adrenal JJ B-NP B-Disease
insufficiency NN I-NP I-Disease
, , O O
and CC O O
accumulation NN B-NP O
of IN B-PP O
very RB B-NP O
long JJ I-NP O
chain NN I-NP O
fatty JJ I-NP O
acids NNS I-NP O
in IN B-PP O
tissue NN B-NP O
and CC I-NP O
body NN I-NP O
fluids NNS I-NP O
. . O O

ALD NN B-NP B-Disease
is VBZ B-VP O
due IN B-PP O
to TO I-PP O
mutation NN B-NP O
of IN B-PP O
a DT B-NP O
gene NN I-NP O
located VBN B-VP O
in IN B-PP O
Xq28 NN B-NP O
that WDT B-NP O
encodes VBZ B-VP O
a DT B-NP O
peroxisomal JJ I-NP O
transporter NN I-NP O
protein NN I-NP O
of IN B-PP O
unknown JJ B-NP O
function NN I-NP O
. . O O

The DT B-NP O
most RBS I-NP O
common JJ I-NP O
phenotype NN I-NP O
of IN B-PP O
ALD NN B-NP B-Disease
is VBZ B-VP O
the DT B-NP O
cerebral JJ I-NP O
form NN I-NP O
( ( O O
45 CD B-NP O
% NN I-NP O
) ) O O
that WDT B-NP O
develops VBZ B-VP O
in IN B-PP O
boys NNS B-NP O
between IN B-PP O
5 CD B-NP O
- HYPH I-NP O
12 CD I-NP O
yr NN I-NP O
. . O O

Adrenomyeloneuropathy NN B-NP B-Disease
( ( O O
AMN NN B-NP B-Disease
) ) O O
involves VBZ B-VP O
the DT B-NP O
spinal JJ I-NP O
cord NN I-NP O
and CC O O
peripheral JJ B-NP O
nerves NNS I-NP O
in IN B-PP O
young JJ B-NP O
adults NNS I-NP O
( ( O O
35 CD B-NP O
% NN I-NP O
) ) O O
. . O O

Adrenal JJ B-NP B-Disease
insufficiency NN I-NP I-Disease
( ( O O
Addisons NNS B-NP B-Disease
disease NN I-NP I-Disease
) ) O O
is VBZ B-VP O
frequently RB I-VP O
associated VBN I-VP O
with IN B-PP O
AMN NN B-NP B-Disease
or CC O O
cerebral JJ B-NP B-Disease
ALD NN I-NP I-Disease
and CC O O
may MD B-VP O
remain VB I-VP O
the DT B-NP O
only RB I-NP O
clinical JJ I-NP O
expression NN I-NP O
of IN B-PP O
ALD NN B-NP B-Disease
( ( O O
8 CD B-NP O
% NN I-NP O
of IN B-PP O
cases NNS B-NP O
) ) O O
. . O O

The DT B-NP O
prevalence NN I-NP O
of IN B-PP O
ALD NN B-NP B-Disease
among IN B-PP O
adults NNS B-NP O
with IN B-PP O
Addisons NNS B-NP B-Disease
disease NN I-NP I-Disease
remains VBZ B-VP O
unknown JJ B-ADJP O
. . O O

To TO B-VP O
evaluate VB I-VP O
this DT B-NP O
prevalence NN I-NP O
, , O O
we PRP B-NP O
performed VBD B-VP O
biochemical JJ B-NP O
analysis NN I-NP O
of IN B-PP O
very RB B-NP O
long JJ I-NP O
chain NN I-NP O
fatty JJ I-NP O
acids NNS I-NP O
in IN B-PP O
14 CD B-NP O
male JJ I-NP O
patients NNS I-NP O
( ( O O
age NN B-NP O
ranging VBG B-VP O
from IN B-PP O
12 CD B-NP O
- HYPH I-NP O
45 CD I-NP O
yr NN I-NP O
at IN B-PP O
diagnosis NN B-NP O
) ) O O
previously RB B-VP O
diagnosed VBN I-VP O
as IN B-PP O
having VBG B-VP O
primary JJ B-NP O
idiopathic JJ I-NP O
adrenocortical JJ I-NP B-Disease
insufficiency NN I-NP I-Disease
. . O O

In IN B-PP O
5 CD B-NP O
of IN B-PP O
14 CD B-NP O
patients NNS I-NP O
( ( O O
35 CD B-NP O
% NN I-NP O
) ) O O
, , O O
elevated VBN B-NP O
plasma NN I-NP O
concentrations NNS I-NP O
of IN B-PP O
very RB B-NP O
long JJ I-NP O
chain NN I-NP O
fatty JJ I-NP O
acids NNS I-NP O
were VBD B-VP O
detected VBN I-VP O
. . O O

None NN B-NP O
of IN B-PP O
these DT B-NP O
patients NNS I-NP O
had VBD B-VP O
adrenocortical JJ B-NP O
antibodies NNS I-NP O
. . O O

By IN B-PP O
electrophysiological JJ B-NP O
tests NNS I-NP O
and CC O O
magnetic JJ B-NP O
resonance NN I-NP O
imaging VBG B-VP O
it PRP B-NP O
was VBD B-VP O
determined VBN I-VP O
that IN B-SBAR O
two CD B-NP O
patients NNS I-NP O
had VBD B-VP O
cerebral JJ B-NP B-Disease
ALD NN I-NP I-Disease
, , O O
one CD B-NP O
had VBD B-VP O
adrenomyeloneuropathy NN B-NP B-Disease
with IN B-PP O
cerebral JJ B-NP O
involvement NN I-NP O
, , O O
and CC O O
two CD B-NP O
had VBD B-VP O
preclinical JJ B-NP O
AMN NN I-NP B-Disease
. . O O

Our PRP$ B-NP O
data NNS I-NP O
support VBP B-VP O
the DT B-NP O
hypothesis NN I-NP O
that IN B-SBAR O
ALD NN B-NP B-Disease
is VBZ B-VP O
a DT B-NP O
frequent JJ I-NP O
cause NN I-NP O
of IN B-PP O
idiopathic JJ B-NP O
Addisons NNS I-NP B-Disease
disease NN I-NP I-Disease
in IN B-PP O
children NNS B-NP O
and CC I-NP O
adults NNS I-NP O
. . O O

. . O O

Tumor NN B-NP B-Disease
suppression NN I-NP O
and CC O O
apoptosis NN B-NP O
of IN B-PP O
human JJ B-NP O
prostate NN I-NP B-Disease
carcinoma NN I-NP I-Disease
mediated VBN B-VP O
by IN B-PP O
a DT B-NP O
genetic JJ I-NP O
locus NN I-NP O
within IN B-PP O
human JJ B-NP O
chromosome NN I-NP O
10pter NN I-NP O
- HYPH B-NP O
q11 NN I-NP O
. . O O

Prostate NN B-NP B-Disease
cancer NN I-NP I-Disease
is VBZ B-VP O
the DT B-NP O
second JJ I-NP O
leading VBG I-NP O
cause NN I-NP O
of IN B-PP O
male JJ B-NP O
cancer NN I-NP B-Disease
deaths NNS I-NP O
in IN B-PP O
the DT B-NP O
United NNP I-NP O
States NNPS I-NP O
. . O O

Yet RB B-ADVP O
, , O O
despite IN B-PP O
a DT B-NP O
large JJ I-NP O
international JJ I-NP O
effort NN I-NP O
, , O O
little JJ B-NP O
is VBZ B-VP O
known VBN I-VP O
about IN B-PP O
the DT B-NP O
molecular JJ I-NP O
mechanisms NNS I-NP O
that WDT B-NP O
underlie VBP B-VP O
this DT B-NP O
devastating VBG I-NP O
disease NN I-NP O
. . O O

Prostate NN B-NP O
secretory JJ I-NP O
epithelial JJ I-NP O
cells NNS I-NP O
and CC O O
androgen NN B-NP O
- HYPH B-NP O
dependent JJ I-NP O
prostate NN I-NP B-Disease
carcinomas NNS I-NP I-Disease
undergo VBP B-VP O
apoptosis NN B-NP O
in IN B-PP O
response NN B-NP O
to TO B-PP O
androgen NN B-NP O
deprivation NN I-NP O
and CC O O
, , O O
furthermore RB B-ADVP O
, , O O
most JJS B-NP O
prostate NN I-NP B-Disease
carcinomas NNS I-NP I-Disease
become VBP B-VP O
androgen NN B-NP O
independent JJ B-ADJP O
and CC I-ADJP O
refractory JJ I-ADJP O
to TO B-PP O
further JJ B-NP O
therapeutic JJ I-NP O
manipulations NNS I-NP O
during IN B-PP O
disease NN B-NP O
progression NN I-NP O
. . O O

Definition NN B-NP O
of IN B-PP O
the DT B-NP O
genetic JJ I-NP O
events NNS I-NP O
that WDT B-NP O
trigger VBP B-VP O
apoptosis NN B-NP O
in IN B-PP O
the DT B-NP O
prostate NN I-NP O
could MD B-VP O
provide VB I-VP O
important JJ B-NP O
insights NNS I-NP O
into IN B-PP O
critical JJ B-NP O
pathways NNS I-NP O
in IN B-PP O
normal JJ B-NP O
development NN I-NP O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
elucidate VB B-VP O
the DT B-NP O
perturbations NNS I-NP O
of IN B-PP O
those DT B-NP O
key JJ I-NP O
pathways NNS I-NP O
in IN B-PP O
neoplastic JJ B-NP O
transformation NN I-NP O
. . O O

We PRP B-NP O
report VBP B-VP O
the DT B-NP O
functional JJ I-NP O
definition NN I-NP O
of IN B-PP O
a DT B-NP O
novel JJ I-NP O
genetic JJ I-NP O
locus NN I-NP O
within IN B-PP O
human JJ B-NP O
chromosome NN I-NP O
10pter NN I-NP O
- HYPH B-NP O
q11 NN I-NP O
that WDT B-NP O
mediates VBZ B-VP O
both CC O O
in FW B-NP O
vivo FW I-NP O
tumor NN I-NP O
suppression NN I-NP O
and CC O O
in FW B-NP O
vitro FW I-NP O
apoptosis NN I-NP O
of IN B-PP O
prostatic JJ B-NP B-Disease
adenocarcinoma NN I-NP I-Disease
cells NNS I-NP O
. . O O

A DT B-NP O
defined VBN I-NP O
fragment NN I-NP O
of IN B-PP O
human JJ B-NP O
chromosome NN I-NP O
10 CD I-NP O
was VBD B-VP O
transferred VBN I-VP O
via IN B-PP O
microcell NN B-NP O
fusion NN I-NP O
into IN B-PP O
a DT B-NP O
prostate NN I-NP B-Disease
adenocarcinoma NN I-NP I-Disease
cell NN I-NP O
line NN I-NP O
. . O O

Microcell NN B-NP O
hybrids NNS I-NP O
containing VBG B-VP O
only RB B-ADVP O
the DT B-NP O
region NN I-NP O
10pter NN I-NP O
- HYPH B-NP O
q11 NN I-NP O
were VBD B-VP O
suppressed VBN I-VP O
for IN B-PP O
tumorigenicity NN B-NP O
following VBG B-PP O
injection NN B-NP O
of IN B-PP O
microcell NN B-NP O
hybrids NNS I-NP O
into IN B-PP O
nude JJ B-NP O
mice NNS I-NP O
. . O O

Furthermore RB B-ADVP O
, , O O
the DT B-NP O
complemented VBN I-NP O
hybrids NNS I-NP O
undergo VBP B-VP O
programmed VBN I-VP O
cell NN B-NP O
death NN I-NP O
in FW B-ADVP O
vitro FW I-ADVP O
via IN B-PP O
a DT B-NP O
mechanism NN I-NP O
that WDT B-NP O
does VBZ B-VP O
not RB I-VP O
require VB I-VP O
nuclear JJ B-NP O
localization NN I-NP O
of IN B-PP O
p53 NN B-NP O
. . O O

These DT B-NP O
data NNS I-NP O
functionally RB B-ADVP O
define VBP B-VP O
a DT B-NP O
novel JJ I-NP O
genetic JJ I-NP O
locus NN I-NP O
, , O O
designated VBN B-VP O
PAC1 NN B-NP O
, , O O
for IN B-PP O
prostate NN B-NP O
adenocarcinoma NN I-NP O
1 CD I-NP O
, , O O
involved VBN B-VP O
in IN B-PP O
tumor NN B-NP O
suppression NN I-NP O
of IN B-PP O
human JJ B-NP O
prostate NN I-NP B-Disease
carcinoma NN I-NP I-Disease
and CC O O
furthermore RB B-VP O
strongly RB I-VP O
suggest VBP I-VP O
that IN B-SBAR O
the DT B-NP O
cell NN I-NP O
death NN I-NP O
pathway NN I-NP O
can MD B-VP O
be VB I-VP O
functionally RB I-VP O
restored VBN I-VP O
in IN B-PP O
prostatic JJ B-NP B-Disease
adenocarcinoma NN I-NP I-Disease
. . O O

. . O O

Low JJ B-NP O
incidence NN I-NP O
of IN B-PP O
BRCA2 NN B-NP O
mutations NNS I-NP O
in IN B-PP O
breast NN B-NP B-Disease
carcinoma NN I-NP I-Disease
and CC O O
other JJ B-NP O
cancers NNS I-NP B-Disease
. . O O

Inherited VBN B-NP O
mutant JJ I-NP O
alleles NNS I-NP O
of IN B-PP O
familial JJ B-NP O
tumour NN I-NP B-Disease
suppressor NN I-NP O
genes NNS I-NP O
predispose VBP B-VP O
individuals NNS B-NP O
to TO B-PP O
particular JJ B-NP O
types NNS I-NP O
of IN B-PP O
cancer NN B-NP B-Disease
. . O O

In IN B-PP O
addition NN B-NP O
to TO B-PP O
an DT B-NP O
involvement NN I-NP O
in IN B-PP O
inherited VBN B-NP O
susceptibility NN I-NP O
to TO B-PP O
cancer NN B-NP B-Disease
, , O O
these DT B-NP O
tumour NN I-NP B-Disease
suppressor NN I-NP O
genes NNS I-NP O
are VBP B-VP O
targets NNS B-NP O
for IN B-PP O
somatic JJ B-NP O
mutations NNS I-NP O
in IN B-PP O
sporadic JJ B-NP B-Disease
cancers NNS I-NP I-Disease
of IN B-PP O
the DT B-NP O
same JJ I-NP O
type NN I-NP O
found VBN B-VP O
in IN B-PP O
the DT B-NP O
familial JJ I-NP O
forms NNS I-NP O
. . O O

An DT B-NP O
exception NN I-NP O
is VBZ B-VP O
BRCA1 NN B-NP O
, , O O
which WDT B-NP O
contributes VBZ B-VP O
to TO B-PP O
a DT B-NP O
significant JJ I-NP O
fraction NN I-NP O
of IN B-PP O
familial JJ B-NP B-Disease
breast NN I-NP I-Disease
and CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
, , O O
but CC O O
undergoes VBZ B-VP O
mutation NN B-NP O
at IN B-PP O
very RB B-NP O
low JJ I-NP O
rates NNS I-NP O
in IN B-PP O
sporadic JJ B-NP B-Disease
breast NN I-NP I-Disease
and CC O I-Disease
ovarian JJ B-NP I-Disease
cancers NNS I-NP I-Disease
. . O O

This DT B-NP O
finding NN I-NP O
suggests VBZ B-VP O
that IN B-SBAR O
other JJ B-NP O
genes NNS I-NP O
may MD B-VP O
be VB I-VP O
the DT B-NP O
principal JJ I-NP O
targets NNS I-NP O
for IN B-PP O
somatic JJ B-NP O
mutation NN I-NP O
in IN B-PP O
breast NN B-NP B-Disease
carcinoma NN I-NP I-Disease
. . O O

A DT B-NP O
second JJ I-NP O
, , O O
recently RB B-ADVP O
identified VBD B-VP O
familial JJ B-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
gene NN I-NP O
, , O O
BRCA2 NN B-NP O
( ( O O
refs NNS B-NP O
5 CD B-NP O
- HYPH I-NP O
8 CD I-NP O
) ) O O
, , O O
accounts VBZ B-VP O
for IN B-PP O
a DT B-NP O
proportion NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
roughly RB B-ADJP O
equal JJ I-ADJP O
to TO B-PP O
BRCA1 NN B-NP O
. . O O

Like IN B-PP O
BRCA1 NN B-NP O
, , O O
BRCA2 NN B-NP O
behaves VBZ B-VP O
as IN B-PP O
a DT B-NP O
dominantly RB I-NP O
inherited VBN I-NP O
tumour NN I-NP B-Disease
suppressor NN I-NP O
gene NN I-NP O
. . O O

Individuals NNS B-NP O
who WP B-NP O
inherit VBP B-VP O
one CD B-NP O
mutant JJ I-NP O
allele NN I-NP O
are VBP B-VP O
at IN B-PP O
increased VBN B-NP O
risk NN I-NP O
for IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
, , O O
and CC O O
the DT B-NP O
tumours NNS I-NP B-Disease
they PRP B-NP O
develop VBP B-VP O
lose VB I-VP O
the DT B-NP O
wild JJ I-NP O
- HYPH I-NP O
type NN I-NP O
allele NN I-NP O
by IN B-PP O
heterozygous JJ B-NP O
deletion NN I-NP O
. . O O

The DT B-NP O
BRCA2 NN I-NP O
coding NN I-NP O
sequence NN I-NP O
is VBZ B-VP O
huge JJ B-ADJP O
, , O O
composed VBN B-VP O
of IN B-PP O
26 CD B-NP O
exons NNS I-NP O
that WDT B-NP O
span VBP B-VP O
10 CD B-NP O
, , I-NP O
443 CD I-NP O
bp NN I-NP O
. . O O

Here RB B-ADVP O
we PRP B-NP O
investigate VBP B-VP O
the DT B-NP O
rate NN I-NP O
of IN B-PP O
BRCA2 NN B-NP O
mutation NN I-NP O
in IN B-PP O
sporadic JJ B-NP B-Disease
breast NN I-NP I-Disease
cancers NNS I-NP I-Disease
and CC B-PP O
in IN B-PP O
a DT B-NP O
set NN I-NP O
of IN B-PP O
cell NN B-NP O
lines NNS I-NP O
that WDT B-NP O
represent VBP B-VP O
twelve CD B-NP O
other JJ I-NP O
tumour NN I-NP B-Disease
types NNS I-NP O
. . O O

Surprisingly RB B-ADVP O
, , O O
mutations NNS B-NP O
in IN B-PP O
BRCA2 NN B-NP O
are VBP B-VP O
infrequent JJ B-ADJP O
in IN B-PP O
cancers NNS B-NP B-Disease
including VBG B-PP O
breast NN B-NP B-Disease
carcinoma NN I-NP I-Disease
. . O O

However RB B-ADVP O
, , O O
a DT B-NP O
probable JJ I-NP O
germline NN I-NP O
mutation NN I-NP O
in IN B-PP O
a DT B-NP O
pancreatic JJ I-NP B-Disease
tumour NN I-NP I-Disease
cell NN I-NP O
line NN I-NP O
suggests VBZ B-VP O
a DT B-NP O
role NN I-NP O
for IN B-PP O
BRCA2 NN B-NP O
in IN B-PP O
susceptibility NN B-NP O
to TO B-PP O
pancreatic JJ B-NP B-Disease
cancer NN I-NP I-Disease
. . O O

. . O O

Founding VBG B-VP O
BRCA1 NN B-NP O
mutations NNS I-NP O
in IN B-PP O
hereditary JJ B-NP B-Disease
breast NN I-NP I-Disease
and CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
in IN B-PP O
southern JJ B-NP O
Sweden NNP I-NP O
. . O O

Nine CD B-NP O
different JJ I-NP O
germ NN I-NP O
- HYPH I-NP O
line NN I-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
BRCA1 NN I-NP O
breast NN I-NP B-Disease
and CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
susceptibility NN I-NP O
gene NN I-NP O
were VBD B-VP O
identified VBN I-VP O
in IN B-PP O
15 CD B-NP O
of IN B-PP O
47 CD B-NP O
kindreds NNS I-NP O
from IN B-PP O
southern JJ B-NP O
Sweden NNP I-NP O
, , O O
by IN B-PP O
use NN B-NP O
of IN B-PP O
SSCP NN B-NP O
and CC I-NP O
heteroduplex NN I-NP O
analysis NN I-NP O
of IN B-PP O
all DT B-NP O
exons NNS I-NP O
and CC O O
flanking VBG B-VP O
intron NN B-NP O
region NN I-NP O
and CC B-PP O
by IN B-PP O
a DT B-NP O
protein NN I-NP O
- HYPH B-NP O
truncation NN I-NP O
test NN I-NP O
for IN B-PP O
exon NN B-NP O
11 CD I-NP O
, , O O
followed VBN B-VP O
by IN B-PP O
direct JJ B-NP O
sequencing NN I-NP O
. . O O

All DT B-NP O
but IN B-PP O
one CD B-NP O
of IN B-PP O
the DT B-NP O
mutations NNS I-NP O
are VBP B-VP O
predicted VBN I-VP O
to TO I-VP O
give VB I-VP O
rise NN B-NP O
to TO B-PP O
premature JJ B-NP O
translation NN I-NP O
termination NN I-NP O
and CC O O
include VBP B-VP O
seven CD B-NP O
frameshift NN I-NP O
insertions NNS I-NP O
or CC I-NP O
deletions NNS I-NP O
, , O O
a DT B-NP O
nonsense JJ I-NP O
mutation NN I-NP O
, , O O
and CC O O
a DT B-NP O
splice NN I-NP O
acceptor NN I-NP O
site NN I-NP O
mutation NN I-NP O
. . O O

The DT B-NP O
remaining VBG I-NP O
mutation NN I-NP O
is VBZ B-VP O
a DT B-NP O
missense JJ I-NP O
mutation NN I-NP O
( ( O O
Cys61Gly NN B-NP O
) ) O O
in IN B-PP O
the DT B-NP O
zinc NN I-NP O
- HYPH B-VP O
binding VBG B-NP O
motif NN I-NP O
. . O O

Four CD B-NP O
novel JJ I-NP O
Swedish JJ I-NP O
founding NN I-NP O
mutations NNS I-NP O
were VBD B-VP O
identified VBN I-VP O
the DT B-NP O
nucleotide NN I-NP O
2595 CD I-NP O
deletion NN I-NP O
A NN I-NP O
was VBD B-VP O
found VBN I-VP O
in IN B-PP O
five CD B-NP O
families NNS I-NP O
, , O O
the DT B-NP O
C NN I-NP O
1806 CD I-NP O
T NN I-NP O
nonsense JJ I-NP O
mutation NN I-NP O
in IN B-PP O
three CD B-NP O
families NNS I-NP O
, , O O
the DT B-NP O
3166 CD I-NP O
insertion NN I-NP O
TGAGA NN I-NP O
in IN B-PP O
three CD B-NP O
families NNS I-NP O
, , O O
and CC O O
the DT B-NP O
nucleotide NN I-NP O
1201 CD I-NP O
deletion NN I-NP O
11 CD I-NP O
in IN B-PP O
two CD B-NP O
families NNS I-NP O
. . O O

Analysis NN B-NP O
of IN B-PP O
the DT B-NP O
intragenic JJ I-NP O
polymorphism NN I-NP O
D17S855 NN I-NP O
supports VBZ B-VP O
common JJ B-NP O
origins NNS I-NP O
of IN B-PP O
the DT B-NP O
mutations NNS I-NP O
. . O O

Eleven CD B-NP O
of IN B-PP O
the DT B-NP O
15 CD I-NP O
kindreds NNS I-NP O
manifesting VBG B-VP O
BRCA1 NN B-NP O
mutations NNS I-NP O
were VBD B-VP O
breast NN B-NP B-Disease
- HYPH O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
families NNS I-NP O
, , O O
several JJ B-NP O
of IN B-PP O
them PRP B-NP O
with IN B-PP O
a DT B-NP O
predominant JJ I-NP O
ovarian JJ I-NP B-Disease
cancer NN I-NP I-Disease
phenotype NN I-NP O
. . O O

The DT B-NP O
set NN I-NP O
of IN B-PP O
32 CD B-NP O
families NNS I-NP O
in IN B-PP O
which WDT B-NP O
no DT B-NP O
BRCA1 NN I-NP O
alterations NNS I-NP O
were VBD B-VP O
detected VBN I-VP O
included VBN I-VP O
1 CD B-NP O
breast NN I-NP B-Disease
- HYPH B-NP I-Disease
ovarian JJ I-NP I-Disease
cancer NN I-NP I-Disease
kindred NN I-NP O
manifesting VBG B-VP O
clear JJ B-NP O
linkage NN I-NP O
to TO B-PP O
the DT B-NP O
BRCA1 NN I-NP O
region NN I-NP O
and CC I-NP O
loss NN I-NP O
of IN B-PP O
the DT B-NP O
wild JJ I-NP O
- HYPH I-NP O
type NN I-NP O
chromosome NN I-NP O
in IN B-PP O
associated VBN B-NP O
tumors NNS I-NP B-Disease
. . O O

Other JJ B-NP O
tumor NN I-NP B-Disease
types NNS I-NP O
found VBN B-VP O
in IN B-PP O
BRCA1 NN B-NP O
mutation NN I-NP O
/ SYM B-NP O
haplotype NN I-NP O
carriers NNS I-NP O
included VBD B-VP O
prostatic JJ B-ADJP B-Disease
, , O I-Disease
pancreas NN B-NP I-Disease
, , O I-Disease
skin NN B-NP I-Disease
, , O I-Disease
and CC O I-Disease
lung NN B-NP I-Disease
cancer NN I-NP I-Disease
, , O O
a DT B-NP O
malignant JJ I-NP B-Disease
melanoma NN I-NP I-Disease
, , O O
an DT B-NP O
oligodendroglioma NN I-NP B-Disease
, , O O
and CC O O
a DT B-NP O
carcinosarcoma NN I-NP B-Disease
. . O O

In IN B-PP O
all DT B-NP O
, , O O
12 CD B-NP O
of IN B-PP O
16 CD B-NP O
kindreds NNS I-NP O
manifesting VBG B-VP O
BRCA1 NN B-NP O
mutation NN I-NP O
or CC O O
linkage NN B-NP O
contained VBD B-VP O
ovarian JJ B-NP B-Disease
cancer NN I-NP I-Disease
, , O O
as IN B-SBAR O
compared VBN B-PP O
with IN B-PP O
only RB B-NP O
6 CD I-NP O
of IN B-PP O
the DT B-NP O
remaining VBG I-NP O
31 CD I-NP O
families NNS I-NP O
( ( O O
P NN B-NP O
< SYM B-NP O
. . I-NP O

001 CD I-NP O
) ) O O
. . O O

The DT B-NP O
present JJ I-NP O
study NN I-NP O
confirms VBZ B-VP O
the DT B-NP O
involvement NN I-NP O
of IN B-PP O
BRCA1 NN B-NP O
in IN B-PP O
disease NN B-NP O
predisposition NN I-NP O
for IN B-PP O
a DT B-NP O
subset NN I-NP O
of IN B-PP O
hereditary JJ B-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
families NNS I-NP O
often RB B-VP O
characterized VBN I-VP O
by IN B-PP O
ovarian JJ B-NP B-Disease
cancers NNS I-NP I-Disease
. . O O

Rapid JJ B-NP O
detection NN I-NP O
of IN B-PP O
regionally RB B-NP O
clustered VBN I-NP O
germ NN I-NP O
- HYPH I-NP O
line NN I-NP O
BRCA1 NN I-NP O
mutations NNS I-NP O
by IN B-PP O
multiplex JJ B-NP O
heteroduplex NN I-NP O
analysis NN I-NP O
. . O O

UKCCCR NNP B-NP O
Familial NNP I-NP O
Ovarian NNP I-NP B-Disease
Cancer NNP I-NP I-Disease
Study NNP I-NP O
Group NNP I-NP O
. . O O

Germ NN B-NP O
- HYPH I-NP O
line NN I-NP O
mutations NNS I-NP O
of IN B-PP O
the DT B-NP O
BRCA1 NN I-NP O
gene NN I-NP O
are VBP B-VP O
responsible JJ B-ADJP O
for IN B-PP O
a DT B-NP O
substantial JJ I-NP O
proportion NN I-NP O
of IN B-PP O
families NNS B-NP O
with IN B-PP O
multiple JJ B-NP O
cases NNS I-NP O
of IN B-PP O
early JJ B-NP O
- HYPH I-NP O
onset NN I-NP O
breast NN I-NP B-Disease
and CC O I-Disease
/ SYM B-NP I-Disease
or CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
. . O O

Since IN B-SBAR O
the DT B-NP O
isolation NN I-NP O
of IN B-PP O
BRCA1 NN B-NP O
last JJ B-NP O
year NN I-NP O
, , O O
> SYM B-NP O
65 CD B-NP O
distinct JJ I-NP O
mutations NNS I-NP O
scattered VBN B-VP O
throughout IN B-PP O
the DT B-NP O
coding VBG I-NP O
region NN I-NP O
have VBP B-VP O
been VBN I-VP O
detected VBN I-VP O
, , O O
making VBG B-VP O
analysis NN B-NP O
of IN B-PP O
the DT B-NP O
gene NN I-NP O
time NN I-NP O
consuming NN I-NP O
and CC O O
technically RB B-ADJP O
challenging JJ I-ADJP O
. . O O

We PRP B-NP O
have VBP B-VP O
developed VBN I-VP O
a DT B-NP O
multiplex JJ I-NP O
heteroduplex NN I-NP O
analysis NN I-NP O
that WDT B-NP O
is VBZ B-VP O
designed VBN I-VP O
to TO I-VP O
analyze VB I-VP O
one CD B-NP O
- HYPH I-NP O
quarter NN I-NP O
of IN B-PP O
the DT B-NP O
coding VBG I-NP O
sequence NN I-NP O
in IN B-PP O
a DT B-NP O
single JJ I-NP O
- HYPH I-NP O
step NN I-NP O
screening NN I-NP O
procedure NN I-NP O
and CC O O
that WDT B-NP O
will MD B-VP O
detect VB I-VP O
approximately RB B-NP O
50 CD I-NP O
% NN I-NP O
of IN B-PP O
all DT B-NP O
BRCA1 NN I-NP O
mutations NNS I-NP O
so RB B-VP O
far RB I-VP O
reported VBN I-VP O
in IN B-PP O
breast NN B-NP B-Disease
/ SYM B-NP I-Disease
ovarian JJ I-NP I-Disease
cancer NN I-NP I-Disease
families NNS I-NP O
. . O O

We PRP B-NP O
have VBP B-VP O
used VBN I-VP O
this DT B-NP O
technique NN I-NP O
to TO B-VP O
analyze VB I-VP O
BRCA1 NN B-NP O
in IN B-PP O
162 CD B-NP O
families NNS I-NP O
with IN B-PP O
a DT B-NP O
history NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
and CC O I-Disease
/ SYM B-NP I-Disease
or CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
and CC O O
identified VBD B-VP O
12 CD B-NP O
distinct JJ I-NP O
mutations NNS I-NP O
in IN B-PP O
35 CD B-NP O
families NNS I-NP O
. . O O

. . O O

A DT B-NP O
previously RB I-NP O
undescribed JJ I-NP O
mutation NN I-NP O
within IN B-PP O
the DT B-NP O
tetramerisation NN I-NP O
domain NN I-NP O
of IN B-PP O
TP53 NN B-NP O
in IN B-PP O
a DT B-NP O
family NN I-NP O
with IN B-PP O
Li NNP B-NP B-Disease
- HYPH I-NP I-Disease
Fraumeni NNP I-NP I-Disease
syndrome NN I-NP I-Disease
. . O O

We PRP B-NP O
report VBP B-VP O
details NNS B-NP O
of IN B-PP O
a DT B-NP O
family NN I-NP O
with IN B-PP O
classic JJ B-NP O
Li NNP I-NP B-Disease
- HYPH I-NP I-Disease
Fraumeni NNP I-NP I-Disease
syndrome NN I-NP I-Disease
in IN B-PP O
which WDT B-NP O
there EX B-NP O
is VBZ B-VP O
a DT B-NP O
mutation NN I-NP O
in IN B-PP O
codon NN B-NP O
344 CD I-NP O
of IN B-PP O
the DT B-NP O
tumour NN I-NP B-Disease
suppressor NN I-NP O
gene NN I-NP O
TP53 NN I-NP O
. . O O

Codon NN B-NP O
344 CD I-NP O
is VBZ B-VP O
a DT B-NP O
key JJ I-NP O
residue NN I-NP O
within IN B-PP O
the DT B-NP O
tetramerisation NN I-NP O
domain NN I-NP O
, , O O
and CC O O
the DT B-NP O
amino JJ I-NP O
acid NN I-NP O
substitution NN I-NP O
of IN B-PP O
a DT B-NP O
proline NN I-NP O
for IN B-PP O
a DT B-NP O
leucine NN I-NP O
is VBZ B-VP O
predicted VBN I-VP O
to TO I-VP O
have VB I-VP O
profound JJ B-NP O
implications NNS I-NP O
for IN B-PP O
tetramerisation NN B-NP O
and CC O O
potentially RB B-ADVP O
DNA NN B-NP O
binding NN I-NP O
. . O O

This DT B-NP O
is VBZ B-VP O
the DT B-NP O
first JJ I-NP O
report NN I-NP O
of IN B-PP O
a DT B-NP O
mutation NN I-NP O
at IN B-PP O
this DT B-NP O
residue NN I-NP O
in IN B-PP O
either CC B-NP O
sporadic JJ I-NP B-Disease
tumours NNS I-NP I-Disease
or CC B-PP O
in IN B-PP O
the DT B-NP O
germline NN I-NP O
and CC O O
the DT B-NP O
first JJ I-NP O
report NN I-NP O
of IN B-PP O
a DT B-NP O
germline NN I-NP O
mutation NN I-NP O
within IN B-PP O
the DT B-NP O
tetramerisation NN I-NP O
domain NN I-NP O
. . O O

The DT B-NP O
family NN I-NP O
does VBZ B-VP O
not RB I-VP O
appear VB I-VP O
to TO I-VP O
be VB I-VP O
remarkable JJ B-ADJP O
in IN B-PP O
the DT B-NP O
spectrum NN I-NP O
of IN B-PP O
tumours NNS B-NP B-Disease
, , O O
and CC O O
there EX B-NP O
is VBZ B-VP O
loss NN B-NP O
of IN B-PP O
the DT B-NP O
wild JJ I-NP O
- HYPH I-NP O
type NN I-NP O
allele NN I-NP O
in IN B-PP O
a DT B-NP O
leiomyosarcoma NN I-NP B-Disease
from IN B-PP O
the DT B-NP O
proband NN I-NP O
. . O O

A DT B-NP O
cell NN I-NP O
line NN I-NP O
has VBZ B-VP O
been VBN I-VP O
established VBN I-VP O
from IN B-PP O
the DT B-NP O
tumour NN I-NP B-Disease
of IN B-PP O
the DT B-NP O
proband NN I-NP O
and CC O O
cytogenetic JJ B-NP O
and CC I-NP O
molecular JJ I-NP O
studies NNS I-NP O
carried VBN B-VP O
out RP B-PRT O
, , O O
providing VBG B-VP O
an DT B-NP O
extensive JJ I-NP O
analysis NN I-NP O
in IN B-PP O
this DT B-NP O
family NN I-NP O
. . O O

. . O O

The DT B-NP O
spectrum NN I-NP O
of IN B-PP O
RB1 NN B-NP O
germ NN I-NP O
- HYPH B-NP O
line NN I-NP O
mutations NNS I-NP O
in IN B-PP O
hereditary JJ B-NP B-Disease
retinoblastoma NN I-NP I-Disease
. . O O

We PRP B-NP O
have VBP B-VP O
searched VBN I-VP O
for IN B-PP O
germ NN B-NP O
- HYPH I-NP O
line NN I-NP O
RB1 NN I-NP O
mutations NNS I-NP O
in IN B-PP O
119 CD B-NP O
patients NNS I-NP O
with IN B-PP O
hereditary JJ B-NP B-Disease
retinoblastoma NN I-NP I-Disease
. . O O

Previous JJ B-NP O
investigations NNS I-NP O
by IN B-PP O
Southern JJ B-NP O
blot NN I-NP O
hybridization NN I-NP O
and CC O O
PCR NN B-NP O
fragment NN I-NP O
- HYPH B-NP O
length NN I-NP O
analysis NN I-NP O
had VBD B-VP O
revealed VBN I-VP O
mutations NNS B-NP O
in IN B-PP O
48 CD B-NP O
patients NNS I-NP O
. . O O

Here RB B-ADVP O
we PRP B-NP O
report VBP B-VP O
on IN B-PP O
the DT B-NP O
analysis NN I-NP O
of IN B-PP O
the DT B-NP O
remaining VBG I-NP O
71 CD I-NP O
patients NNS I-NP O
. . O O

By IN B-PP O
applying VBG B-VP O
heteroduplex NN B-NP O
analysis NN I-NP O
, , O O
nonisotopic JJ B-NP O
SSCP NN I-NP O
, , O O
and CC O O
direct JJ B-NP O
sequencing NN I-NP O
, , O O
we PRP B-NP O
detected VBD B-VP O
germ NN B-NP O
- HYPH B-NP O
line NN I-NP O
mutations NNS I-NP O
resulting VBG B-VP O
in IN B-PP O
premature JJ B-NP O
termination NN I-NP O
codons NNS I-NP O
or CC O O
disruption NN B-NP O
of IN B-PP O
splice NN B-NP O
signals NNS I-NP O
in IN B-PP O
51 CD B-NP O
( ( O O
72 CD B-NP O
% NN I-NP O
) ) O O
of IN B-PP O
the DT B-NP O
71 CD I-NP O
patients NNS I-NP O
. . O O

Four CD B-NP O
patients NNS I-NP O
also RB B-ADVP O
showed VBD B-VP O
rare JJ B-NP O
sequence NN I-NP O
variants NNS I-NP O
. . O O

No DT B-NP O
region NN I-NP O
of IN B-PP O
the DT B-NP O
RB1 NN I-NP O
gene NN I-NP O
was VBD B-VP O
preferentially RB I-VP O
involved VBN I-VP O
in IN B-PP O
single JJ B-NP O
base NN I-NP O
substitutions NNS I-NP O
. . O O

Recurrent JJ B-NP O
transitions NNS I-NP O
were VBD B-VP O
observed VBN I-VP O
at IN B-PP O
most JJS B-NP O
of IN B-PP O
the DT B-NP O
14 CD I-NP O
codons NNS I-NP O
within IN B-PP O
the DT B-NP O
RB1 NN I-NP O
. . O O

No DT B-NP O
mutation NN I-NP O
was VBD B-VP O
observed VBN I-VP O
in IN B-PP O
exons NNS B-NP O
25 CD B-NP O
- HYPH I-NP O
27 CD I-NP O
, , O O
although IN B-SBAR O
this DT B-NP O
region NN I-NP O
contains VBZ B-VP O
two CD B-NP O
CGA NN I-NP O
codons NNS I-NP O
. . O O

This DT B-NP O
suggests VBZ B-VP O
that IN B-SBAR O
mutations NNS B-NP O
within IN B-PP O
the DT B-NP O
3 CD I-NP O
- HYPH I-NP O
terminal JJ I-NP O
region NN I-NP O
of IN B-PP O
the DT B-NP O
RB1 NN I-NP O
gene NN I-NP O
may MD B-VP O
not RB I-VP O
be VB I-VP O
oncogenic JJ B-ADJP O
. . O O

When WRB B-ADVP O
these DT B-NP O
data NNS I-NP O
were VBD B-VP O
combined VBN I-VP O
with IN B-PP O
the DT B-NP O
results NNS I-NP O
of IN B-PP O
our PRP$ B-NP O
previous JJ I-NP O
investigations NNS I-NP O
, , O O
mutations NNS B-NP O
were VBD B-VP O
identified VBN I-VP O
in IN B-PP O
a DT B-NP O
total NN I-NP O
of IN B-PP O
99 CD B-NP O
( ( O O
83 CD B-NP O
% NN I-NP O
) ) O O
of IN B-PP O
119 CD B-NP O
patients NNS I-NP O
. . O O

The DT B-NP O
spectrum NN I-NP O
comprises VBZ B-VP O
15 CD B-NP O
% NN I-NP O
large JJ I-NP O
deletions NNS I-NP O
, , O O
26 CD B-NP O
% NN I-NP O
small JJ I-NP O
length NN I-NP O
alterations NNS I-NP O
, , O O
and CC O O
42 CD B-NP O
% NN I-NP O
base NN I-NP O
substitutions NNS I-NP O
. . O O

No DT B-NP O
correlation NN I-NP O
between IN B-PP O
the DT B-NP O
location NN I-NP O
of IN B-PP O
frameshift NN B-NP O
or CC O O
nonsense JJ B-NP O
mutations NNS I-NP O
and CC O O
phenotypic JJ B-NP O
features NNS I-NP O
, , O O
including VBG B-PP O
age NN B-NP O
at IN B-PP O
diagnosis NN B-NP O
, , O O
the DT B-NP O
number NN I-NP O
of IN B-PP O
tumor NN B-NP B-Disease
foci NNS I-NP O
, , O O
and CC O O
manifestation NN B-NP O
of IN B-PP O
nonocular JJ B-NP B-Disease
tumors NNS I-NP I-Disease
was VBD B-VP O
observed VBN I-VP O
. . O O

. . O O

Phenotypic JJ B-NP O
characterization NN I-NP O
of IN B-PP O
individuals NNS B-NP O
with IN B-PP O
30 CD B-NP O
- HYPH I-NP O
40 CD I-NP O
CAG NN I-NP O
repeats NNS I-NP O
in IN B-PP O
the DT B-NP O
Huntington NNP I-NP B-Disease
disease NN I-NP I-Disease
( ( O O
HD NN B-NP B-Disease
) ) O O
gene NN B-NP O
reveals VBZ B-VP O
HD NN B-NP B-Disease
cases NNS I-NP O
with IN B-PP O
36 CD B-NP O
repeats NNS I-NP O
and CC O O
apparently RB B-ADVP O
normal JJ B-NP O
elderly JJ I-NP O
individuals NNS I-NP O
with IN B-PP O
36 CD B-NP O
- HYPH I-NP O
39 CD I-NP O
repeats NNS I-NP O
. . O O

Abnormal JJ B-NP O
CAG NN I-NP O
expansions NNS I-NP O
in IN B-PP O
the DT B-NP O
IT NN I-NP O
- HYPH B-NP O
15 CD I-NP O
gene NN I-NP O
are VBP B-VP O
associated VBN I-VP O
with IN B-PP O
Huntington NNP B-NP B-Disease
disease NN I-NP I-Disease
( ( O O
HD NN B-NP B-Disease
) ) O O
. . O O

In IN B-PP O
the DT B-NP O
diagnostic JJ I-NP O
setting NN I-NP O
it PRP B-NP O
is VBZ B-VP O
necessary JJ B-ADJP O
to TO B-VP O
define VB I-VP O
the DT B-NP O
limits NNS I-NP O
of IN B-PP O
the DT B-NP O
CAG NN I-NP O
size NN I-NP O
ranges NNS I-NP O
on IN B-PP O
normal JJ B-NP O
and CC I-NP O
HD NN I-NP B-Disease
- HYPH B-NP O
associated VBN I-NP O
chromosomes NNS I-NP O
. . O O

Most JJS B-NP O
large JJ I-NP O
analyses NNS I-NP O
that WDT B-NP O
defined VBD B-VP O
the DT B-NP O
limits NNS I-NP O
of IN B-PP O
the DT B-NP O
normal JJ I-NP O
and CC I-NP O
pathological JJ I-NP O
size NN I-NP O
ranges VBZ B-VP O
employed VBN I-VP O
PCR NN B-NP O
assays NNS I-NP O
, , O O
which WDT B-NP O
included VBD B-VP O
the DT B-NP O
CAG NN I-NP O
repeats NNS I-NP O
and CC O O
a DT B-NP O
CCG NN I-NP O
repeat NN I-NP O
tract NN I-NP O
that WDT B-NP O
was VBD B-VP O
thought VBN I-VP O
to TO I-VP O
be VB I-VP O
invariant JJ B-ADJP O
. . O O

Many JJ B-NP O
of IN B-PP O
these DT B-NP O
experiments NNS I-NP O
found VBD B-VP O
an DT B-NP O
overlap NN I-NP O
between IN B-PP O
the DT B-NP O
normal JJ I-NP O
and CC I-NP O
disease NN I-NP O
size NN I-NP O
ranges NNS I-NP O
. . O O

Subsequent JJ B-NP O
findings NNS I-NP O
that IN B-SBAR O
the DT B-NP O
CCG NN I-NP O
repeats NNS I-NP O
vary VBP B-VP O
by IN B-PP O
8 CD B-NP O
trinucleotide NN I-NP O
lengths NNS I-NP O
suggested VBD B-VP O
that IN B-SBAR O
the DT B-NP O
limits NNS I-NP O
of IN B-PP O
the DT B-NP O
normal JJ I-NP O
and CC I-NP O
disease NN I-NP O
size NN I-NP O
ranges NNS I-NP O
should MD B-VP O
be VB I-VP O
reevaluated VBN I-VP O
with IN B-PP O
assays NNS B-NP O
that WDT B-NP O
exclude VBP B-VP O
the DT B-NP O
CCG NN I-NP O
polymorphism NN I-NP O
. . O O

Since IN B-SBAR O
patients NNS B-NP O
with IN B-PP O
between IN B-NP O
30 CD I-NP O
and CC I-NP O
40 CD I-NP O
repeats NNS I-NP O
are VBP B-VP O
rare JJ B-ADJP O
, , O O
a DT B-NP O
consortium NN I-NP O
was VBD B-VP O
assembled VBN I-VP O
to TO I-VP O
collect VB I-VP O
such JJ B-NP O
individuals NNS I-NP O
. . O O

All DT B-NP O
178 CD I-NP O
samples NNS I-NP O
were VBD B-VP O
reanalyzed VBN I-VP O
in IN B-PP O
Cambridge NNP B-NP O
by IN B-PP O
using VBG B-VP O
assays NNS B-NP O
specific JJ B-ADJP O
for IN B-PP O
the DT B-NP O
CAG NN I-NP O
repeats NNS I-NP O
. . O O

We PRP B-NP O
have VBP B-VP O
optimized VBN I-VP O
methods NNS B-NP O
for IN B-PP O
reliable JJ B-NP O
sizing NN I-NP O
of IN B-PP O
CAG NN B-NP O
repeats NNS I-NP O
and CC O O
show NN B-NP O
cases NNS I-NP O
that WDT B-NP O
demonstrate VBP B-VP O
the DT B-NP O
dangers NNS I-NP O
of IN B-PP O
using VBG B-VP O
PCR NN B-NP O
assays NNS I-NP O
that WDT B-NP O
include VBP B-VP O
both CC O O
the DT B-NP O
CAG NN I-NP O
and CC I-NP O
CCG NN I-NP O
polymorphisms NNS I-NP O
. . O O

Seven CD B-NP O
HD NN I-NP B-Disease
patients NNS I-NP O
had VBD B-VP O
36 CD B-NP O
repeats NNS I-NP O
, , O O
which WDT B-NP O
confirms VBZ B-VP O
that IN B-SBAR O
this DT B-NP O
allele NN I-NP O
is VBZ B-VP O
associated VBN I-VP O
with IN B-PP O
disease NN B-NP O
. . O O

Individuals NNS B-NP O
without IN B-PP O
apparent JJ B-NP O
symptoms NNS I-NP O
or CC I-NP O
signs NNS I-NP O
of IN B-PP O
HD NN B-NP B-Disease
were VBD B-VP O
found VBN I-VP O
at IN B-PP O
36 CD B-NP O
repeats NNS I-NP O
( ( O O
aged VBN B-NP O
74 CD I-NP O
, , I-NP O
78 CD I-NP O
, , I-NP O
79 CD I-NP O
, , O O
and CC O O
87 CD B-NP O
years NNS I-NP O
) ) O O
, , O O
37 CD B-NP O
repeats NNS I-NP O
( ( O O
aged VBN B-VP O
69 CD B-NP O
years NNS I-NP O
) ) O O
, , O O
38 CD B-NP O
repeats NNS I-NP O
( ( O O
aged VBN B-VP O
69 CD B-NP O
and CC I-NP O
90 CD I-NP O
years NNS I-NP O
) ) O O
, , O O
and CC O O
39 CD B-NP O
repeats NNS I-NP O
( ( O O
aged VBN B-NP O
67 CD I-NP O
, , I-NP O
90 CD I-NP O
, , O O
and CC O O
95 CD B-NP O
years NNS I-NP O
) ) O O
. . O O

The DT B-NP O
detailed JJ I-NP O
case NN I-NP O
histories NNS I-NP O
of IN B-PP O
an DT B-NP O
exceptional JJ I-NP O
case NN I-NP O
from IN B-PP O
this DT B-NP O
series NN I-NP O
will MD B-VP O
be VB I-VP O
presented VBN I-VP O
a DT B-NP O
95 CD I-NP O
- HYPH I-NP O
year NN I-NP O
- HYPH O O
old JJ B-NP O
man NN I-NP O
with IN B-PP O
39 CD B-NP O
repeats NNS I-NP O
who WP B-NP O
did VBD B-VP O
not RB I-VP O
have VB I-VP O
classical JJ B-NP O
features NNS I-NP O
of IN B-PP O
HD NN B-NP B-Disease
. . O O

The DT B-NP O
apparently RB I-NP O
healthy JJ I-NP O
survival NN I-NP O
into IN B-PP O
old JJ B-NP O
age NN I-NP O
of IN B-PP O
some DT B-NP O
individuals NNS I-NP O
with IN B-PP O
36 CD B-NP O
- HYPH I-NP O
39 CD I-NP O
repeats NNS I-NP O
suggests VBZ B-VP O
that IN B-SBAR O
the DT B-NP O
HD NN I-NP B-Disease
mutation NN I-NP O
may MD B-VP O
not RB I-VP O
always RB I-VP O
be VB I-VP O
fully RB B-ADJP O
penetrant JJ I-ADJP O
. . O O

. . O O

Identification NN B-NP O
and CC I-NP O
expression NN I-NP O
of IN B-PP O
eight CD B-NP O
novel JJ I-NP O
mutations NNS I-NP O
among IN B-PP O
non AFX B-NP O
- HYPH I-NP O
Jewish JJ B-NP O
patients NNS I-NP O
with IN B-PP O
Canavan NN B-NP B-Disease
disease NN I-NP I-Disease
. . O O

Canavan NN B-NP B-Disease
disease NN I-NP I-Disease
is VBZ B-VP O
inherited VBN I-VP O
as IN B-PP O
an DT B-NP O
autosomal JJ I-NP O
recessive JJ I-NP O
trait NN I-NP O
that WDT B-NP O
is VBZ B-VP O
caused VBN I-VP O
by IN B-PP O
the DT B-NP O
deficiency NN I-NP B-Disease
of IN B-PP I-Disease
aspartoacylase NN B-NP I-Disease
( ( O O
ASPA NN B-NP O
) ) O O
. . O O

The DT B-NP O
majority NN I-NP O
of IN B-PP O
patients NNS B-NP O
with IN B-PP O
Canavan NNP B-NP B-Disease
disease NN I-NP I-Disease
are VBP B-VP O
from IN B-PP O
an DT B-NP O
Ashkenazi NNP I-NP O
Jewish JJ I-NP O
background NN I-NP O
. . O O

Mutations NNS B-NP O
in IN B-PP O
ASPA NN B-NP O
that WDT B-NP O
lead VBP B-VP O
to TO B-PP O
loss NN B-NP O
of IN B-PP O
enzymatic JJ B-NP O
activity NN I-NP O
have VBP B-VP O
been VBN I-VP O
identified VBN I-VP O
, , O O
and CC O O
E285A NN B-NP O
and CC I-NP O
Y231X NN I-NP O
are VBP B-VP O
the DT B-NP O
two CD I-NP O
predominant JJ I-NP O
mutations NNS I-NP O
that WDT B-NP O
account VBP B-VP O
for IN B-PP O
97 CD B-NP O
% NN I-NP O
of IN B-PP O
the DT B-NP O
mutant JJ I-NP O
chromosomes NNS I-NP O
in IN B-PP O
Ashkenazi NNP B-NP O
Jewish JJ I-NP O
patients NNS I-NP O
. . O O

The DT B-NP O
current JJ I-NP O
study NN I-NP O
was VBD B-VP O
aimed VBN I-VP O
at IN B-PP O
finding VBG B-VP O
the DT B-NP O
molecular JJ I-NP O
basis NN I-NP O
of IN B-PP O
Canavan NNP B-NP B-Disease
disease NN I-NP I-Disease
in IN B-PP O
25 CD B-NP O
independent JJ I-NP O
patients NNS I-NP O
of IN B-PP O
non AFX B-NP O
- HYPH I-NP O
Jewish JJ I-NP O
background NN I-NP O
. . O O

Eight CD B-NP O
novel JJ I-NP O
and CC I-NP O
three CD I-NP O
previously RB I-NP O
characterized VBN I-NP O
mutations NNS I-NP O
accounted VBD B-VP O
for IN B-PP O
80 CD B-NP O
% NN I-NP O
( ( O O
40 CD B-NP O
/ SYM I-NP O
50 CD I-NP O
) ) O O
of IN B-PP O
mutant JJ B-NP O
chromosomes NNS I-NP O
. . O O

The DT B-NP O
A305E NN I-NP O
missense JJ I-NP O
mutation NN I-NP O
accounted VBD B-VP O
for IN B-PP O
48 CD B-NP O
% NN I-NP O
( ( O O
24 CD B-NP O
/ SYM I-NP O
50 CD I-NP O
) ) O O
of IN B-PP O
mutant JJ B-NP O
chromosomes NNS I-NP O
in IN B-PP O
patients NNS B-NP O
of IN B-PP O
western JJ B-NP O
European JJ I-NP O
descent NN I-NP O
, , O O
while IN B-SBAR O
the DT B-NP O
two CD I-NP O
predominant JJ I-NP O
Jewish JJ I-NP O
mutations NNS I-NP O
each DT O O
accounted VBD B-VP O
for IN B-PP O
a DT B-NP O
single JJ I-NP O
mutant JJ I-NP O
chromosome NN I-NP O
. . O O

The DT B-NP O
eight CD I-NP O
novel JJ I-NP O
mutations NNS I-NP O
identified VBN B-VP O
included VBD B-VP O
1 CD B-NP O
- HYPH B-NP O
and CC I-NP O
4 CD I-NP O
- HYPH I-NP O
bp NN I-NP O
deletions NNS I-NP O
( ( O O
32 CD B-NP O
deltaT NN I-NP O
and CC O O
876 CD B-NP O
deltaAGAA NN I-NP O
, , O O
respectively RB B-ADVP O
) ) O O
and CC O O
I16T NN B-NP O
, , O O
G27R NN B-NP O
, , O O
D114E NN B-NP O
, , O O
G123E NN B-NP O
, , O O
C152Y NN B-NP O
, , O O
and CC O O
R168C NN B-NP O
missense JJ I-NP O
mutations NNS I-NP O
. . O O

The DT B-NP O
homozygous JJ I-NP O
32 CD I-NP O
deltaT NN I-NP O
deletion NN I-NP O
was VBD B-VP O
identified VBN I-VP O
in IN B-PP O
the DT B-NP O
only JJ I-NP O
known JJ I-NP O
patient NN I-NP O
of IN B-PP O
African JJ B-NP O
- HYPH I-NP O
American JJ I-NP O
origin NN I-NP O
with IN B-PP O
Canavan NNP B-NP B-Disease
disease NN I-NP I-Disease
. . O O

The DT B-NP O
heterozygosity NN I-NP O
for IN B-PP O
876 CD B-NP O
deltaAGAA NN I-NP O
mutation NN I-NP O
was VBD B-VP O
identified VBN I-VP O
in IN B-PP O
three CD B-NP O
independent JJ I-NP O
patients NNS I-NP O
from IN B-PP O
England NNP B-NP O
. . O O

Six CD B-NP O
single JJ I-NP O
- HYPH I-NP O
base NN I-NP O
changes NNS I-NP O
leading VBG B-VP O
to TO B-PP O
missense JJ B-NP O
mutations NNS I-NP O
were VBD B-VP O
identified VBN I-VP O
in IN B-PP O
patients NNS B-NP O
from IN B-PP O
Turkey NNP B-NP O
( ( O O
D114E NN B-NP O
, , O O
R168C NN B-NP O
) ) O O
, , O O
The DT B-NP O
Netherlands NNP I-NP O
( ( O O
I16T NN B-NP O
) ) O O
, , O O
Germany NNP B-NP O
( ( O O
G27R NN B-NP O
) ) O O
, , O O
Ireland NN B-NP O
( ( O O
C152Y NN B-NP O
) ) O O
, , O O
and CC O O
Canada NNP B-NP O
( ( O O
G123E NN B-NP O
) ) O O
. . O O

A DT B-NP O
PCR NN I-NP O
- HYPH B-VP O
based VBN B-NP O
protocol NN I-NP O
is VBZ B-VP O
described VBN I-VP O
that WDT B-NP O
was VBD B-VP O
used VBN I-VP O
to TO B-VP O
introduce VB I-VP O
mutations NNS B-NP O
in IN B-PP O
wild JJ B-NP O
- HYPH I-NP O
type NN I-NP O
cDNA NN I-NP O
. . O O

In FW B-NP O
vitro FW I-NP O
expression NN I-NP O
of IN B-PP O
mutant JJ B-NP O
cDNA NN I-NP O
clones NNS I-NP O
demonstrated VBD B-VP O
that IN B-SBAR O
all DT B-NP O
of IN B-PP O
these DT B-NP O
mutations NNS I-NP O
led VBD B-VP O
to TO B-PP O
a DT B-NP O
deficiency NN I-NP B-Disease
of IN B-PP I-Disease
ASPA NN B-NP I-Disease
and CC O O
should MD B-VP O
therefore RB I-VP O
result VB I-VP O
in IN B-PP O
Canavan NNP B-NP B-Disease
disease NN I-NP I-Disease
. . O O

. . O O

Identification NN B-NP O
and CC O O
chromosomal JJ B-NP O
localization NN I-NP O
of IN B-PP O
Atm NNP B-NP O
, , O O
the DT B-NP O
mouse NN I-NP O
homolog NN I-NP O
of IN B-PP O
the DT B-NP O
ataxia NN I-NP B-Disease
- HYPH B-NP I-Disease
telangiectasia NN I-NP I-Disease
gene NN I-NP O
. . O O

Atm NNP B-NP O
, , O O
the DT B-NP O
mouse NN I-NP O
homolog NN I-NP O
of IN B-PP O
the DT B-NP O
human JJ I-NP O
ATM NN I-NP O
gene NN I-NP O
defective JJ B-ADJP O
in IN B-PP O
ataxia NN B-NP B-Disease
- HYPH B-NP I-Disease
telangiectasia NN I-NP I-Disease
( ( O O
A NN B-NP B-Disease
- HYPH O I-Disease
T NN B-NP I-Disease
) ) O O
, , O O
has VBZ B-VP O
been VBN I-VP O
identified VBN I-VP O
. . O O

The DT B-NP O
entire JJ I-NP O
coding VBG I-NP O
sequence NN I-NP O
of IN B-PP O
the DT B-NP O
Atm NNP I-NP O
transcript NN I-NP O
was VBD B-VP O
cloned VBN I-VP O
and CC O O
found VBN B-VP O
to TO I-VP O
contain VB I-VP O
an DT B-NP O
open JJ I-NP O
reading NN I-NP O
frame NN I-NP O
encoding VBG B-VP O
a DT B-NP O
protein NN I-NP O
of IN B-PP O
3066 CD B-NP O
amino NN I-NP O
acids NNS I-NP O
with IN B-PP O
84 CD B-NP O
% NN I-NP O
overall JJ I-NP O
identity NN I-NP O
and CC O O
91 CD B-NP O
% NN I-NP O
similarity NN I-NP O
to TO B-PP O
the DT B-NP O
human JJ I-NP O
ATM NN I-NP O
protein NN I-NP O
. . O O

Variable JJ B-NP O
levels NNS I-NP O
of IN B-PP O
expression NN B-NP O
of IN B-PP O
Atm NN B-NP O
were VBD B-VP O
observed VBN I-VP O
in IN B-PP O
different JJ B-NP O
tissues NNS I-NP O
. . O O

Fluorescence NN B-NP O
in FW B-NP O
situ FW I-NP O
hybridization NN I-NP O
and CC I-NP O
linkage NN I-NP O
analysis NN I-NP O
located JJ B-VP O
the DT B-NP O
Atm NN I-NP O
gene NN I-NP O
on IN B-PP O
mouse NN B-NP O
chromosome NN I-NP O
9 CD I-NP O
, , O O
band NN B-NP O
9C NN I-NP O
, , O O
in IN B-PP O
a DT B-NP O
region NN I-NP O
homologous JJ B-ADJP O
to TO B-PP O
the DT B-NP O
ATM NN I-NP O
region NN I-NP O
on IN B-PP O
human JJ B-NP O
chromosome NN I-NP O
11q22 NN I-NP O
- HYPH B-NP O
q23 NN I-NP O
. . O O

. . O O

The DT B-NP O
mouse NN I-NP O
homolog NN I-NP O
of IN B-PP O
the DT B-NP O
Wiskott NNP I-NP B-Disease
- HYPH I-NP I-Disease
Aldrich NNP I-NP I-Disease
syndrome NN I-NP I-Disease
protein NN I-NP O
( ( O O
WASP NN B-NP O
) ) O O
gene NN B-NP O
is VBZ B-VP O
highly RB I-VP O
conserved VBN I-VP O
and CC O O
maps NNS B-NP O
near IN B-PP O
the DT B-NP O
scurfy NN I-NP O
( ( O O
sf NN B-NP O
) ) O O
mutation NN B-NP O
on IN B-PP O
the DT B-NP O
X NN I-NP O
chromosome NN I-NP O
. . O O

The DT B-NP O
mouse NN I-NP O
WASP NN I-NP O
gene NN I-NP O
, , O O
the DT B-NP O
homolog NN I-NP O
of IN B-PP O
the DT B-NP O
gene NN I-NP O
mutated VBN B-VP O
in IN B-PP O
Wiskott NNP B-NP B-Disease
- HYPH I-NP I-Disease
Aldrich NNP I-NP I-Disease
syndrome NN I-NP I-Disease
, , O O
has VBZ B-VP O
been VBN I-VP O
isolated VBN I-VP O
and CC I-VP O
sequenced VBN I-VP O
. . O O

the DT B-NP O
predicted VBN I-NP O
amino NN I-NP O
acid NN I-NP O
sequence NN I-NP O
is VBZ B-VP O
86 CD B-NP O
% NN I-NP O
identical JJ B-ADJP O
to TO B-PP O
the DT B-NP O
human JJ I-NP O
WASP NN I-NP O
sequence NN I-NP O
. . O O

A DT B-NP O
distinct JJ I-NP O
feature NN I-NP O
of IN B-PP O
the DT B-NP O
mouse NN I-NP O
gene NN I-NP O
is VBZ B-VP O
an DT B-NP O
expanded VBN I-NP O
polymorphic JJ I-NP O
GGA NN I-NP O
trinucleotide NN I-NP O
repeat NN I-NP O
that WDT B-NP O
codes VBZ B-VP O
for IN B-PP O
polyglycine NN B-NP O
and CC O O
varies VBZ B-VP O
from IN B-PP O
15 CD B-NP O
to TO I-NP O
17 CD I-NP O
triplets NNS I-NP O
in IN B-PP O
different JJ B-NP O
Mus NN I-NP O
musculus NN I-NP O
strains NNS I-NP O
. . O O

The DT B-NP O
genomic JJ I-NP O
structure NN I-NP O
of IN B-PP O
the DT B-NP O
mouse NN I-NP O
WASP NN I-NP O
gene NN I-NP O
is VBZ B-VP O
expressed VBN I-VP O
as IN B-PP O
an DT B-NP O
approximately RB I-NP O
2 CD I-NP O
. . O O

4 CD B-NP O
- HYPH I-NP O
kb NN I-NP O
mRNA NN I-NP O
in IN B-PP O
thymus NN B-NP O
and CC I-NP O
spleen NN I-NP O
. . O O

Chromosomal JJ B-NP O
mapping NN I-NP O
in IN B-PP O
an DT B-NP O
interspecific JJ I-NP O
M NN I-NP O
. . O O

Musculus NN B-NP O
/ SYM I-NP O
M NN I-NP O
. SYM I-NP O

spretus NN I-NP O
backcross RB B-ADVP O
placed VBD B-VP O
the DT B-NP O
Wasp NNP I-NP O
locus NN I-NP O
near IN B-PP O
the DT B-NP O
centromere NN I-NP O
of IN B-PP O
the DT B-NP O
mouse NN I-NP O
X NN I-NP O
chromosome NN I-NP O
, , O O
inseparable JJ B-ADJP O
from IN B-PP O
Gata1 NN B-NP O
, , O O
Tcfe3 NN B-NP O
, , O O
and CC O O
scurfy NN B-NP O
( ( O O
sf NN B-NP O
) ) O O
. . O O

This DT B-NP O
localization NN I-NP O
makes VBZ B-VP O
Wasp NNP B-NP O
a DT B-NP O
candidate NN I-NP O
for IN B-PP O
involvement NN B-NP O
in IN B-PP O
scurfy NN B-NP O
, , O O
a DT B-NP O
T NN I-NP O
cell NN I-NP O
- HYPH O O
mediated VBN B-VP O
fatal JJ B-NP B-Disease
lymphoreticular JJ I-NP I-Disease
disease NN I-NP I-Disease
of IN B-PP O
mice NNS B-NP O
that WDT B-NP O
has VBZ B-VP O
previously RB I-VP O
been VBN I-VP O
proposed VBN I-VP O
as IN B-PP O
a DT B-NP O
mouse NN I-NP O
homolog NN I-NP O
of IN B-PP O
Wiskott NNP B-NP B-Disease
- HYPH I-NP I-Disease
Aldrich NNP I-NP I-Disease
syndrome NN I-NP I-Disease
. . O O

Northern JJ B-NP O
analysis NN I-NP O
of IN B-PP O
sf NN B-NP O
tissue NN I-NP O
samples NNS I-NP O
indicated VBD B-VP O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
WASP NN B-NP O
mRNA NN I-NP O
in IN B-PP O
liver NN B-NP O
and CC I-NP O
skin NN I-NP O
, , O O
presumably RB B-ADVP O
as IN B-PP O
a DT B-NP O
consequence NN I-NP O
of IN B-PP O
lymphocytic JJ B-NP O
infiltration NN I-NP O
, , O O
but CC O O
non JJ B-NP O
abnormalities NNS I-NP O
in IN B-PP O
the DT B-NP O
amount NN I-NP O
or CC I-NP O
size NN I-NP O
of IN B-PP O
mRNA NN B-NP O
present JJ B-ADJP O
. . O O

Colchicine NN B-NP O
in IN B-PP O
breast NN B-NP O
milk NN I-NP O
of IN B-PP O
patients NNS B-NP O
with IN B-PP O
familial JJ B-NP B-Disease
Mediterranean JJ I-NP I-Disease
fever NN I-NP I-Disease
. . O O

OBJECTIVE NN B-NP O
. . O O

To TO B-VP O
clarify VB I-VP O
whether IN B-SBAR O
colchicine NN B-NP O
is VBZ B-VP O
excreted VBN I-VP O
in IN B-PP O
breast NN B-NP O
milk NN I-NP O
, , O O
and CC O O
to TO B-VP O
compare VB I-VP O
its PRP$ B-NP O
concentrations NNS I-NP O
in IN B-PP O
the DT B-NP O
serum NN I-NP O
and CC I-NP O
breast NN I-NP O
milk NN I-NP O
of IN B-PP O
lactating VBG B-NP O
women NNS I-NP O
who WP B-NP O
have VBP B-VP O
familial JJ B-NP B-Disease
Mediterranean JJ I-NP I-Disease
fever NN I-NP I-Disease
( ( O O
FMF NN B-NP B-Disease
) ) O O
. . O O

METHODS NNS B-NP O
. . O O

Using VBG B-VP O
a DT B-NP O
specific JJ I-NP O
radioimmunoassay NN I-NP O
, , O O
we PRP B-NP O
determined VBD B-VP O
colchicine NN B-NP O
concentrations NNS I-NP O
in IN B-PP O
the DT B-NP O
serum NN I-NP O
and CC I-NP O
breast NN I-NP O
milk NN I-NP O
of IN B-PP O
4 CD B-NP O
patients NNS I-NP O
at IN B-PP O
various JJ B-NP O
time NN I-NP O
points NNS I-NP O
, , O O
following VBG B-PP O
oral JJ B-NP O
administration NN I-NP O
of IN B-PP O
the DT B-NP O
drug NN I-NP O
. . O O

The DT B-NP O
study NN I-NP O
evaluated VBD B-VP O
4 CD B-NP O
patients NNS I-NP O
with IN B-PP O
FMF NN B-NP B-Disease
who WP B-NP O
had VBD B-VP O
been VBN I-VP O
taking VBG I-VP O
colchicine NN B-NP O
on IN B-PP O
a DT B-NP O
long JJ I-NP O
- HYPH I-NP O
term NN I-NP O
basis NN I-NP O
. . O O

RESULTS NNS B-NP O
. . O O

Colchicine NN B-NP O
was VBD B-VP O
found VBN I-VP O
to TO I-VP O
be VB I-VP O
excreted VBN I-VP O
in IN B-PP O
breast NN B-NP O
milk NN I-NP O
. . O O

Its PRP$ B-NP O
levels NNS I-NP O
ranged VBD B-VP O
between IN B-PP O
1 CD B-NP O
. . O O

9 CD B-NP O
and CC I-NP O
8 CD I-NP O
. . O O

6 CD B-NP O
ng NN I-NP O
/ SYM I-NP O
ml NN I-NP O
, , O O
which WDT B-NP O
were VBD B-VP O
similar JJ B-ADJP O
to TO B-PP O
those DT B-NP O
found VBN B-VP O
in IN B-PP O
the DT B-NP O
serum NN I-NP O
( ( O O
parallel JJ B-NP O
concentration NN I-NP O
time NN I-NP O
curves NNS I-NP O
) ) O O
. . O O

However RB B-ADVP O
, , O O
there EX B-NP O
appeared VBD B-VP O
to TO I-VP O
be VB I-VP O
a DT B-NP O
considerable JJ I-NP O
variation NN I-NP O
in IN B-PP O
colchicine NN B-NP O
milk NN I-NP O
concentration NN I-NP O
among IN B-PP O
the DT B-NP O
different JJ I-NP O
patients NNS I-NP O
, , O O
which WDT B-NP O
might MD B-VP O
be VB I-VP O
related JJ B-ADJP O
to TO B-PP O
individual JJ B-NP O
breast NN I-NP O
milk NN I-NP O
composition NN I-NP O
and CC O O
, , O O
possibly RB B-ADVP O
, , O O
to TO B-PP O
other JJ B-NP O
nutritional JJ I-NP O
or CC I-NP O
metabolic JJ I-NP O
factors NNS I-NP O
. . O O

CONCLUSION NN B-NP O
. . O O

The DT B-NP O
extensive JJ I-NP O
peripheral JJ I-NP O
tissue NN I-NP O
binding NN I-NP O
and CC O O
relatively RB B-NP O
low JJ I-NP O
concentration NN I-NP O
of IN B-PP O
colchicine NN B-NP O
in IN B-PP O
breast NN B-NP O
milk NN I-NP O
suggests VBZ B-VP O
that IN B-SBAR O
the DT B-NP O
amount NN I-NP O
ingested VBN B-VP O
by IN B-PP O
the DT B-NP O
infant NN I-NP O
is VBZ B-VP O
small JJ B-ADJP O
. . O O

Furthermore RB B-ADVP O
, , O O
based VBN B-PP O
on IN B-PP O
our PRP$ B-NP O
clinical JJ I-NP O
experience NN I-NP O
, , O O
nursing NN B-NP O
appears VBZ B-VP O
to TO I-VP O
be VB I-VP O
safe JJ B-ADJP O
for IN B-PP O
lactating VBG B-VP O
women NNS B-NP O
with IN B-PP O
FMF NNP B-NP B-Disease
who WP B-NP O
continue VBP B-VP O
to TO I-VP O
take VB I-VP O
colchicine NN B-NP O
. . O O

Abnormal JJ B-NP O
myotonic JJ I-NP B-Disease
dystrophy NN I-NP I-Disease
protein NN I-NP O
kinase NN I-NP O
levels NNS I-NP O
produce VBP B-VP O
only RB B-NP O
mild JJ I-NP O
myopathy NN I-NP B-Disease
in IN B-PP O
mice NNS B-NP O
. . O O

Myotonic JJ B-NP B-Disease
dystrophy NN I-NP I-Disease
( ( O O
DM NN B-NP B-Disease
) ) O O
is VBZ B-VP O
commonly RB I-VP O
associated VBN I-VP O
with IN B-PP O
CTG NN B-NP O
repeat NN I-NP O
expansions NNS I-NP O
within IN B-PP O
the DT B-NP O
gene NN I-NP O
for IN B-PP O
DM NN B-NP O
- HYPH O O
protein NN B-NP O
kinase NN I-NP O
( ( O O
DMPK NN B-NP O
) ) O O
. . O O

The DT B-NP O
effect NN I-NP O
of IN B-PP O
altered VBN B-NP O
expression NN I-NP O
levels NNS I-NP O
of IN B-PP O
DMPK NN B-NP O
, , O O
which WDT B-NP O
is VBZ B-VP O
ubiquitously RB I-VP O
expressed VBN I-VP O
in IN B-PP O
all DT B-NP O
muscle NN I-NP O
cell NN I-NP O
lineages NNS I-NP O
during IN B-PP O
development NN B-NP O
, , O O
was VBD B-VP O
examined VBN I-VP O
by IN B-PP O
disrupting VBG B-VP O
the DT B-NP O
endogenous JJ I-NP O
Dmpk NN I-NP O
gene NN I-NP O
and CC O O
overexpressing VBG B-VP O
a DT B-NP O
normal JJ I-NP O
human JJ I-NP O
DMPK NN I-NP O
transgene NN I-NP O
in IN B-PP O
mice NNS B-NP O
. . O O

Nullizygous JJ B-ADJP O
( ( O O
- SYM O O
/ SYM O O
- SYM O O
) ) O O
mice NNS B-NP O
showed VBD B-VP O
only RB B-NP O
inconsistent JJ I-NP O
and CC I-NP O
minor JJ I-NP O
size NN I-NP O
changes NNS I-NP O
in IN B-PP O
head NN B-NP O
and CC I-NP O
neck NN I-NP O
muscle NN I-NP O
fibres NNS I-NP O
at IN B-PP O
older JJR B-NP O
age NN I-NP O
, , O O
animals NNS B-NP O
with IN B-PP O
the DT B-NP O
highest JJS I-NP O
DMPK NN I-NP O
transgene NN I-NP O
expression NN I-NP O
showed VBD B-VP O
hypertrophic JJ B-NP B-Disease
cardiomyopathy NN I-NP I-Disease
and CC O O
enhanced VBD B-VP O
neonatal JJ B-NP O
mortality NN I-NP O
. . O O

However RB B-ADVP O
, , O O
both DT B-NP O
models NNS I-NP O
lack VBP B-VP O
other JJ B-NP O
frequent JJ I-NP O
DM NN I-NP B-Disease
symptoms NNS I-NP O
including VBG B-PP O
the DT B-NP O
fibre NN I-NP O
- HYPH I-NP O
type NN I-NP O
dependent JJ I-NP O
atrophy NN I-NP B-Disease
, , O O
myotonia NN B-NP B-Disease
, , O O
cataract NN B-NP B-Disease
and CC O O
male JJ B-NP B-Disease
- HYPH I-NP I-Disease
infertility NN I-NP I-Disease
. . O O

These DT B-NP O
results NNS I-NP O
strengthen VBP B-VP O
the DT B-NP O
contention NN I-NP O
that IN B-SBAR O
simple JJ B-NP O
loss NN I-NP O
- HYPH B-NP O
or CC I-NP O
gain NN I-NP O
- HYPH B-NP O
of IN B-PP O
- HYPH B-NP O
expression NN I-NP O
of IN B-PP O
DMPK NN B-NP O
is VBZ B-VP O
not RB O O
the DT B-NP O
only JJ I-NP O
crucial JJ I-NP O
requirement NN I-NP O
for IN B-PP O
development NN B-NP O
of IN B-PP O
the DT B-NP O
disease NN I-NP O
. . O O

. . O O

Mice NNS B-NP O
lacking VBG B-VP O
the DT B-NP O
myotonic JJ I-NP B-Disease
dystrophy NN I-NP I-Disease
protein NN I-NP O
kinase NN I-NP O
develop VBP B-VP O
a DT B-NP O
late JJ I-NP O
onset NN I-NP O
progressive JJ I-NP O
myopathy NN I-NP B-Disease
. . O O

Myotonic JJ B-NP B-Disease
dystrophy NN I-NP I-Disease
( ( O O
DM NN B-NP B-Disease
) ) O O
is VBZ B-VP O
an DT B-NP O
autosomal JJ I-NP B-Disease
dominant JJ I-NP I-Disease
disorder NN I-NP I-Disease
resulting VBG B-VP O
from IN B-PP O
the DT B-NP O
expansion NN I-NP O
of IN B-PP O
a DT B-NP O
CTG NN I-NP O
repeat NN I-NP O
in IN B-PP O
the DT B-NP O
3 CD I-NP O
untranslated JJ I-NP O
region NN I-NP O
of IN B-PP O
a DT B-NP O
putative JJ I-NP O
protein NN I-NP O
kinase NN I-NP O
( ( O O
DMPK NN B-NP O
) ) O O
. . O O

To TO B-VP O
elucidate VB I-VP O
the DT B-NP O
role NN I-NP O
of IN B-PP O
DMPK NN B-NP O
in IN B-PP O
DM NN B-NP B-Disease
pathogenesis NN I-NP O
we PRP B-NP O
have VBP B-VP O
developed VBN I-VP O
Dmpk NN B-NP B-Disease
deficient JJ I-NP I-Disease
( ( O O
Dmpk NN B-NP O
- HYPH O O
/ SYM O O
- SYM O O
) ) O O
mice NNS B-NP O
. . O O

Dmpk NN B-NP O
- HYPH O O
/ SYM O O
- HYPH O O
mice NNS B-NP O
develop VBP B-VP O
a DT B-NP O
late JJ I-NP O
- HYPH I-NP O
onset NN I-NP O
, , O O
progressive JJ B-NP B-Disease
skeletal JJ I-NP I-Disease
myopathy NN I-NP I-Disease
that WDT B-NP O
shares VBZ B-VP O
some DT B-NP O
pathological JJ I-NP O
features NNS I-NP O
with IN B-PP O
DM NN B-NP B-Disease
. . O O

Muscles NNS B-NP O
from IN B-PP O
mature JJ B-NP O
mice NNS I-NP O
show VBP B-VP O
variation NN B-NP O
in IN B-PP O
fibre NN B-NP O
size NN I-NP O
, , O O
increased VBD B-VP O
fibre NN B-NP B-Disease
degeneration NN I-NP I-Disease
and CC I-NP O
fibrosis NN I-NP B-Disease
. . O O

Adult JJ B-NP O
Dmpk NN I-NP O
- HYPH O O
/ SYM O O
- HYPH O O
mice NNS B-NP O
show VBP B-VP O
ultrastructural JJ B-NP O
changes NNS I-NP O
in IN B-PP O
muscle NN B-NP O
and CC O O
a DT B-NP O
50 CD I-NP O
% NN I-NP O
decrease NN I-NP O
in IN B-PP O
force NN B-NP O
generation NN I-NP O
compared VBN B-VP O
to TO B-PP O
young JJ B-NP O
mice NNS I-NP O
. . O O

Our PRP$ B-NP O
results NNS I-NP O
indicate VBP B-VP O
that IN B-SBAR O
DMPK NN B-NP O
may MD B-VP O
be VB I-VP O
necessary JJ B-ADJP O
for IN B-PP O
the DT B-NP O
maintenance NN I-NP O
of IN B-PP O
skeletal JJ B-NP O
muscle NN I-NP O
structure NN I-NP O
and CC I-NP O
function NN I-NP O
and CC O O
suggest VBP B-VP O
that IN B-SBAR O
a DT B-NP O
decrease NN I-NP O
in IN B-PP O
DMPK NN B-NP O
levels NNS I-NP O
may MD B-VP O
contribute VB I-VP O
to TO B-PP O
DM NN B-NP B-Disease
pathology NN I-NP O
. . O O

. . O O

The DT B-NP O
tumor NN I-NP B-Disease
suppressor NN I-NP O
gene NN I-NP O
Brca1 NN I-NP O
is VBZ B-VP O
required VBN I-VP O
for IN B-PP O
embryonic JJ B-NP O
cellular JJ I-NP O
proliferation NN I-NP O
in IN B-PP O
the DT B-NP O
mouse NN I-NP O
. . O O

Mutations NNS B-NP O
of IN B-PP O
the DT B-NP O
BRCA1 NN I-NP O
gone VBN B-VP O
in IN B-PP O
humans NNS B-NP O
are VBP B-VP O
associated VBN I-VP O
with IN B-PP O
predisposition NN B-NP O
to TO B-PP O
breast NN B-NP B-Disease
and CC O I-Disease
ovarian JJ B-NP I-Disease
cancers NNS I-NP I-Disease
. . O O

We PRP B-NP O
show VBP B-VP O
here RB B-ADVP O
that IN B-SBAR O
Brca1 NN B-NP O
+ SYM O O
/ SYM O O
- HYPH O O
mice NNS B-NP O
are VBP B-VP O
normal JJ B-NP O
and CC I-NP O
fertile JJ I-NP O
and CC I-NP O
lack JJ I-NP O
tumors NNS I-NP B-Disease
by IN B-PP O
age NN B-NP O
eleven CD B-NP O
months NNS I-NP O
. . O O

Homozygous JJ B-NP O
Brca1 NN I-NP O
( ( O O
5 CD B-NP O
- HYPH I-NP O
6 CD I-NP O
) ) O O
mutant JJ B-NP O
mice NNS I-NP O
die VBP B-VP O
before IN B-SBAR O
day NN B-NP O
7 CD I-NP O
. . O O

5 CD B-NP O
of IN B-PP O
embryogenesis NN B-NP O
. . O O

Mutant JJ B-NP O
embryos NNS I-NP O
are VBP B-VP O
poorly RB I-VP O
developed VBN I-VP O
, , O O
with IN B-PP O
no DT B-NP O
evidence NN I-NP O
of IN B-PP O
mesoderm NN B-NP O
formation NN I-NP O
. . O O

The DT B-NP O
extraembryonic JJ I-NP O
region NN I-NP O
is VBZ B-VP O
abnormal JJ B-ADJP O
, , O O
but CC O O
aggregation NN B-NP O
with IN B-PP O
wild JJ B-NP O
- HYPH I-NP O
type NN I-NP O
tetraploid JJ I-NP O
embryos NNS I-NP O
does VBZ B-VP O
not RB I-VP O
rescue VB I-VP O
the DT B-NP O
lethality NN I-NP O
. . O O

In FW B-ADVP O
vivo FW I-ADVP O
, , O O
mutant JJ B-NP O
embryos NNS I-NP O
do VBP B-VP O
not RB I-VP O
exhibit VB I-VP O
increased VBN B-NP O
apoptosis NN I-NP O
but CC O O
show VBP B-VP O
reduced VBN I-VP O
cell NN B-NP O
proliferation NN I-NP O
accompanied VBN B-VP O
by IN B-PP O
decreased VBN B-NP O
expression NN I-NP O
of IN B-PP O
cyclin NN B-NP O
E NN I-NP O
and CC I-NP O
mdm NN I-NP O
- HYPH O O
2 CD B-NP O
, , O O
a DT B-NP O
regulator NN I-NP O
of IN B-PP O
p53 NN B-NP O
activity NN I-NP O
. . O O

The DT B-NP O
expression NN I-NP O
of IN B-PP O
cyclin NN B-NP O
- HYPH B-NP O
dependent JJ I-NP O
kinase NN I-NP O
inhibitor NN I-NP O
p21 NN I-NP O
is VBZ B-VP O
dramatically RB I-VP O
increased VBN I-VP O
in IN B-PP O
the DT B-NP O
mutant JJ I-NP O
embryos NNS I-NP O
. . O O

Buttressing VBG B-VP O
these DT B-NP O
in FW I-NP O
vivo FW I-NP O
observations NNS I-NP O
is VBZ B-VP O
the DT B-NP O
fact NN I-NP O
that IN B-SBAR O
mutant JJ B-NP O
blastocyst JJ I-NP O
growth NN I-NP O
is VBZ B-VP O
grossly RB B-ADJP O
impaired JJ I-ADJP O
in FW B-ADJP O
vitro FW I-ADJP O
. . O O

Thus RB B-ADVP O
, , O O
the DT B-NP O
death NN I-NP O
of IN B-PP O
Brca1 NN B-NP O
( ( O O
5 CD B-NP O
- HYPH I-NP O
6 CD I-NP O
) ) O O
mutant JJ B-NP O
embryos NNS I-NP O
prior RB B-ADVP O
to TO B-PP O
gastrulation NN B-NP O
may MD B-VP O
be VB I-VP O
due JJ B-ADVP O
to TO B-PP O
a DT B-NP O
failure NN I-NP O
of IN B-PP O
the DT B-NP O
proliferative JJ I-NP O
burst NN I-NP O
required VBN B-VP O
for IN B-PP O
the DT B-NP O
development NN I-NP O
of IN B-PP O
the DT B-NP O
different JJ I-NP O
germ NN I-NP O
layers NNS I-NP O
. . O O

Increased VBN B-NP O
coronary JJ I-NP B-Disease
heart NN I-NP I-Disease
disease NN I-NP I-Disease
in IN B-PP O
Japanese JJ B-NP O
- HYPH I-NP O
American JJ I-NP O
men NNS I-NP O
with IN B-PP O
mutation NN B-NP O
in IN B-PP O
the DT B-NP O
cholesteryl NN I-NP O
ester NN I-NP O
transfer NN I-NP O
protein NN I-NP O
gene NN I-NP O
despite IN B-PP O
increased VBN B-NP O
HDL NN I-NP O
levels NNS I-NP O
. . O O

Plasma NN B-NP O
high JJ I-NP O
density NN I-NP O
lipoprotein NN I-NP O
( ( O O
HDL NN B-NP O
) ) O O
levels NNS B-NP O
are VBP B-VP O
strongly RB I-VP O
genetically RB I-VP O
determined VBN I-VP O
and CC O O
show VBP B-VP O
a DT B-NP O
general JJ I-NP O
inverse JJ I-NP O
relationship NN I-NP O
with IN B-PP O
coronary JJ B-NP B-Disease
heart NN I-NP I-Disease
disease NN I-NP I-Disease
( ( O O
CHD NN B-NP B-Disease
) ) O O
. . O O

The DT B-NP O
cholesteryl NN I-NP O
ester NN I-NP O
transfer NN I-NP O
protein NN I-NP O
( ( O O
CETP NN B-NP O
) ) O O
mediates VBZ B-VP O
the DT B-NP O
transfer NN I-NP O
of IN B-PP O
cholesteryl NN B-NP O
esters NNS I-NP O
from IN B-PP O
HDL NN B-NP O
to TO B-PP O
other JJ B-NP O
lipoproteins NNS I-NP O
and CC O O
is VBZ B-VP O
a DT B-NP O
key JJ I-NP O
participant NN I-NP O
in IN B-PP O
the DT B-NP O
reverse JJ I-NP O
transport NN I-NP O
of IN B-PP O
cholesterol NN B-NP O
from IN B-PP O
the DT B-NP O
periphery NN I-NP O
to TO B-PP O
the DT B-NP O
liver NN I-NP O
. . O O

A DT B-NP O
high JJ I-NP O
prevalence NN I-NP O
of IN B-PP O
two CD B-NP O
different JJ I-NP O
CETP NN I-NP O
gene NN I-NP O
mutations NNS I-NP O
( ( O O
D442G NN B-NP O
, , O O
5 CD B-NP O
. . O O

1 CD B-NP O
% NN I-NP O
; : O O
intron NN B-NP O
14G NN I-NP O
A NN I-NP O
, , O O
0 CD B-NP O
. . O O

5 CD B-NP O
% NN I-NP O
) ) O O
, , O O
was VBD B-VP O
found VBN I-VP O
in IN B-PP O
3 CD B-NP O
, , O O
469 CD B-NP O
men NNS I-NP O
of IN B-PP O
Japanese JJ B-NP O
ancestry NN I-NP O
in IN B-PP O
the DT B-NP O
Honolulu NNP I-NP O
Heart NNP I-NP O
Program NNP I-NP O
and CC O O
mutations NNS B-NP O
were VBD B-VP O
associated VBN I-VP O
with IN B-PP O
decreased VBN B-NP O
CETP NN I-NP O
( ( O O
- SYM B-NP O
35 CD B-NP O
% NN I-NP O
) ) O O
and CC O O
increased VBD B-VP O
HDL NN B-NP O
chol NN I-NP O
levels NNS I-NP O
( ( O O
+ SYM B-NP O
10 CD B-NP O
% NN I-NP O
for IN B-PP O
D442G NN B-NP O
) ) O O
. . O O

However RB B-ADVP O
, , O O
the DT B-NP O
overall JJ I-NP O
prevalence NN I-NP O
of IN B-PP O
definite JJ B-NP O
CHD NN I-NP B-Disease
was VBD B-VP O
21 CD B-NP O
% NN I-NP O
in IN B-PP O
men NNS B-NP O
with IN B-PP O
mutations NNS B-NP O
and CC O O
16 CD B-NP O
% NN I-NP O
in IN B-PP O
men NNS B-NP O
without IN B-PP O
mutations NNS B-NP O
. . O O

The DT B-NP O
relative JJ I-NP O
risk NN I-NP O
( ( O O
RR NN B-NP O
) ) O O
of IN B-PP O
CHD NN B-NP B-Disease
was VBD B-VP O
1 CD B-NP O
. . O O

43 CD B-NP O
in IN B-PP O
men NNS B-NP O
with IN B-PP O
mutations NNS B-NP O
( ( O O
P NN B-NP O
< SYM B-ADJP O
. . O O

05 CD B-NP O
) ) O O
; : O O
after IN B-PP O
adjustment NN B-NP O
for IN B-PP O
CHD NN B-NP B-Disease
risk NN I-NP O
factors NNS I-NP O
, , O O
the DT B-NP O
RR NN I-NP O
was VBD B-VP O
1 CD B-NP O
. . O O

55 CD B-NP O
( ( O O
P NN B-NP O
= SYM B-VP O
. . O O

02 CD B-NP O
) ) O O
; : O O
after IN B-PP O
additional JJ B-NP O
adjustment NN I-NP O
for IN B-PP O
HDL NN B-NP O
levels NNS I-NP O
, , O O
the DT B-NP O
RR NN I-NP O
was VBD B-VP O
1 CD B-NP O
. . O O

68 CD B-NP O
( ( O O
P NN B-NP O
= SYM B-VP O
. . B-NP O

008 CD I-NP O
) ) O O
. . O O

Similar JJ B-NP O
RR NN I-NP O
values NNS I-NP O
were VBD B-VP O
obtained VBN I-VP O
for IN B-PP O
the DT B-NP O
D442G NN I-NP O
mutation NN I-NP O
alone RB B-ADVP O
. . O O

Increased VBN B-NP O
CHD NN I-NP B-Disease
in IN B-PP O
men NNS B-NP O
with IN B-PP O
mutations NNS B-NP O
was VBD B-VP O
primarily RB I-VP O
observed VBN I-VP O
for IN B-PP O
HDL NN B-NP O
chol NN I-NP O
41 CD I-NP O
- HYPH I-NP O
60 CD I-NP O
mg NN I-NP O
/ SYM B-NP O
dl NN I-NP O
; : O O
for IN B-PP O
HDL NN B-NP O
chol NN I-NP O
> SYM B-NP O
60 CD B-NP O
mg NN I-NP O
/ SYM B-NP O
dl NN B-NP O
men NNS I-NP O
with IN B-PP O
and CC I-PP O
without IN I-PP O
mutations NNS B-NP O
had VBD B-VP O
low JJ B-NP O
CHD NN I-NP B-Disease
prevalence NN I-NP O
. . O O

Thus RB B-ADVP O
, , O O
genetic JJ B-NP O
CETP NN I-NP B-Disease
deficiency NN I-NP I-Disease
appears VBZ B-VP O
to TO I-VP O
be VB I-VP O
an DT B-NP O
independent JJ I-NP O
risk NN I-NP O
factor NN I-NP O
for IN B-PP O
CHD NN B-NP B-Disease
, , O O
primarily RB B-ADVP O
due JJ B-PP O
to TO B-PP O
increased VBN B-NP O
CHD NN I-NP B-Disease
prevalence NN I-NP O
in IN B-PP O
men NNS B-NP O
with IN B-PP O
the DT B-NP O
D442G NN I-NP O
mutation NN I-NP O
and CC O O
HDL NN B-NP O
cholesterol NN I-NP O
between IN B-PP O
41 CD B-NP O
and CC I-NP O
60 CD I-NP O
mg NN I-NP O
/ SYM B-NP O
dl NN I-NP O
. . O O

The DT B-NP O
findings NNS I-NP O
suggest VBP B-VP O
that IN B-SBAR O
both CC O O
HDL NN B-NP O
concentration NN I-NP O
and CC O O
the DT B-NP O
dynamics NNS I-NP O
of IN B-PP O
cholesterol NN B-NP O
transport NN I-NP O
through IN B-PP O
HDL NN B-NP O
( ( O O
i NN B-NP O
. . I-NP O

e NN I-NP O
. . O O

, , O O
reverse JJ B-NP O
cholesterol NN I-NP O
transport NN I-NP O
) ) O O
determine VBP B-VP O
the DT B-NP O
anti AFX I-NP O
- HYPH I-NP O
atherogenicity NN I-NP O
of IN B-PP O
the DT B-NP O
HDL NN I-NP O
fraction NN I-NP O
. . O O

Mapping VBG B-VP O
the DT B-NP O
homolog NN I-NP O
of IN B-PP O
the DT B-NP O
human JJ I-NP O
Rb1 NN I-NP O
gene NN I-NP O
to TO B-PP O
chromosome NN B-NP O
14 CD I-NP O
of IN B-PP O
higher JJR B-NP O
primates NNS I-NP O
. . O O

The DT B-NP O
Rb1 NN I-NP O
gene NN I-NP O
has VBZ B-VP O
been VBN I-VP O
implicated VBN I-VP O
with IN B-PP O
retinoblastoma NN B-NP B-Disease
and CC O O
is VBZ B-VP O
located JJ B-ADJP O
on IN B-PP O
human JJ B-NP O
Chromosome NN I-NP O
( ( O O
Chr NN B-NP O
) ) O O
13q14 CD B-NP O
. . O O

2 CD B-NP O
2 CD I-NP O
. . O O

A DT B-NP O
unique JJ I-NP O
sequence NN I-NP O
human JJ I-NP O
Rb1 NN I-NP O
cosmid NN I-NP O
DNA NN I-NP O
probe NN I-NP O
has VBZ B-VP O
been VBN I-VP O
used VBN I-VP O
to TO I-VP O
localize VB I-VP O
this DT B-NP O
region NN I-NP O
on IN B-PP O
apes NNS B-NP O
Chr NN B-NP O
14 CD I-NP O
by IN B-PP O
the DT B-NP O
FISH NN I-NP O
technique NN I-NP O
. . O O

The DT B-NP O
conservation NN I-NP O
of IN B-PP O
the DT B-NP O
Rb1 NN I-NP O
gene NN I-NP O
in IN B-PP O
higher JJR B-NP O
primates NNS I-NP O
at IN B-PP O
the DT B-NP O
corresponding VBG I-NP O
equivalent JJ I-NP O
chromosome NN I-NP O
locus NN I-NP O
( ( O O
14q14 CD B-NP O
) ) O O
of IN B-PP O
the DT B-NP O
human NN I-NP O
may MD B-VP O
serve VB I-VP O
as IN B-PP O
a DT B-NP O
phylogenetic JJ I-NP O
marker NN I-NP O
to TO B-VP O
further RB I-VP O
trace VB I-VP O
the DT B-NP O
evolutionary JJ I-NP O
pathway NN I-NP O
of IN B-PP O
human JJ B-NP O
descent NN I-NP O
. . O O

Wiskott NNP B-NP B-Disease
- HYPH I-NP I-Disease
Aldrich NNP I-NP I-Disease
syndrome NN I-NP I-Disease
: : O O
no DT B-NP O
strict JJ I-NP O
genotype NN I-NP O
- HYPH I-NP O
phenotype NN I-NP O
correlations NNS I-NP O
but CC O O
clustering VBG B-VP O
of IN B-PP O
missense JJ B-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
amino JJ I-NP O
- HYPH I-NP O
terminal JJ I-NP O
part NN I-NP O
of IN B-PP O
the DT B-NP O
WASP NN I-NP O
gene NN I-NP O
product NN I-NP O
. . O O

The DT B-NP O
Wiskott NNP I-NP B-Disease
- HYPH I-NP I-Disease
Aldrich NNP I-NP I-Disease
syndrome NN I-NP I-Disease
protein NN I-NP O
( ( O O
WASP NN B-NP O
) ) O O
gene NN B-NP O
was VBD B-VP O
found VBN I-VP O
to TO I-VP O
be VB I-VP O
mutated VBN I-VP O
in IN B-PP O
patients NNS B-NP O
presenting VBG B-VP O
with IN B-PP O
WAS NN B-NP B-Disease
and CC B-PP O
in IN B-PP O
patients NNS B-NP O
showing VBG B-VP O
X NN B-NP B-Disease
- HYPH O I-Disease
linked VBN B-NP I-Disease
thrombocytopenia NN I-NP I-Disease
. . O O

Mutation NN B-NP O
analysis NN I-NP O
in IN B-PP O
19 CD B-NP O
families NNS I-NP O
of IN B-PP O
German JJ B-NP O
, , I-NP O
Swiss JJ I-NP O
and CC I-NP O
Turkish JJ I-NP O
descent NN I-NP O
by IN B-PP O
single JJ B-NP O
- HYPH I-NP O
strand NN I-NP O
conformation NN I-NP O
polymorphism NN I-NP O
and CC I-NP O
sequencing NN I-NP O
resulted VBD B-VP O
in IN B-PP O
the DT B-NP O
detection NN I-NP O
of IN B-PP O
seven CD B-NP O
novel JJ I-NP O
and CC I-NP O
10 CD I-NP O
known VBN I-NP O
mutations NNS I-NP O
. . O O

A DT B-NP O
striking JJ I-NP O
clustering NN I-NP O
of IN B-PP O
missense JJ B-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
first JJ I-NP O
four CD I-NP O
exons NNS I-NP O
contrasted VBN B-VP O
with IN B-PP O
a DT B-NP O
random JJ I-NP O
distribution NN I-NP O
of IN B-PP O
nonsense JJ B-NP O
mutations NNS I-NP O
. . O O

More JJR B-NP O
than IN I-NP O
85 CD I-NP O
% NN I-NP O
of IN B-PP O
all DT B-NP O
known VBN I-NP O
missense NN I-NP O
mutations NNS I-NP O
were VBD B-VP O
localized VBN I-VP O
in IN B-PP O
the DT B-NP O
amino JJ I-NP O
- HYPH I-NP O
terminal JJ I-NP O
stretch NN I-NP O
of IN B-PP O
the DT B-NP O
WASP NN I-NP O
gene NN I-NP O
product NN I-NP O
; : O O
this DT B-NP O
region NN I-NP O
contained VBD B-VP O
a DT B-NP O
mutational JJ I-NP O
hot JJ I-NP O
spot NN I-NP O
at IN B-PP O
codon NN B-NP O
86 CD I-NP O
. . O O

No DT B-NP O
genotype NN I-NP O
- HYPH B-NP O
phenotype NN I-NP O
correlation NN I-NP O
emerged VBD B-VP O
after IN B-PP O
a DT B-NP O
comparison NN I-NP O
of IN B-PP O
the DT B-NP O
identified VBN I-NP O
mutations NNS I-NP O
with IN B-PP O
the DT B-NP O
resulting VBG I-NP O
clinical JJ I-NP O
picture NN I-NP O
for IN B-PP O
a DT B-NP O
classical JJ I-NP O
WAS NN I-NP B-Disease
phenotype NN I-NP O
. . O O

A DT B-NP O
substitution NN I-NP O
at IN B-PP O
codon NN B-NP O
86 CD I-NP O
resulted VBD B-VP O
in IN B-PP O
an DT B-NP O
extremely RB I-NP O
variable JJ I-NP O
expression NN I-NP O
of IN B-PP O
the DT B-NP O
disease NN I-NP O
in IN B-PP O
a DT B-NP O
large JJ I-NP O
Swiss JJ I-NP O
family NN I-NP O
. . O O

An DT B-NP O
extended VBN I-NP O
homology NN I-NP O
search NN I-NP O
revealed VBD B-VP O
a DT B-NP O
distant JJ I-NP O
relationship NN I-NP O
of IN B-PP O
this DT B-NP O
stretch NN I-NP O
to TO B-PP O
the DT B-NP O
vasodilator NN I-NP O
- HYPH O O
stimulated VBN B-VP O
phosphoprotein NN B-NP O
( ( O O
VASP NN B-NP O
) ) O O
, , O O
which WDT B-NP O
is VBZ B-VP O
involved VBN I-VP O
in IN B-PP O
the DT B-NP O
maintenance NN I-NP O
of IN B-PP O
cyto AFX B-NP O
- HYPH I-NP O
architecture NN I-NP O
by IN B-PP O
interacting VBG B-VP O
with IN B-PP O
actin NN B-NP O
- HYPH B-NP O
like JJ I-NP O
filaments NNS I-NP O
. . O O

. . O O

Influence NN B-NP O
of IN B-PP O
PAX6 NN B-NP O
gene NN I-NP O
dosage NN I-NP O
on IN B-PP O
development NN B-NP O
: : O O
overexpression NN B-NP O
causes VBZ B-VP O
severe JJ B-NP O
eye NN I-NP B-Disease
abnormalities NNS I-NP I-Disease
. . O O

Aniridia NN B-NP B-Disease
in IN B-PP O
man NN B-NP O
and CC O O
Small JJ B-NP O
eye NN I-NP O
in IN B-PP O
mice NNS B-NP O
are VBP B-VP O
semidominant JJ B-NP B-Disease
developmental JJ I-NP I-Disease
disorders NNS I-NP I-Disease
caused VBN B-VP O
by IN B-PP O
mutations NNS B-NP O
within IN B-PP O
the DT B-NP O
paired JJ I-NP O
box NN I-NP O
gene NN I-NP O
PAX6 NN I-NP O
. . O O

Whereas IN B-SBAR O
heterozygotes NNS B-NP O
suffer VBP B-VP O
from IN B-PP O
iris NN B-NP B-Disease
hypoplasia NN I-NP I-Disease
, , O O
homozygous JJ B-NP O
mice NNS I-NP O
lack VBP B-VP O
eyes NNS B-NP O
and CC O O
nasal JJ B-NP O
cavities NNS I-NP O
and CC O O
exhibit VBP B-VP O
brain NN B-NP B-Disease
abnormalities NNS I-NP I-Disease
. . O O

To TO B-VP O
investigate VB I-VP O
the DT B-NP O
role NN I-NP O
of IN B-PP O
gene NN B-NP O
dosage NN I-NP O
in IN B-PP O
more JJR B-NP O
detail NN I-NP O
, , O O
we PRP B-NP O
have VBP B-VP O
generated VBN I-VP O
yeast NN B-NP O
artificial JJ I-NP O
chromosome NN I-NP O
transgenic JJ I-NP O
mice NNS I-NP O
carrying VBG B-VP O
the DT B-NP O
human JJ I-NP O
PAX6 NN I-NP O
locus NN I-NP O
. . O O

When WRB B-ADVP O
crossed VBN B-VP O
onto IN B-PP O
the DT B-NP O
Small JJ I-NP O
eye NN I-NP O
background NN I-NP O
, , O O
the DT B-NP O
transgene NN I-NP O
rescues VBZ B-VP O
the DT B-NP O
mutant JJ I-NP O
phenotype NN I-NP O
. . O O

Strikingly RB B-ADVP O
, , O O
mice NNS B-NP O
carrying VBG B-VP O
multiple JJ B-NP O
copies NNS I-NP O
on IN B-PP O
a DT B-NP O
wild JJ I-NP O
- HYPH I-NP O
type NN I-NP O
background NN I-NP O
show VBP B-VP O
specific JJ B-NP O
developmental JJ I-NP B-Disease
abnormalities NNS I-NP I-Disease
of IN B-PP I-Disease
the DT B-NP I-Disease
eye NN I-NP I-Disease
, , O O
but CC O O
not RB O O
of IN B-PP O
other JJ B-NP O
tissues NNS I-NP O
expressing VBG B-VP O
the DT B-NP O
gene NN I-NP O
. . O O

Thus RB B-ADVP O
, , O O
at IN B-NP O
least JJS I-NP O
five CD I-NP O
different JJ I-NP O
eye NN I-NP O
phenotypes NNS I-NP O
are VBP B-VP O
associated VBN I-VP O
with IN B-PP O
changes NNS B-NP O
in IN B-PP O
PAX6 NN B-NP O
expression NN I-NP O
. . O O

We PRP B-NP O
provide VBP B-VP O
evidence NN B-NP O
that IN B-SBAR O
not RB B-CONJP O
only RB I-CONJP O
reduced VBN B-VP O
, , O O
but CC B-CONJP O
also RB I-CONJP O
increased VBN B-NP O
levels NNS I-NP O
of IN B-PP O
transcriptional JJ B-NP O
regulators NNS I-NP O
can MD B-VP O
cause VB I-VP O
developmental JJ B-NP B-Disease
defects NNS I-NP I-Disease
. . O O

. . O O

Heterodimer NN B-NP O
formation NN I-NP O
and CC I-NP O
activity NN I-NP O
in IN B-PP O
the DT B-NP O
human JJ I-NP O
enzyme NN I-NP O
galactose NN I-NP O
- HYPH B-NP O
1 CD I-NP O
- HYPH I-NP O
phosphate NN I-NP O
uridylyltransferase NN I-NP O
. . O O

One CD B-NP O
of IN B-PP O
the DT B-NP O
fundamental JJ I-NP O
questions NNS I-NP O
concerning VBG B-VP O
expression NN B-NP O
and CC O O
function NN B-NP O
of IN B-PP O
dimeric JJ B-NP O
enzymes NNS I-NP O
involves VBZ B-VP O
the DT B-NP O
impact NN I-NP O
of IN B-PP O
naturally RB B-VP O
occurring VBG I-VP O
mutations NNS B-NP O
on IN B-PP O
subunit NN B-NP O
assembly NN I-NP O
and CC O O
heterodimer NN B-NP O
activity NN I-NP O
. . O O

This DT B-NP O
question NN I-NP O
is VBZ B-VP O
of IN B-PP O
particular JJ B-NP O
interest NN I-NP O
for IN B-PP O
the DT B-NP O
human JJ I-NP O
enzyme NN I-NP O
galactose NN I-NP O
- HYPH B-NP O
l NN I-NP O
- HYPH O O
phosphate NN B-NP O
uridylyl NN I-NP O
- HYPH O O
transferase NN B-NP O
( ( O O
GALT NN B-NP O
) ) O O
, , O O
impairment NN B-NP O
of IN B-PP O
which WDT B-NP O
results VBZ B-VP O
in IN B-PP O
the DT B-NP O
inherited VBN I-NP B-Disease
metabolic JJ I-NP I-Disease
disorder NN I-NP I-Disease
galactosemia NN I-NP B-Disease
, , O O
because IN B-SBAR O
many JJ B-NP O
if IN B-SBAR O
not RB O O
most JJS B-NP O
patients NNS I-NP O
studied VBN B-VP O
to TO B-PP O
date NN B-NP O
are VBP B-VP O
compound NN B-NP O
heterozygotes NNS I-NP O
rather RB B-PP O
than IN I-PP O
true JJ B-NP O
molecular JJ I-NP O
homozygotes NNS I-NP O
. . O O

Furthermore RB B-ADVP O
, , O O
the DT B-NP O
broad JJ I-NP O
range NN I-NP O
of IN B-PP O
phenotypic JJ B-NP O
severity NN I-NP O
observed VBN B-VP O
in IN B-PP O
these DT B-NP O
patients NNS I-NP O
raises VBZ B-VP O
the DT B-NP O
possibility NN I-NP O
that IN B-SBAR O
allelic JJ B-NP O
combination NN I-NP O
, , O O
not RB O O
just RB B-NP O
allelic JJ I-NP O
constitution NN I-NP O
, , O O
may MD B-VP O
play VB I-VP O
some DT B-NP O
role NN I-NP O
in IN B-PP O
determining VBG B-VP O
outcome NN B-NP O
. . O O

In IN B-PP O
the DT B-NP O
work NN I-NP O
described VBN B-VP O
herein RB B-ADVP O
, , O O
we PRP B-NP O
have VBP B-VP O
selected VBN I-VP O
two CD B-NP O
distinct JJ I-NP O
naturally RB B-VP O
occurring VBG I-VP O
mutations NNS I-NP O
of IN B-PP O
GALT NN B-NP O
, , I-NP O
Q188R NN I-NP O
and CC I-NP O
R333W NN I-NP O
, , O O
and CC O O
asked VBD B-VP O
the DT B-NP O
questions NNS I-NP O
( ( O O
i NNS B-NP O
) ) O O
what WP B-NP O
are VBP B-VP O
the DT B-NP O
impacts NNS I-NP O
of IN B-PP O
these DT B-NP O
mutations NNS I-NP O
on IN B-PP O
subunit NN B-NP O
assembly NN I-NP O
, , O O
and CC O O
( ( B-LST O
ii LS I-LST O
) ) O O
if IN B-SBAR O
heterodimers NNS B-NP O
do VBP B-VP O
form VB I-VP O
, , O O
are VBP B-VP O
they PRP B-NP O
active JJ B-ADJP O
? . O O

To TO B-VP O
answer VB I-VP O
these DT B-NP O
questions NNS I-NP O
, , O O
we PRP B-NP O
have VBP B-VP O
established VBN I-VP O
a DT B-NP O
yeast NN I-NP O
system NN I-NP O
for IN B-PP O
the DT B-NP O
coexpression NN I-NP O
of IN B-PP O
epitope NN B-NP O
- HYPH B-NP O
tagged VBN I-NP O
alleles NNS I-NP O
of IN B-PP O
human JJ B-NP O
GALT NN I-NP O
and CC O O
investigated VBD B-VP O
both CC O O
the DT B-NP O
extent NN I-NP O
of IN B-PP O
specific JJ B-NP O
GALT NN I-NP O
subunit NN I-NP O
interactions NNS I-NP O
and CC O O
the DT B-NP O
activity NN I-NP O
of IN B-PP O
defined VBN B-NP O
heterodimer NN I-NP O
pools NNS I-NP O
. . O O

We PRP B-NP O
have VBP B-VP O
found VBN I-VP O
that IN B-SBAR O
both CC O O
homodimers NNS B-NP O
and CC I-NP O
heterodimers NNS I-NP O
do VBP B-VP O
form VB I-VP O
involving VBG I-VP O
each DT B-NP O
of IN B-PP O
the DT B-NP O
mutant JJ I-NP O
subunits NNS I-NP O
tested VBN B-VP O
and CC O O
that IN B-SBAR O
both CC O O
heterodimer NN B-NP O
pools NNS I-NP O
retain VBP B-VP O
substantial JJ B-NP O
enzymatic JJ I-NP O
activity NN I-NP O
. . O O

These DT B-NP O
results NNS I-NP O
are VBP B-VP O
significant JJ B-ADJP O
not RB B-CONJP O
only RB I-CONJP O
in IN B-PP O
terms NNS B-NP O
of IN B-PP O
their PRP$ B-NP O
implications NNS I-NP O
for IN B-PP O
furthering VBG B-VP O
our PRP$ B-NP O
understanding NN I-NP O
of IN B-PP O
galactosemia NN B-NP B-Disease
and CC I-NP O
GALT NN I-NP O
holoenzyme NN I-NP O
structure NN I-NP O
- HYPH B-NP O
function NN I-NP O
relationships NNS I-NP O
but CC O O
also RB B-ADVP O
because IN B-SBAR O
the DT B-NP O
system NN I-NP O
described VBN B-VP O
may MD B-VP O
serve VB I-VP O
as IN B-PP O
a DT B-NP O
model NN I-NP O
for IN B-PP O
similar JJ B-NP O
studies NNS I-NP O
of IN B-PP O
other JJ B-NP O
complexes NNS I-NP O
composed VBN B-VP O
of IN B-PP O
multiple JJ B-NP O
subunits NNS I-NP O
. . O O

. . O O

Cleavage NN B-NP O
of IN B-PP O
huntingtin NN B-NP O
by IN B-PP O
apopain NN B-NP O
, , O O
a DT B-NP O
proapoptotic JJ I-NP O
cysteine NN I-NP O
protease NN I-NP O
, , O O
is VBZ B-VP O
modulated VBN I-VP O
by IN B-PP O
the DT B-NP O
polyglutamine NN I-NP O
tract NN I-NP O
. . O O

Apoptosis NN B-NP O
has VBZ B-VP O
recently RB I-VP O
been VBN I-VP O
recognized VBN I-VP O
as IN B-PP O
a DT B-NP O
mode NN I-NP O
of IN B-PP O
cell NN B-NP O
death NN I-NP O
in IN B-PP O
Huntington NNP B-NP B-Disease
disease NN I-NP I-Disease
( ( O O
HD NN B-NP B-Disease
) ) O O
. . O O

Apopain NNP B-NP O
, , O O
a DT B-NP O
human JJ I-NP O
counterpart NN I-NP O
of IN B-PP O
the DT B-NP O
nematode JJ I-NP O
cysteine NN I-NP O
protease NN I-NP O
death NN I-NP O
- HYPH B-NP O
gene NN I-NP O
product NN I-NP O
, , O O
CED VBN B-VP O
- HYPH B-NP O
3 CD I-NP O
, , O O
has VBZ B-VP O
a DT B-NP O
key JJ I-NP O
role NN I-NP O
in IN B-PP O
proteolytic JJ B-NP O
events NNS I-NP O
leading VBG B-VP O
to TO B-PP O
apoptosis NN B-NP O
. . O O

Here RB B-ADVP O
we PRP B-NP O
show VBP B-VP O
that IN B-SBAR O
apoptotic JJ B-NP O
extracts NNS I-NP O
and CC O O
apopain VB B-VP O
itself PRP B-NP O
specifically RB B-ADVP O
cleave VBP B-VP O
the DT B-NP O
HD NN I-NP B-Disease
gene NN I-NP O
product NN I-NP O
, , O O
huntingtin NN B-NP O
. . O O

The DT B-NP O
rate NN I-NP O
of IN B-PP O
cleavage NN B-NP O
increases VBZ B-VP O
with IN B-PP O
the DT B-NP O
length NN I-NP O
of IN B-PP O
the DT B-NP O
huntingtin NN I-NP O
polyglutamine NN I-NP O
tract NN I-NP O
, , O O
providing VBG B-VP O
an DT B-NP O
explanation NN I-NP O
for IN B-PP O
the DT B-NP O
gain NN I-NP O
- HYPH B-ADJP O
of IN B-PP O
- HYPH B-NP O
function NN I-NP O
associated VBN B-VP O
with IN B-PP O
CAG NN B-NP O
expansion NN I-NP O
. . O O

Our PRP$ B-NP O
results NNS I-NP O
show VBP B-VP O
that IN B-SBAR O
huntingtin NN B-NP O
is VBZ B-VP O
cleaved VBN I-VP O
by IN B-PP O
cysteine NN B-NP O
proteases NNS I-NP O
and CC O O
suggest VBP B-VP O
that IN B-SBAR O
HD NN B-NP B-Disease
might MD B-VP O
be VB I-VP O
a DT B-NP O
disorder NN I-NP B-Disease
of IN B-PP I-Disease
inappropriate JJ B-NP I-Disease
apoptosis NN I-NP I-Disease
. . O O

. . O O

The DT B-NP O
5 CD I-NP O
' SYM I-NP O
end NN I-NP O
of IN B-PP O
the DT B-NP O
BRCA1 NN I-NP O
gene NN I-NP O
lies VBZ B-VP O
within IN B-PP O
a DT B-NP O
duplicated JJ I-NP O
region NN I-NP O
of IN B-PP O
human JJ B-NP O
chromosome NN I-NP O
17q21 NN I-NP O
. . O O

To TO B-VP O
begin VB I-VP O
to TO I-VP O
address VB I-VP O
the DT B-NP O
hypothesis NN I-NP O
that IN B-SBAR O
abnormal JJ B-NP O
regulation NN I-NP O
of IN B-PP O
the DT B-NP O
breast NN I-NP B-Disease
/ SYM B-NP I-Disease
ovarian JJ I-NP I-Disease
cancer NN I-NP I-Disease
susceptibility NN I-NP O
gene NN I-NP O
BRCA1 NN I-NP O
is VBZ B-VP O
a DT B-NP O
critical JJ I-NP O
step NN I-NP O
in IN B-PP O
sporadic JJ B-NP O
breast NN I-NP O
/ SYM B-NP O
ovarian JJ I-NP O
tumorigenesis NN I-NP O
, , O O
we PRP B-NP O
have VBP B-VP O
determined VBN I-VP O
the DT B-NP O
detailed JJ I-NP O
structure NN I-NP O
of IN B-PP O
the DT B-NP O
BRCA1 NN I-NP O
genomic JJ I-NP O
region NN I-NP O
. . O O

We PRP B-NP O
show VBP B-VP O
that IN B-SBAR O
this DT B-NP O
region NN I-NP O
of IN B-PP O
the DT B-NP O
genome NN I-NP O
contains VBZ B-VP O
a DT B-NP O
tandem JJ I-NP O
duplication NN I-NP O
of IN B-PP O
approximately RB B-NP O
30 CD I-NP O
kilobases NNS I-NP O
, , O O
which WDT B-NP O
results VBZ B-VP O
in IN B-PP O
two CD B-NP O
copies NNS I-NP O
of IN B-PP O
BRCA1 NN B-NP O
exons NNS I-NP O
1 CD B-NP O
and CC I-NP O
2 CD I-NP O
, , O O
of IN B-PP O
exons NNS B-NP O
1 CD I-NP O
and CC I-NP O
3 CD I-NP O
of IN B-PP O
the DT B-NP O
adjacent JJ I-NP O
1A1 NN I-NP O
- HYPH B-NP O
3B NN I-NP O
gene NN I-NP O
and CC B-PP O
of IN B-PP O
the DT B-NP O
previously RB I-NP O
reported VBN I-NP O
295 CD I-NP O
base NN I-NP O
pair NN I-NP O
intergenic JJ I-NP O
region NN I-NP O
. . O O

Sequence NN B-NP O
analysis NN I-NP O
of IN B-PP O
the DT B-NP O
duplicated VBN I-NP O
exons NNS I-NP O
of IN B-PP O
BRCA1 NN B-NP O
and CC I-NP O
1A1 NN I-NP O
- HYPH B-NP O
3B NN I-NP O
and CC O O
flanking NN B-NP O
genomic JJ I-NP O
DNA NN I-NP O
reveals VBZ B-VP O
maintenance NN B-NP O
of IN B-PP O
the DT B-NP O
intron NN I-NP O
- HYPH B-NP O
exon NN I-NP O
structure NN I-NP O
and CC O O
a DT B-NP O
high JJ I-NP O
degree NN I-NP O
of IN B-PP O
nucleotide NN B-NP O
sequence NN I-NP O
identity NN I-NP O
, , O O
suggesting VBG B-VP O
that IN B-SBAR O
these DT B-NP O
are VBP B-VP O
non AFX O O
- HYPH O O
processed VBN B-NP O
pseudogenes NNS I-NP O
and CC O O
that IN B-SBAR O
the DT B-NP O
duplication NN I-NP O
is VBZ B-VP O
a DT B-NP O
recent JJ I-NP O
event NN I-NP O
in IN B-PP O
evolutionary JJ B-NP O
terms NNS I-NP O
. . O O

We PRP B-NP O
also RB B-ADVP O
show VBP B-VP O
that IN B-SBAR O
a DT B-NP O
processed VBN I-NP O
pseudogene NN I-NP O
of IN B-PP O
the DT B-NP O
acidic JJ I-NP O
ribosomal JJ I-NP O
phosphoprotein NN I-NP O
P1 NN I-NP O
( ( O O
ARPP1 NN B-NP O
) ) O O
is VBZ B-VP O
inserted VBN I-VP O
directly RB B-ADVP O
upstream RB B-ADVP O
of IN B-PP O
pseudo AFX B-NP O
- HYPH I-NP O
BRCA1 NN I-NP O
exon NN I-NP O
1A NN I-NP O
. . O O

We PRP B-NP O
believe VBP B-VP O
that IN B-SBAR O
these DT B-NP O
findings NNS I-NP O
could MD B-VP O
not RB I-VP O
only RB I-VP O
confound VB I-VP O
BRCA1 NN B-NP O
mutation NN I-NP O
analysis NN I-NP O
, , O O
but CC O O
could MD B-VP O
have VB I-VP O
implications NNS B-NP O
for IN B-PP O
the DT B-NP O
normal JJ I-NP O
and CC I-NP O
abnormal JJ I-NP O
regulation NN I-NP O
of IN B-PP O
BRCA1 NN B-NP O
transcription NN I-NP O
, , O O
translation NN B-NP O
and CC I-NP O
function NN I-NP O
. . O O

. . O O

Deletion NN B-NP O
of IN B-PP O
small JJ B-NP O
nuclear JJ I-NP O
ribonucleoprotein NN I-NP O
polypeptide NN I-NP O
N NN I-NP O
( ( O O
SNRPN NN B-NP O
) ) O O
in IN B-PP O
Prader NNP B-NP B-Disease
- HYPH I-NP I-Disease
Willi NNP I-NP I-Disease
syndrome NN I-NP I-Disease
detected VBN B-VP O
by IN B-PP O
fluorescence NN B-NP O
in FW B-NP O
situ FW I-NP O
hybridization NN I-NP O
: : O O
two CD B-NP O
sibs NNS I-NP O
with IN B-PP O
the DT B-NP O
typical JJ I-NP O
phenotype NN I-NP O
without IN B-PP O
a DT B-NP O
cytogenetic JJ I-NP O
deletion NN I-NP O
in IN B-PP O
chromosome NN B-NP O
15q NN I-NP O
. . O O

The DT B-NP O
small JJ I-NP O
nuclear JJ I-NP O
ribonucleoprotein NN I-NP O
polypeptide NN I-NP O
N NN I-NP O
( ( O O
SNRPN NN B-NP O
) ) O O
gene NN B-NP O
is VBZ B-VP O
regarded VBN I-VP O
as IN B-PP O
one CD B-NP O
of IN B-PP O
the DT B-NP O
candidates NNS I-NP O
for IN B-PP O
Prader NNP B-NP B-Disease
- HYPH I-NP I-Disease
Willi NNP I-NP I-Disease
syndrome NN I-NP I-Disease
( ( O O
PWS NN B-NP B-Disease
) ) O O
. . O O

We PRP B-NP O
describe VBP B-VP O
two CD B-NP O
sibs NNS I-NP O
with IN B-PP O
typical JJ B-NP O
PWS NN I-NP B-Disease
presenting VBG B-VP O
deletion NN B-NP O
of IN B-PP O
SNRPN NN B-NP O
detected VBN B-VP O
by IN B-PP O
fluorescence NN B-NP O
in FW B-NP O
situ FW I-NP O
hybridization NN I-NP O
( ( O O
FISH NN B-NP O
) ) O O
. . O O

Neither CC O O
a DT B-NP O
cytogenetically RB I-NP O
detectable JJ I-NP O
15q12 CD I-NP O
deletion NN I-NP O
nor CC O O
a DT B-NP O
deletion NN I-NP O
for IN B-PP O
the DT B-NP O
D15S11 NN I-NP O
, , O O
D15S10 NN B-NP O
, , O O
and CC O O
GABRB3 NN B-NP O
cosmid NN I-NP O
probes NNS I-NP O
were VBD B-VP O
found VBN I-VP O
in IN B-PP O
either DT B-NP O
patient NN I-NP O
. . O O

This DT B-NP O
implies VBZ B-VP O
a DT B-NP O
smaller JJR I-NP O
deletion NN I-NP O
limited VBN B-VP O
to TO B-PP O
the DT B-NP O
PWS NN I-NP B-Disease
critical JJ I-NP O
region NN I-NP O
. . O O

FISH NN B-NP O
with IN B-PP O
a DT B-NP O
SNRPN NN I-NP O
probe NN I-NP O
will MD B-VP O
permit VB I-VP O
analysis NN B-NP O
of IN B-PP O
PWS NN B-NP B-Disease
patients NNS I-NP O
with IN B-PP O
limited JJ B-NP O
deletions NNS I-NP O
not RB B-ADJP O
detectable JJ I-ADJP O
with IN B-PP O
other JJ B-NP O
probes NNS I-NP O
. . O O

. . O O

Expression NN B-NP O
of IN B-PP O
the DT B-NP O
von NNP I-NP B-Disease
Hippel NNP I-NP I-Disease
- HYPH I-NP I-Disease
Lindau NNP I-NP I-Disease
disease NN I-NP I-Disease
tumour NN I-NP I-Disease
suppressor NN I-NP O
gene NN I-NP O
during IN B-PP O
human JJ B-NP O
embryogenesis NN I-NP O
. . O O

The DT B-NP O
von NNP I-NP B-Disease
Hippel NNP I-NP I-Disease
- HYPH I-NP I-Disease
Lindau NNP I-NP I-Disease
( ( O I-Disease
VHL NNP O I-Disease
) ) O I-Disease
disease NN B-NP I-Disease
product NN I-NP O
is VBZ B-VP O
thought VBN I-VP O
to TO B-PP O
down RB B-VP O
- HYPH I-VP O
regulate VB I-VP O
transcription NN B-NP O
by IN B-PP O
antagonizing VBG B-VP O
elongin NN B-NP O
- HYPH O O
enhanced VBN B-VP O
transcriptional JJ B-NP O
elongation NN I-NP O
. . O O

Germline NN B-NP O
VHL NN I-NP B-Disease
gene NN I-NP O
mutations NNS I-NP O
predispose VBP B-VP O
to TO B-PP O
the DT B-NP O
development NN I-NP O
of IN B-PP O
retinal JJ B-NP B-Disease
, , I-NP I-Disease
cerebellar JJ I-NP I-Disease
and CC I-NP I-Disease
spinal JJ I-NP I-Disease
haemangioblastomas NNS I-NP I-Disease
, , O O
renal JJ B-NP B-Disease
cell NN I-NP I-Disease
carcinoma NN I-NP I-Disease
and CC I-NP O
phaeochromocytoma NN I-NP B-Disease
. . O O

In IN B-PP O
addition NN B-NP O
, , O O
somatic JJ B-NP O
Inactivation NN I-NP O
of IN B-PP O
the DT B-NP O
VHL NN I-NP B-Disease
gene NN I-NP O
is VBZ B-VP O
frequent JJ B-ADJP O
in IN B-PP O
sporadic JJ B-NP B-Disease
renal JJ I-NP I-Disease
cell NN I-NP I-Disease
carcinoma NN I-NP I-Disease
and CC I-NP O
haemangioblastoma NN I-NP B-Disease
. . O O

Regulation NN B-NP O
of IN B-PP O
transcript NN B-NP O
elongation NN I-NP O
is VBZ B-VP O
an DT B-NP O
important JJ I-NP O
control NN I-NP O
mechanism NN I-NP O
for IN B-PP O
gene NN B-NP O
expression NN I-NP O
and CC O O
the DT B-NP O
VHL NN I-NP B-Disease
gene NN I-NP O
might MD B-VP O
modify VB I-VP O
the DT B-NP O
expression NN I-NP O
of IN B-PP O
proto AFX B-NP O
- HYPH I-NP O
oncogenes NNS B-NP O
and CC O O
growth NN B-NP O
suppressor NN I-NP O
genes NNS I-NP O
during IN B-PP O
embryogenesis NN B-NP O
. . O O

We PRP B-NP O
therefore RB B-ADVP O
investigated VBD B-VP O
the DT B-NP O
expression NN I-NP O
of IN B-PP O
VHL NN B-NP B-Disease
mRNA NN I-NP O
during IN B-PP O
human JJ B-NP O
embryogenesis NN I-NP O
by IN B-PP O
in FW B-NP O
situ FW I-NP O
hybridization NN I-NP O
studies NNS I-NP O
at IN B-PP O
4 CD B-NP O
, , I-NP O
6 CD I-NP O
and CC I-NP O
10 CD I-NP O
weeks NNS I-NP O
post JJ I-NP O
conception NN I-NP O
. . O O

Although IN B-SBAR O
VHL NN B-NP B-Disease
mRNA NN I-NP O
was VBD B-VP O
expressed VBN I-VP O
in IN B-PP O
all DT B-NP O
three CD I-NP O
germ NN I-NP O
layers NNS I-NP O
, , O O
strong JJ B-NP O
expression NN I-NP O
was VBD B-VP O
noted VBN I-VP O
in IN B-PP O
the DT B-NP O
central JJ I-NP O
nervous JJ I-NP O
system NN I-NP O
, , O O
kidneys NNS B-NP O
, , O O
testis NN B-NP O
and CC I-NP O
lung NN I-NP O
. . O O

Within IN B-PP O
the DT B-NP O
kidney NN I-NP O
, , O O
VHL NN B-NP B-Disease
mRNA NN I-NP O
was VBD B-VP O
differentially RB I-VP O
expressed VBN I-VP O
within IN B-PP O
renal JJ B-NP O
tubules NNS I-NP O
suggesting VBG B-VP O
that IN B-SBAR O
the DT B-NP O
VHL NN I-NP B-Disease
gene NN I-NP O
product NN I-NP O
may MD B-VP O
have VB I-VP O
a DT B-NP O
specific JJ I-NP O
role NN I-NP O
in IN B-PP O
kidney NN B-NP O
development NN I-NP O
. . O O

Two CD B-NP O
alternatively RB I-NP O
spliced VBN I-NP O
VHL NN I-NP B-Disease
mRNAs NNS I-NP O
characterized VBN B-VP O
by IN B-PP O
inclusion NN B-NP O
( ( O O
isoform NN B-NP O
I CD I-NP O
) ) O O
or CC O O
exclusion NN B-NP O
( ( O O
isoform NN B-NP O
II CD I-NP O
) ) O O
of IN B-PP O
exon NN B-NP O
2 CD I-NP O
are VBP B-VP O
transcribed VBN I-VP O
in IN B-PP O
adult JJ B-NP O
tissues NNS I-NP O
. . O O

To TO B-VP O
investigate VB I-VP O
if IN B-SBAR O
the DT B-NP O
two CD I-NP O
isoforms NNS I-NP O
are VBP B-VP O
differentially RB I-VP O
expressed VBN I-VP O
during IN B-PP O
embryogenesis NN B-NP O
, , O O
VHL NN B-NP B-Disease
mRNA NN I-NP O
was VBD B-VP O
reverse NN B-NP O
transcribed VBN B-VP O
from IN B-PP O
13 CD B-NP O
fetal JJ I-NP O
tissues NNS I-NP O
( ( O O
8 CD B-NP O
- HYPH I-NP O
10 CD I-NP O
weeks NNS I-NP O
gestation NN I-NP O
) ) O O
. . O O

The DT B-NP O
quantitative JJ I-NP O
distribution NN I-NP O
of IN B-PP O
VHL NN B-NP B-Disease
mRNA NN I-NP O
within IN B-PP O
fetal JJ B-NP O
tissues NNS I-NP O
reflected VBD B-VP O
that IN B-SBAR O
seen VBN B-VP O
by IN B-PP O
in FW B-NP O
situ FW I-NP O
hybridization NN I-NP O
and CC O O
the DT B-NP O
ratio NN I-NP O
of IN B-PP O
the DT B-NP O
two CD I-NP O
VHL NN I-NP B-Disease
isoforms NNS I-NP O
was VBD B-VP O
similar JJ B-ADJP O
between IN B-PP O
tissues NNS B-NP O
. . O O

Although IN B-SBAR O
the DT B-NP O
genes NNS I-NP O
regulated VBN B-VP O
by IN B-PP O
the DT B-NP O
VHL NN I-NP B-Disease
gene NN I-NP O
product NN I-NP O
have VBP B-VP O
not RB I-VP O
yet RB I-VP O
been VBN I-VP O
identified VBN I-VP O
, , O O
our PRP$ B-NP O
findings NNS I-NP O
are VBP B-VP O
compatible JJ B-ADJP O
with IN B-PP O
the DT B-NP O
hypothesis NN I-NP O
that IN B-SBAR O
VHL NN B-NP B-Disease
- HYPH O O
mediated VBN B-VP O
control NN B-NP O
of IN B-PP O
transcriptional JJ B-NP O
elongation NN I-NP O
may MD B-VP O
have VB I-VP O
a DT B-NP O
role NN I-NP O
in IN B-PP O
normal JJ B-NP O
human JJ I-NP O
development NN I-NP O
. . O O

. . O O

Genetic JJ B-NP O
heterogeneity NN I-NP O
in IN B-PP O
hereditary JJ B-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
: : O O
role NN B-NP O
of IN B-PP O
BRCA1 NN B-NP O
and CC I-NP O
BRCA2 NN I-NP O
. . O O

The DT B-NP O
common JJ I-NP O
hereditary JJ I-NP O
forms NNS I-NP O
of IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
have VBP B-VP O
been VBN I-VP O
largely RB I-VP O
attributed VBN I-VP O
to TO B-PP O
the DT B-NP O
inheritance NN I-NP O
of IN B-PP O
mutations NNS B-NP O
in IN B-PP O
the DT B-NP O
BRCA1 NN I-NP O
or CC I-NP O
BRCA2 NN I-NP O
genes NNS I-NP O
. . O O

However RB B-ADVP O
, , O O
it PRP B-NP O
is VBZ B-VP O
not RB O O
yet RB B-ADJP O
clear JJ I-ADJP O
what WDT B-NP O
proportion NN I-NP O
of IN B-PP O
hereditary JJ B-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
is VBZ B-VP O
explained VBN I-VP O
by IN B-PP O
BRCA1 NN B-NP O
and CC I-NP O
BRCA2 NN I-NP O
or CC O O
by IN B-PP O
some DT B-NP O
other JJ I-NP O
unidentified JJ I-NP O
susceptibility NN I-NP O
gene NN I-NP O
( ( I-NP O
s NNS I-NP O
) ) O O
. . O O

We PRP B-NP O
describe VBP B-VP O
the DT B-NP O
proportion NN I-NP O
of IN B-PP O
hereditary JJ B-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
explained VBN B-VP O
by IN B-PP O
BRCA1 NN B-NP O
or CC I-NP O
BRCA2 NN I-NP O
in IN B-PP O
a DT B-NP O
sample NN I-NP O
of IN B-PP O
North JJ B-NP O
American JJ I-NP O
hereditary JJ I-NP B-Disease
breast NN I-NP I-Disease
cancers NNS I-NP I-Disease
and CC O O
assess VB B-VP O
the DT B-NP O
evidence NN I-NP O
for IN B-PP O
additional JJ B-NP O
susceptibility NN I-NP O
genes NNS I-NP O
that WDT B-NP O
may MD B-VP O
confer VB I-VP O
hereditary JJ B-NP B-Disease
breast NN I-NP I-Disease
or CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
risk NN I-NP O
. . O O

Twenty CD B-NP O
- HYPH I-NP O
three CD I-NP O
families NNS I-NP O
were VBD B-VP O
identified VBN I-VP O
through IN B-PP O
two CD B-NP O
high JJ I-NP O
- HYPH I-NP O
risk NN I-NP O
breast NN I-NP B-Disease
cancer NN I-NP I-Disease
research NN I-NP O
programs NNS I-NP O
. . O O

Genetic JJ B-NP O
analysis NN I-NP O
was VBD B-VP O
undertaken VBN I-VP O
to TO I-VP O
establish VB I-VP O
linkage NN B-NP O
between IN B-PP O
the DT B-NP O
breast NN I-NP B-Disease
or CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
cases NNS I-NP O
and CC I-NP O
markers NNS I-NP O
on IN B-PP O
chromosomes NNS B-NP O
17q NN I-NP O
( ( O O
BRCA1 NN B-NP O
) ) O O
and CC O O
13q NN B-NP O
( ( O O
BRCA2 NN B-NP O
) ) O O
. . O O

Mutation NN B-NP O
analysis NN I-NP O
in IN B-PP O
the DT B-NP O
BRCA1 NN I-NP O
and CC I-NP O
BRCA2 NN I-NP O
genes NNS I-NP O
was VBD B-VP O
also RB I-VP O
undertaken VBN I-VP O
in IN B-PP O
all DT B-NP O
families NNS I-NP O
. . O O

The DT B-NP O
pattern NN I-NP O
of IN B-PP O
hereditary JJ B-NP B-Disease
cancer NN I-NP I-Disease
in IN B-PP O
14 CD B-NP O
( ( O O
61 CD B-NP O
% NN I-NP O
) ) O O
of IN B-PP O
the DT B-NP O
23 CD I-NP O
families NNS I-NP O
studied VBN B-VP O
was VBD B-VP O
attributed VBN I-VP O
to TO B-PP O
BRCA1 NN B-NP O
by IN B-PP O
a DT B-NP O
combination NN I-NP O
of IN B-PP O
linkage NN B-NP O
and CC I-NP O
mutation NN I-NP O
analyses NNS I-NP O
. . O O

No DT B-NP O
families NNS I-NP O
were VBD B-VP O
attributed VBN I-VP O
to TO B-PP O
BRCA2 NN B-NP O
. . O O

Five CD B-NP O
families NNS I-NP O
( ( O O
22 CD B-NP O
% NN I-NP O
) ) O O
provided VBD B-VP O
evidence NN B-NP O
against IN B-PP O
linkage NN B-NP O
to TO B-PP O
both CC O O
BRCA1 NN B-NP O
and CC I-NP O
BRCA2 NN I-NP O
. . O O

No DT B-NP O
BRCA1 NN I-NP O
or CC I-NP O
BRCA2 NN I-NP O
mutations NNS I-NP O
were VBD B-VP O
detected VBN I-VP O
in IN B-PP O
these DT B-NP O
five CD I-NP O
families NNS I-NP O
. . O O

The DT B-NP O
BRCA1 NN I-NP O
or CC I-NP O
BRCA2 NN I-NP O
status NN I-NP O
of IN B-PP O
four CD B-NP O
families NNS I-NP O
( ( O O
17 CD B-NP O
% NN I-NP O
) ) O O
could MD B-VP O
not RB I-VP O
be VB I-VP O
determined VBN I-VP O
. . O O

BRCA1 NN B-NP O
and CC I-NP O
BRCA2 NN I-NP O
probably RB B-ADVP O
explain VBP B-VP O
the DT B-NP O
majority NN I-NP O
of IN B-PP O
hereditary JJ B-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
that WDT B-NP O
exists VBZ B-VP O
in IN B-PP O
the DT B-NP O
North JJ I-NP O
American JJ I-NP O
population NN I-NP O
. . O O

However RB B-ADVP O
, , O O
one CD B-NP O
or CC I-NP O
more JJR I-NP O
additional JJ I-NP O
genes NNS I-NP O
may MD B-VP O
yet RB I-VP O
be VB I-VP O
found VBN I-VP O
that IN B-SBAR O
explain VB B-VP O
some DT B-NP O
proportion NN I-NP O
of IN B-PP O
hereditary JJ B-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
. . O O

. . O O

An DT B-NP O
intronic JJ I-NP O
mutation NN I-NP O
in IN B-PP O
a DT B-NP O
lariat NN I-NP O
branchpoint NN I-NP O
sequence NN I-NP O
is VBZ B-VP O
a DT B-NP O
direct JJ I-NP O
cause NN I-NP O
of IN B-PP O
an DT B-NP O
inherited VBN I-NP B-Disease
human JJ I-NP I-Disease
disorder NN I-NP I-Disease
( ( O O
fish NN B-NP B-Disease
- HYPH B-NP I-Disease
eye NN I-NP I-Disease
disease NN I-NP I-Disease
) ) O O
. . O O

The DT B-NP O
first JJ I-NP O
step NN I-NP O
in IN B-PP O
the DT B-NP O
splicing NN I-NP O
of IN B-PP O
an DT B-NP O
intron NN I-NP O
from IN B-PP O
nuclear JJ B-NP O
precursors NNS I-NP O
of IN B-PP O
mRNA NN B-NP O
results VBZ B-VP O
in IN B-PP O
the DT B-NP O
formation NN I-NP O
of IN B-PP O
a DT B-NP O
lariat NN I-NP O
structure NN I-NP O
. . O O

A DT B-NP O
distinct JJ I-NP O
intronic JJ I-NP O
nucleotide NN I-NP O
sequence NN I-NP O
, , O O
known VBN B-VP O
as IN B-PP O
the DT B-NP O
branchpoint NN I-NP O
region NN I-NP O
, , O O
plays VBZ B-VP O
a DT B-NP O
central JJ I-NP O
role NN I-NP O
in IN B-PP O
this DT B-NP O
process NN I-NP O
. . O O

We PRP B-NP O
here RB B-ADVP O
describe VBP B-VP O
a DT B-NP O
point NN I-NP O
mutation NN I-NP O
in IN B-PP O
such JJ B-NP O
a DT I-NP O
sequence NN I-NP O
. . O O

Three CD B-NP O
sisters NNS I-NP O
were VBD B-VP O
shown VBN I-VP O
to TO I-VP O
suffer VB I-VP O
from IN B-PP O
fish NN B-NP B-Disease
- HYPH B-NP I-Disease
eye NN I-NP I-Disease
disease NN I-NP I-Disease
( ( O O
FED VBN B-VP B-Disease
) ) O O
, , O O
a DT B-NP O
disorder NN I-NP O
which WDT B-NP O
is VBZ B-VP O
caused VBN I-VP O
by IN B-PP O
mutations NNS B-NP O
in IN B-PP O
the DT B-NP O
gene NN I-NP O
coding VBG B-VP O
for IN B-PP O
lecithin JJ B-NP O
cholesterol NN I-NP O
acyltransferase NN I-NP O
( ( O O
LCAT NN B-NP O
) ) O O
. . O O

Sequencing NN B-NP O
of IN B-PP O
the DT B-NP O
LCAT NN I-NP O
gene NN I-NP O
of IN B-PP O
all DT B-NP O
three CD I-NP O
probands NNS I-NP O
revealed VBD B-VP O
compound NN B-NP O
heterozygosity NN I-NP O
for IN B-PP O
a DT B-NP O
missense JJ I-NP O
mutation NN I-NP O
in IN B-PP O
exon NN B-NP O
4 CD I-NP O
which WDT B-NP O
is VBZ B-VP O
reported VBN I-VP O
to TO I-VP O
underlie VB I-VP O
the DT B-NP O
FED JJ I-NP B-Disease
phenotype NN I-NP O
, , O O
and CC O O
a DT B-NP O
point NN I-NP O
mutation NN I-NP O
located VBN B-VP O
in IN B-PP O
intron NN B-NP O
4 CD I-NP O
( ( O O
IVS4 CD B-NP O
T NN I-NP O
- HYPH B-NP O
22C NN I-NP O
) ) O O
. . O O

By IN B-PP O
performing VBG B-VP O
in FW B-NP O
vitro FW I-NP O
expression NN I-NP O
of IN B-PP O
LCAT NN B-NP O
minigenes NNS I-NP O
and CC O O
reverse JJ B-NP O
transcriptase NN I-NP O
PCR NN I-NP O
on IN B-PP O
mRNA NN B-NP O
isolated VBN B-VP O
from IN B-PP O
leukocytes NNS B-NP O
of IN B-PP O
the DT B-NP O
patient NN I-NP O
, , O O
this DT B-NP O
gene NN I-NP O
defect NN I-NP O
was VBD B-VP O
shown VBN I-VP O
to TO I-VP O
cause VB I-VP O
a DT B-NP O
allele NN I-NP O
as IN B-PP O
the DT B-NP O
result NN I-NP O
of IN B-PP O
complete JJ B-NP O
intron NN I-NP O
retention NN I-NP O
. . O O

In IN B-PP O
conclusion NN B-NP O
, , O O
we PRP B-NP O
demonstrated VBD B-VP O
that IN B-SBAR O
a DT B-NP O
point NN I-NP O
mutation NN I-NP O
in IN B-PP O
a DT B-NP O
lariat NN I-NP O
branchpoint NN I-NP O
consensus NN I-NP O
sequence NN I-NP O
causes VBZ B-VP O
a DT B-NP O
allele NN I-NP O
in IN B-PP O
a DT B-NP O
patient NN I-NP O
with IN B-PP O
FED NNP B-NP B-Disease
. . O O

In IN B-PP O
addition NN B-NP O
, , O O
our PRP$ B-NP O
finding NN I-NP O
illustrates VBZ B-VP O
the DT B-NP O
importance NN I-NP O
of IN B-PP O
this DT B-NP O
sequence NN I-NP O
for IN B-PP O
normal JJ B-NP O
human JJ I-NP O
mRNA NN I-NP O
processing NN I-NP O
. . O O

Finally RB B-ADVP O
, , O O
this DT B-NP O
report NN I-NP O
provides VBZ B-VP O
a DT B-NP O
widely RB I-NP O
applicable JJ I-NP O
strategy NN I-NP O
which WDT B-NP O
ensures VBZ B-VP O
fast JJ B-NP O
and CC I-NP O
effective JJ I-NP O
screening NN I-NP O
for IN B-PP O
intronic JJ B-NP O
defects NNS I-NP O
that WDT B-NP O
underlie VBP B-VP O
differential JJ B-NP O
gene NN I-NP O
expression NN I-NP O
. . O O

. . O O

Mutations NNS B-NP O
associated VBN B-VP O
with IN B-PP O
variant JJ B-NP O
phenotypes NNS I-NP O
in IN B-PP O
ataxia NN B-NP B-Disease
- HYPH B-NP I-Disease
telangiectasia NN I-NP I-Disease
. . O O

We PRP B-NP O
have VBP B-VP O
identified VBN I-VP O
14 CD B-NP O
families NNS I-NP O
with IN B-PP O
ataxia NN B-NP B-Disease
- HYPH O I-Disease
telangiectasia NN B-NP I-Disease
( ( O O
A NN B-NP B-Disease
- HYPH I-NP I-Disease
T NN I-NP I-Disease
) ) O O
in IN B-PP O
which WDT B-NP O
mutation NN B-NP O
of IN B-PP O
the DT B-NP O
ATM NN I-NP O
gene NN I-NP O
is VBZ B-VP O
associated VBN I-VP O
with IN B-PP O
a DT B-NP O
less RBR I-NP O
severe JJ I-NP O
clinical JJ I-NP O
and CC I-NP O
cellular JJ I-NP O
phenotype NN I-NP O
( ( O O
approximately RB B-NP O
10 CD I-NP O
% NN I-NP O
- HYPH O O
15 CD B-NP O
% NN I-NP O
of IN B-PP O
A NN B-NP B-Disease
- HYPH I-NP I-Disease
T NN I-NP I-Disease
families NNS I-NP O
identified VBN B-VP O
in IN B-PP O
the DT B-NP O
United NNP I-NP O
Kingdom NNP I-NP O
) ) O O
. . O O

In IN B-PP O
10 CD B-NP O
of IN B-PP O
these DT B-NP O
families NNS I-NP O
, , O O
all PDT B-NP O
the DT I-NP O
homozygotes NNS I-NP O
have VBP B-VP O
a DT B-NP O
137 CD I-NP O
- HYPH I-NP O
bp NN I-NP O
insertion NN I-NP O
in IN B-PP O
their PRP$ B-NP O
cDNA NN I-NP O
caused VBN B-VP O
by IN B-PP O
a DT B-NP O
point NN I-NP O
mutation NN I-NP O
in IN B-PP O
a DT B-NP O
sequence NN I-NP O
resembling VBG B-VP O
a DT B-NP O
splice NN I-NP O
- HYPH B-NP O
donor NN I-NP O
site NN I-NP O
. . O O

The DT B-NP O
second JJ I-NP O
A NN I-NP B-Disease
- HYPH I-NP I-Disease
T NN I-NP I-Disease
allele NN I-NP O
has VBZ B-VP O
a DT B-NP O
different JJ I-NP O
mutation NN I-NP O
in IN B-PP O
each DT B-NP O
patient NN I-NP O
. . O O

We PRP B-NP O
show VBP B-VP O
that IN B-SBAR O
the DT B-NP O
less RBR I-NP O
severe JJ I-NP O
phenotype NN I-NP O
in IN B-PP O
these DT B-NP O
patients NNS I-NP O
is VBZ B-VP O
caused VBN I-VP O
by IN B-PP O
some DT B-NP O
degree NN I-NP O
of IN B-PP O
normal JJ B-NP O
splicing NN I-NP O
, , O O
which WDT B-NP O
occurs VBZ B-VP O
as IN B-PP O
an DT B-NP O
alternative JJ I-NP O
product NN I-NP O
from IN B-PP O
the DT B-NP O
insertion NN I-NP O
- HYPH O O
containing VBG B-VP O
allele NN B-NP O
. . O O

The DT B-NP O
level NN I-NP O
of IN B-PP O
the DT B-NP O
137 CD I-NP O
- HYPH I-NP O
bp NN I-NP O
PCR NN I-NP O
product NN I-NP O
containing VBG B-VP O
the DT B-NP O
insertion NN I-NP O
was VBD B-VP O
lowest JJS B-ADJP O
in IN B-PP O
two CD B-NP O
patients NNS I-NP O
who WP B-NP O
showed VBD B-VP O
a DT B-NP O
later JJ I-NP O
onset NN I-NP O
of IN B-PP O
cerebellar JJ B-NP B-Disease
ataxia NN I-NP I-Disease
. . O O

A DT B-NP O
further JJ I-NP O
four CD I-NP O
families NNS I-NP O
who WP B-NP O
do VBP B-VP O
not RB I-VP O
have VB I-VP O
this DT B-NP O
insertion NN I-NP O
have VBP B-VP O
been VBN I-VP O
identified VBN I-VP O
. . O O

Mutations NNS B-NP O
detected VBN B-VP O
in IN B-PP O
two CD B-NP O
of IN B-PP O
four CD B-NP O
of IN B-PP O
these DT B-NP O
are VBP B-VP O
missense JJ B-NP O
mutations NNS I-NP O
, , O O
normally RB B-ADJP O
rare JJ I-ADJP O
in IN B-PP O
A NN B-NP B-Disease
- HYPH I-NP I-Disease
T NN I-NP I-Disease
patients NNS I-NP O
. . O O

The DT B-NP O
demonstration NN I-NP O
of IN B-PP O
mutations NNS B-NP O
giving VBG B-VP O
rise NN B-NP O
to TO B-PP O
a DT B-NP O
slightly RB I-NP O
milder JJR I-NP O
phenotype NN I-NP O
in IN B-PP O
A NN B-NP B-Disease
- HYPH O I-Disease
T NN B-NP I-Disease
raises VBZ B-VP O
the DT B-NP O
interesting JJ I-NP O
question NN I-NP O
of IN B-PP O
what WP B-NP O
range NN B-NP O
of IN B-PP O
phenotypes NNS B-NP O
might MD B-VP O
occur VB I-VP O
in IN B-PP O
individuals NNS B-NP O
in IN B-PP O
whom WP B-NP O
both DT B-NP O
mutations NNS I-NP O
are VBP B-VP O
milder JJR B-ADJP O
. . O O

One CD B-NP O
possibility NN I-NP O
might MD B-VP O
be VB I-VP O
that IN B-SBAR O
individuals NNS B-NP O
who WP B-NP O
are VBP B-VP O
compound JJ B-NP O
heterozygotes NNS I-NP O
for IN B-PP O
ATM NN B-NP O
mutations NNS I-NP O
are VBP B-VP O
more RBR B-ADJP O
common JJ I-ADJP O
than IN B-SBAR O
we PRP B-NP O
realize VBP B-VP O
. . O O

. . O O

Mutation NN B-NP O
of IN B-PP O
the DT B-NP O
VHL NN I-NP O
gene NN I-NP O
is VBZ B-VP O
associated VBN I-VP O
exclusively RB B-ADVP O
with IN B-PP O
the DT B-NP O
development NN I-NP O
of IN B-PP O
non AFX B-NP B-Disease
- HYPH I-NP I-Disease
papillary JJ I-NP I-Disease
renal JJ I-NP I-Disease
cell NN I-NP I-Disease
carcinomas NNS I-NP I-Disease
. . O O

To TO B-VP O
define VB I-VP O
the DT B-NP O
possible JJ I-NP O
role NN I-NP O
of IN B-PP O
the DT B-NP O
VHL NN I-NP B-Disease
gene NN I-NP O
in IN B-PP O
the DT B-NP O
development NN I-NP O
of IN B-PP O
sporadic JJ B-NP B-Disease
renal JJ I-NP I-Disease
cell NN I-NP I-Disease
carcinomas NNS I-NP I-Disease
, , O O
91 CD B-NP O
different JJ I-NP O
parenchymal JJ I-NP B-Disease
tumours NNS I-NP I-Disease
of IN B-PP I-Disease
the DT B-NP I-Disease
kidney NN I-NP I-Disease
have VBP B-VP O
been VBN I-VP O
investigated VBN I-VP O
for IN B-PP O
mutation NN B-NP O
of IN B-PP O
the DT B-NP O
VHL NN I-NP B-Disease
gene NN I-NP O
by IN B-PP O
single JJ B-NP O
strand NN I-NP O
conformation NN I-NP O
polymorphism NN I-NP O
( ( O O
SSCP NN B-NP O
) ) O O
and CC O O
/ SYM B-NP O
or CC O O
heteroduplex NN B-NP O
( ( O O
HD NN B-NP O
) ) O O
techniques NNS B-NP O
. . O O

Chromosome NN B-NP O
3p NN I-NP O
deletion NN I-NP O
was VBD B-VP O
detected VBN I-VP O
in IN B-PP O
98 CD B-NP O
per IN B-PP O
cent NN B-NP O
of IN B-PP O
non AFX B-NP B-Disease
- HYPH I-NP I-Disease
papillary JJ I-NP I-Disease
renal JJ I-NP I-Disease
cell NN I-NP I-Disease
carcinomas NNS I-NP I-Disease
and CC O O
in IN B-PP O
25 CD B-NP O
per IN B-PP O
cent NN B-NP O
of IN B-PP O
chromophobe NN B-NP O
renal JJ I-NP B-Disease
cell NN I-NP I-Disease
carcinomas NNS I-NP I-Disease
. . O O

In IN B-PP O
22 CD B-NP O
of IN B-PP O
the DT B-NP O
43 CD I-NP O
non AFX I-NP B-Disease
- HYPH I-NP I-Disease
papillary JJ I-NP I-Disease
renal JJ I-NP I-Disease
cell NN I-NP I-Disease
carcinomas NNS I-NP I-Disease
, , O O
abnormally RB B-VP O
migrating VBG I-VP O
DNA NN B-NP O
bands NNS I-NP O
were VBD B-VP O
detected VBN I-VP O
by IN B-PP O
SSCP NN B-NP O
and CC O O
/ SYM B-NP O
or CC O O
HD NN B-NP O
analysis NN I-NP O
. . O O

No DT B-NP O
mobility NN I-NP O
shift NN I-NP O
was VBD B-VP O
seen VBN I-VP O
in IN B-PP O
any DT B-NP O
of IN B-PP O
the DT B-NP O
23 CD I-NP O
chromophobe NN I-NP O
renal JJ I-NP B-Disease
cell NN I-NP I-Disease
carcinomas NNS I-NP I-Disease
. . O O

In IN B-PP O
addition NN B-NP O
, , O O
15 CD B-NP O
papillary JJ I-NP B-Disease
renal JJ I-NP I-Disease
cell NN I-NP I-Disease
tumours NNS I-NP I-Disease
and CC O O
ten CD B-NP O
renal JJ I-NP B-Disease
oncocytomas NNS I-NP I-Disease
, , O O
which WDT B-NP O
are VBP B-VP O
characterized VBN I-VP O
by IN B-PP O
genetic JJ B-NP O
changes NNS I-NP O
other JJ B-ADJP O
than IN B-PP O
loss NN B-NP O
of IN B-PP O
chromosome NN B-NP O
3p NN I-NP O
sequences NNS I-NP O
, , O O
were VBD B-VP O
analysed VBN I-VP O
for IN B-PP O
mutation NN B-NP O
of IN B-PP O
the DT B-NP O
VHL NN I-NP B-Disease
gene NN I-NP O
. . O O

None NN B-NP O
of IN B-PP O
these DT B-NP O
tumours NNS I-NP B-Disease
showed VBD B-VP O
abnormal JJ B-NP O
migration NN I-NP O
patterns NNS I-NP O
. . O O

The DT B-NP O
results NNS I-NP O
indicate VBP B-VP O
that IN B-SBAR O
mutation NN B-NP O
of IN B-PP O
the DT B-NP O
VHL NN I-NP B-Disease
gene NN I-NP O
is VBZ B-VP O
associated VBN I-VP O
exclusively RB B-ADVP O
with IN B-PP O
the DT B-NP O
development NN I-NP O
of IN B-PP O
non AFX B-NP B-Disease
- HYPH I-NP I-Disease
papillary JJ I-NP I-Disease
renal JJ I-NP I-Disease
cell NN I-NP I-Disease
carcinoma NN I-NP I-Disease
. . O O

. . O O

The DT B-NP O
Emery NNP I-NP B-Disease
- HYPH I-NP I-Disease
Dreifuss NNP I-NP I-Disease
muscular JJ I-NP I-Disease
dystrophy NN I-NP I-Disease
protein NN I-NP O
, , O O
emerin NN B-NP O
, , O O
is VBZ B-VP O
a DT B-NP O
nuclear JJ I-NP O
membrane NN I-NP O
protein NN I-NP O
. . O O

A DT B-NP O
large JJ I-NP O
fragment NN I-NP O
of IN B-PP O
emerin NN B-NP O
cDNA NN I-NP O
was VBD B-VP O
prepared VBN I-VP O
by IN B-PP O
PCR NN B-NP O
and CC O O
expressed VBN B-VP O
as IN B-PP O
a DT B-NP O
recombinant JJ I-NP O
protein NN I-NP O
in IN B-PP O
Escherichia NNP B-NP O
coli NNP I-NP O
. . O O

Using VBG B-VP O
this DT B-NP O
as IN B-PP O
immunogen NN B-NP O
, , O O
we PRP B-NP O
prepared VBD B-VP O
a DT B-NP O
panel NN I-NP O
of IN B-PP O
12 CD B-NP O
monoclonal JJ I-NP O
antibodies NNS I-NP O
which WDT B-NP O
recognise VBP B-VP O
at IN B-NP O
least JJS I-NP O
four CD I-NP O
different JJ I-NP O
epitopes NNS I-NP O
on IN B-PP O
emerin NN B-NP O
in IN B-SBAR O
order NN O O
to TO B-VP O
ensure VB I-VP O
that DT B-NP O
emerin NN I-NP O
can MD B-VP O
be VB I-VP O
distinguished VBN I-VP O
from IN B-PP O
non AFX B-NP O
- HYPH I-NP O
specific JJ I-NP O
cross AFX I-NP O
- HYPH I-NP O
reacting VBG B-VP O
proteins NNS B-NP O
. . O O

All PDT B-NP O
the DT I-NP O
mAbs NNS I-NP O
recognised VBD B-VP O
a DT B-NP O
34 CD I-NP O
kDa NN I-NP O
protein NN I-NP O
in IN B-PP O
all DT B-NP O
tissues NNS I-NP O
tested VBN B-VP O
, , O O
though IN B-SBAR O
minor JJ B-NP O
emerin NN I-NP O
- HYPH B-NP O
related VBN I-NP O
bands NNS I-NP O
were VBD B-VP O
also RB I-VP O
detected VBN I-VP O
in IN B-PP O
some DT B-NP O
tissues NNS I-NP O
. . O O

Immunofluorescence NN B-NP O
microscopy NN I-NP O
showed VBD B-VP O
that IN B-SBAR O
emerin NN B-NP O
is VBZ B-VP O
located JJ B-ADJP O
at IN B-PP O
the DT B-NP O
nuclear JJ I-NP O
rim NN I-NP O
in IN B-PP O
all DT B-NP O
tissues NNS I-NP O
examined VBN B-VP O
. . O O

A DT B-NP O
muscle NN I-NP O
biopsy NN I-NP O
from IN B-PP O
an DT B-NP O
Emery NNP I-NP B-Disease
- HYPH I-NP I-Disease
Dreifuss NNP I-NP I-Disease
muscular JJ I-NP I-Disease
dystrophy NN I-NP I-Disease
( ( O O
EMDM NN B-NP B-Disease
) ) O O
patient NN B-NP O
showed VBD B-VP O
complete JJ B-NP O
absence NN I-NP O
of IN B-PP O
emerin NN B-NP O
by IN B-PP O
both CC O O
Western JJ B-NP O
blotting NN I-NP O
and CC O O
immunohistochemistry NN B-NP O
, , O O
suggesting VBG B-VP O
a DT B-NP O
simple JJ I-NP O
diagnostic JJ I-NP O
antibody NN I-NP O
test NN I-NP O
for IN B-PP O
EDMD NN B-NP B-Disease
families NNS I-NP O
. . O O

Biochemical JJ B-NP O
fractionation NN I-NP O
of IN B-PP O
brain NN B-NP O
and CC I-NP O
liver NN I-NP O
tissues NNS I-NP O
showed VBD B-VP O
that IN B-SBAR O
emerin NN B-NP O
was VBD B-VP O
present JJ B-ADJP O
in IN B-PP O
nuclei NNS B-NP O
purified VBN B-VP O
by IN B-PP O
centrifugation NN B-NP O
through IN B-PP O
65 CD B-NP O
% NN I-NP O
sucrose NN I-NP O
and CC O O
was VBD B-VP O
absent JJ B-ADJP O
from IN B-PP O
soluble JJ B-NP O
fractions NNS I-NP O
( ( O O
post AFX B-NP O
- HYPH I-NP O
100 CD B-NP O
, , O O
000 CD B-NP O
g NN I-NP O
) ) O O
. . O O

From IN B-PP O
these DT B-NP O
results NNS I-NP O
, , O O
together RB B-ADVP O
with IN B-PP O
sequence NN B-NP O
and CC O O
structural JJ B-NP O
homologies NNS I-NP O
between IN B-PP O
emerin NN B-NP O
, , O O
thymopoietins NNS B-NP O
and CC O O
the DT B-NP O
nuclear JJ I-NP O
lamina NN I-NP O
- HYPH O O
associated VBN B-NP O
protein NN I-NP O
, , O O
LAP2 NN B-NP O
, , O O
we PRP B-NP O
suggest VBP B-VP O
that IN B-SBAR O
emerin NN B-NP O
will MD B-VP O
prove VB I-VP O
to TO I-VP O
be VB I-VP O
one CD B-NP O
member NN I-NP O
of IN B-PP O
a DT B-NP O
family NN I-NP O
of IN B-PP O
inner JJ B-NP O
nuclear JJ I-NP O
membrane NN I-NP O
proteins NNS I-NP O
. . O O

. . O O

Mutation NN B-NP O
of IN B-PP O
MSH3 NN B-NP O
in IN B-PP O
endometrial JJ B-NP B-Disease
cancer NN I-NP I-Disease
and CC I-NP O
evidence NN I-NP O
for IN B-PP O
its PRP$ B-NP O
functional JJ I-NP O
role NN I-NP O
in IN B-PP O
heteroduplex NN B-NP O
repair NN I-NP O
. . O O

Many JJ B-NP O
human JJ I-NP O
tumours NNS I-NP B-Disease
have VBP B-VP O
length NN B-NP O
alterations NNS I-NP O
in IN B-PP O
repetitive JJ B-NP O
sequence NN I-NP O
elements NNS I-NP O
. . O O

Although IN B-SBAR O
this DT B-NP O
microsatellite NN I-NP B-Disease
instability NN I-NP I-Disease
has VBZ B-VP O
been VBN I-VP O
attributed VBN I-VP O
to TO B-PP O
mutations NNS B-NP O
in IN B-PP O
four CD B-NP O
DNA NN I-NP O
mismatch NN I-NP O
repair NN I-NP O
genes NNS I-NP O
in IN B-PP O
hereditary JJ B-NP B-Disease
nonpolyposis NN I-NP I-Disease
colorectal JJ I-NP I-Disease
cancer NN I-NP I-Disease
( ( O O
HNPCC NN B-NP B-Disease
) ) O O
kindreds NNS B-NP O
, , O O
many JJ B-NP O
sporadic JJ I-NP B-Disease
tumours NNS I-NP I-Disease
exhibit VBP B-VP O
instability NN B-NP O
but CC O O
no DT B-NP O
detectable JJ I-NP O
mutations NNS I-NP O
in IN B-PP O
these DT B-NP O
genes NNS I-NP O
. . O O

It PRP B-NP O
is VBZ B-VP O
therefore RB B-ADVP O
of IN B-PP O
interest NN B-NP O
to TO B-VP O
identify VB I-VP O
other JJ B-NP O
genes NNS I-NP O
that WDT B-NP O
contribute VBP B-VP O
to TO B-PP O
this DT B-NP O
instability NN I-NP O
. . O O

In IN B-PP O
yeast NN B-NP O
, , O O
mutations NNS B-NP O
in IN B-PP O
several JJ B-NP O
genes NNS I-NP O
, , O O
including VBG B-PP O
RTH NN B-NP O
and CC I-NP O
MSH3 NN I-NP O
, , O O
cause VBP B-VP O
microsatellite NN B-NP O
instability NN I-NP O
. . O O

Thus RB B-ADVP O
, , O O
we PRP B-NP O
screened VBD B-VP O
16 CD B-NP O
endometrial JJ I-NP B-Disease
carcinomas NNS I-NP I-Disease
with IN B-PP O
microsatellite NN B-NP O
instability NN I-NP O
for IN B-PP O
alterations NNS B-NP O
in IN B-PP O
FEN1 NN B-NP O
( ( O O
the DT B-NP O
human JJ I-NP O
homolog NN I-NP O
of IN B-PP O
RTH NN B-NP O
) ) O O
and CC O O
in IN B-PP O
MSH3 NN B-NP O
( ( O O
refs NNS B-NP O
12 CD B-NP O
- HYPH I-NP O
14 CD I-NP O
) ) O O
. . O O

Although IN B-SBAR O
we PRP B-NP O
found VBD B-VP O
no DT B-NP O
FEN1 NN I-NP O
mutations NNS I-NP O
, , O O
a DT B-NP O
frameshift NN I-NP O
mutation NN I-NP O
in IN B-PP O
MSH3 NN B-NP O
was VBD B-VP O
observed VBN I-VP O
in IN B-PP O
an DT B-NP O
endometrial JJ I-NP B-Disease
carcinoma NN I-NP I-Disease
and CC B-PP O
in IN B-PP O
an DT B-NP O
endometrial JJ I-NP B-Disease
carcinoma NN I-NP I-Disease
cell NN I-NP O
line NN I-NP O
. . O O

Extracts NNS B-NP O
of IN B-PP O
the DT B-NP O
cell NN I-NP O
line NN I-NP O
were VBD B-VP O
deficient JJ B-ADJP O
in IN B-PP O
repair NN B-NP O
of IN B-PP O
DNA NN B-NP O
substrates NNS I-NP O
containing VBG B-VP O
mismatches NNS B-NP O
or CC O O
extra JJ B-NP O
nucleotides NNS I-NP O
. . O O

Introducing VBG B-VP O
chromosome NN B-NP O
5 CD I-NP O
, , O O
encoding VBG B-VP O
the DT B-NP O
MSH3 NN I-NP O
gene NN I-NP O
, , O O
into IN B-PP O
the DT B-NP O
mutant JJ I-NP O
cell NN I-NP O
line NN I-NP O
increased VBD B-VP O
the DT B-NP O
stability NN I-NP O
of IN B-PP O
some DT B-NP O
but CC I-NP O
not RB I-NP O
all DT B-NP O
microsatellites NNS I-NP O
. . O O

Extracts NNS B-NP O
of IN B-PP O
these DT B-NP O
cells NNS I-NP O
repaired VBD B-VP O
certain JJ B-NP O
substrates NNS I-NP O
containing VBG B-VP O
extra JJ B-NP O
nucleotides NNS I-NP O
, , O O
but CC O O
were VBD B-VP O
deficient JJ B-ADJP O
in IN B-PP O
repair NN B-NP O
of IN B-PP O
those DT B-NP O
containing VBG I-NP O
mismatches NNS I-NP O
or CC O O
other JJ B-NP O
extra JJ I-NP O
nucleotides NNS I-NP O
. . O O

A DT B-NP O
subsequent JJ I-NP O
search NN I-NP O
revealed VBD B-VP O
a DT B-NP O
second JJ I-NP O
gene NN I-NP O
mutation NN I-NP O
in IN B-PP O
HHUA NN B-NP O
cells NNS I-NP O
, , O O
a DT B-NP O
missense JJ I-NP O
mutation NN I-NP O
in IN B-PP O
the DT B-NP O
MSH6 NN I-NP O
gene NN I-NP O
. . O O

Together RB B-ADVP O
the DT B-NP O
data NNS I-NP O
suggest VBP B-VP O
that IN B-SBAR O
the DT B-NP O
MSH3 NN I-NP O
gene NN I-NP O
encodes VBZ B-VP O
a DT B-NP O
product NN I-NP O
that WDT B-NP O
functions VBZ B-VP O
in IN B-PP O
repair NN B-NP O
of IN B-PP O
some DT B-NP O
but CC I-NP O
not RB I-NP O
all DT B-NP O
pre AFX B-NP O
- HYPH I-NP O
mutational JJ I-NP O
intermediates NNS I-NP O
, , O O
its PRP$ B-NP O
mutation NN I-NP O
in IN B-PP O
tumours NNS B-NP B-Disease
can MD B-VP O
result VB I-VP O
in IN B-PP O
genomic JJ B-NP O
instability NN I-NP O
and CC O O
, , O O
as IN B-PP O
in IN B-PP O
yeast NN B-NP O
, , O O
MSH3 NN B-NP O
and CC I-NP O
MSH6 NN I-NP O
are VBP B-VP O
partially RB B-ADJP O
redundant JJ I-ADJP O
for IN B-PP O
mismatch NN B-NP O
repair NN I-NP O
. . O O

. . O O

Comparative JJ B-NP O
genome NN I-NP O
mapping NN I-NP O
of IN B-PP O
the DT B-NP O
ataxia NN I-NP B-Disease
- HYPH B-NP I-Disease
telangiectasia NN I-NP I-Disease
region NN I-NP O
in IN B-PP O
mouse NN B-NP O
, , O O
rat NN B-NP O
, , O O
and CC O O
Syrian JJ B-NP O
hamster NN I-NP O
. . O O

Chromosomal JJ B-NP O
locations NNS I-NP O
of IN B-PP O
the DT B-NP O
Atm NN I-NP O
( ( O O
ataxia NN B-NP B-Disease
- HYPH O I-Disease
telangiectasia NN B-NP I-Disease
( ( O O
AT NN B-NP B-Disease
) ) O O
- HYPH B-VP O
mutated VBN I-VP O
) ) O O
and CC O O
Acat1 NN B-NP O
( ( O O
mitochondrial JJ B-NP O
acetoacetyl NN I-NP O
- HYPH B-NP O
CoA NN I-NP O
thiolase NN I-NP O
) ) O O
genes NNS B-NP O
in IN B-PP O
mouse NN B-NP O
, , O O
rat NN B-NP O
, , O O
and CC O O
Syrian JJ B-NP O
hamster NN I-NP O
were VBD B-VP O
determined VBN I-VP O
by IN B-PP O
direct JJ B-NP O
R NN I-NP O
- HYPH O O
banding VBG B-VP O
FISH NN B-NP O
. . O O

Both DT B-NP O
genes NNS I-NP O
were VBD B-VP O
colocalized VBN I-VP O
to TO B-PP O
the DT B-NP O
C NN I-NP O
- HYPH B-NP O
D NN I-NP O
band NN I-NP O
of IN B-PP O
mouse NN B-NP O
chromosome NN I-NP O
9 CD I-NP O
, , O O
the DT B-NP O
proximal JJ I-NP O
end NN I-NP O
of IN B-PP O
q24 NN B-NP O
. . O O

1 CD B-NP O
of IN B-PP O
rat NN B-NP O
chromosome NN I-NP O
8 CD I-NP O
, , O O
and CC O O
qa4 NN B-NP O
- HYPH I-NP O
qa5 NN I-NP O
of IN B-PP O
Syrian JJ B-NP O
hamster NN I-NP O
chromosome NN I-NP O
12 CD I-NP O
. . O O

The DT B-NP O
regions NNS I-NP O
in IN B-PP O
the DT B-NP O
mouse NN I-NP O
and CC O O
rat NN B-NP O
were VBD B-VP O
homologous JJ B-ADJP O
to TO B-PP O
human JJ B-NP O
chromosome NN I-NP O
11q NN I-NP O
. . O O

Fine JJ B-NP O
genetic JJ I-NP O
linkage NN I-NP O
mapping NN I-NP O
of IN B-PP O
the DT B-NP O
mouse NN I-NP O
AT NN I-NP B-Disease
region NN I-NP O
was VBD B-VP O
performed VBN I-VP O
using VBG B-VP O
the DT B-NP O
interspecific JJ I-NP O
backcross NN I-NP O
mice NNS I-NP O
. . O O

Atm NN B-NP O
, , O O
Acat1 NN B-NP O
, , O O
and CC O O
Npat NN B-NP O
, , O O
which WDT B-NP O
is VBZ B-VP O
a DT B-NP O
new JJ I-NP O
gene NN I-NP O
isolated VBN B-VP O
from IN B-PP O
the DT B-NP O
AT NN I-NP O
region NN I-NP O
, , O O
and CC O O
12 CD B-NP O
flanking NN I-NP O
microsatellite NN I-NP O
DNA NN I-NP O
markers NNS I-NP O
were VBD B-VP O
examined VBN I-VP O
. . O O

No DT B-NP O
recombinations NNS I-NP O
were VBD B-VP O
found VBN I-VP O
among IN B-PP O
the DT B-NP O
Atm NN I-NP O
, , O O
Npat NN B-NP O
, , O O
Acat1 NN B-NP O
, , O O
and CC O O
D9Mit6 NN B-NP O
loci NNS I-NP O
, , O O
and CC O O
these DT B-NP O
loci NNS I-NP O
were VBD B-VP O
mapped VBN I-VP O
2 CD B-NP O
. . O O

0 CD B-NP O
cM NN I-NP O
distal JJ B-ADJP O
to TO B-PP O
D9Mit99 NN B-NP O
and CC O O
1 CD B-NP O
. . O O

3 CD B-NP O
cM NN I-NP O
proximal JJ B-ADJP O
to TO B-PP O
D9Mit102 NN B-NP O
. . O O

Comparison NN B-NP O
of IN B-PP O
the DT B-NP O
linkage NN I-NP O
map NN I-NP O
of IN B-PP O
mouse NN B-NP O
chromosome NN I-NP O
9 CD I-NP O
( ( O O
MMU9 NN B-NP O
) ) O O
and CC O O
that DT B-NP O
of IN B-PP O
human JJ B-NP O
chromosome NN I-NP O
11 CD I-NP O
( ( O O
HSA11 NN B-NP O
) ) O O
indicates VBZ B-VP O
that IN B-SBAR O
there EX B-NP O
is VBZ B-VP O
a DT B-NP O
chromosomal JJ I-NP O
rearrangement NN I-NP O
due JJ B-PP O
to TO B-PP O
an DT B-NP O
inversion NN I-NP O
between IN B-PP O
Ets1 NN B-NP O
and CC I-NP O
Atm NN I-NP O
- HYPH B-NP O
Npat NN I-NP O
- HYPH B-NP O
Acat1 NN I-NP O
and CC O O
that IN B-SBAR O
the DT B-NP O
inversion NN I-NP O
of IN B-PP O
MMU9 NN B-NP O
originated VBN B-VP O
from IN B-PP O
the DT B-NP O
chromosomal JJ I-NP O
breakage NN I-NP O
at IN B-PP O
the DT B-NP O
boundary NN I-NP O
between IN B-PP O
Gria4 NN B-NP O
and CC I-NP O
Atm NN I-NP O
- HYPH B-NP O
Npat NN I-NP O
- HYPH B-NP O
Acat1 NN I-NP O
on IN B-PP O
HSA11 NN B-NP O
. . O O

This DT B-NP O
type NN I-NP O
of IN B-PP O
inversion NN B-NP O
appeared VBD B-VP O
to TO I-VP O
be VB I-VP O
conserved VBN I-VP O
in IN B-PP O
the DT B-NP O
three CD I-NP O
rodent NN I-NP O
species NNS I-NP O
, , O O
mouse NN B-NP O
, , O O
rat NN B-NP O
, , O O
and CC O O
Syrian JJ B-NP O
hamster NN I-NP O
, , O O
using VBG B-VP O
additional JJ B-NP O
comparative JJ I-NP O
mapping NN I-NP O
data NNS I-NP O
with IN B-PP O
the DT B-NP O
Rck NN I-NP O
gene NN I-NP O
An DT B-NP O
animal NN I-NP O
model NN I-NP O
for IN B-PP O
Norrie NNP B-NP B-Disease
disease NN I-NP I-Disease
( ( O O
ND NN B-NP B-Disease
) ) O O
: : O O
gene NN B-NP O
targeting NN I-NP O
of IN B-PP O
the DT B-NP O
mouse NN I-NP O
ND NN I-NP B-Disease
gene NN I-NP O
. . O O

In IN B-SBAR O
order NN O O
to TO B-VP O
elucidate VB I-VP O
the DT B-NP O
cellular JJ I-NP O
and CC I-NP O
molecular JJ I-NP O
processes NNS I-NP O
which WDT B-NP O
are VBP B-VP O
involved VBN I-VP O
in IN B-PP O
Norrie NNP B-NP B-Disease
disease NN I-NP I-Disease
( ( O O
ND NN B-NP B-Disease
) ) O O
, , O O
we PRP B-NP O
have VBP B-VP O
used VBN I-VP O
gene NN B-NP O
targeting VBG B-VP O
technology NN B-NP O
to TO B-VP O
generate VB I-VP O
ND NN B-NP B-Disease
mutant JJ I-NP O
mice NNS I-NP O
. . O O

The DT B-NP O
murine JJ I-NP O
homologue NN I-NP O
of IN B-PP O
the DT B-NP O
ND NN I-NP B-Disease
gene NN I-NP O
was VBD B-VP O
cloned VBN I-VP O
and CC O O
shown VBN B-VP O
to TO I-VP O
encode VB I-VP O
a DT B-NP O
polypeptide NN I-NP O
that WDT B-NP O
shares VBZ B-VP O
94 CD B-NP O
% NN I-NP O
of IN B-PP O
the DT B-NP O
amino JJ I-NP O
acid NN I-NP O
sequence NN I-NP O
with IN B-PP O
its PRP$ B-NP O
human JJ I-NP O
counterpart NN I-NP O
. . O O

RNA NN B-NP O
in FW B-NP O
situ FW I-NP O
hybridization NN I-NP O
revealed VBD B-VP O
expression NN B-NP O
in IN B-PP O
retina NN B-NP O
, , O O
brain NN B-NP O
and CC O O
the DT B-NP O
olfactory JJ I-NP O
bulb NN I-NP O
and CC I-NP O
epithelium NN I-NP O
of IN B-PP O
2 CD B-NP O
week NN I-NP O
old JJ I-NP O
mice NNS I-NP O
. . O O

Hemizygous JJ B-NP O
mice NNS I-NP O
carrying VBG B-VP O
a DT B-NP O
replacement NN I-NP O
mutation NN I-NP O
in IN B-PP O
exon NN B-NP O
2 CD I-NP O
of IN B-PP O
the DT B-NP O
ND NN I-NP B-Disease
gene NN I-NP O
developed VBD B-VP O
retrolental JJ B-NP O
structures NNS I-NP O
in IN B-PP O
the DT B-NP O
vitreous JJ I-NP O
body NN I-NP O
and CC O O
showed VBD B-VP O
an DT B-NP O
overall JJ I-NP O
disorganization NN I-NP O
of IN B-PP O
the DT B-NP O
retinal JJ I-NP O
ganglion NN I-NP O
cell NN I-NP O
layer NN I-NP O
. . O O

The DT B-NP O
outer JJ I-NP O
plexiform NN I-NP O
layer NN I-NP O
disappears VBZ B-VP O
occasionally RB B-ADVP O
, , O O
resulting VBG B-VP O
in IN B-PP O
a DT B-NP O
juxtaposed VBN I-NP O
inner JJ I-NP O
and CC I-NP O
outer JJ I-NP O
nuclear JJ I-NP O
layer NN I-NP O
. . O O

At IN B-PP O
the DT B-NP O
same JJ I-NP O
regions NNS I-NP O
, , O O
the DT B-NP O
outer JJ I-NP O
segments NNS I-NP O
of IN B-PP O
the DT B-NP O
photoreceptor NN I-NP O
cell NN I-NP O
layer NN I-NP O
are VBP B-VP O
no RB I-VP O
longer RB I-VP O
present JJ I-VP O
. . O O

These DT B-NP O
ocular JJ I-NP O
findings NNS I-NP O
are VBP B-VP O
consistent JJ B-ADJP O
with IN B-PP O
observations NNS B-NP O
in IN B-PP O
ND NN B-NP B-Disease
patients NNS I-NP O
and CC O O
the DT B-NP O
generated VBN I-NP O
mouse NN I-NP O
line NN I-NP O
provides VBZ B-VP O
a DT B-NP O
faithful JJ I-NP O
model NN I-NP O
for IN B-PP O
study NN B-NP O
of IN B-PP O
early JJ B-NP O
pathogenic JJ I-NP O
events NNS I-NP O
in IN B-PP O
this DT B-NP O
severe JJ I-NP O
X NN I-NP B-Disease
- HYPH O I-Disease
linked VBN B-VP I-Disease
recessive JJ B-NP I-Disease
neurological JJ I-NP I-Disease
disorder NN I-NP I-Disease
. . O O

. . O O

The DT B-NP O
hybrid NN I-NP O
PAX3 NN I-NP O
- HYPH B-NP O
FKHR NN I-NP O
fusion NN I-NP O
protein NN I-NP O
of IN B-PP O
alveolar JJ B-NP B-Disease
rhabdomyosarcoma NN I-NP I-Disease
transforms VBZ B-VP O
fibroblasts NNS B-NP O
in IN B-PP O
culture NN B-NP O
. . O O

Pediatric JJ B-NP B-Disease
alveolar JJ I-NP I-Disease
rhabdomyosarcoma NN I-NP I-Disease
is VBZ B-VP O
characterized VBN I-VP O
by IN B-PP O
a DT B-NP O
chromosomal JJ I-NP O
translocation NN I-NP O
that WDT B-NP O
fuses VBZ B-VP O
parts NNS B-NP O
of IN B-PP O
the DT B-NP O
PAX3 NN I-NP O
and CC I-NP O
FKHR NN I-NP O
genes NNS I-NP O
. . O O

PAX3 NN B-NP O
codes VBZ B-VP O
for IN B-PP O
a DT B-NP O
transcriptional JJ I-NP O
regulator NN I-NP O
that WDT B-NP O
controls VBZ B-VP O
developmental JJ B-NP O
programs NNS I-NP O
, , O O
and CC O O
FKHR NN B-NP O
codes NNS I-NP O
for IN B-PP O
a DT B-NP O
forkhead NN I-NP O
- HYPH O O
winged VBN B-NP O
helix NN I-NP O
protein NN I-NP O
, , O O
also RB B-ADVP O
a DT B-NP O
likely JJ I-NP O
transcription NN I-NP O
factor NN I-NP O
. . O O

The DT B-NP O
PAX3 NN I-NP O
- HYPH I-NP O
FKHR NN I-NP O
fusion NN I-NP O
product NN I-NP O
retains VBZ B-VP O
the DT B-NP O
DNA NN I-NP O
binding NN I-NP O
domains NNS I-NP O
of IN B-PP O
the DT B-NP O
PAX3 NN I-NP O
protein NN I-NP O
and CC O O
the DT B-NP O
putative JJ I-NP O
activator NN I-NP O
domain NN I-NP O
of IN B-PP O
the DT B-NP O
FKHR NN I-NP O
protein NN I-NP O
. . O O

The DT B-NP O
PAX3 NN I-NP O
- HYPH I-NP O
FKHR NN I-NP O
protein NN I-NP O
has VBZ B-VP O
been VBN I-VP O
shown VBN I-VP O
to TO I-VP O
function VB I-VP O
as IN B-PP O
a DT B-NP O
transcriptional JJ I-NP O
activator NN I-NP O
. . O O

Using VBG B-VP O
the DT B-NP O
RCAS NN I-NP O
retroviral JJ I-NP O
vector NN I-NP O
, , O O
we PRP B-NP O
have VBP B-VP O
introduced VBN I-VP O
the DT B-NP O
PAX3 NN I-NP O
- HYPH B-NP O
FKHR NN I-NP O
gene NN I-NP O
into IN B-PP O
chicken NN B-NP O
embryo NN I-NP O
fibroblasts NNS I-NP O
. . O O

Expression NN B-NP O
of IN B-PP O
the DT B-NP O
PAX3 NN I-NP O
- HYPH B-NP O
FKHR NN I-NP O
protein NN I-NP O
in IN B-PP O
these DT B-NP O
cells NNS I-NP O
leads VBZ B-VP O
to TO I-VP O
transformation VB I-VP O
the DT B-NP O
cells NNS I-NP O
become VBP B-VP O
enlarged VBN I-VP O
, , O O
grow VB B-VP O
tightly RB I-VP O
packed VBN I-VP O
and CC O O
in IN B-PP O
multiple JJ B-NP O
layers NNS I-NP O
, , O O
and CC O O
acquire VB B-VP O
the DT B-NP O
ability NN I-NP O
for IN B-PP O
anchorage NN B-NP O
- HYPH B-NP O
independent JJ I-NP O
growth NN I-NP O
. . O O

This DT B-NP O
cellular JJ I-NP O
transformation NN I-NP O
in FW B-ADVP O
vitro FW I-ADVP O
will MD B-VP O
facilitate VB I-VP O
studies NNS B-NP O
on IN B-PP O
the DT B-NP O
mechanism NN I-NP O
of IN B-PP O
PAX3 NN B-NP O
- HYPH B-NP O
FKHR NN I-NP O
- HYPH B-NP O
induced VBN I-NP O
oncogenesis NN I-NP O
. . O O

. . O O

Somatic JJ B-NP O
- HYPH I-NP O
cell NN I-NP O
selection NN I-NP O
is VBZ B-VP O
a DT B-NP O
major JJ I-NP O
determinant NN I-NP O
of IN B-PP O
the DT B-NP O
blood NN I-NP O
- HYPH B-NP O
cell NN I-NP O
phenotype NN I-NP O
in IN B-PP O
heterozygotes NNS B-NP O
for IN B-PP O
glucose NN B-NP O
- HYPH B-NP O
6 CD I-NP O
- HYPH I-NP O
phosphate NN I-NP O
dehydrogenase NN I-NP O
mutations NNS I-NP O
causing VBG B-VP O
severe JJ B-NP O
enzyme NN I-NP B-Disease
deficiency NN I-NP I-Disease
. . O O

X SYM O O
- HYPH B-NP O
chromosome NN I-NP O
inactivation NN I-NP O
in IN B-PP O
mammals NNS B-NP O
is VBZ B-VP O
regarded VBN I-VP O
as IN B-PP O
an DT B-NP O
essentially RB I-NP O
random JJ I-NP O
process NN I-NP O
, , O O
but CC O O
the DT B-NP O
resulting VBG I-NP O
somatic JJ I-NP O
- HYPH I-NP O
cell NN I-NP O
mosaicism NN I-NP O
creates VBZ B-VP O
the DT B-NP O
opportunity NN I-NP O
for IN B-PP O
cell NN B-NP O
selection NN I-NP O
. . O O

In IN B-PP O
most JJS B-NP O
people NNS I-NP O
with IN B-PP O
red JJ B-NP O
- HYPH I-NP O
blood NN I-NP O
- HYPH O O
cell NN B-NP O
glucose NN I-NP B-Disease
- HYPH B-NP I-Disease
6 CD I-NP I-Disease
- HYPH I-NP I-Disease
phosphate NN I-NP I-Disease
dehydrogenase NN I-NP I-Disease
( ( O I-Disease
G6PD NN B-NP I-Disease
) ) O I-Disease
deficiency NN B-NP I-Disease
, , O O
the DT B-NP O
enzyme NN I-NP O
- HYPH B-NP O
deficient JJ I-NP O
phenotype NN I-NP O
is VBZ B-VP O
only RB I-VP O
moderately RB I-VP O
expressed VBN I-VP O
in IN B-PP O
nucleated JJ B-NP O
cells NNS I-NP O
. . O O

However RB B-ADVP O
, , O O
in IN B-PP O
a DT B-NP O
small JJ I-NP O
subset NN I-NP O
of IN B-PP O
hemizygous JJ B-NP O
males NNS I-NP O
who WP B-NP O
suffer VBP B-VP O
from IN B-PP O
chronic JJ B-NP B-Disease
nonspherocytic JJ I-NP I-Disease
hemolytic JJ I-NP I-Disease
anemia NN I-NP I-Disease
, , O O
the DT B-NP O
underlying VBG I-NP O
mutations NNS I-NP O
( ( O O
designated VBN B-VP O
class NN B-NP O
I CD I-NP O
) ) O O
cause VBP B-VP O
more JJR B-NP O
- HYPH I-NP O
severe JJ I-NP O
G6PD NN I-NP B-Disease
deficiency NN I-NP I-Disease
, , O O
and CC O O
this DT B-NP O
might MD B-VP O
provide VB I-VP O
an DT B-NP O
opportunity NN I-NP O
for IN B-PP O
selection NN B-NP O
in IN B-PP O
heterozygous JJ B-NP O
females NNS I-NP O
during IN B-PP O
development NN B-NP O
. . O O

In IN B-SBAR O
order NN O O
to TO B-VP O
test VB I-VP O
this DT B-NP O
possibility NN I-NP O
we PRP B-NP O
have VBP B-VP O
analyzed VBN I-VP O
four CD B-NP O
heterozygotes NNS I-NP O
for IN B-PP O
class NN B-NP O
I CD I-NP O
G6PD NN I-NP O
mutations NNS I-NP O
two CD B-NP O
with IN B-PP O
G6PD NN B-NP O
Portici NN I-NP O
( ( O O
1178G NN B-NP O
- SYM O O
- HYPH B-NP O
> SYM I-NP O
A NN I-NP O
) ) O O
and CC O O
two CD B-NP O
with IN B-PP O
G6PD NN B-NP O
Bari NN I-NP O
( ( O O
1187C NN B-NP O
- SYM O O
- HYPH O O
> SYM O O
T NN B-NP O
) ) O O
. . O O

We PRP B-NP O
found VBD B-VP O
that IN B-SBAR O
in IN B-PP O
fractionated VBN B-NP O
blood NN I-NP O
cell NN I-NP O
types NNS I-NP O
( ( O O
including VBG B-PP O
erythroid JJ B-NP O
, , I-NP O
myeloid JJ I-NP O
, , O O
and CC O O
lymphoid JJ B-NP O
cell NN I-NP O
lineages NNS I-NP O
) ) O O
there EX B-NP O
was VBD B-VP O
a DT B-NP O
significant JJ I-NP O
excess NN I-NP O
of IN B-PP O
G6PD NN B-NP O
- HYPH B-NP O
normal JJ I-NP O
cells NNS I-NP O
. . O O

The DT B-NP O
significant JJ I-NP O
concordance NN I-NP O
that IN B-NP O
we PRP B-NP O
have VBP B-VP O
observed VBN I-VP O
in IN B-PP O
the DT B-NP O
degree NN I-NP O
of IN B-PP O
imbalance NN B-NP O
in IN B-PP O
the DT B-NP O
different JJ I-NP O
blood NN I-NP O
- HYPH B-NP O
cell NN I-NP O
lineages NNS I-NP O
indicates VBZ B-VP O
that IN B-SBAR O
a DT B-NP O
selective JJ I-NP O
mechanism NN I-NP O
is VBZ B-VP O
likely JJ B-ADJP O
to TO B-VP O
operate VB I-VP O
at IN B-PP O
the DT B-NP O
level NN I-NP O
of IN B-PP O
pluripotent JJ B-NP O
blood NN I-NP O
stem NN I-NP O
cells NNS I-NP O
. . O O

Thus RB B-ADVP O
, , O O
it PRP B-NP O
appears VBZ B-VP O
that IN B-SBAR O
severe JJ B-NP O
G6PD NN I-NP B-Disease
deficiency NN I-NP I-Disease
affects VBZ B-VP O
adversely RB B-ADVP O
the DT B-NP O
proliferation NN I-NP O
or CC O O
the DT B-NP O
survival NN I-NP O
of IN B-PP O
nucleated JJ B-NP O
blood NN I-NP O
cells NNS I-NP O
and CC O O
that IN B-SBAR O
this DT B-NP O
phenotypic JJ I-NP O
characteristic NN I-NP O
is VBZ B-VP O
critical JJ B-ADJP O
during IN B-PP O
hematopoiesis NN B-NP O
. . O O

. . O O

Analysis NN B-NP O
of IN B-PP O
meiotic JJ B-NP O
segregation NN I-NP O
, , O O
using VBG B-VP O
single JJ B-NP O
- HYPH I-NP O
sperm NN I-NP O
typing NN I-NP O
: : O O
meiotic JJ B-NP O
drive NN I-NP O
at IN B-PP O
the DT B-NP O
myotonic JJ I-NP B-Disease
dystrophy NN I-NP I-Disease
locus NN I-NP O
. . O O

Meiotic JJ B-NP O
drive NN I-NP O
at IN B-PP O
the DT B-NP O
myotonic JJ I-NP B-Disease
dystrophy NN I-NP I-Disease
( ( O O
DM NN B-NP B-Disease
) ) O O
locus NN B-NP O
has VBZ B-VP O
recently RB I-VP O
been VBN I-VP O
suggested VBN I-VP O
as IN B-PP O
being VBG B-VP O
responsible JJ B-ADJP O
for IN B-PP O
maintaining VBG B-VP O
the DT B-NP O
frequency NN I-NP O
, , O O
in IN B-PP O
the DT B-NP O
human JJ I-NP O
population NN I-NP O
, , O O
of IN B-PP O
DM NN B-NP B-Disease
chromosomes NNS I-NP O
capable JJ B-ADJP O
of IN B-PP O
expansion NN B-NP O
to TO B-PP O
the DT B-NP O
disease NN I-NP O
state NN I-NP O
. . O O

In IN B-SBAR O
order NN O O
to TO B-VP O
test VB I-VP O
this DT B-NP O
hypothesis NN I-NP O
, , O O
we PRP B-NP O
have VBP B-VP O
studied VBN I-VP O
samples NNS B-NP O
of IN B-PP O
single JJ B-NP O
sperm NN I-NP O
from IN B-PP O
three CD B-NP O
individuals NNS I-NP O
heterozygous JJ B-ADJP O
at IN B-PP O
the DT B-NP O
DM NN I-NP B-Disease
locus NN I-NP O
, , O O
each DT B-NP O
with IN B-PP O
one CD B-NP O
allele NN I-NP O
larger JJR B-ADJP O
and CC O O
one CD B-NP O
allele NN I-NP O
smaller JJR B-NP O
than IN I-NP O
19 CD I-NP O
CTG NN I-NP O
repeats NNS I-NP O
. . O O

To TO B-VP O
guard VB I-VP O
against IN B-PP O
the DT B-NP O
possible JJ I-NP O
problem NN I-NP O
of IN B-PP O
differential JJ B-NP O
PCR NN I-NP O
amplification NN I-NP O
rates NNS I-NP O
based VBN B-PP O
on IN B-PP O
the DT B-NP O
lengths NNS I-NP O
of IN B-PP O
the DT B-NP O
alleles NNS I-NP O
, , O O
the DT B-NP O
sperm NN I-NP O
were VBD B-VP O
also RB I-VP O
typed VBN I-VP O
at IN B-PP O
another DT B-NP O
closely RB I-NP O
linked VBN I-NP O
marker NN I-NP O
whose WP$ B-NP O
allele NN I-NP O
size NN I-NP O
was VBD B-VP O
unrelated JJ B-ADJP O
to TO B-PP O
the DT B-NP O
allele NN I-NP O
size NN I-NP O
at IN B-PP O
the DT B-NP O
DM NN I-NP B-Disease
locus NN I-NP O
. . O O

Using VBG B-VP O
statistical JJ B-NP O
models NNS I-NP O
specifically RB B-VP O
designed VBN I-VP O
to TO B-VP O
study VB I-VP O
single JJ B-NP O
- HYPH I-NP O
sperm NN I-NP O
segregation NN I-NP O
data NNS I-NP O
, , O O
we PRP B-NP O
find VBP B-VP O
no DT B-NP O
evidence NN I-NP O
of IN B-PP O
meiotic JJ B-NP O
segregation NN I-NP O
distortion NN I-NP O
. . O O

The DT B-NP O
upper JJ I-NP O
limit NN I-NP O
of IN B-PP O
the DT B-NP O
two CD I-NP O
- HYPH I-NP O
sided JJ I-NP O
95 CD I-NP O
% NN I-NP O
confidence NN I-NP O
interval NN I-NP O
for IN B-PP O
the DT B-NP O
estimate NN I-NP O
of IN B-PP O
the DT B-NP O
common JJ I-NP O
segregation NN I-NP O
probability NN I-NP O
for IN B-PP O
the DT B-NP O
three CD I-NP O
donors NNS I-NP O
is VBZ B-VP O
at IN B-PP O
or CC I-PP O
below IN I-PP O
. . O O

515 CD B-NP O
for IN B-PP O
all DT B-NP O
models NNS I-NP O
considered VBN B-VP O
, , O O
and CC O O
no DT B-NP O
statistically RB I-NP O
significant JJ I-NP O
difference NN I-NP O
from IN B-PP O
. . O O

5 CD B-NP O
is VBZ B-VP O
detected VBN I-VP O
in IN B-PP O
any DT B-NP O
of IN B-PP O
the DT B-NP O
models NNS I-NP O
. . O O

This DT B-NP O
suggests VBZ B-VP O
that IN B-SBAR O
any DT B-NP O
greater JJR I-NP O
amount NN I-NP O
of IN B-PP O
segregation NN B-NP O
distortion NN I-NP O
at IN B-PP O
the DT B-NP O
myotonic JJ I-NP B-Disease
dystrophy NN I-NP I-Disease
locus NN I-NP O
must MD B-VP O
result VB I-VP O
from IN B-PP O
events NNS B-NP O
following VBG B-PP O
sperm NN B-NP O
ejaculation NN I-NP O
. . O O

LPP NN B-NP O
, , O O
the DT B-NP O
preferred JJ I-NP O
fusion NN I-NP O
partner NN I-NP O
gene NN I-NP O
of IN B-PP O
HMGIC NN B-NP O
in IN B-PP O
lipomas NNS B-NP B-Disease
, , O O
is VBZ B-VP O
a DT B-NP O
novel JJ I-NP O
member NN I-NP O
of IN B-PP O
the DT B-NP O
LIM NN I-NP O
protein NN I-NP O
gene NN I-NP O
family NN I-NP O
. . O O

A DT B-NP O
major JJ I-NP O
cytogenetic JJ I-NP O
subgroup NN I-NP O
of IN B-PP O
lipomas NNS B-NP B-Disease
is VBZ B-VP O
characterized VBN I-VP O
by IN B-PP O
recurrent JJ B-NP O
chromosome NN I-NP O
aberrations NNS I-NP O
, , O O
mainly RB B-NP O
translocations NNS I-NP O
, , O O
that WDT B-NP O
involve VBP B-VP O
chromosome NN B-NP O
segment NN I-NP O
12q13 CD I-NP O
- HYPH I-NP O
q15 NN I-NP O
. . O O

Multiple JJ B-NP O
chromosomes NNS I-NP O
have VBP B-VP O
been VBN I-VP O
found VBN I-VP O
as IN B-PP O
the DT B-NP O
translocation NN I-NP O
partners NNS I-NP O
of IN B-PP O
chromosome NN B-NP O
12 CD I-NP O
but CC I-NP O
3q27 CD I-NP O
- HYPH I-NP O
q28 NN I-NP O
is VBZ B-VP O
preferentially RB I-VP O
involved VBN I-VP O
. . O O

In IN B-PP O
previous JJ B-NP O
studies NNS I-NP O
, , O O
it PRP B-NP O
has VBZ B-VP O
been VBN I-VP O
shown VBN I-VP O
that IN B-SBAR O
the DT B-NP O
high JJ I-NP O
mobility NN I-NP O
group NN I-NP O
( ( O O
HMG NN B-NP O
) ) O O
protein NN B-NP O
gene NN I-NP O
HMGIC NN I-NP O
at IN B-PP O
12q15 CD B-NP O
is VBZ B-VP O
consistently RB I-VP O
rearranged VBN I-VP O
as IN B-PP O
a DT B-NP O
consequence NN I-NP O
of IN B-PP O
these DT B-NP O
translocations NNS I-NP O
. . O O

Here RB B-ADVP O
, , O O
we PRP B-NP O
report VBP B-VP O
the DT B-NP O
identification NN I-NP O
and CC I-NP O
characterization NN I-NP O
of IN B-PP O
the DT B-NP O
chromosome NN I-NP O
3 CD I-NP O
- HYPH I-NP O
derived VBN I-NP O
translocation NN I-NP O
partner NN I-NP O
gene NN I-NP O
, , O O
which WDT B-NP O
we PRP B-NP O
have VBP B-VP O
designated VBN I-VP O
LPP NN B-NP O
( ( O O
lipoma NN B-NP B-Disease
preferred VBN I-NP O
partner NN I-NP O
gene NN I-NP O
) ) O O
. . O O

Using VBG B-VP O
3 CD B-NP O
- HYPH I-NP O
RACE NN I-NP O
analysis NN I-NP O
of IN B-PP O
HMGIC NN B-NP O
fusion NN I-NP O
transcripts NNS I-NP O
in IN B-PP O
lipoma NN B-NP B-Disease
cell NN I-NP O
line NN I-NP O
Li AFX O O
- HYPH O O
501 CD B-NP O
/ SYM I-NP O
SV40 NN I-NP O
, , O O
ectopic JJ B-NP O
genetic JJ I-NP O
sequences NNS I-NP O
were VBD B-VP O
obtained VBN I-VP O
, , O O
which WDT B-NP O
by IN B-PP O
CASH NN B-NP O
( ( O O
chromosome NN B-NP O
assignment NN I-NP O
using VBG B-VP O
somatic JJ B-NP O
cell NN I-NP O
hybrids NNS I-NP O
) ) O O
and CC O O
FISH NN B-NP O
( ( O O
fluorescence NN B-NP O
in FW B-NP O
situ FW I-NP O
hybridization NN I-NP O
) ) O O
analysis NN B-NP O
were VBD B-VP O
found VBN I-VP O
to TO I-VP O
originate VB I-VP O
from IN B-PP O
chromosome NN B-NP O
segment NN I-NP O
3q27 CD I-NP O
- HYPH I-NP O
q28 NN I-NP O
. . O O

In IN B-PP O
Northern JJ B-NP O
blot NN I-NP O
analysis NN I-NP O
, , O O
an DT B-NP O
mRNA NN I-NP O
of IN B-PP O
over IN B-NP O
10 CD I-NP O
kb NN I-NP O
was VBD B-VP O
detected VBN I-VP O
by IN B-PP O
these DT B-NP O
ectopic JJ I-NP O
sequences NNS I-NP O
in IN B-PP O
a DT B-NP O
variety NN I-NP O
of IN B-PP O
human JJ B-NP O
tissues NNS I-NP O
but CC B-PP O
not RB B-PP O
in IN I-PP O
brain NN B-NP O
and CC O O
peripheral JJ B-NP O
blood NN I-NP O
leukocytes NNS I-NP O
. . O O

Upon IN B-PP O
partial JJ B-NP O
cDNA NN I-NP O
cloning NN I-NP O
, , O O
features NNS B-NP O
of IN B-PP O
the DT B-NP O
genetic JJ I-NP O
organization NN I-NP O
of IN B-PP O
LPP NN B-NP O
were VBD B-VP O
established VBN I-VP O
. . O O

The DT B-NP O
gene NN I-NP O
was VBD B-VP O
found VBN I-VP O
to TO I-VP O
span VB I-VP O
a DT B-NP O
genomic JJ I-NP O
region NN I-NP O
of IN B-PP O
over IN B-NP O
400 CD I-NP O
kb NN I-NP O
. . O O

Nucleotide NN B-NP O
sequence NN I-NP O
analysis NN I-NP O
of IN B-PP O
a DT B-NP O
composite JJ I-NP O
cDNA NN I-NP O
of IN B-PP O
LPP NN B-NP O
revealed VBD B-VP O
an DT B-NP O
open JJ I-NP O
reading NN I-NP O
frame NN I-NP O
of IN B-PP O
1836 CD B-NP O
nucleotides NNS I-NP O
encoding VBG B-VP O
a DT B-NP O
proline NN I-NP O
- HYPH B-NP O
rich JJ I-NP O
protein NN I-NP O
containing VBG B-VP O
a DT B-NP O
leucine NN I-NP O
- HYPH I-NP O
zipper NN I-NP O
motif NN I-NP O
in IN B-PP O
its PRP$ B-NP O
amino JJ I-NP O
- HYPH I-NP O
terminal JJ I-NP O
region NN I-NP O
and CC O O
three CD B-NP O
LIM NN I-NP O
domains NNS I-NP O
in IN B-PP O
its PRP$ B-NP O
carboxy NN I-NP O
- HYPH I-NP O
terminal JJ I-NP O
region NN I-NP O
. . O O

The DT B-NP O
LPP NN I-NP O
- HYPH B-VP O
encoded VBN B-NP O
protein NN I-NP O
should MD B-VP O
be VB I-VP O
classified VBN I-VP O
as IN B-PP O
a DT B-NP O
novel JJ I-NP O
member NN I-NP O
of IN B-PP O
the DT B-NP O
group NN I-NP O
3 CD B-NP O
proteins NNS I-NP O
of IN B-PP O
the DT B-NP O
LIM NN I-NP O
protein NN I-NP O
gene NN I-NP O
family NN I-NP O
. . O O

Using VBG B-VP O
reverse JJ B-NP O
transcriptase NN I-NP O
combined VBN B-VP O
with IN B-PP O
polymerase NN B-NP O
chain NN I-NP O
reactions NNS I-NP O
in IN B-PP O
the DT B-NP O
analysis NN I-NP O
of IN B-PP O
a DT B-NP O
number NN I-NP O
of IN B-PP O
lipoma NN B-NP B-Disease
cell NN I-NP O
lines NNS I-NP O
and CC O O
primary JJ B-NP B-Disease
lipomas NNS I-NP I-Disease
, , O O
it PRP B-NP O
appeared VBD B-VP O
that IN B-SBAR O
LPP NN B-NP O
is VBZ B-VP O
frequently RB I-VP O
rearranged VBN I-VP O
also RB B-ADVP O
in IN B-PP O
cases NNS B-NP O
without IN B-PP O
a DT B-NP O
cytogenetically RB I-NP O
detectable JJ I-NP O
involvement NN I-NP O
of IN B-PP O
3q27 CD B-NP O
- HYPH I-NP O
q28 NN I-NP O
. . O O

Two CD B-NP O
alternative JJ I-NP O
HMGIC NN I-NP O
/ SYM B-NP O
LPP NN I-NP O
hybrid NN I-NP O
transcripts NNS I-NP O
have VBP B-VP O
been VBN I-VP O
detected VBN I-VP O
; : O O
the DT B-NP O
difference NN I-NP O
between IN B-PP O
them PRP B-NP O
is VBZ B-VP O
mainly RB B-ADVP O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
either CC B-NP O
two CD I-NP O
or CC I-NP O
three CD I-NP O
LIM NN I-NP O
domains NNS I-NP O
in IN B-PP O
the DT B-NP O
predicted VBN I-NP O
HMGI NN I-NP O
- HYPH I-NP O
C NN I-NP O
/ SYM I-NP O
LPP NN I-NP O
fusion NN I-NP O
proteins NNS I-NP O
. . O O

. . O O

Absence NN B-NP O
of IN B-PP O
disease NN B-NP O
phenotype NN I-NP O
and CC O O
intergenerational JJ B-NP O
stability NN I-NP O
of IN B-PP O
the DT B-NP O
CAG NN I-NP O
repeat NN I-NP O
in IN B-PP O
transgenic JJ B-NP O
mice NNS I-NP O
expressing VBG B-VP O
the DT B-NP O
human JJ I-NP O
Huntington NNP I-NP B-Disease
disease NN I-NP I-Disease
transcript NN I-NP O
. . O O

The DT B-NP O
mutation NN I-NP O
underlying VBG B-VP O
Huntington NNP B-NP B-Disease
disease NN I-NP I-Disease
( ( O O
HD NN B-NP B-Disease
) ) O O
is VBZ B-VP O
CAG NN B-NP O
expansion NN I-NP O
in IN B-PP O
the DT B-NP O
first JJ I-NP O
exon NN I-NP O
of IN B-PP O
the DT B-NP O
HD NN I-NP B-Disease
gene NN I-NP O
. . O O

In IN B-SBAR O
order NN O O
to TO B-VP O
investigate VB I-VP O
the DT B-NP O
role NN I-NP O
of IN B-PP O
CAG NN B-NP O
expansion NN I-NP O
in IN B-PP O
the DT B-NP O
pathogenesis NN I-NP O
of IN B-PP O
HD NN B-NP B-Disease
, , O O
we PRP B-NP O
have VBP B-VP O
produced VBN I-VP O
transgenic JJ B-NP O
mice NNS I-NP O
containing VBG B-VP O
the DT B-NP O
full JJ I-NP O
length NN I-NP O
human JJ I-NP O
HD NN I-NP B-Disease
cDNA NN I-NP O
with IN B-PP O
44 CD B-NP O
CAG NN I-NP O
repeats NNS I-NP O
. . O O

By IN B-PP O
1 CD B-NP O
year NN I-NP O
, , O O
these DT B-NP O
mice NNS I-NP O
have VBP B-VP O
no DT B-NP O
behavioral JJ I-NP B-Disease
abnormalities NNS I-NP I-Disease
and CC O O
morphometric JJ B-NP O
analysis NN I-NP O
at IN B-PP O
6 CD B-NP O
( ( O O
one CD B-NP O
animal NN I-NP O
) ) O O
and CC O O
9 CD B-NP O
( ( O O
two CD B-NP O
animals NNS I-NP O
) ) O O
months NNS B-NP O
age NN I-NP O
revealed VBD B-VP O
no DT B-NP O
changes NNS I-NP O
. . O O

Despite IN B-PP O
high JJ B-NP O
levels NNS I-NP O
of IN B-PP O
mRNA NN B-NP O
expression NN I-NP O
, , O O
there EX B-NP O
was VBD B-VP O
no DT B-NP O
evidence NN I-NP O
of IN B-PP O
the DT B-NP O
HD NN I-NP B-Disease
gene NN I-NP O
product NN I-NP O
in IN B-PP O
any DT B-NP O
of IN B-PP O
these DT B-NP O
transgenic JJ I-NP O
mice NNS I-NP O
. . O O

In FW B-NP O
vitro FW I-NP O
transfection NN I-NP O
studies NNS I-NP O
indicated VBD B-VP O
that IN B-SBAR O
the DT B-NP O
inclusion NN I-NP O
of IN B-PP O
120 CD B-NP O
bp NN I-NP O
of IN B-PP O
the DT B-NP O
5 CD I-NP O
UTR NN I-NP O
in IN B-PP O
the DT B-NP O
cDNA NN I-NP O
construct NN I-NP O
and CC O O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
a DT B-NP O
frameshift NN I-NP O
mutation NN I-NP O
at IN B-PP O
nucleotide NN B-NP O
2349 CD I-NP O
prevented VBD B-VP O
expression NN B-NP O
of IN B-PP O
the DT B-NP O
HD NN I-NP B-Disease
cDNA NN I-NP O
. . O O

These DT B-NP O
findings NNS I-NP O
suggest VBP B-VP O
that IN B-SBAR O
the DT B-NP O
pathogenesis NN I-NP O
of IN B-PP O
HD NN B-NP B-Disease
is VBZ B-VP O
not RB I-VP O
mediated VBN I-VP O
through IN B-PP O
DNA NN B-NP O
- HYPH B-NP O
protein NN I-NP O
interaction NN I-NP O
and CC O O
that IN B-SBAR O
presence NN B-NP O
of IN B-PP O
the DT B-NP O
RNA NN I-NP O
transcript NN I-NP O
with IN B-PP O
an DT B-NP O
expanded VBN I-NP O
CAG NN I-NP O
repeat NN I-NP O
is VBZ B-VP O
insufficient JJ B-ADJP O
to TO B-VP O
cause VB I-VP O
the DT B-NP O
disease NN I-NP O
. . O O

Rather RB B-ADVP O
, , O O
translation NN B-NP O
of IN B-PP O
the DT B-NP O
CAG NN I-NP O
is VBZ B-VP O
crucial JJ B-ADJP O
for IN B-PP O
the DT B-NP O
pathogenesis NN I-NP O
of IN B-PP O
HD NN B-NP B-Disease
. . O O

In IN B-PP O
contrast NN B-NP O
to TO B-PP O
that DT B-NP O
seen VBN B-VP O
in IN B-PP O
humans NNS B-NP O
, , O O
the DT B-NP O
CAG NN I-NP O
repeat NN I-NP O
in IN B-PP O
these DT B-NP O
mice NNS I-NP O
was VBD B-VP O
remarkably RB B-ADJP O
stable JJ I-ADJP O
in IN B-PP O
97 CD B-NP O
meioses NNS I-NP O
. . O O

This DT B-NP O
suggests VBZ B-VP O
that IN B-SBAR O
genomic JJ B-NP O
sequences NNS I-NP O
may MD B-VP O
play VB I-VP O
a DT B-NP O
critical JJ I-NP O
role NN I-NP O
in IN B-PP O
influencing VBG B-VP O
repeat NN B-NP O
instability NN I-NP O
. . O O

. . O O

FISH NN B-NP O
studies NNS I-NP O
in IN B-PP O
a DT B-NP O
patient NN I-NP O
with IN B-PP O
sporadic JJ B-NP B-Disease
aniridia NN I-NP I-Disease
and CC O O
t NN B-NP O
( ( O O
7 CD B-NP O
; : O O
11 CD B-NP O
) ) O O
( ( O O
q31 NN B-NP O
. . I-NP O

2 CD I-NP O
; : O O
p13 NN B-NP O
) ) O O
. . O O

A DT B-NP O
2 CD I-NP O
year NN I-NP O
old JJ I-NP O
female NN I-NP O
presenting VBG B-VP O
with IN B-PP O
bilateral JJ B-NP B-Disease
sporadic JJ I-NP I-Disease
aniridia NN I-NP I-Disease
was VBD B-VP O
found VBN I-VP O
to TO I-VP O
have VB I-VP O
an DT B-NP O
apparently RB I-NP O
balanced JJ I-NP O
reciprocal JJ I-NP O
translocation NN I-NP O
with IN B-PP O
a DT B-NP O
chromosome NN I-NP O
11 CD I-NP O
breakpoint NN I-NP O
within IN B-PP O
band NN B-NP O
p13 NN I-NP O
. . O O

Fluorescence NN B-NP O
in FW B-NP O
situ FW I-NP O
hybridisation NN I-NP O
( ( O O
FISH NN B-NP O
) ) O O
studies NNS B-NP O
with IN B-PP O
distal JJ B-NP O
11p13 NN I-NP O
specific JJ I-NP O
cosmids NNS I-NP O
showed VBD B-VP O
that IN B-SBAR O
the DT B-NP O
chromosome NN I-NP O
11 CD I-NP O
breakpoint NN I-NP O
lay NN I-NP O
between IN B-PP O
the DT B-NP O
aniridia NN I-NP B-Disease
( ( O O
PAX6 NN B-NP O
) ) O O
locus NN B-NP O
and CC O O
a DT B-NP O
region NN I-NP O
approximately RB B-NP O
100 CD I-NP O
kb NN I-NP O
distal JJ B-ADJP O
to TO B-PP O
PAX6 NN B-NP O
defined VBN B-VP O
by IN B-PP O
the DT B-NP O
cosmid NN I-NP O
FO2121 NN I-NP O
. . O O

Although IN B-SBAR O
this DT B-NP O
patient NN I-NP O
did VBD B-VP O
not RB I-VP O
have VB I-VP O
a DT B-NP O
detectable JJ I-NP O
deletion NN I-NP O
within IN B-PP O
PAX6 NN B-NP O
, , O O
her PRP$ B-NP O
aniridia NN I-NP B-Disease
may MD B-VP O
have VB I-VP O
resulted VBN I-VP O
from IN B-PP O
a DT B-NP O
disruption NN I-NP O
of IN B-PP O
the DT B-NP O
distal JJ I-NP O
chromatin NN I-NP O
domain NN I-NP O
containing VBG B-VP O
either CC O O
enhancers NNS B-NP O
or CC O O
regulators NNS B-NP O
for IN B-PP O
PAX6 NN B-NP O
. . O O

This DT B-NP O
case NN I-NP O
may MD B-VP O
therefore RB I-VP O
be VB I-VP O
another DT B-NP O
example NN I-NP O
of IN B-PP O
aniridia NN B-NP B-Disease
caused VBN B-VP O
by IN B-PP O
a DT B-NP O
position NN I-NP O
effect NN I-NP O
as IN B-PP O
recently RB B-ADVP O
described VBN B-VP O
in IN B-PP O
two CD B-NP O
familial JJ I-NP B-Disease
aniridia NN I-NP I-Disease
patients NNS I-NP O
in IN B-PP O
which WDT B-NP O
the DT B-NP O
phenotype NN I-NP O
cosegregated VBN B-VP O
with IN B-PP O
chromosome NN B-NP B-Disease
abnormalities NNS I-NP I-Disease
with IN B-PP O
11p13 NN B-NP O
breakpoints NNS I-NP O
. . O O

. . O O

Muscle NN B-NP O
expression NN I-NP O
of IN B-PP O
glucose NN B-NP B-Disease
- HYPH B-NP I-Disease
6 CD I-NP I-Disease
- HYPH I-NP I-Disease
phosphate NN I-NP I-Disease
dehydrogenase NN I-NP I-Disease
deficiency NN I-NP I-Disease
in IN B-PP O
different JJ B-NP O
variants NNS I-NP O
. . O O

Muscle NN B-NP O
expression NN I-NP O
of IN B-PP O
G6PD NN B-NP B-Disease
deficiency NN I-NP I-Disease
has VBZ B-VP O
been VBN I-VP O
investigated VBN I-VP O
in IN B-PP O
Mediterranean NNP B-NP O
, , O O
Seattle NNP B-NP O
- HYPH B-NP O
like JJ I-NP O
and CC I-NP O
A NN I-NP O
- HYPH I-NP O
variants NNS I-NP O
. . O O

G6PD NN B-NP O
activity NN I-NP O
was VBD B-VP O
detected VBN I-VP O
in IN B-PP O
samples NNS B-NP O
obtained VBN B-VP O
from IN B-PP O
biopsies NNS B-NP O
on IN B-PP O
the DT B-NP O
quadriceps NNS I-NP O
muscle NN I-NP O
of IN B-PP O
seven CD B-NP O
males NNS I-NP O
and CC O O
one CD B-NP O
female JJ I-NP O
. . O O

The DT B-NP O
type NN I-NP O
of IN B-PP O
genetic JJ B-NP O
variant NN I-NP O
was VBD B-VP O
determined VBN I-VP O
by IN B-PP O
molecular JJ B-NP O
analysis NN I-NP O
of IN B-PP O
DNA NN B-NP O
, , O O
extracted VBN B-VP O
from IN B-PP O
blood NN B-NP O
samples NNS I-NP O
. . O O

All DT B-NP O
variants NNS I-NP O
showed VBD B-VP O
the DT B-NP O
enzyme NN I-NP O
defect NN I-NP O
in IN B-PP O
muscle NN B-NP O
. . O O

A DT B-NP O
statistically RB I-NP O
significant JJ I-NP O
relationship NN I-NP O
was VBD B-VP O
found VBN I-VP O
in IN B-PP O
the DT B-NP O
activity NN I-NP O
of IN B-PP O
G6PD NN B-NP O
between IN B-PP O
erythrocytes NNS B-NP O
and CC O O
muscle NN B-NP O
of IN B-PP O
the DT B-NP O
male JJ I-NP O
subjects NNS I-NP O
( ( O O
r NN B-NP O
= SYM B-VP O
0 CD B-NP O
. . O O

968 CD B-NP O
; : O O
p NN B-NP O
= SYM B-VP O
0 CD B-NP O
. SYM I-NP O

00008 CD I-NP O
) ) O O
. . O O

The DT B-NP O
equation NN I-NP O
for IN B-PP O
the DT B-NP O
best JJS I-NP O
fit NN I-NP O
line NN I-NP O
was VBD B-VP O
Y NN B-NP O
= SYM B-VP O
0 CD B-NP O
. . O O

390X NN B-NP O
+ SYM B-VP O
0 CD B-NP O
. . O O

198 CD B-NP O
198 CD I-NP O
. . O O

The DT B-NP O
results NNS I-NP O
suggest VBP B-VP O
that IN B-SBAR O
, , O O
for IN B-PP O
a DT B-NP O
given VBN I-NP O
variant NN I-NP O
, , O O
the DT B-NP O
extent NN I-NP O
of IN B-PP O
the DT B-NP O
enzyme NN I-NP O
defect NN I-NP O
in IN B-PP O
muscle NN B-NP O
may MD B-VP O
be VB I-VP O
determined VBN I-VP O
, , O O
using VBG B-VP O
this DT B-NP O
equation NN I-NP O
, , O O
from IN B-PP O
the DT B-NP O
G6PD NN I-NP O
activity NN I-NP O
of IN B-PP O
erythrocytes NNS B-NP O
Gene NN B-NP O
therapy NN I-NP O
for IN B-PP O
phenylketonuria NN B-NP B-Disease
. . O O

Classical JJ B-NP O
phenylketonuria NN I-NP B-Disease
( ( O O
PKU NN B-NP B-Disease
) ) O O
is VBZ B-VP O
an DT B-NP O
autosomal JJ I-NP B-Disease
recessive JJ I-NP I-Disease
disorder NN I-NP I-Disease
caused VBN B-VP O
by IN B-PP O
a DT B-NP O
deficiency NN I-NP B-Disease
of IN B-PP I-Disease
hepatic JJ B-NP I-Disease
phenylalanine NN I-NP I-Disease
hydroxylase NN I-NP I-Disease
( ( O O
PAH NN B-NP O
) ) O O
. . O O

Limitations NNS B-NP O
of IN B-PP O
the DT B-NP O
current JJ I-NP O
dietary JJ I-NP O
treatment NN I-NP O
for IN B-PP O
PKU NN B-NP B-Disease
have VBP B-VP O
led VBN I-VP O
to TO B-PP O
the DT B-NP O
development NN I-NP O
of IN B-PP O
potential JJ B-NP O
treatments NNS I-NP O
based VBN B-VP O
on IN B-PP O
somatic JJ B-NP O
gene NN I-NP O
transfer NN I-NP O
. . O O

Three CD B-NP O
different JJ I-NP O
vector NN I-NP O
systems NNS I-NP O
have VBP B-VP O
been VBN I-VP O
examined VBN I-VP O
. . O O

Vectors NNS B-NP O
derived VBN B-VP O
from IN B-PP O
a DT B-NP O
recombinant JJ I-NP O
retrovirus NN I-NP O
or CC O O
a DT B-NP O
DNA NN I-NP O
/ SYM B-NP O
protein NN I-NP O
complex NN I-NP O
can MD B-VP O
efficiently RB I-VP O
transduce VB I-VP O
the DT B-NP O
PAH NN I-NP O
cDNA NN I-NP O
into IN B-PP O
PAH NN B-NP B-Disease
- HYPH B-NP I-Disease
deficient JJ I-NP I-Disease
hepatocytes NNS I-NP O
in FW B-ADVP O
vitro FW I-ADVP O
, , O O
but CC O O
the DT B-NP O
application NN I-NP O
of IN B-PP O
these DT B-NP O
vector NN I-NP O
systems NNS I-NP O
is VBZ B-VP O
presently RB I-VP O
limited VBN I-VP O
by IN B-PP O
their PRP$ B-NP O
low JJ I-NP O
transduction NN I-NP O
efficiency NN I-NP O
in FW B-ADVP O
vivo FW I-ADVP O
. . O O

In IN B-PP O
contrast NN B-NP O
, , O O
a DT B-NP O
vector NN I-NP O
derived VBN B-VP O
from IN B-PP O
a DT B-NP O
recombinant JJ I-NP O
adenovirus NN I-NP O
can MD B-VP O
restore VB I-VP O
10 CD B-NP O
% NN I-NP O
- HYPH B-NP O
80 CD I-NP O
% NN I-NP O
of IN B-PP O
normal JJ B-NP O
hepatic JJ I-NP O
PAH NN I-NP O
activity NN I-NP O
into IN B-PP O
PAH NN B-NP B-Disease
- HYPH B-NP I-Disease
deficient JJ I-NP I-Disease
mice NNS I-NP O
, , O O
which WDT B-NP O
completely RB B-VP O
normalizes VBZ I-VP O
serum NN B-NP O
phenylalanine NN I-NP O
levels NNS I-NP O
. . O O

This DT B-NP O
treatment NN I-NP O
is VBZ B-VP O
transient JJ B-ADJP O
and CC O O
cannot MD B-VP O
be VB I-VP O
effectively RB B-ADVP O
re AFX O O
- HYPH O O
administered VBN B-VP O
due JJ B-ADJP O
to TO B-PP O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
neutralizing VBG B-VP O
antibodies NNS B-NP O
directed VBN B-VP O
against IN B-PP O
the DT B-NP O
recombinant JJ I-NP O
adenoviral JJ I-NP O
vector NN I-NP O
. . O O

However RB B-ADVP O
, , O O
these DT B-NP O
findings NNS I-NP O
suggest VBP B-VP O
that IN B-SBAR O
PKU NN B-NP B-Disease
can MD B-VP O
be VB I-VP O
completely RB I-VP O
corrected VBN I-VP O
by IN B-PP O
somatic JJ B-NP O
gene NN I-NP O
therapy NN I-NP O
, , O O
and CC O O
provide VBP B-VP O
some DT B-NP O
direction NN I-NP O
for IN B-PP O
the DT B-NP O
future JJ I-NP O
development NN I-NP O
of IN B-PP O
adenoviral JJ B-NP O
vectors NNS I-NP O
. . O O

. . O O

Exon NN B-NP O
- HYPH I-NP O
intron NN I-NP O
structure NN I-NP O
of IN B-PP O
the DT B-NP O
human JJ I-NP O
neuronal JJ I-NP O
nicotinic JJ I-NP O
acetylcholine NN I-NP O
receptor NN I-NP O
alpha NN I-NP O
4 CD I-NP O
subunit NN I-NP O
( ( O O
CHRNA4 NN B-NP O
) ) O O
. . O O

The DT B-NP O
human JJ I-NP O
neuronal JJ I-NP O
nicotinic JJ I-NP O
acetylcholine NN I-NP O
receptor NN I-NP O
alpha NN I-NP O
4 CD I-NP O
subunit NN I-NP O
gene NN I-NP O
( ( O O
CHRNA4 NN B-NP O
) ) O O
is VBZ B-VP O
located VBN I-VP O
in IN B-PP O
the DT B-NP O
candidate NN I-NP O
region NN I-NP O
for IN B-PP O
three CD B-NP O
different JJ I-NP O
phenotypes NNS I-NP O
benign JJ B-NP B-Disease
familial JJ I-NP I-Disease
neonatal JJ I-NP I-Disease
convulsions NNS I-NP I-Disease
, , O O
autosomal JJ B-NP B-Disease
dominant JJ I-NP I-Disease
nocturnal JJ I-NP I-Disease
frontal JJ I-NP I-Disease
lobe NN I-NP I-Disease
epilepsy NN I-NP I-Disease
, , O O
and CC O O
low JJ B-NP O
- HYPH I-NP O
voltage NN I-NP O
EEG NN I-NP O
. . O O

Recently RB B-ADVP O
, , O O
a DT B-NP O
missense JJ I-NP O
mutation NN I-NP O
in IN B-PP O
transmembrane NN B-NP O
domain NN I-NP O
2 CD I-NP O
of IN B-PP O
CHRNA4 NN B-NP O
was VBD B-VP O
found VBN I-VP O
to TO I-VP O
be VB I-VP O
associated VBN I-VP O
with IN B-PP O
autosomal JJ B-NP B-Disease
dominant JJ I-NP I-Disease
nocturnal JJ I-NP I-Disease
frontal JJ I-NP I-Disease
lobe NN I-NP I-Disease
epilepsy NN I-NP I-Disease
in IN B-PP O
one CD B-NP O
extended VBN I-NP O
pedigree NN I-NP O
. . O O

We PRP B-NP O
have VBP B-VP O
determined VBN I-VP O
the DT B-NP O
genomic JJ I-NP O
organization NN I-NP O
of IN B-PP O
CHRNA4 NN B-NP O
, , O O
which WDT B-NP O
consists VBZ B-VP O
of IN B-PP O
six CD B-NP O
exons NNS I-NP O
distributed VBN B-VP O
over IN B-PP O
approximately RB B-NP O
17 CD I-NP O
kb NN I-NP O
of IN B-PP O
genomic JJ B-NP O
DNA NN I-NP O
. . O O

The DT B-NP O
nucleotide NN I-NP O
sequence NN I-NP O
obtained VBN B-VP O
from IN B-PP O
the DT B-NP O
genomic JJ I-NP O
regions NNS I-NP O
adjacent JJ B-ADJP O
to TO B-PP O
the DT B-NP O
exon NN I-NP O
boundaries NNS I-NP O
enabled VBD B-VP O
us PRP B-NP O
to TO B-VP O
develop VB I-VP O
a DT B-NP O
set NN I-NP O
of IN B-PP O
primer NN B-NP O
pairs NNS I-NP O
for IN B-PP O
PCR NN B-NP O
amplification NN I-NP O
of IN B-PP O
the DT B-NP O
complete JJ I-NP O
coding VBG I-NP O
region NN I-NP O
. . O O

The DT B-NP O
sequence NN I-NP O
analysis NN I-NP O
provides VBZ B-VP O
the DT B-NP O
basis NN I-NP O
for IN B-PP O
a DT B-NP O
comprehensive JJ I-NP O
mutation NN I-NP O
screening NN I-NP O
of IN B-PP O
CHRNA4 NN B-NP O
in IN B-PP O
the DT B-NP O
above RB I-NP O
- HYPH I-NP O
mentioned VBN I-NP O
phenotypes NNS I-NP O
and CC O O
possibly RB B-ADVP O
in IN B-PP O
other JJ B-NP O
types NNS I-NP O
of IN B-PP O
idiopathic JJ B-NP B-Disease
epilepsies NNS I-NP I-Disease
. . O O

. . O O

Ashkenazi NN B-NP O
Jewish JJ I-NP O
population NN I-NP O
frequencies NNS I-NP O
for IN B-PP O
common JJ B-NP O
mutations NNS I-NP O
in IN B-PP O
BRCA1 NN B-NP O
and CC I-NP O
BRCA2 NN I-NP O
. . O O

BRCA1 NN B-NP O
and CC I-NP O
BRCA2 NN I-NP O
are VBP B-VP O
the DT B-NP O
two CD I-NP O
major JJ I-NP O
identified VBN I-NP O
causes NNS I-NP O
of IN B-PP O
inherited VBN B-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
, , O O
with IN B-PP O
mutations NNS B-NP O
in IN B-PP O
either DT B-NP O
gene NN I-NP O
conferring VBG B-VP O
up IN B-NP O
to TO I-NP O
80 CD I-NP O
- HYPH I-NP O
90 CD I-NP O
% NN I-NP O
lifetime NN I-NP O
risk NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
in IN B-PP O
carrier NN B-NP O
females NNS I-NP O
. . O O

Mutations NNS B-NP O
in IN B-PP O
BRCA1 NN B-NP O
account NN I-NP O
for IN B-PP O
approximately RB B-NP O
45 CD I-NP O
% NN I-NP O
of IN B-PP O
familial JJ B-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
and CC O O
90 CD B-NP O
% NN I-NP O
of IN B-PP O
inherited VBN B-NP B-Disease
breast NN I-NP I-Disease
/ SYM B-NP I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
, , O O
whereas IN O O
mutations NNS B-NP O
in IN B-PP O
BRCA2 NN B-NP O
account NN I-NP O
for IN B-PP O
a DT B-NP O
comparable JJ I-NP O
percentage NN I-NP O
of IN B-PP O
inherited VBN B-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
cases NNS I-NP O
. . O O

Over IN B-PP O
85 CD B-NP O
distinct JJ I-NP O
BRCA1 NN I-NP O
mutations NNS I-NP O
and CC O O
a DT B-NP O
growing VBG I-NP O
list NN I-NP O
of IN B-PP O
BRCA2 NN B-NP O
mutations NNS I-NP O
have VBP B-VP O
been VBN I-VP O
identified VBN I-VP O
, , O O
with IN B-PP O
the DT B-NP O
majority NN I-NP O
resulting VBG B-VP O
in IN B-PP O
protein NN B-NP O
truncation NN I-NP O
. . O O

A DT B-NP O
specific JJ I-NP O
BRCA1 NN I-NP O
mutation NN I-NP O
, , O O
185delAG NN B-NP O
, , O O
has VBZ B-VP O
a DT B-NP O
reported VBN I-NP O
increased VBN I-NP O
carrier NN I-NP O
frequency NN I-NP O
of IN B-PP O
approximately RB B-NP O
0 CD I-NP O
. . O O

9 CD B-NP O
% NN I-NP O
in IN B-PP O
the DT B-NP O
Ashkenazi NNP I-NP O
Jewish NNP I-NP O
population NN I-NP O
, , O O
but CC O O
is VBZ B-VP O
also RB I-VP O
found VBN I-VP O
in IN B-PP O
rare JJ B-NP O
non AFX I-NP O
- HYPH I-NP O
Jewish JJ B-NP O
patients NNS I-NP O
with IN B-PP O
a DT B-NP O
different JJ I-NP O
haplotype NN I-NP O
. . O O

The DT B-NP O
6174delT NN I-NP O
mutation NN I-NP O
in IN B-PP O
BRCA2 NN B-NP O
was VBD B-VP O
recently RB I-VP O
identified VBN I-VP O
as IN B-PP O
a DT B-NP O
frequent JJ I-NP O
mutation NN I-NP O
in IN B-PP O
8 CD B-NP O
out IN I-NP O
of IN I-NP O
107 CD I-NP O
Ashkenazi NN I-NP O
Jewish JJ I-NP O
women NNS I-NP O
diagnosed VBN B-VP O
with IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
by IN B-PP O
age NN B-NP O
50 CD I-NP O
( ( O O
ref NN B-NP O
. . O O

8 CD B-NP O
) ) O O
, , O O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
in IN B-PP O
three CD B-NP O
Ashkenazi NNP I-NP O
male JJ I-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
patients NNS I-NP O
. . O O

We PRP B-NP O
have VBP B-VP O
conducted VBN I-VP O
a DT B-NP O
large JJ I-NP O
- HYPH I-NP O
scale NN I-NP O
population NN I-NP O
study NN I-NP O
to TO B-VP O
investigate VB I-VP O
the DT B-NP O
prevalence NN I-NP O
of IN B-PP O
specific JJ B-NP O
BRCA1 NN I-NP O
and CC I-NP O
BRCA2 NN I-NP O
mutations NNS I-NP O
in IN B-PP O
Ashkenazi NNP B-NP O
Jewish JJ I-NP O
individuals NNS I-NP O
who WP B-NP O
were VBD B-VP O
unselected VBN I-VP O
for IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
. . O O

BRCA1 NN B-NP O
mutation NN I-NP O
screening NN I-NP O
on IN B-PP O
approximately RB B-NP O
3 CD I-NP O
, , I-NP O
000 CD I-NP O
Ashkenazi NNP I-NP O
Jewish NNP I-NP O
samples NNS I-NP O
determined VBD B-VP O
a DT B-NP O
carrier NN I-NP O
frequency NN I-NP O
of IN B-PP O
1 CD B-NP O
. . O O

09 CD B-NP O
% NN I-NP O
for IN B-PP O
the DT B-NP O
185delAG NN I-NP O
mutation NN I-NP O
and CC O O
0 CD B-NP O
. . O O

13 CD B-NP O
% NN I-NP O
for IN B-PP O
the DT B-NP O
5382insC NN I-NP O
mutation NN I-NP O
. . O O

BRCA2 NN B-NP O
analysis NN I-NP O
on IN B-PP O
3 CD B-NP O
, , O O
085 CD B-NP O
individuals NNS I-NP O
from IN B-PP O
the DT B-NP O
same JJ I-NP O
population NN I-NP O
showed VBD B-VP O
a DT B-NP O
carrier NN I-NP O
frequency NN I-NP O
of IN B-PP O
1 CD B-NP O
. . O O

52 CD B-NP O
% NN I-NP O
for IN B-PP O
the DT B-NP O
6174delT NN I-NP O
mutation NN I-NP O
. . O O

This DT B-NP O
expanded VBN I-NP O
population NN I-NP O
- HYPH O O
based VBN B-NP O
study NN I-NP O
confirms VBZ B-VP O
that IN B-SBAR O
the DT B-NP O
BRCA1 NN I-NP O
185delAG NN I-NP O
mutation NN I-NP O
and CC O O
the DT B-NP O
BRCA2 NN I-NP O
6174delT NN I-NP O
mutation NN I-NP O
constitute VBP B-VP O
the DT B-NP O
two CD I-NP O
most RBS I-NP O
frequent JJ I-NP O
mutation NN I-NP O
alleles NNS I-NP O
predisposing VBG B-VP O
to TO B-PP O
hereditary JJ B-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
among IN B-PP O
the DT B-NP O
Ashkenazim NNP I-NP O
, , O O
and CC O O
suggests VBZ B-VP O
a DT B-NP O
relatively RB I-NP O
lower JJR I-NP O
penetrance NN I-NP O
for IN B-PP O
the DT B-NP O
6174delT NN I-NP O
mutation NN I-NP O
in IN B-PP O
BRCA2 NN B-NP O
Dual JJ B-NP O
roles NNS I-NP O
of IN B-PP O
ATM NN B-NP O
in IN B-PP O
the DT B-NP O
cellular JJ I-NP O
response NN I-NP O
to TO B-PP O
radiation NN B-NP O
and CC O O
in IN B-PP O
cell NN B-NP O
growth NN I-NP O
control NN I-NP O
. . O O

The DT B-NP O
gene NN I-NP O
mutated VBN B-VP O
in IN B-PP O
ataxia NN B-NP B-Disease
- HYPH O I-Disease
telangiectasia NN B-NP I-Disease
( ( O O
AT NN B-NP B-Disease
) ) O O
patients NNS B-NP O
, , O O
denoted VBN B-VP O
ATM NNP B-NP O
, , O O
encodes VBZ B-VP O
a DT B-NP O
putative JJ I-NP O
protein NN I-NP O
or CC I-NP O
lipid NN I-NP O
kinase NN I-NP O
. . O O

To TO B-VP O
elucidate VB I-VP O
the DT B-NP O
functions NNS I-NP O
of IN B-PP O
ATM NN B-NP O
, , O O
we PRP B-NP O
disrupted VBD B-VP O
the DT B-NP O
mouse NN I-NP O
ATM NN I-NP O
gene NN I-NP O
through IN B-PP O
homologous JJ B-NP O
recombination NN I-NP O
in IN B-PP O
mice NNS B-NP O
. . O O

Consistent JJ B-ADJP O
with IN B-PP O
cellular JJ B-NP O
defects NNS I-NP O
of IN B-PP O
AT NN B-NP B-Disease
patients NNS I-NP O
, , O O
the DT B-NP O
ATM NN I-NP O
- HYPH O O
/ SYM O O
- HYPH O O
cells NNS B-NP O
are VBP B-VP O
hypersensitive JJ B-ADJP O
to TO B-PP O
gamma SYM O O
- HYPH O O
irradiation NN B-NP O
and CC O O
defective JJ B-ADJP O
in IN B-PP O
cell NN B-NP O
- HYPH B-NP O
cycle NN I-NP O
arrest NN I-NP O
following VBG B-PP O
radiation NN B-NP O
, , O O
correlating VBG B-VP O
with IN B-PP O
a DT B-NP O
defective JJ I-NP O
up RB I-NP O
- HYPH I-NP O
regulation NN B-NP O
of IN B-PP O
p53 NN B-NP O
. . O O

In IN B-PP O
addition NN B-NP O
, , O O
ATM NN B-NP O
- HYPH O O
/ SYM O O
- HYPH O O
mouse NN B-NP O
thymocytes NNS I-NP O
are VBP B-VP O
more RBR B-ADJP O
resistant JJ I-ADJP O
to TO B-PP O
apoptosis NN B-NP O
induced VBN B-VP O
by IN B-PP O
gamma SYM B-NP O
- HYPH O O
irradiation NN B-NP O
than IN B-PP O
normal JJ B-NP O
thymocytes NNS I-NP O
. . O O

ATM NN B-NP O
- HYPH O O
/ SYM O O
- HYPH O O
fibroblasts NNS B-NP O
are VBP B-VP O
inefficient JJ B-ADJP O
in IN B-PP O
G1 NN B-NP O
to TO B-PP O
S NN B-NP O
- HYPH B-NP O
phase NN I-NP O
progression NN I-NP O
following VBG B-PP O
serum NN B-NP O
stimulation NN I-NP O
and CC O O
senesce NN B-NP O
after IN B-PP O
only RB B-NP O
a DT I-NP O
few JJ I-NP O
passages NNS I-NP O
in IN B-PP O
culture NN B-NP O
. . O O

They PRP B-NP O
have VBP B-VP O
an DT B-NP O
increased VBN I-NP O
constitutive JJ I-NP O
level NN I-NP O
of IN B-PP O
p21CP1 NN B-NP O
/ SYM B-NP O
WAF1 NN I-NP O
. . O O

The DT B-NP O
ATM NN I-NP O
protein NN I-NP O
is VBZ B-VP O
therefore RB B-ADVP O
critical JJ B-ADJP O
both CC B-PP O
for IN I-PP O
cellular JJ B-NP O
responses NNS I-NP O
to TO B-PP O
ionizing VBG B-VP O
radiation NN B-NP O
and CC B-PP O
for IN B-PP O
normal JJ B-NP O
cell NN I-NP O
- HYPH B-NP O
cycle NN I-NP O
progression NN I-NP O
. . O O

ATM NN B-NP O
+ SYM O O
/ SYM B-NP O
- HYPH B-NP O
fibroblasts NNS I-NP O
and CC I-NP O
thymocytes NNS I-NP O
showed VBD B-VP O
intermediately RB B-NP O
defective JJ I-NP O
responses NNS I-NP O
to TO B-PP O
irradiation NN B-NP O
but CC O O
no DT B-NP O
growth NN I-NP O
defect NN I-NP O
, , O O
suggesting VBG B-VP O
that IN B-SBAR O
the DT B-NP O
increased VBN I-NP O
cancer NN I-NP B-Disease
risk NN I-NP O
of IN B-PP O
AT NN B-NP B-Disease
heterozygotes NNS I-NP O
could MD B-VP O
be VB I-VP O
attributable JJ B-ADJP O
to TO B-PP O
poor JJ B-NP O
checkpoint NN I-NP O
function NN I-NP O
. . O O

. . O O

Targeted VBN B-NP O
disruption NN I-NP O
of IN B-PP O
ATM NN B-NP O
leads VBZ B-VP O
to TO B-PP O
growth NN B-NP B-Disease
retardation NN I-NP I-Disease
, , O O
chromosomal JJ B-NP B-Disease
fragmentation NN I-NP I-Disease
during IN B-PP I-Disease
meiosis NN B-NP I-Disease
, , O O
immune JJ B-NP B-Disease
defects NNS I-NP I-Disease
, , O O
and CC O O
thymic JJ B-NP B-Disease
lymphoma NN I-NP I-Disease
. . O O

ATM NN B-NP O
, , O O
the DT B-NP O
gene NN I-NP O
mutated VBN B-VP O
in IN B-PP O
the DT B-NP O
inherited VBN I-NP B-Disease
human JJ I-NP I-Disease
disease NN I-NP I-Disease
ataxia NN I-NP B-Disease
- HYPH B-NP I-Disease
telangiectasia NN I-NP I-Disease
, , O O
is VBZ B-VP O
a DT B-NP O
member NN I-NP O
of IN B-PP O
a DT B-NP O
family NN I-NP O
of IN B-PP O
kinases NNS B-NP O
involved VBN B-VP O
in IN B-PP O
DNA NN B-NP O
metabolism NN I-NP O
and CC I-NP O
cell NN I-NP O
- HYPH B-NP O
cycle NN I-NP O
checkpoint NN I-NP O
control NN I-NP O
. . O O

To TO B-VP O
help VB I-VP O
clarify VB I-VP O
the DT B-NP O
physiological JJ I-NP O
roles NNS I-NP O
of IN B-PP O
the DT B-NP O
ATM NN I-NP O
protein NN I-NP O
, , O O
we PRP B-NP O
disrupted VBD B-VP O
the DT B-NP O
ATM NN I-NP O
gene NN I-NP O
in IN B-PP O
mice NNS B-NP O
through IN B-PP O
homologous JJ B-NP O
recombination NN I-NP O
. . O O

Initial JJ B-NP O
evaluation NN I-NP O
of IN B-PP O
the DT B-NP O
ATM NN I-NP O
knockout NN I-NP O
animals NNS I-NP O
indicates VBZ B-VP O
that IN B-SBAR O
inactivation NN B-NP O
of IN B-PP O
the DT B-NP O
mouse NN I-NP O
ATM NN I-NP O
gene NN I-NP O
recreates VBZ B-VP O
much JJ B-NP O
of IN B-PP O
the DT B-NP O
phenotype NN I-NP O
of IN B-PP O
ataxia NN B-NP B-Disease
- HYPH B-NP I-Disease
telangiectasia NN I-NP I-Disease
. . O O

The DT B-NP O
homozygous JJ I-NP O
mutant NN I-NP O
( ( O O
ATM NN B-NP O
- HYPH O O
/ SYM O O
- SYM O O
) ) O O
mice NNS B-NP O
are VBP B-VP O
viable JJ B-ADJP O
, , O O
growth NN B-NP O
- HYPH O O
retarded VBN B-VP O
, , O O
and CC O O
infertile JJ B-ADJP O
. . O O

The DT B-NP O
infertility NN I-NP B-Disease
of IN B-PP O
ATM NN B-NP O
- HYPH B-NP O
/ SYM I-NP O
- HYPH I-NP O
mice NNS I-NP O
results VBZ B-VP O
from IN B-PP O
meiotic JJ B-NP O
failure NN I-NP O
. . O O

Meiosis NN B-NP O
is VBZ B-VP O
arrested VBN I-VP O
at IN B-PP O
the DT B-NP O
zygotene NN I-NP O
/ SYM B-NP O
pachytene NN I-NP O
stage NN I-NP O
of IN B-PP O
prophase NN B-NP O
I CD I-NP O
as IN B-PP O
a DT B-NP O
result NN I-NP O
of IN B-PP O
abnormal JJ B-NP O
chromosomal JJ I-NP O
synapsis NN I-NP O
and CC O O
subsequent JJ B-NP O
chromosome NN I-NP O
fragmentation NN I-NP O
. . O O

Immune JJ B-NP B-Disease
defects NNS I-NP I-Disease
also RB B-ADVP O
are VBP B-VP O
evident JJ B-ADJP O
in IN B-PP O
ATM NN B-NP O
- HYPH B-NP O
/ SYM I-NP O
- HYPH I-NP O
mice NNS I-NP O
, , O O
including VBG B-PP O
reduced VBN B-NP O
numbers NNS I-NP O
of IN B-PP O
B220 NN B-NP O
+ SYM B-NP O
CD43 NN I-NP O
- HYPH B-NP O
pre AFX I-NP O
- HYPH I-NP O
B NN I-NP O
cells NNS I-NP O
, , O O
thymocytes NNS B-NP O
, , O O
and CC O O
peripheral JJ B-NP O
T NN I-NP O
cells NNS I-NP O
, , O O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
functional JJ B-NP O
impairment NN I-NP O
of IN B-PP O
T NN B-NP O
- HYPH B-NP O
cell NN I-NP O
- HYPH I-NP O
dependent JJ I-NP O
immune JJ I-NP O
responses NNS I-NP O
. . O O

The DT B-NP O
cerebella NN I-NP O
of IN B-PP O
ATM NN B-NP O
- HYPH O O
/ SYM O O
- HYPH O O
mice NNS B-NP O
appear VBP B-VP O
normal JJ B-ADJP O
by IN B-PP O
histologic JJ B-NP O
examination NN I-NP O
at IN B-PP O
3 CD B-NP O
to TO I-NP O
4 CD I-NP O
months NNS I-NP O
and CC O O
the DT B-NP O
mice NNS I-NP O
have VBP B-VP O
no DT B-NP O
gross JJ I-NP O
behavioral JJ I-NP B-Disease
abnormalities NNS I-NP I-Disease
. . O O

The DT B-NP O
majority NN I-NP O
of IN B-PP O
mutant JJ B-NP O
mice NNS I-NP O
rapidly RB B-ADVP O
develop VBP B-VP O
thymic JJ B-NP B-Disease
lymphomas NNS I-NP I-Disease
and CC O O
die VB B-VP O
before IN B-PP O
4 CD B-NP O
months NNS I-NP O
of IN B-PP O
age NN B-NP O
. . O O

These DT B-NP O
findings NNS I-NP O
indicate VBP B-VP O
that IN B-SBAR O
the DT B-NP O
ATM NN I-NP O
gene NN I-NP O
product NN I-NP O
plays VBZ B-VP O
an DT B-NP O
essential JJ I-NP O
role NN I-NP O
in IN B-PP O
a DT B-NP O
diverse JJ I-NP O
group NN I-NP O
of IN B-PP O
cellular JJ B-NP O
processes NNS I-NP O
, , O O
including VBG B-PP O
meiosis NN B-NP O
, , O O
the DT B-NP O
normal JJ I-NP O
growth NN I-NP O
of IN B-PP O
somatic JJ B-NP O
tissues NNS I-NP O
, , O O
immune JJ B-NP O
development NN I-NP O
, , O O
and CC O O
tumor NN B-NP B-Disease
suppression NN I-NP O
. . O O

. . O O

Cloning NN B-NP O
and CC I-NP O
characterization NN I-NP O
of IN B-PP O
human JJ B-NP O
very RB I-NP O
- HYPH I-NP O
long JJ I-NP O
- HYPH I-NP O
chain NN I-NP O
acyl NN I-NP O
- HYPH B-NP O
CoA NN I-NP O
dehydrogenase NN I-NP O
cDNA NN I-NP O
, , O O
chromosomal JJ B-NP O
assignment NN I-NP O
of IN B-PP O
the DT B-NP O
gene NN I-NP O
and CC I-NP O
identification NN I-NP O
in IN B-PP O
four CD B-NP O
patients NNS I-NP O
of IN B-PP O
nine CD B-NP O
different JJ I-NP O
mutations NNS I-NP O
within IN B-PP O
the DT B-NP O
VLCAD NN I-NP O
gene NN I-NP O
. . O O

Very NN B-NP O
- HYPH B-NP O
long JJ I-NP O
- HYPH I-NP O
chain NN I-NP O
acyl NN I-NP O
- HYPH O O
CoA NN B-NP O
dehydrogenase NN I-NP O
( ( O O
VLCAD NN B-NP O
) ) O O
is VBZ B-VP O
one CD B-NP O
of IN B-PP O
four CD B-NP O
straight JJ I-NP O
- HYPH I-NP O
chain NN I-NP O
acyl NN I-NP O
- HYPH O O
CoA NN B-NP O
dehydrogenase NN I-NP O
( ( O O
ACD NN B-NP O
) ) O O
enzymes NNS B-NP O
, , O O
which WDT B-NP O
are VBP B-VP O
all DT B-NP O
nuclear JJ I-NP O
encoded VBN I-NP O
mitochondrial JJ I-NP O
flavoproteins NNS I-NP O
catalyzing VBG B-VP O
the DT B-NP O
initial JJ I-NP O
step NN I-NP O
in IN B-PP O
fatty JJ B-NP O
acid NN I-NP O
beta SYM B-VP O
- HYPH O O
oxidation NN B-NP O
. . O O

We PRP B-NP O
have VBP B-VP O
used VBN I-VP O
the DT B-NP O
very RB I-NP O
fast JJ I-NP O
, , I-NP O
Rapid JJ I-NP O
Amplification NN I-NP O
of IN B-PP O
cDNA NN B-NP O
Ends NNS I-NP O
( ( O O
RACE NN B-NP O
) ) O O
based JJ B-NP O
strategy NN I-NP O
to TO B-VP O
obtain VB I-VP O
the DT B-NP O
sequence NN I-NP O
of IN B-PP O
cDNAs NNS B-NP O
encoding VBG B-VP O
human JJ B-NP O
VLCAD NN I-NP O
from IN B-PP O
placenta NN B-NP O
and CC I-NP O
fibroblasts NNS I-NP O
. . O O

Alignment NN B-NP O
of IN B-PP O
the DT B-NP O
predicted VBN I-NP O
amino NN I-NP O
acid NN I-NP O
sequence NN I-NP O
of IN B-PP O
human JJ B-NP O
VLCAD NN I-NP O
with IN B-PP O
those DT B-NP O
of IN B-PP O
the DT B-NP O
other JJ I-NP O
human JJ I-NP O
ACD NN I-NP O
enzymes NNS I-NP O
revealed VBD B-VP O
extensive JJ B-NP O
sequence NN I-NP O
homology NN I-NP O
. . O O

Moreover RB B-ADVP O
, , O O
human JJ B-NP O
VLCAD NN I-NP O
and CC O O
human JJ B-NP O
acyl NN I-NP O
- HYPH B-NP O
CoA NN I-NP O
oxidase NN I-NP O
showed VBD B-VP O
extensive JJ B-NP O
sequence NN I-NP O
homology NN I-NP O
corroborating VBG B-VP O
the DT B-NP O
notion NN I-NP O
that IN B-SBAR O
these DT B-NP O
genes NNS I-NP O
are VBP B-VP O
evolutionarily RB B-ADJP O
related VBN I-ADJP O
. . O O

Southern NN B-NP O
blot NN I-NP O
analysis NN I-NP O
of IN B-PP O
genomic JJ B-NP O
DNA NN I-NP O
from IN B-PP O
hybrid JJ B-NP O
cell NN I-NP O
lines NNS I-NP O
was VBD B-VP O
used VBN I-VP O
to TO B-VP O
localize VB I-VP O
the DT B-NP O
VLCAD NN I-NP O
gene NN I-NP O
to TO B-PP O
human JJ B-NP O
chromosome NN I-NP O
17p11 NN I-NP O
. . O O

2 CD B-NP O
- HYPH I-NP O
p11 NN I-NP O
. . O O

13105 CD B-NP O
. . O O

Using VBG B-VP O
Northern JJ B-NP O
and CC I-NP O
Western JJ I-NP O
blot NN I-NP O
analysis NN I-NP O
to TO B-VP O
investigate VB I-VP O
the DT B-NP O
tissue NN I-NP O
specific JJ I-NP O
distribution NN I-NP O
of IN B-PP O
VLCAD NN B-NP O
mRNA NN I-NP O
and CC I-NP O
protein NN I-NP O
in IN B-PP O
several JJ B-NP O
human JJ I-NP O
tissues NNS I-NP O
we PRP B-NP O
showed VBD B-VP O
that IN B-SBAR O
VLCAD NN B-NP O
is VBZ B-VP O
most RBS B-ADJP O
abundant JJ I-ADJP O
in IN B-PP O
heart NN B-NP O
and CC O O
skeletal JJ B-NP O
muscle NN I-NP O
. . O O

This DT B-NP O
agrees VBZ B-VP O
well RB B-ADVP O
with IN B-PP O
the DT B-NP O
fact NN I-NP O
that IN B-SBAR O
cardiac JJ B-NP O
and CC I-NP O
muscle NN I-NP O
symptoms NNS I-NP O
are VBP B-VP O
characteristic JJ B-ADJP O
for IN B-PP O
patients NNS B-NP O
with IN B-PP O
VLCAD NN B-NP B-Disease
deficiency NN I-NP I-Disease
. . O O

Northern NN B-NP O
blot NN I-NP O
analysis NN I-NP O
and CC I-NP O
sequencing NN I-NP O
of IN B-PP O
cloned VBN B-NP O
PCR NN I-NP O
amplified VBN I-NP O
VLCAD NN I-NP O
cDNA NN I-NP O
from IN B-PP O
four CD B-NP O
unrelated JJ I-NP O
patients NNS I-NP O
with IN B-PP O
VLCAD NN B-NP B-Disease
deficiency NN I-NP I-Disease
showed VBD B-VP O
that IN B-SBAR O
VLCAD NN B-NP O
mRNA NN I-NP O
was VBD B-VP O
undetectable JJ B-ADJP O
in IN B-PP O
one CD B-NP O
patient NN I-NP O
and CC O O
that IN B-SBAR O
the DT B-NP O
other JJ I-NP O
three CD I-NP O
have VBP B-VP O
mutations NNS B-NP O
in IN B-PP O
both DT B-NP O
VLCAD NN I-NP O
alleles NNS I-NP O
. . O O

Western NN B-NP O
blot NN I-NP O
analysis NN I-NP O
of IN B-PP O
patient NN B-NP O
fibroblasts NNS I-NP O
showed VBD B-VP O
that IN B-SBAR O
the DT B-NP O
identified VBN I-NP O
mutations NNS I-NP O
result VBP B-VP O
in IN B-PP O
severely RB B-NP O
reduced VBN I-NP O
amounts NNS I-NP O
of IN B-PP O
VLCAD NN B-NP O
protein NN I-NP O
. . O O

Molecular JJ B-NP O
bases NNS I-NP O
of IN B-PP O
combined JJ B-NP B-Disease
subtotal JJ I-NP I-Disease
deficiencies NNS I-NP I-Disease
of IN B-PP I-Disease
C6 NN B-NP I-Disease
and CC I-NP I-Disease
C7 NN I-NP I-Disease
: : O O
their PRP$ B-NP O
effects NNS I-NP O
in IN B-PP O
combination NN B-NP O
with IN B-PP O
other JJ B-NP O
C6 NN I-NP B-Disease
and CC I-NP I-Disease
C7 NN I-NP I-Disease
deficiencies NNS I-NP I-Disease
. . O O

Combined VBN B-NP B-Disease
subtotal JJ I-NP I-Disease
deficiency NN I-NP I-Disease
of IN B-PP I-Disease
C6 NN B-NP I-Disease
and CC I-NP I-Disease
C7 NN I-NP I-Disease
, , O O
in IN B-PP O
which WDT B-NP O
both DT B-NP O
proteins NNS I-NP O
are VBP B-VP O
expressed VBN I-VP O
at IN B-PP O
very RB B-NP O
low JJ I-NP O
levels NNS I-NP O
, , O O
has VBZ B-VP O
been VBN I-VP O
observed VBN I-VP O
in IN B-PP O
homozygous JJ B-NP O
form NN I-NP O
in IN B-PP O
two CD B-NP O
families NNS I-NP O
. . O O

A DT B-NP O
defect NN I-NP O
at IN B-PP O
the DT B-NP O
5 CD I-NP O
splice NN I-NP O
donor NN I-NP O
site NN I-NP O
of IN B-PP O
intron NN B-NP O
15 CD I-NP O
of IN B-PP O
the DT B-NP O
C6 NN I-NP O
gene NN I-NP O
explains VBZ B-VP O
the DT B-NP O
low JJ I-NP O
molecular JJ I-NP O
weight NN I-NP O
of IN B-PP O
the DT B-NP O
C6 NN I-NP O
protein NN I-NP O
and CC O O
is VBZ B-VP O
probably RB B-ADVP O
responsible JJ B-ADJP O
for IN B-PP O
its PRP$ B-NP O
low JJ I-NP O
expressed VBN I-NP O
concentration NN I-NP O
. . O O

The DT B-NP O
C7 NN I-NP O
defect NN I-NP O
is VBZ B-VP O
more RBR B-ADJP O
enigmatic JJ I-ADJP O
the DT B-NP O
protein NN I-NP O
is VBZ B-VP O
of IN B-PP O
normal JJ B-NP O
molecular JJ I-NP O
weight NN I-NP O
, , O O
low JJ B-NP O
circulating VBG I-NP O
concentration NN I-NP O
, , O O
and CC O O
altered VBN B-VP O
isoelectric JJ B-NP O
point NN I-NP O
. . O O

An DT B-NP O
Arg NN I-NP O
> SYM B-NP O
Ser NN I-NP O
codon NN I-NP O
substitution NN I-NP O
in IN B-PP O
exon NN B-NP O
11 CD I-NP O
is VBZ B-VP O
the DT B-NP O
only RB I-NP O
molecular JJ I-NP O
alteration NN I-NP O
within IN B-PP O
the DT B-NP O
mature JJ I-NP O
C7 NN I-NP O
protein NN I-NP O
. . O O

These DT B-NP O
defects NNS I-NP O
are VBP B-VP O
associated VBN I-VP O
with IN B-PP O
a DT B-NP O
characteristic JJ I-NP O
set NN I-NP O
of IN B-PP O
polymorphic JJ B-NP O
DNA NN I-NP O
markers NNS I-NP O
in IN B-PP O
the DT B-NP O
C6 NN I-NP O
/ SYM B-NP O
C7 NN I-NP O
region NN I-NP O
, , O O
forming VBG B-VP O
a DT B-NP O
distinct JJ I-NP O
haplotype NN I-NP O
. . O O

The DT B-NP O
haplotype NN I-NP O
has VBZ B-VP O
been VBN I-VP O
found VBN I-VP O
in IN B-PP O
combination NN B-NP O
with IN B-PP O
a DT B-NP O
number NN I-NP O
of IN B-PP O
other JJ B-NP O
haplotypes NNS I-NP O
containing VBG B-VP O
defective JJ B-NP O
genes NNS I-NP O
that WDT B-NP O
lead VBP B-VP O
either CC B-PP O
to TO B-PP O
C6 NN B-NP B-Disease
or CC I-NP I-Disease
C7 NN I-NP I-Disease
deficiency NN I-NP I-Disease
, , O O
but CC O O
with IN B-PP O
different JJ B-NP O
consequences NNS I-NP O
. . O O

Where WRB B-ADVP O
it PRP B-NP O
is VBZ B-VP O
combined VBN I-VP O
with IN B-PP O
a DT B-NP O
C6 NN I-NP B-Disease
- HYPH B-NP I-Disease
deficient JJ I-NP I-Disease
gene NN I-NP O
, , O O
the DT B-NP O
serum NN I-NP O
C7 NN I-NP O
levels NNS I-NP O
can MD B-VP O
be VB I-VP O
surprisingly RB B-ADJP O
high JJ I-ADJP O
, , O O
possibly RB B-ADVP O
because IN B-SBAR O
there EX B-NP O
is VBZ B-VP O
no DT B-NP O
C6 NN I-NP O
generating VBG B-VP O
C56 NN B-NP O
to TO B-VP O
consume VB I-VP O
the DT B-NP O
C7 NN I-NP O
. . O O

In IN B-PP O
contrast NN B-NP O
, , O O
where WRB B-ADVP O
the DT B-NP O
C7 NN I-NP O
genes NNS I-NP O
are VBP B-VP O
both CC O O
defective JJ O O
( ( O O
but CC O O
still RB B-ADJP O
partially RB I-ADJP O
functional JJ I-ADJP O
) ) O O
, , O O
there EX B-NP O
may MD B-VP O
be VB I-VP O
a DT B-NP O
profound JJ I-NP O
deficit NN I-NP O
of IN B-PP O
circulating VBG B-VP O
C7 NN B-NP O
because IN B-SBAR O
there EX B-NP O
is VBZ B-VP O
ample JJ B-NP O
C6 NN I-NP O
to TO B-VP O
produce VB I-VP O
C56 NN B-NP O
and CC O O
consume VB B-VP O
the DT B-NP O
already RB I-NP O
small JJ I-NP O
amount NN I-NP O
of IN B-PP O
C7 NN B-NP O
. . O O

Each DT B-NP O
molecular JJ I-NP O
defect NN I-NP O
has VBZ B-VP O
also RB I-VP O
been VBN I-VP O
found VBN I-VP O
in IN B-PP O
isolation NN B-NP O
and CC O O
has VBZ B-VP O
the DT B-NP O
expected VBN I-NP O
effect NN I-NP O
. . O O

. . O O

Genetic JJ B-NP O
bases NNS I-NP O
of IN B-PP O
human JJ B-NP O
complement NN I-NP B-Disease
C7 NN I-NP I-Disease
deficiency NN I-NP I-Disease
. . O O

Complement NN B-NP B-Disease
C7 NN I-NP I-Disease
deficiency NN I-NP I-Disease
( ( O O
C7D NN B-NP B-Disease
) ) O O
is VBZ B-VP O
associated VBN I-VP O
frequently RB B-ADVP O
with IN B-PP O
recurrent JJ B-NP O
bacterial JJ I-NP B-Disease
infections NNS I-NP I-Disease
, , O O
especially RB B-NP O
meningitis NN I-NP B-Disease
caused VBN B-VP O
by IN B-PP O
Neisseria NNP B-NP B-Disease
meningitidis NNP I-NP I-Disease
. . O O

We PRP B-NP O
report VBP B-VP O
in IN B-PP O
this DT B-NP O
work NN I-NP O
the DT B-NP O
molecular JJ I-NP O
bases NNS I-NP O
of IN B-PP O
C7D NN B-NP B-Disease
in IN B-PP O
two CD B-NP O
unrelated JJ I-NP O
Japanese JJ I-NP O
males NNS I-NP O
. . O O

We PRP B-NP O
used VBD B-VP O
exon NN B-NP O
- HYPH B-NP O
specific JJ I-NP O
PCR NN I-NP O
/ SYM B-NP O
single JJ I-NP O
- HYPH I-NP O
strand NN I-NP O
conformation NN I-NP O
polymorphism NN I-NP O
analysis NN I-NP O
as IN B-PP O
a DT B-NP O
screening NN I-NP O
step NN I-NP O
for IN B-PP O
mutations NNS B-NP O
. . O O

Subsequent JJ B-NP O
direct JJ I-NP O
sequencing NN I-NP O
of IN B-PP O
the DT B-NP O
target NN I-NP O
exons NNS I-NP O
identified VBD B-VP O
homozygous JJ B-NP O
mutations NNS I-NP O
in IN B-PP O
exon NN B-NP O
16 CD I-NP O
of IN B-PP O
case NN B-NP O
1 CD I-NP O
and CC O O
in IN B-PP O
exon NN B-NP O
15 CD I-NP O
of IN B-PP O
case NN B-NP O
2 CD I-NP O
. . O O

The DT B-NP O
mutation NN I-NP O
of IN B-PP O
case NN B-NP O
1 CD I-NP O
was VBD B-VP O
a DT B-NP O
homozygous JJ I-NP O
T NN I-NP O
to TO B-PP O
A NN B-NP O
transversion NN I-NP O
at IN B-PP O
nucleotide NN B-NP O
2250 CD I-NP O
, , O O
the DT B-NP O
third JJ I-NP O
nucleotide NN I-NP O
of IN B-PP O
the DT B-NP O
codon NN I-NP O
TGT NN I-NP O
for IN B-PP O
Cys728 NN B-NP O
, , O O
leading VBG B-VP O
to TO B-PP O
a DT B-NP O
stop NN I-NP O
codon NN I-NP O
TGA NN I-NP O
( ( O O
C728X NN B-NP O
) ) O O
. . O O

In IN B-SBAR O
case NN O O
2 CD B-NP O
, , O O
a DT B-NP O
homozygous JJ I-NP O
2 CD I-NP O
- HYPH I-NP O
bp NN I-NP O
deletion NN I-NP O
( ( O O
2137delTG NN B-NP O
/ SYM B-NP O
2138delGT NN I-NP O
/ SYM I-NP O
2139delTG NN I-NP O
) ) O O
caused VBD B-VP O
a DT B-NP O
frameshift NN I-NP O
, , O O
generating VBG B-VP O
a DT B-NP O
premature JJ I-NP O
termination NN I-NP O
codon NN I-NP O
4 CD B-NP O
to TO I-NP O
6 CD I-NP O
nucleotides NNS I-NP O
downstream RB B-ADVP O
. . O O

Family RB B-NP O
study NN I-NP O
in IN B-PP O
case NN B-NP O
1 CD I-NP O
confirmed VBD B-VP O
the DT B-NP O
genetic JJ I-NP O
nature NN I-NP O
of IN B-PP O
the DT B-NP O
defect NN I-NP O
. . O O

Moreover RB B-ADVP O
, , O O
we PRP B-NP O
detected VBD B-VP O
a DT B-NP O
novel JJ I-NP O
polymorphism NN I-NP O
in IN B-PP O
intron NN B-NP O
11 CD I-NP O
that WDT B-NP O
presumably RB B-ADVP O
is VBZ B-VP O
linked VBN I-VP O
to TO B-PP O
the DT B-NP O
mutation NN I-NP O
responsible JJ B-ADJP O
for IN B-PP O
C7D NN B-NP B-Disease
in IN B-PP O
case NN B-NP O
1 CD I-NP O
. . O O

Our PRP$ B-NP O
results NNS I-NP O
indicate VBP B-VP O
that IN B-SBAR O
the DT B-NP O
pathogenesis NN I-NP O
of IN B-PP O
C7D NN B-NP B-Disease
is VBZ B-VP O
heterogeneous JJ B-ADJP O
like IN B-PP O
most JJS B-NP O
of IN B-PP O
the DT B-NP O
other JJ I-NP O
deficiencies NNS I-NP B-Disease
of IN B-PP I-Disease
complement NN B-NP I-Disease
components NNS I-NP I-Disease
. . O O

. . O O

HPRT NN B-NP B-Disease
- HYPH I-NP I-Disease
APRT NN I-NP I-Disease
- HYPH I-NP I-Disease
deficient JJ I-NP I-Disease
mice NNS I-NP O
are VBP B-VP O
not RB O O
a DT B-NP O
model NN I-NP O
for IN B-PP O
lesch NN B-NP B-Disease
- HYPH I-NP I-Disease
nyhan NN I-NP I-Disease
syndrome NN I-NP I-Disease
. . O O

Complete JJ B-NP B-Disease
hypoxanthine NN I-NP I-Disease
- HYPH O I-Disease
guanine NN B-NP I-Disease
phosphoribosyl NN I-NP I-Disease
- HYPH B-NP I-Disease
transferase NN I-NP I-Disease
( ( O I-Disease
HPRT NN B-NP I-Disease
) ) O I-Disease
deficiency NN B-NP I-Disease
in IN B-PP O
humans NNS B-NP O
results VBZ B-VP O
in IN B-PP O
the DT B-NP O
Lesch NNP I-NP B-Disease
- HYPH I-NP I-Disease
Nyhan NNP I-NP I-Disease
syndrome NN I-NP I-Disease
which WDT B-NP O
is VBZ B-VP O
characterized VBN I-VP O
, , O O
among IN B-PP O
other JJ B-NP O
features NNS I-NP O
, , O O
by IN B-PP O
compulsive JJ B-NP O
self AFX I-NP O
- HYPH I-NP O
injurious JJ I-NP O
behavior NN I-NP O
. . O O

HPRT NN B-NP B-Disease
- HYPH I-NP I-Disease
deficient JJ I-NP I-Disease
mice NNS I-NP O
generated VBN B-VP O
using VBG B-VP O
mouse NN B-NP O
embryonic JJ I-NP O
stem NN I-NP O
cells NNS I-NP O
exhibit VBP B-VP O
none NN B-NP O
of IN B-PP O
the DT B-NP O
behavioral JJ I-NP O
symptoms NNS I-NP O
associated VBN B-VP O
with IN B-PP O
the DT B-NP O
Lesch NNP I-NP B-Disease
- HYPH I-NP I-Disease
Nyhan NNP I-NP I-Disease
syndrome NN I-NP I-Disease
. . O O

Administration NN B-NP O
of IN B-PP O
drugs NNS B-NP O
that WDT B-NP O
inhibit VBP B-VP O
adenine NN B-NP O
phosphoribosyltransferase NN I-NP O
( ( O O
APRT NN B-NP O
) ) O O
in IN B-PP O
HPRT NN B-NP B-Disease
- HYPH B-NP I-Disease
deficient JJ I-NP I-Disease
mice NNS I-NP O
has VBZ B-VP O
produced VBN I-VP O
the DT B-NP O
suggestion NN I-NP O
that IN B-SBAR O
deficiency NN B-NP B-Disease
of IN B-PP I-Disease
APRT NN B-NP I-Disease
in IN B-PP O
combination NN B-NP O
with IN B-PP O
HPRT NN B-NP B-Disease
- HYPH I-NP I-Disease
deficiency NN I-NP I-Disease
in IN B-PP O
mice NNS B-NP O
may MD B-VP O
lead VB I-VP O
to TO B-PP O
self AFX B-NP O
- HYPH I-NP O
mutilation NN B-NP O
behavior NN I-NP O
[ ( O O
C NN B-NP O
. . O O

L NN B-NP O
. . O O

Wu NNP B-NP O
and CC I-NP O
D NNP I-NP O
. . I-NP O

W NNP I-NP O
. . I-NP O

Melton NNP I-NP O
( ( O O
1993 CD B-NP O
) ) O O
Nature NNP B-NP O
Genet NNP I-NP O
. . I-NP O

3 CD I-NP O
, , I-NP O
235 CD I-NP O
- HYPH B-NP O
240 CD I-NP O
] ) O O
. . O O

To TO B-VP O
test VB I-VP O
this DT B-NP O
proposition NN I-NP O
, , O O
we PRP B-NP O
bred VBD B-VP O
HPRT NN B-NP B-Disease
- HYPH B-NP I-Disease
APRT NN I-NP I-Disease
- HYPH B-NP I-Disease
deficient JJ I-NP I-Disease
mice NNS I-NP O
. . O O

Although IN B-SBAR O
the DT B-NP O
doubly RB I-NP O
- HYPH I-NP O
deficient JJ I-NP O
mice NNS I-NP O
excrete VBP B-VP O
adenine NN B-NP O
and CC O O
its PRP$ B-NP O
highly RB I-NP O
insoluble JJ I-NP O
derivative NN I-NP O
, , O O
2 CD B-NP O
, , I-NP O
8 CD I-NP O
- HYPH I-NP O
dihydroxyadenine NN I-NP O
, , O O
which WDT B-NP O
are VBP B-VP O
also RB I-VP O
associated VBN I-VP O
with IN B-PP O
human JJ B-NP O
APRT NN I-NP B-Disease
deficiency NN I-NP I-Disease
, , O O
additional JJ B-NP O
abnormalities NNS I-NP O
or CC O O
any DT B-NP O
self AFX I-NP O
- HYPH I-NP O
injurious JJ I-NP O
behavior NN I-NP O
were VBD B-VP O
not RB I-VP O
detected VBN I-VP O
. . O O

Thus RB B-ADVP O
, , O O
APRT NN B-NP B-Disease
- HYPH B-NP I-Disease
HPRT NN I-NP I-Disease
- HYPH I-NP I-Disease
deficient JJ I-NP I-Disease
mice NNS I-NP O
, , O O
which WDT B-NP O
are VBP B-VP O
devoid JJ B-ADJP O
of IN B-PP O
any DT B-NP O
purine NN I-NP O
salvage NN I-NP O
pathways NNS I-NP O
, , O O
show VBP B-VP O
no DT B-NP O
novel JJ I-NP O
phenotype NN I-NP O
and CC O O
are VBP B-VP O
not RB O O
a DT B-NP O
model NN I-NP O
for IN B-PP O
the DT B-NP O
behavioral JJ I-NP B-Disease
abnormalities NNS I-NP I-Disease
associated VBN B-VP O
with IN B-PP O
the DT B-NP O
Lesch NNP I-NP B-Disease
- HYPH I-NP I-Disease
Nyhan NNP I-NP I-Disease
syndrome NN I-NP I-Disease
as IN B-SBAR O
previously RB B-ADVP O
suggested VBN B-VP O
Somatic JJ B-NP O
alterations NNS I-NP O
of IN B-PP O
the DT B-NP O
DPC4 NN I-NP O
gene NN I-NP O
in IN B-PP O
human JJ B-NP O
colorectal JJ I-NP B-Disease
cancers NNS I-NP I-Disease
in FW B-ADVP O
vivo FW I-ADVP O
. . O O

BACKGROUND NN B-NP O
& CC I-NP O
AIMS NNS I-NP O
The DT B-NP O
chromosome NN I-NP O
region NN I-NP O
18q21 NN I-NP O
has VBZ B-VP O
been VBN I-VP O
shown VBN I-VP O
to TO I-VP O
be VB I-VP O
frequently RB I-VP O
deleted VBN I-VP O
in IN B-PP O
colorectal JJ B-NP B-Disease
cancers NNS I-NP I-Disease
, , O O
and CC O O
such JJ B-NP O
frequent JJ I-NP O
allelic JJ I-NP O
loss NN I-NP O
is VBZ B-VP O
a DT B-NP O
hallmark NN I-NP O
of IN B-PP O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
a DT B-NP O
tumor NN I-NP O
- HYPH I-NP O
suppressor NN I-NP O
gene NN I-NP O
. . O O

The DT B-NP O
DPC4 NN I-NP O
gene NN I-NP O
, , O O
which WDT B-NP O
is VBZ B-VP O
located JJ B-ADJP O
at IN B-PP O
18q21 NN B-NP O
, , O O
has VBZ B-VP O
been VBN I-VP O
identified VBN I-VP O
as IN B-PP O
a DT B-NP O
tumor NN I-NP O
- HYPH B-NP O
suppressor NN I-NP O
gene NN I-NP O
from IN B-PP O
examination NN B-NP O
of IN B-PP O
pancreatic JJ B-NP B-Disease
cancers NNS I-NP I-Disease
. . O O

The DT B-NP O
aim NN I-NP O
of IN B-PP O
the DT B-NP O
present JJ I-NP O
study NN I-NP O
was VBD B-VP O
to TO B-VP O
determine VB I-VP O
if IN B-SBAR O
it PRP B-NP O
might MD B-VP O
also RB I-VP O
be VB I-VP O
altered VBN I-VP O
in IN B-PP O
colorectal JJ B-NP B-Disease
cancers NNS I-NP I-Disease
. . O O

METHODS NNS B-NP O
Mutation NN I-NP O
analyses NNS I-NP O
of IN B-PP O
the DT B-NP O
DPC4 NN I-NP O
gene NN I-NP O
were VBD B-VP O
performed VBN I-VP O
on IN B-PP O
complementary JJ B-NP O
DNA NN I-NP O
samples NNS I-NP O
from IN B-PP O
31 CD B-NP O
primary JJ I-NP O
colorectal JJ I-NP B-Disease
cancer NN I-NP I-Disease
specimens NNS I-NP O
using VBG B-VP O
a DT B-NP O
combination NN I-NP O
of IN B-PP O
polymerase NN B-NP O
chain NN I-NP O
reaction NN I-NP O
, , O O
single JJ B-NP O
- HYPH I-NP O
strand NN I-NP O
conformation NN I-NP O
polymorphism NN I-NP O
, , O O
and CC O O
DNA NN B-NP O
sequencing NN I-NP O
. . O O

RESULTS NNS B-NP O
Four CD B-NP O
missense JJ I-NP O
mutations NNS I-NP O
producing VBG B-VP O
amino NN B-NP O
acid NN I-NP O
substitutions NNS I-NP O
and CC O O
a DT B-NP O
somatic JJ I-NP O
12 CD I-NP O
- HYPH I-NP O
base NN I-NP O
pair NN I-NP O
deletion NN I-NP O
in IN B-PP O
the DT B-NP O
coding VBG I-NP O
region NN I-NP O
of IN B-PP O
the DT B-NP O
DPC4 NN I-NP O
gene NN I-NP O
were VBD B-VP O
detected VBN I-VP O
in IN B-PP O
the DT B-NP O
31 CD I-NP O
cancers NNS I-NP B-Disease
( ( O O
16 CD B-NP O
% NN I-NP O
; : O O
5 CD B-NP O
of IN B-PP O
31 CD B-NP O
) ) O O
. . O O

CONCLUSIONS NNS B-NP O
The DT B-NP O
DPC4 NN I-NP O
gene NN I-NP O
may MD B-VP O
play VB I-VP O
a DT B-NP O
role NN I-NP O
as IN B-PP O
a DT B-NP O
tumor NN I-NP O
- HYPH B-NP O
suppressor NN I-NP O
gene NN I-NP O
in IN B-PP O
a DT B-NP O
fraction NN I-NP O
of IN B-PP O
colorectal JJ B-NP B-Disease
cancers NNS I-NP I-Disease
; : O O
however RB B-ADVP O
, , O O
while IN B-SBAR O
allelic JJ B-NP O
loss NN I-NP O
at IN B-PP O
18q21 NN B-NP O
is VBZ B-VP O
very RB B-VP O
often RB I-VP O
seen VBN I-VP O
in IN B-PP O
colorectal JJ B-NP B-Disease
cancers NNS I-NP I-Disease
, , O O
only RB B-NP O
a DT I-NP O
minority NN I-NP O
show NN I-NP O
DPC4 NN I-NP O
mutations NNS I-NP O
, , O O
suggesting VBG B-VP O
that IN B-SBAR O
there EX B-NP O
might MD B-VP O
be VB I-VP O
another DT B-NP O
tumor NN I-NP O
- HYPH B-NP O
suppressor NN I-NP O
gene NN I-NP O
in IN B-PP O
this DT B-NP O
chromosome NN I-NP O
region NN I-NP O
. . O O

. . O O

Pleiotropic JJ B-NP O
defects NNS I-NP O
in IN B-PP O
ataxia NN B-NP B-Disease
- HYPH O I-Disease
telangiectasia NN B-NP I-Disease
protein NN I-NP O
- HYPH B-NP O
deficient JJ I-NP O
mice NNS I-NP O
. . O O

We PRP B-NP O
have VBP B-VP O
generated VBN I-VP O
a DT B-NP O
mouse NN I-NP O
model NN I-NP O
for IN B-PP O
ataxia NN B-NP B-Disease
- HYPH B-NP I-Disease
telangiectasia NN I-NP I-Disease
by IN B-PP O
using VBG B-VP O
gene NN B-NP O
targeting NN I-NP O
to TO B-VP O
generate VB I-VP O
mice NNS B-NP O
that WDT B-NP O
do VBP B-VP O
not RB I-VP O
express VB I-VP O
the DT B-NP O
Atm NNP I-NP O
protein NN I-NP O
. . O O

Atm NN B-NP O
- HYPH I-NP O
deficient JJ I-NP O
mice NNS I-NP O
are VBP B-VP O
retarded VBN I-VP O
in IN B-PP O
growth NN B-NP O
, , O O
do VBP B-VP O
not RB I-VP O
produce VB I-VP O
mature JJ B-NP O
sperm NN I-NP O
, , O O
and CC O O
exhibit VBP B-VP O
severe JJ B-NP O
defects NNS I-NP O
in IN B-PP O
T NN B-NP O
cell NN I-NP O
maturation NN I-NP O
while IN B-SBAR O
going VBG B-VP O
on RP B-PRT O
to TO B-VP O
develop VB I-VP O
thymomas NNS B-NP B-Disease
. . O O

Atm NN B-NP O
- HYPH I-NP O
deficient JJ I-NP O
fibroblasts NNS I-NP O
grow VBP B-VP O
poorly RB B-ADVP O
in IN B-PP O
culture NN B-NP O
and CC O O
display VBP B-VP O
a DT B-NP O
high JJ I-NP O
level NN I-NP O
of IN B-PP O
double JJ B-NP O
- HYPH I-NP O
stranded JJ I-NP O
chromosome NN I-NP O
breaks NNS I-NP O
. . O O

Atm NN B-NP O
- HYPH I-NP O
deficient JJ I-NP O
thymocytes NNS I-NP O
undergo VBP B-VP O
spontaneous JJ B-NP O
apoptosis NN I-NP O
in FW B-ADVP O
vitro FW I-ADVP O
significantly RB B-NP O
more JJR I-NP O
than IN B-PP O
controls NNS B-NP O
. . O O

Atm NN B-NP O
- HYPH I-NP O
deficient JJ I-NP O
mice NNS I-NP O
then RB B-ADVP O
exhibit VBP B-VP O
many JJ B-NP O
of IN B-PP O
the DT B-NP O
same JJ I-NP O
symptoms NNS I-NP O
found VBN B-VP O
in IN B-PP O
ataxia NN B-NP B-Disease
- HYPH B-NP I-Disease
telangiectasia NN I-NP I-Disease
patients NNS I-NP O
and CC B-PP O
in IN B-PP O
cells NNS B-NP O
derived VBN B-VP O
from IN B-PP O
them PRP B-NP O
. . O O

Furthermore RB B-ADVP O
, , O O
we PRP B-NP O
demonstrate VBP B-VP O
that IN B-SBAR O
the DT B-NP O
Atm NN I-NP O
protein NN I-NP O
exists VBZ B-VP O
as IN B-SBAR O
two CD B-NP O
discrete JJ I-NP O
molecular JJ I-NP O
species NNS I-NP O
, , O O
and CC O O
that IN B-SBAR O
loss NN B-NP O
of IN B-PP O
one CD B-NP O
or CC I-NP O
of IN B-PP O
both DT B-NP O
of IN B-PP O
these DT B-NP O
can MD B-VP O
lead VB I-VP O
to TO B-PP O
the DT B-NP O
development NN I-NP O
of IN B-PP O
the DT B-NP O
disease NN I-NP O
. . O O

. . O O

The DT B-NP O
DCC NN I-NP O
protein NN I-NP O
and CC I-NP O
prognosis NN I-NP O
in IN B-PP O
colorectal JJ B-NP B-Disease
cancer NN I-NP I-Disease
. . O O

BACKGROUND NN B-NP O
Allelic JJ I-NP O
loss NN I-NP O
of IN B-PP O
chromosome NN B-NP O
18q NN I-NP O
predicts VBZ B-VP O
a DT B-NP O
poor JJ I-NP O
outcome NN I-NP O
in IN B-PP O
patients NNS B-NP O
with IN B-PP O
stage NN B-NP B-Disease
II CD I-NP I-Disease
colorectal JJ I-NP I-Disease
cancer NN I-NP I-Disease
. . O O

Although IN B-SBAR O
the DT B-NP O
specific JJ I-NP O
gene NN I-NP O
inactivated VBN B-VP O
by IN B-PP O
this DT B-NP O
allelic JJ I-NP O
loss NN I-NP O
has VBZ B-VP O
not RB I-VP O
been VBN I-VP O
elucidated VBN I-VP O
, , O O
the DT B-NP O
DCC NN I-NP O
( ( O O
deleted VBN B-VP O
in IN B-PP O
colorectal JJ B-NP B-Disease
cancer NN I-NP I-Disease
) ) O O
gene NN B-NP O
is VBZ B-VP O
a DT B-NP O
candidate NN I-NP O
. . O O

We PRP B-NP O
investigated VBD B-VP O
whether IN B-SBAR O
the DT B-NP O
expression NN I-NP O
of IN B-PP O
the DT B-NP O
DCC NN I-NP O
protein NN I-NP O
in IN B-PP O
tumor NN B-NP B-Disease
cells NNS I-NP O
is VBZ B-VP O
a DT B-NP O
prognostic JJ I-NP O
marker NN I-NP O
in IN B-PP O
colorectal JJ B-NP B-Disease
carcinoma NN I-NP I-Disease
. . O O

METHODS NNS B-NP O
The DT B-NP O
expression NN I-NP O
of IN B-PP O
DCC NN B-NP O
was VBD B-VP O
evaluated VBN I-VP O
immunohistochemically RB B-ADVP O
in IN B-PP O
132 CD B-NP O
paraffin NN I-NP O
- HYPH O O
embedded VBN B-VP O
samples NNS B-NP O
from IN B-PP O
patients NNS B-NP O
with IN B-PP O
curatively RB B-NP O
resected VBN I-NP O
stage NN I-NP B-Disease
II CD I-NP I-Disease
and CC I-NP I-Disease
III CD I-NP I-Disease
colorectal JJ I-NP I-Disease
carcinomas NNS I-NP I-Disease
. . O O

The DT B-NP O
Cox NNP I-NP O
proportional JJ I-NP O
- HYPH I-NP O
hazards NNS I-NP O
model NN I-NP O
was VBD B-VP O
used VBN I-VP O
to TO B-VP O
adjust VB I-VP O
for IN B-PP O
covariates NNS B-NP O
including VBG B-PP O
age NN B-NP O
, , O O
sex NN B-NP O
, , O O
tumor NN B-NP B-Disease
site NN I-NP O
, , O O
degree NN B-NP O
of IN B-PP O
tumor NN B-NP B-Disease
differentiation NN I-NP O
, , O O
and CC O O
use NN B-NP O
of IN B-PP O
adjuvant JJ B-NP O
therapy NN I-NP O
. . O O

RESULTS NNS B-NP O
The DT B-NP O
expression NN I-NP O
of IN B-PP O
DCC NN B-NP O
was VBD B-VP O
a DT B-NP O
strong JJ I-NP O
positive JJ I-NP O
predictive JJ I-NP O
factor NN I-NP O
for IN B-PP O
survival NN B-NP O
in IN B-PP O
both CC O O
stage NN B-NP B-Disease
II CD I-NP I-Disease
and CC O I-Disease
stage NN B-NP I-Disease
III CD I-NP I-Disease
colorectal JJ I-NP I-Disease
carcinomas NNS I-NP I-Disease
. . O O

In IN B-PP O
patients NNS B-NP O
with IN B-PP O
stage NN B-NP O
II CD I-NP O
disease NN I-NP O
whose WP$ B-NP O
tumors NNS I-NP B-Disease
expressed VBD B-VP O
DCC NN B-NP O
, , O O
the DT B-NP O
five CD I-NP O
- HYPH I-NP O
year NN I-NP O
survival NN I-NP O
rate NN I-NP O
was VBD B-VP O
94 CD B-NP O
. . O O

3 CD B-NP O
percent NN I-NP O
, , O O
whereas IN O O
in IN B-PP O
patients NNS B-NP O
with IN B-PP O
DCC NN B-NP B-Disease
- HYPH B-NP I-Disease
negative JJ I-NP I-Disease
tumors NNS I-NP I-Disease
, , O O
the DT B-NP O
survival NN I-NP O
rate NN I-NP O
was VBD B-VP O
61 CD B-NP O
. . O O

6 CD B-NP O
percent NN I-NP O
( ( O O
P NN B-NP O
< SYM B-ADJP O
0 CD B-NP O
. . I-NP O

001 CD I-NP O
) ) O O
. . O O

In IN B-PP O
patients NNS B-NP O
with IN B-PP O
stage NN B-NP B-Disease
III CD I-NP I-Disease
disease NN I-NP I-Disease
, , O O
the DT B-NP O
respective JJ I-NP O
survival NN I-NP O
rates NNS I-NP O
were VBD B-VP O
59 CD B-NP O
. . O O

3 CD B-NP O
percent NN I-NP O
and CC O O
33 CD B-NP O
. . O O

2 CD B-NP O
percent NN I-NP O
( ( O O
P NN B-NP O
= SYM B-VP O
0 CD B-NP O
. . O O

03 CD B-NP O
) ) O O
. . O O

CONCLUSIONS NNS B-NP O
DCC NN I-NP O
is VBZ B-VP O
a DT B-NP O
prognostic JJ I-NP O
marker NN I-NP O
in IN B-PP O
patients NNS B-NP O
with IN B-PP O
stage NN B-NP B-Disease
II CD I-NP I-Disease
or CC O I-Disease
stage NN B-NP I-Disease
III CD I-NP I-Disease
colorectal JJ I-NP I-Disease
cancer NN I-NP I-Disease
. . O O

In IN B-PP O
stage NN B-NP B-Disease
II CD I-NP I-Disease
colorectal JJ I-NP I-Disease
carcinomas NNS I-NP I-Disease
, , O O
the DT B-NP O
absence NN I-NP O
of IN B-PP O
DCC NN B-NP O
identifies VBZ B-VP O
a DT B-NP O
subgroup NN I-NP O
of IN B-PP O
patients NNS B-NP O
with IN B-PP O
lesions NNS B-NP O
that WDT B-NP O
behave VBP B-VP O
like IN B-PP O
stage NN B-NP B-Disease
III CD B-NP I-Disease
cancers NNS I-NP I-Disease
. . O O

These DT B-NP O
findings NNS I-NP O
may MD B-VP O
thus RB I-VP O
have VB I-VP O
therapeutic JJ B-NP O
implications NNS I-NP O
in IN B-PP O
this DT B-NP O
group NN I-NP O
of IN B-PP O
patients NNS B-NP O
Association NN B-NP O
of IN B-PP O
anxiety NN B-NP B-Disease
- HYPH B-NP I-Disease
related VBN I-NP I-Disease
traits NNS I-NP I-Disease
with IN B-PP O
a DT B-NP O
polymorphism NN I-NP O
in IN B-PP O
the DT B-NP O
serotonin NN I-NP O
transporter NN I-NP O
gene NN I-NP O
regulatory JJ I-NP O
region NN I-NP O
. . O O

Transporter NN B-NP O
- HYPH B-PP O
facilitated VBN B-NP O
uptake NN I-NP O
of IN B-PP O
serotonin NN B-NP O
( ( O O
5 CD B-NP O
- HYPH I-NP O
hydroxytryptamine NN I-NP O
or CC I-NP O
5 CD I-NP O
- HYPH I-NP O
HT NN I-NP O
) ) O O
has VBZ B-VP O
been VBN I-VP O
implicated VBN I-VP O
in IN B-PP O
anxiety NN B-NP B-Disease
in IN B-PP O
humans NNS B-NP O
and CC I-NP O
animal NN I-NP O
models NNS I-NP O
and CC O O
is VBZ B-VP O
the DT B-NP O
site NN I-NP O
of IN B-PP O
action NN B-NP O
of IN B-PP O
widely RB B-NP O
used VBN I-NP O
uptake NN I-NP O
- HYPH O O
inhibiting VBG B-VP O
antidepressant NN B-NP O
and CC O O
antianxiety JJ B-NP O
drugs NNS I-NP O
. . O O

Human JJ B-NP O
5 CD I-NP O
- HYPH I-NP O
HT NN I-NP O
transporter NN I-NP O
( ( O O
5 CD B-NP O
- HYPH I-NP O
HTT NN I-NP O
) ) I-NP O
gene NN I-NP O
transcription NN I-NP O
is VBZ B-VP O
modulated VBN I-VP O
by IN B-PP O
a DT B-NP O
common JJ I-NP O
polymorphism NN I-NP O
in IN B-PP O
its PRP$ B-NP O
upstream JJ I-NP O
regulatory JJ I-NP O
region NN I-NP O
. . O O

The DT B-NP O
short JJ I-NP O
variant NN I-NP O
of IN B-PP O
the DT B-NP O
polymorphism NN I-NP O
reduces VBZ B-VP O
the DT B-NP O
transcriptional JJ I-NP O
efficiency NN I-NP O
of IN B-PP O
the DT B-NP O
5 CD I-NP O
- HYPH I-NP O
HTT NN I-NP O
gene NN I-NP O
promoter NN I-NP O
, , O O
resulting VBG B-VP O
in IN B-PP O
decreased VBN B-NP O
5 CD I-NP O
- HYPH I-NP O
HTT NN I-NP O
expression NN I-NP O
and CC O O
5 CD B-NP O
- HYPH I-NP O
HT NN I-NP O
uptake NN I-NP O
in IN B-PP O
lymphoblasts NNS B-NP O
. . O O

Association NN B-NP O
studies NNS I-NP O
in IN B-PP O
two CD B-NP O
independent JJ I-NP O
samples NNS I-NP O
totaling VBG B-VP O
505 CD B-NP O
individuals NNS I-NP O
revealed VBD B-VP O
that IN B-SBAR O
the DT B-NP O
5 CD I-NP O
- HYPH I-NP O
HTT NN I-NP O
polymorphism NN I-NP O
accounts VBZ B-VP O
for IN B-PP O
3 CD B-NP O
to TO I-NP O
4 CD I-NP O
percent NN I-NP O
of IN B-PP O
total JJ B-NP O
variation NN I-NP O
and CC O O
7 CD B-NP O
to TO I-NP O
9 CD I-NP O
percent NN I-NP O
of IN B-PP O
inherited VBN B-NP O
variance NN I-NP O
in IN B-PP O
anxiety NN B-NP B-Disease
- HYPH O I-Disease
related VBN B-NP I-Disease
personality NN I-NP I-Disease
traits NNS I-NP I-Disease
in IN B-PP O
individuals NNS B-NP O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
sibships NNS B-NP O
. . O O

. . O O

Phenotypic JJ B-NP O
and CC I-NP O
genotypic JJ I-NP O
overlap NN I-NP O
between IN B-PP O
atelosteogenesis NN B-NP B-Disease
type NN I-NP I-Disease
2 CD I-NP I-Disease
and CC O O
diastrophic JJ B-NP B-Disease
dysplasia NN I-NP I-Disease
. . O O

Mutations NNS B-NP O
in IN B-PP O
the DT B-NP O
diastrophic JJ I-NP B-Disease
dysplasia NN I-NP I-Disease
sulfate NN I-NP O
transporter NN I-NP O
gene NN I-NP O
DTDST NN I-NP O
have VBP B-VP O
been VBN I-VP O
associated VBN I-VP O
with IN B-PP O
a DT B-NP O
family NN I-NP O
of IN B-PP O
chondrodysplasias NNS B-NP B-Disease
that WDT B-NP O
comprises VBZ B-VP O
, , O O
in IN B-PP O
order NN B-NP O
of IN B-PP O
increasing VBG B-NP O
severity NN I-NP O
, , O O
diastrophic JJ B-NP B-Disease
dysplasia NN I-NP I-Disease
( ( O O
DTD NN B-NP B-Disease
) ) O O
, , O O
atelosteogenesis NN B-NP B-Disease
type NN I-NP I-Disease
2 CD I-NP I-Disease
( ( O O
AO2 NN B-NP B-Disease
) ) O O
, , O O
and CC O O
achondrogenesis NN B-NP B-Disease
type NN I-NP I-Disease
1B NN I-NP I-Disease
( ( O O
ACG1B NN B-NP B-Disease
) ) O O
. . O O

To TO B-VP O
learn VB I-VP O
more JJR B-NP O
about IN B-PP O
the DT B-NP O
molecular JJ I-NP O
basis NN I-NP O
of IN B-PP O
DTDST NN B-NP B-Disease
chondrodysplasias NNS I-NP I-Disease
and CC O O
about IN B-NP O
genotype NN I-NP O
- HYPH I-NP O
phenotype NN I-NP O
correlations NNS I-NP O
, , O O
we PRP B-NP O
studied VBD B-VP O
fibroblast NN B-NP O
cultures NNS I-NP O
of IN B-PP O
three CD B-NP O
new JJ I-NP O
patients NNS I-NP O
one CD B-NP O
with IN B-PP O
AO NN B-NP B-Disease
- HYPH B-NP I-Disease
2 CD I-NP I-Disease
, , O O
one CD B-NP O
with IN B-PP O
DTD NN B-NP B-Disease
, , O O
and CC O O
one CD B-NP O
with IN B-PP O
an DT B-NP O
intermediate JJ I-NP O
phenotype NN I-NP O
( ( O O
AO2 NN B-NP B-Disease
/ SYM O O
DTD NN B-NP B-Disease
) ) O O
. . O O

Reduced VBN B-NP O
incorporation NN I-NP O
of IN B-PP O
inorganic JJ B-NP O
sulfate NN I-NP O
into IN B-PP O
macromolecules NNS B-NP O
was VBD B-VP O
found VBN I-VP O
in IN B-PP O
all DT B-NP O
three CD I-NP O
. . O O

Each DT B-NP O
of IN B-PP O
the DT B-NP O
three CD I-NP O
patients NNS I-NP O
was VBD B-VP O
found VBN I-VP O
to TO I-VP O
be VB I-VP O
heterozygous JJ B-ADJP O
for IN B-PP O
a DT B-NP O
c862t NN I-NP O
transition NN I-NP O
predicting VBG B-VP O
a DT B-NP O
R279W NN I-NP O
substitution NN I-NP O
in IN B-PP O
the DT B-NP O
third JJ I-NP O
extracellular JJ I-NP O
loop NN I-NP O
of IN B-PP O
DTDST NN B-NP O
. . O O

In IN B-PP O
two CD B-NP O
patients NNS I-NP O
( ( O O
DTD NN B-NP B-Disease
and CC I-NP O
AO2 NN I-NP B-Disease
/ SYM B-NP O
DTD NN I-NP B-Disease
) ) O O
, , O O
no DT B-NP O
other JJ I-NP O
structural JJ I-NP O
mutation NN I-NP O
was VBD B-VP O
found VBN I-VP O
, , O O
but CC O O
polymerase NN B-NP O
chain NN I-NP O
reaction NN I-NP O
amplification NN I-NP O
and CC O O
single JJ B-NP O
- HYPH I-NP O
strand NN I-NP O
conformation NN I-NP O
polymorphism NN I-NP O
analysis NN I-NP O
of IN B-PP O
fibroblast NN B-NP O
cDNA NN I-NP O
showed VBD B-VP O
reduced VBN B-NP O
mRNA NN I-NP O
levels NNS I-NP O
of IN B-PP O
the DT B-NP O
wild JJ I-NP O
- HYPH I-NP O
type NN I-NP O
DTDST NN I-NP O
allele NN I-NP O
these DT B-NP O
two CD I-NP O
patients NNS I-NP O
may MD B-VP O
be VB I-VP O
compound JJ B-NP O
heterozygotes NNS I-NP O
for IN B-PP O
the DT B-NP O
Finnish JJ I-NP O
mutation NN I-NP O
( ( O O
as IN B-PP O
yet RB B-ADJP O
uncharacterized JJ I-ADJP O
at IN B-PP O
the DT B-NP O
DNA NN I-NP O
level NN I-NP O
) ) O O
, , O O
which WDT B-NP O
causes VBZ B-VP O
reduced VBN I-VP O
expression NN B-NP O
of IN B-PP O
DTDST NN B-NP O
. . O O

The DT B-NP O
third JJ I-NP O
patient NN I-NP O
( ( O O
with IN B-PP O
AO2 NN B-NP B-Disease
) ) O O
had VBD B-VP O
the DT B-NP O
R279W NN I-NP O
mutation NN I-NP O
compounded VBN B-VP O
with IN B-PP O
a DT B-NP O
novel JJ I-NP O
mutation NN I-NP O
, , O O
the DT B-NP O
deletion NN I-NP O
of IN B-PP O
cytosine NN B-NP O
418 CD I-NP O
( ( O O
delta SYM O O
c418 NN B-NP O
) ) O O
, , O O
predicting VBG B-VP O
a DT B-NP O
frameshift NN I-NP O
with IN B-PP O
premature JJ B-NP O
termination NN I-NP O
. . O O

Also RB B-ADVP O
the DT B-NP O
delta NN I-NP O
c418 NN I-NP O
allele NN I-NP O
was VBD B-VP O
underrepresented VBN I-VP O
in IN B-PP O
the DT B-NP O
cDNA NN I-NP O
, , O O
in IN B-PP O
accordance NN B-NP O
with IN B-PP O
previous JJ B-NP O
observations NNS I-NP O
that IN B-NP O
premature JJ B-NP O
stop NN I-NP O
codons NNS I-NP O
reduce VBP B-VP O
mRNA NN B-NP O
levels NNS I-NP O
. . O O

The DT B-NP O
presence NN I-NP O
of IN B-PP O
the DT B-NP O
DTDST NN I-NP O
R279W NN I-NP O
mutation NN I-NP O
in IN B-PP O
a DT B-NP O
total NN I-NP O
of IN B-PP O
11 CD B-NP O
patients NNS I-NP O
with IN B-PP O
AO2 NN B-NP B-Disease
or CC I-NP O
DTD NN I-NP B-Disease
emphasizes VBZ B-VP O
the DT B-NP O
overlap NN I-NP O
between IN B-PP O
these DT B-NP O
conditions NNS I-NP O
. . O O

This DT B-NP O
mutation NN I-NP O
has VBZ B-VP O
not RB I-VP O
been VBN I-VP O
found VBN I-VP O
so RB B-ADVP O
far RB I-ADVP O
in IN B-PP O
8 CD B-NP O
analyzed VBN I-NP O
ACG1B NN I-NP B-Disease
patients NNS I-NP O
, , O O
suggesting VBG B-VP O
that IN B-SBAR O
it PRP B-NP O
allows VBZ B-VP O
some DT B-NP O
residual JJ I-NP O
activity NN I-NP O
of IN B-PP O
the DT B-NP O
sulfate NN I-NP O
transporter NN I-NP O
. . O O

. . O O

Identification NN B-NP O
of IN B-PP O
WASP NN B-NP O
mutations NNS I-NP O
, , O O
mutation NN B-NP O
hotspots NNS I-NP O
and CC O O
genotype NN B-NP O
- HYPH I-NP O
phenotype NN I-NP O
disparities NNS I-NP O
in IN B-PP O
24 CD B-NP O
patients NNS I-NP O
with IN B-PP O
the DT B-NP O
Wiskott NNP I-NP B-Disease
- HYPH I-NP I-Disease
Aldrich NNP I-NP I-Disease
syndrome NN I-NP I-Disease
. . O O

The DT B-NP O
Wiskott NNP I-NP B-Disease
- HYPH I-NP I-Disease
Aldrich NNP I-NP I-Disease
syndrome NN I-NP I-Disease
( ( O O
WAS NN B-NP B-Disease
) ) O O
, , O O
an DT B-NP O
X NN I-NP B-Disease
- HYPH B-VP I-Disease
linked VBN B-NP I-Disease
immunodeficiency NN I-NP I-Disease
disease NN I-NP I-Disease
caused VBN B-VP O
by IN B-PP O
mutation NN B-NP O
in IN B-PP O
the DT B-NP O
recently RB I-NP O
isolated VBN I-NP O
gene NN I-NP O
encoding VBG B-VP O
WAS NN B-NP B-Disease
protein NN I-NP O
( ( O O
WASP NN B-NP O
) ) O O
, , O O
is VBZ B-VP O
known VBN I-VP O
to TO I-VP O
be VB I-VP O
associated VBN I-VP O
with IN B-PP O
extensive JJ B-NP O
clinical JJ I-NP O
heterogeneity NN I-NP O
. . O O

Cumulative JJ B-NP O
mutation NN I-NP O
data NNS I-NP O
have VBP B-VP O
revealed VBN I-VP O
that IN B-SBAR O
WASP NN B-NP O
genotypes NNS I-NP O
are VBP B-VP O
also RB B-ADVP O
highly RB B-ADJP O
variable JJ I-ADJP O
among IN B-PP O
WAS NN B-NP B-Disease
patients NNS I-NP O
, , O O
but CC O O
the DT B-NP O
relationship NN I-NP O
of IN B-PP O
phenotype NN B-NP O
with IN B-PP O
genotype NN B-NP O
in IN B-PP O
this DT B-NP O
disease NN I-NP O
remains VBZ B-VP O
unclear JJ B-ADJP O
. . O O

To TO B-VP O
address VB I-VP O
this DT B-NP O
issue NN I-NP O
we PRP B-NP O
characterized VBD B-VP O
WASP NN B-NP O
mutations NNS I-NP O
in IN B-PP O
24 CD B-NP O
unrelated JJ I-NP O
WAS NN I-NP B-Disease
patients NNS I-NP O
, , O O
including VBG B-PP O
18 CD B-NP O
boys NNS I-NP O
with IN B-PP O
severe JJ B-NP O
classical JJ I-NP O
WAS NN I-NP B-Disease
and CC I-NP O
6 CD I-NP O
boys NNS I-NP O
expressing VBG B-VP O
mild JJ B-NP O
forms NNS I-NP O
of IN B-PP O
the DT B-NP O
disease NN I-NP O
, , O O
and CC O O
then RB B-VP O
examined VBD I-VP O
the DT B-NP O
degree NN I-NP O
of IN B-PP O
correlation NN B-NP O
of IN B-PP O
these DT O O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
all DT B-NP O
previously RB I-NP O
published VBN I-NP O
WASP NN I-NP O
mutations NNS I-NP O
with IN B-PP O
disease NN B-NP O
severity NN I-NP O
. . O O

By IN B-PP O
analysis NN B-NP O
of IN B-PP O
these DT B-NP O
compiled VBN I-NP O
mutation NN I-NP O
data NNS I-NP O
, , O O
we PRP B-NP O
demonstrated VBD B-VP O
clustering NN B-NP O
of IN B-PP O
WASP NN B-NP O
mutations NNS I-NP O
within IN B-PP O
the DT B-NP O
four CD I-NP O
most JJS I-NP O
N NN I-NP O
- HYPH I-NP O
terminal JJ I-NP O
exons NNS I-NP O
of IN B-PP O
the DT B-NP O
gene NN I-NP O
and CC O O
also RB B-ADVP O
identified VBD B-VP O
several JJ B-NP O
sites NNS I-NP O
within IN B-PP O
this DT B-NP O
region NN I-NP O
as IN B-PP O
hotspots NNS B-NP O
for IN B-PP O
WASP NN B-NP O
mutation NN I-NP O
. . O O

These DT B-NP O
characteristics NNS I-NP O
were VBD B-VP O
observed VBN I-VP O
, , O O
however RB B-ADVP O
, , O O
in IN B-PP O
both CC B-NP O
severe JJ I-NP O
and CC I-NP O
mild JJ I-NP O
cases NNS I-NP O
of IN B-PP O
the DT B-NP O
disease NN I-NP O
. . O O

Similarly RB B-ADVP O
, , O O
while IN B-SBAR O
the DT B-NP O
cumulative JJ I-NP O
data NNS I-NP O
revealed VBD B-VP O
a DT B-NP O
predominance NN I-NP O
of IN B-PP O
missense JJ B-NP O
mutations NNS I-NP O
among IN B-PP O
the DT B-NP O
WASP NN I-NP O
gene NN I-NP O
lesions NNS I-NP O
observed VBN B-VP O
in IN B-PP O
boys NNS B-NP O
with IN B-PP O
isolated VBN B-NP B-Disease
thrombocytopenia NN I-NP I-Disease
, , O O
missense JJ B-NP O
mutations NNS I-NP O
were VBD B-VP O
not RB I-VP O
exclusively RB I-VP O
associated VBN I-VP O
with IN B-PP O
milder JJR B-NP O
WAS NN I-NP B-Disease
phenotypes NNS I-NP O
, , O O
but CC O O
also RB B-VP O
comprised VBD I-VP O
a DT B-NP O
substantial JJ I-NP O
portion NN I-NP O
( ( O O
38 CD B-NP O
% NN I-NP O
) ) O O
of IN B-PP O
the DT B-NP O
WASP NN I-NP O
gene NN I-NP O
defects NNS I-NP O
found VBN B-VP O
in IN B-PP O
patients NNS B-NP O
with IN B-PP O
severe JJ B-NP O
disease NN I-NP O
. . O O

These DT B-NP O
findings NNS I-NP O
, , O O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
the DT B-NP O
detection NN I-NP O
of IN B-PP O
identical JJ B-NP O
WASP NN I-NP O
mutations NNS I-NP O
in IN B-PP O
patients NNS B-NP O
with IN B-PP O
disparate JJ B-NP O
phenotypes NNS I-NP O
, , O O
reveal VBP B-VP O
a DT B-NP O
lack NN I-NP O
of IN B-PP O
phenotype NN B-NP O
concordance NN I-NP O
with IN B-PP O
genotype NN B-NP O
in IN B-PP O
WAS NN B-NP B-Disease
and CC O O
thus RB B-VP O
imply VBP I-VP O
that IN B-SBAR O
phenotypic JJ B-NP O
outcome NN I-NP O
in IN B-PP O
this DT B-NP O
disease NN I-NP O
cannot MD B-VP O
be VB I-VP O
reliably RB I-VP O
predicted VBN I-VP O
solely RB B-ADVP O
on IN B-PP O
the DT B-NP O
basis NN I-NP O
of IN B-PP O
WASP NN B-NP O
genotypes NNS I-NP O
. . O O

. . O O

Germline NN B-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
3 CD I-NP O
' SYM I-NP O
part NN I-NP O
of IN B-PP O
APC NN B-NP B-Disease
exon NN I-NP O
15 CD I-NP O
do VBP B-VP O
not RB I-VP O
result VB I-VP O
in IN B-PP O
truncated VBN B-NP O
proteins NNS I-NP O
and CC O O
are VBP B-VP O
associated VBN I-VP O
with IN B-PP O
attenuated VBN B-NP O
adenomatous JJ I-NP B-Disease
polyposis NN I-NP I-Disease
coli NN I-NP I-Disease
. . O O

Familial JJ B-NP B-Disease
adenomatous JJ I-NP I-Disease
polyposis NN I-NP I-Disease
( ( O O
FAP NN B-NP B-Disease
) ) O O
is VBZ B-VP O
an DT B-NP O
inherited VBN I-NP O
predisposition NN I-NP O
to TO B-PP O
colorectal JJ B-NP B-Disease
cancer NN I-NP I-Disease
characterized VBN B-VP O
by IN B-PP O
the DT B-NP O
development NN I-NP O
of IN B-PP O
numerous JJ B-NP O
adenomatous JJ I-NP B-Disease
polyps NNS I-NP I-Disease
predominantly RB B-ADVP O
in IN B-PP O
the DT B-NP O
colorectal JJ I-NP O
region NN I-NP O
. . O O

Germline NN B-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
adenomatous JJ I-NP B-Disease
polyposis NN I-NP I-Disease
coli NN I-NP I-Disease
( ( O O
APC NN B-NP B-Disease
) ) O O
gene NN B-NP O
are VBP B-VP O
responsible JJ B-ADJP O
for IN B-PP O
most JJS B-NP O
cases NNS I-NP O
of IN B-PP O
FAP NN B-NP B-Disease
. . O O

Mutations NNS B-NP O
at IN B-PP O
the DT B-NP O
5 CD I-NP O
end NN I-NP O
of IN B-PP O
APC NN B-NP B-Disease
are VBP B-VP O
known VBN I-VP O
to TO I-VP O
be VB I-VP O
associated VBN I-VP O
with IN B-PP O
a DT B-NP O
relatively RB I-NP O
mild JJ I-NP O
form NN I-NP O
of IN B-PP O
the DT B-NP O
disease NN I-NP O
, , O O
called VBN B-VP O
attenuated VBD B-VP B-Disease
adenomatous JJ B-NP I-Disease
polyposis NN I-NP I-Disease
coli NN I-NP I-Disease
( ( O O
AAPC NN B-NP B-Disease
) ) O O
. . O O

We PRP B-NP O
identified VBD B-VP O
a DT B-NP O
frameshift NN I-NP O
mutation NN I-NP O
in IN B-PP O
the DT B-NP O
3 CD I-NP O
part NN I-NP O
of IN B-PP O
exon NN B-NP O
15 CD I-NP O
, , O O
resulting VBG B-VP O
in IN B-PP O
a DT B-NP O
stop NN I-NP O
codon NN I-NP O
at IN B-PP O
1862 CD B-NP O
, , O O
in IN B-PP O
a DT B-NP O
large JJ I-NP O
Dutch JJ I-NP O
kindred NN I-NP O
with IN B-PP O
AAPC NN B-NP B-Disease
. . O O

Western NN B-NP O
blot NN I-NP O
analysis NN I-NP O
of IN B-PP O
lymphoblastoid JJ B-NP O
cell NN I-NP O
lines NNS I-NP O
derived VBN B-VP O
from IN B-PP O
affected VBN B-NP O
family NN I-NP O
members NNS I-NP O
from IN B-PP O
this DT B-NP O
kindred NN I-NP O
, , O O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
from IN B-PP O
a DT B-NP O
previously RB I-NP O
reported VBN I-NP O
Swiss JJ I-NP O
family NN I-NP O
carrying VBG B-VP O
a DT B-NP O
frameshift NN I-NP O
mutation NN I-NP O
at IN B-PP O
codon NN B-NP O
1987 CD I-NP O
and CC O O
displaying VBG B-VP O
a DT B-NP O
similar JJ I-NP O
attenuated VBN I-NP O
phenotype NN I-NP O
, , O O
showed VBD B-VP O
only RB B-NP O
the DT I-NP O
wild JJ I-NP O
- HYPH I-NP O
type NN I-NP O
APC NN I-NP B-Disease
protein NN I-NP O
. . O O

Our PRP$ B-NP O
study NN I-NP O
indicates VBZ B-VP O
that IN B-SBAR O
chain NN B-NP O
- HYPH O O
terminating VBG B-VP O
mutations NNS B-NP O
located VBN B-VP O
in IN B-PP O
the DT B-NP O
3 CD I-NP O
part NN I-NP O
of IN B-PP O
APC NN B-NP B-Disease
do VBP B-VP O
not RB I-VP O
result VB I-VP O
in IN B-PP O
detectable JJ B-NP O
truncated VBN I-NP O
polypeptides NNS I-NP O
and CC O O
we PRP B-NP O
hypothesize VBP B-VP O
that IN B-SBAR O
this DT B-NP O
is VBZ B-VP O
likely JJ B-ADJP O
to TO B-VP O
be VB I-VP O
the DT B-NP O
basis NN I-NP O
for IN B-PP O
the DT B-NP O
observed VBN I-NP O
AAPC NN I-NP B-Disease
phenotype NN I-NP O
. . O O

. . O O

Complete JJ B-NP O
genomic JJ I-NP O
sequence NN I-NP O
and CC O O
analysis NN B-NP O
of IN B-PP O
117 CD B-NP O
kb NN I-NP O
of IN B-PP O
human JJ B-NP O
DNA NN I-NP O
containing VBG B-VP O
the DT B-NP O
gene NN I-NP O
BRCA1 NN I-NP O
. . O O

Over IN B-PP O
100 CD B-NP O
distinct JJ I-NP O
disease NN I-NP O
- HYPH B-NP O
associated VBN I-NP O
mutations NNS I-NP O
have VBP B-VP O
been VBN I-VP O
identified VBN I-VP O
in IN B-PP O
the DT B-NP O
breast NN I-NP B-Disease
- HYPH B-NP I-Disease
ovarian JJ I-NP I-Disease
cancer NN I-NP I-Disease
susceptibility NN I-NP O
gene NN I-NP O
BRCA1 NN I-NP O
. . O O

Loss NN B-NP O
of IN B-PP O
the DT B-NP O
wild JJ I-NP O
- HYPH I-NP O
type NN I-NP O
allele NN I-NP O
in IN B-PP O
> JJR B-NP O
90 CD I-NP O
% NN I-NP O
of IN B-PP O
tumors NNS B-NP B-Disease
from IN B-PP O
patients NNS B-NP O
with IN B-PP O
inherited VBN B-NP O
BRCA1 NN I-NP O
mutations NNS I-NP O
indicates VBZ B-VP O
tumor NN B-NP B-Disease
suppressive JJ I-NP O
function NN I-NP O
. . O O

The DT B-NP O
low JJ I-NP O
incidence NN I-NP O
of IN B-PP O
somatic JJ B-NP O
mutations NNS I-NP O
suggests VBZ B-VP O
that IN B-SBAR O
BRCA1 NN B-NP O
inactivation NN I-NP O
in IN B-PP O
sporadic JJ B-NP O
tumors NNS I-NP B-Disease
occurs VBZ B-VP O
by IN B-PP O
alternative JJ B-NP O
mechanisms NNS I-NP O
, , O O
such JJ B-PP O
as IN I-PP O
interstitial JJ B-NP O
chromosomal JJ I-NP O
deletion NN I-NP O
or CC O O
reduced VBN B-NP O
transcription NN I-NP O
. . O O

To TO B-VP O
identify VB I-VP O
possible JJ B-NP O
features NNS I-NP O
of IN B-PP O
the DT B-NP O
BRCA1 NN I-NP O
genomic JJ I-NP O
region NN I-NP O
that WDT B-NP O
may MD B-VP O
contribute VB I-VP O
to TO B-PP O
chromosomal JJ B-NP O
instability NN I-NP O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
potential JJ B-NP O
transcriptional JJ I-NP O
regulatory JJ I-NP O
elements NNS I-NP O
, , O O
a DT B-NP O
117 CD I-NP O
, , I-NP O
143 CD I-NP O
- HYPH I-NP O
bp NN I-NP O
DNA NN I-NP O
sequence NN I-NP O
encompassing VBG B-VP O
BRCA1 NN B-NP O
was VBD B-VP O
obtained VBN I-VP O
by IN B-PP O
random JJ B-NP O
sequencing NN I-NP O
of IN B-PP O
four CD B-NP O
cosmids NNS I-NP O
identified VBN B-VP O
from IN B-PP O
a DT B-NP O
human JJ I-NP O
chromosome NN I-NP O
17 CD I-NP O
specific JJ I-NP O
library NN I-NP O
. . O O

The DT B-NP O
24 CD I-NP O
exons NNS I-NP O
of IN B-PP O
BRCA1 NN B-NP O
span VBP B-VP O
an DT B-NP O
81 CD I-NP O
- HYPH I-NP O
kb NN I-NP O
region NN I-NP O
that WDT B-NP O
has VBZ B-VP O
an DT B-NP O
unusually RB I-NP O
high JJ I-NP O
density NN I-NP O
of IN B-PP O
Alu NN B-NP O
repetitive JJ I-NP O
DNA NN I-NP O
( ( O O
41 CD B-NP O
. . O O

5 CD B-NP O
% NN I-NP O
) ) O O
, , O O
but CC O O
relatively RB B-NP O
low JJ I-NP O
density NN I-NP O
( ( O O
4 CD B-NP O
. . O O

8 CD B-NP O
% NN I-NP O
) ) O O
of IN B-PP O
other JJ B-NP O
repetitive JJ I-NP O
sequences NNS I-NP O
. . O O

BRCA1 NN B-NP O
intron NN I-NP O
lengths NNS I-NP O
range NN I-NP O
in IN B-PP O
size NN B-NP O
from IN B-PP O
403 CD B-NP O
bp NN I-NP O
to TO B-PP O
9 CD B-NP O
. . O O

2 CD B-NP O
kb NN I-NP O
and CC O O
contain VBP B-VP O
the DT B-NP O
intragenic JJ I-NP O
microsatellite NN I-NP O
markers NNS I-NP O
D17S1323 NN I-NP O
, , O O
D17S1322 NN B-NP O
, , O O
and CC O O
D17S855 NN B-NP O
, , O O
which WDT B-NP O
localize VBP B-VP O
to TO B-PP O
introns NNS B-NP O
12 CD I-NP O
, , I-NP O
19 CD I-NP O
, , O O
and CC O O
20 CD B-NP O
, , O O
respectively RB B-ADVP O
. . O O

In IN B-PP O
addition NN B-NP O
to TO B-PP O
BRCA1 NN B-NP O
, , O O
the DT B-NP O
contig NN I-NP O
contains VBZ B-VP O
two CD B-NP O
complete JJ I-NP O
genes NNS I-NP O
Rho7 NN I-NP O
, , O O
a DT B-NP O
member NN I-NP O
of IN B-PP O
the DT B-NP O
rho JJ I-NP O
family NN I-NP O
of IN B-PP O
GTP NN B-NP O
binding NN I-NP O
proteins NNS I-NP O
, , O O
and CC O O
VAT1 NN B-NP O
, , O O
an DT B-NP O
abundant JJ I-NP O
membrane NN I-NP O
protein NN I-NP O
of IN B-PP O
cholinergic JJ B-NP O
synaptic JJ I-NP O
vesicles NNS I-NP O
. . O O

Partial JJ B-NP O
sequences NNS I-NP O
of IN B-PP O
the DT B-NP O
1A1 NN I-NP O
- HYPH B-VP O
3B NN B-NP O
B NN I-NP O
- HYPH B-NP O
box NN I-NP O
protein NN I-NP O
pseudogene NN I-NP O
and CC O O
IFP NN B-NP O
35 CD I-NP O
, , O O
an DT B-NP O
interferon NN I-NP O
induced VBD B-VP O
leucine NN B-NP O
zipper NN I-NP O
protein NN I-NP O
, , O O
reside NN B-NP O
within IN B-PP O
the DT B-NP O
contig NN I-NP O
. . O O

An DT B-NP O
L21 NN I-NP O
ribosomal JJ I-NP O
protein NN I-NP O
pseudogene NN I-NP O
is VBZ B-VP O
embedded VBN I-VP O
in IN B-PP O
BRCA1 NN B-NP O
intron NN I-NP O
13 CD I-NP O
. . O O

The DT B-NP O
order NN I-NP O
of IN B-PP O
genes NNS B-NP O
on IN B-PP O
the DT B-NP O
chromosome NN I-NP O
is VBZ B-VP O
centromere JJ B-ADJP O
- HYPH O O
1FP NN B-NP O
35 CD I-NP O
- HYPH I-NP O
VAT1 NN I-NP O
- HYPH B-NP O
Rho7 NN I-NP O
- HYPH B-NP O
BRCA1 NN I-NP O
- HYPH B-NP O
1A1 NN I-NP O
- HYPH B-NP O
3B NN I-NP O
- HYPH O O
telomere NN B-NP O
Identification NN B-NP O
of IN B-PP O
a DT B-NP O
RING NN I-NP O
protein NN I-NP O
that WDT B-NP O
can MD B-VP O
interact VB I-VP O
in FW B-ADVP O
vivo FW I-ADVP O
with IN B-PP O
the DT B-NP O
BRCA1 NN I-NP O
gene NN I-NP O
product NN I-NP O
. . O O

The DT B-NP O
hereditary JJ I-NP B-Disease
breast NN I-NP I-Disease
and CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
gene NN I-NP O
, , O O
BRCA1 NN B-NP O
, , O O
encodes VBZ B-VP O
a DT B-NP O
large JJ I-NP O
polypeptide NN I-NP O
that WDT B-NP O
contains VBZ B-VP O
the DT B-NP O
cysteine NN I-NP O
- HYPH B-NP O
rich JJ I-NP O
RING NN I-NP O
motif NN I-NP O
, , O O
a DT B-NP O
zinc NN I-NP O
- HYPH O O
binding VBG B-NP O
domain NN I-NP O
found VBN B-VP O
in IN B-PP O
a DT B-NP O
variety NN I-NP O
of IN B-PP O
regulatory JJ B-NP O
proteins NNS I-NP O
. . O O

Here RB B-ADVP O
we PRP B-NP O
describe VBP B-VP O
a DT B-NP O
novel JJ I-NP O
protein NN I-NP O
that WDT B-NP O
interacts VBZ B-VP O
in FW B-ADVP O
vivo FW I-ADVP O
with IN B-PP O
the DT B-NP O
N NN I-NP O
- HYPH B-NP O
terminal JJ I-NP O
region NN I-NP O
of IN B-PP O
BRCA1 NN B-NP O
. . O O

This DT B-NP O
BRCA1 NN I-NP O
- HYPH B-VP O
associated VBN B-NP O
RING NN I-NP O
domain NN I-NP O
( ( O O
BARD1 NN B-NP O
) ) O O
protein NN B-NP O
contains VBZ B-VP O
an DT B-NP O
N NN I-NP O
- HYPH B-NP O
terminal JJ I-NP O
RING NN I-NP O
motif NN I-NP O
, , O O
three CD B-NP O
tandem JJ I-NP O
ankyrin NN I-NP O
repeats NNS I-NP O
, , O O
and CC O O
a DT B-NP O
C NN I-NP O
- HYPH B-NP O
terminal JJ I-NP O
sequence NN I-NP O
with IN B-PP O
significant JJ B-NP O
homology NN I-NP O
to TO B-PP O
the DT B-NP O
phylogenetically RB I-NP O
conserved VBN I-NP O
BRCT NN I-NP O
domains NNS I-NP O
that WDT B-NP O
lie VBP B-VP O
near IN B-PP O
the DT B-NP O
C NN I-NP O
terminus NN I-NP O
of IN B-PP O
BRCA1 NN B-NP O
. . O O

The DT B-NP O
BARD1 NN I-NP O
/ SYM B-VP O
BRCA1 NN B-NP O
interaction NN I-NP O
is VBZ B-VP O
disrupted VBN I-VP O
by IN B-PP O
BRCA1 NN B-NP O
missense JJ I-NP O
mutations NNS I-NP O
that WDT B-NP O
segregate VBP B-VP O
with IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
susceptibility NN I-NP O
, , O O
indicating VBG B-VP O
that IN B-SBAR O
BARD1 NN B-NP O
may MD B-VP O
be VB I-VP O
involved VBN I-VP O
in IN B-PP O
mediating VBG B-VP O
tumour NN B-NP B-Disease
suppression NN I-NP O
by IN B-PP O
BRCA1 NN B-NP O
. . O O

. . O O

Detection NN B-NP O
of IN B-PP O
heterozygous JJ B-NP O
mutations NNS I-NP O
in IN B-PP O
BRCA1 NN B-NP O
using VBG B-VP O
high JJ B-NP O
density NN I-NP O
oligonucleotide NN I-NP O
arrays NNS I-NP O
and CC O O
two CD B-NP O
- HYPH I-NP O
colour NN I-NP O
fluorescence NN I-NP O
analysis NN I-NP O
. . O O

The DT B-NP O
ability NN I-NP O
to TO B-VP O
scan VB I-VP O
a DT B-NP O
large JJ I-NP O
gene NN I-NP O
rapidly RB B-ADVP O
and CC I-ADVP O
accurately RB I-ADVP O
for IN B-PP O
all DT B-NP O
possible JJ I-NP O
heterozygous JJ I-NP O
mutations NNS I-NP O
in IN B-PP O
large JJ B-NP O
numbers NNS I-NP O
of IN B-PP O
patient NN B-NP O
samples NNS I-NP O
will MD B-VP O
be VB I-VP O
critical JJ B-ADJP O
for IN B-PP O
the DT B-NP O
future NN I-NP O
of IN B-PP O
medicine NN B-NP O
. . O O

We PRP B-NP O
have VBP B-VP O
designed VBN I-VP O
high JJ B-NP O
- HYPH I-NP O
density NN I-NP O
arrays NNS I-NP O
consisting VBG B-VP O
of IN B-PP O
over IN B-PP O
96 CD B-NP O
, , O O
600 CD B-NP O
oligonucleotides NNS I-NP O
20 CD B-NP O
- HYPH I-NP O
nucleotides NNS I-NP O
( ( O O
nt NN B-NP O
) ) O O
in IN B-PP O
length NN B-NP O
to TO B-VP O
screen VB I-VP O
for IN B-PP O
a DT B-NP O
wide JJ I-NP O
range NN I-NP O
of IN B-PP O
heterozygous JJ B-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
3 CD I-NP O
. . O O

45 CD B-NP O
- HYPH I-NP O
kilobases NNS I-NP O
( ( O O
kb NN B-NP O
) ) O O
exon NN B-NP O
11 CD I-NP O
of IN B-PP O
the DT B-NP O
hereditary JJ I-NP B-Disease
breast NN I-NP I-Disease
and CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
gene NN I-NP O
BRCA1 NN I-NP O
. . O O

Reference NN B-NP O
and CC I-NP O
test NN I-NP O
samples NNS I-NP O
were VBD B-VP O
co AFX O O
- HYPH O O
hybridized VBN B-VP O
to TO B-PP O
these DT B-NP O
arrays NNS I-NP O
and CC I-NP O
differences NNS I-NP O
in IN B-PP O
hybridization NN B-NP O
patterns NNS I-NP O
quantitated VBN B-VP O
by IN B-PP O
two CD B-NP O
- HYPH I-NP O
colour NN I-NP O
analysis NN I-NP O
. . O O

Fourteen CD B-NP O
of IN B-PP O
fifteen CD B-NP O
patient NN I-NP O
samples NNS I-NP O
with IN B-PP O
known JJ B-NP O
mutations NNS I-NP O
were VBD B-VP O
accurately RB I-VP O
diagnosed VBN I-VP O
, , O O
and CC O O
no DT B-NP O
false JJ I-NP O
positive JJ I-NP O
mutations NNS I-NP O
were VBD B-VP O
identified VBN I-VP O
in IN B-PP O
20 CD B-NP O
control NN I-NP O
samples NNS I-NP O
. . O O

Eight CD B-NP O
single JJ I-NP O
nucleotide NN I-NP O
polymorphisms NNS I-NP O
were VBD B-VP O
also RB B-ADVP O
readily RB B-ADJP O
detected VBN I-ADJP O
. . O O

DNA NN B-NP O
chip NN I-NP O
- HYPH B-NP O
based VBN I-NP O
assays NNS I-NP O
may MD B-VP O
provide VB I-VP O
a DT B-NP O
valuable JJ I-NP O
new JJ I-NP O
technology NN I-NP O
for IN B-PP O
high JJ B-NP O
- HYPH I-NP O
throughput NN I-NP O
cost AFX O O
- HYPH B-NP O
efficient JJ I-NP O
detection NN I-NP O
of IN B-PP O
genetic JJ B-NP O
alterations NNS I-NP O
. . O O

Autosomal JJ B-NP O
dominant JJ I-NP O
primary JJ I-NP O
hyperparathyroidism NN I-NP B-Disease
and CC I-NP I-Disease
jaw NN I-NP I-Disease
tumor NN I-NP I-Disease
syndrome NN I-NP I-Disease
associated VBN B-VP O
with IN B-PP O
renal JJ B-NP B-Disease
hamartomas NNS I-NP I-Disease
and CC O O
cystic JJ B-NP B-Disease
kidney NN I-NP I-Disease
disease NN I-NP I-Disease
: : O O
linkage NN B-NP O
to TO B-PP O
1q21 NN B-NP O
- HYPH B-NP O
q32 NN I-NP O
and CC I-NP O
loss NN I-NP O
of IN B-PP O
the DT B-NP O
wild JJ I-NP O
type NN I-NP O
allele NN I-NP O
in IN B-PP O
renal JJ B-NP B-Disease
hamartomas NNS I-NP I-Disease
. . O O

Hereditary JJ B-NP B-Disease
hyperparathyroidism NN I-NP I-Disease
- HYPH I-NP I-Disease
jaw NN I-NP I-Disease
tumor NN I-NP I-Disease
syndrome NN I-NP I-Disease
( ( O O
HPT NN B-NP B-Disease
- HYPH B-NP I-Disease
JT NN I-NP I-Disease
) ) O O
is VBZ B-VP O
an DT B-NP O
autosomal JJ I-NP B-Disease
dominant JJ I-NP I-Disease
disease NN I-NP I-Disease
( ( O O
OMIM NN B-NP O
145001 CD I-NP O
) ) O O
that WDT B-NP O
has VBZ B-VP O
recently RB I-VP O
been VBN I-VP O
mapped VBN I-VP O
to TO B-PP O
chromosomal JJ B-NP O
region NN I-NP O
1q21 NN I-NP O
- HYPH O O
q32 NN B-NP O
( ( O O
HRPT2 NN B-NP O
) ) O O
. . O O

Here RB B-ADVP O
we PRP B-NP O
report VBP B-VP O
two CD B-NP O
families NNS I-NP O
with IN B-PP O
HPT NN B-NP B-Disease
- HYPH I-NP I-Disease
JT NN I-NP I-Disease
syndrome NN I-NP I-Disease
in IN B-PP O
which WDT B-NP O
adult JJ B-NP B-Disease
renal JJ I-NP I-Disease
hamartomas NNS I-NP I-Disease
or CC O O
cystic JJ B-NP B-Disease
kidney NN I-NP I-Disease
disease NN I-NP I-Disease
were VBD B-VP O
prominent JJ B-NP O
associated VBN I-NP O
features NNS I-NP O
, , O O
possibly RB B-ADVP O
representing VBG B-VP O
a DT B-NP O
new JJ I-NP O
phenotypic JJ I-NP O
variant NN I-NP O
of IN B-PP O
the DT B-NP O
HPT NN I-NP B-Disease
- HYPH B-NP I-Disease
JT NN I-NP I-Disease
syndrome NN I-NP I-Disease
. . O O

In IN B-PP O
the DT B-NP O
first JJ I-NP O
family NN I-NP O
, , O O
renal JJ B-NP B-Disease
lesions NNS I-NP I-Disease
were VBD B-VP O
present JJ B-ADJP O
in IN B-PP O
five CD B-NP O
out IN I-NP O
of IN I-NP O
six CD I-NP O
affected VBN I-NP O
individuals NNS I-NP O
, , O O
whereas IN O O
HPT NN B-NP B-Disease
and CC I-NP O
JT NN I-NP B-Disease
were VBD B-VP O
seen VBN I-VP O
in IN B-PP O
four CD B-NP O
and CC I-NP O
two CD I-NP O
cases NNS I-NP O
, , O O
respectively RB B-ADVP O
. . O O

In IN B-PP O
the DT B-NP O
second JJ I-NP O
family NN I-NP O
, , O O
JT NN B-NP B-Disease
was VBD B-VP O
found VBN I-VP O
in IN B-PP O
three CD B-NP O
of IN B-PP O
the DT B-NP O
five CD I-NP O
affected VBN I-NP O
individuals NNS I-NP O
and CC O O
two CD B-NP O
affected VBN I-NP O
members NNS I-NP O
also RB B-ADVP O
exhibited VBD B-VP O
polycystic JJ B-NP B-Disease
kidney NN I-NP I-Disease
disease NN I-NP I-Disease
. . O O

The DT B-NP O
possibility NN I-NP O
of IN B-PP O
the DT B-NP O
latter JJ I-NP O
cosegregating NN I-NP O
as IN B-PP O
a DT B-NP O
separate JJ I-NP O
autosomal JJ I-NP O
dominant JJ I-NP O
gene NN I-NP O
can MD B-VP O
not RB I-VP O
be VB I-VP O
ruled VBN I-VP O
out RP B-PRT O
. . O O

A DT B-NP O
sex NN I-NP O
- HYPH B-NP O
dependent JJ I-NP O
penetrance NN I-NP O
of IN B-PP O
primary JJ B-NP B-Disease
HPT NN I-NP I-Disease
, , O O
resulting VBG B-VP O
in IN B-PP O
predominantly RB B-NP O
male JJ I-NP O
- HYPH I-NP O
affected VBN I-NP O
cases NNS I-NP O
was VBD B-VP O
evident JJ B-ADJP O
in IN B-PP O
the DT B-NP O
two CD I-NP O
families NNS I-NP O
. . O O

Twenty CD B-NP O
microsatellite NN I-NP O
markers NNS I-NP O
in IN B-PP O
the DT B-NP O
HRPT2 NN I-NP O
region NN I-NP O
were VBD B-VP O
typed VBN I-VP O
, , O O
in IN B-PP O
addition NN B-NP O
to TO B-PP O
markers NNS B-NP O
in IN B-PP O
the DT B-NP O
multiple JJ I-NP B-Disease
endocrine JJ I-NP I-Disease
neoplasia NN I-NP I-Disease
( ( O I-Disease
MEN NN B-NP I-Disease
) ) O I-Disease
types NNS B-NP I-Disease
1 CD I-NP I-Disease
and CC I-NP I-Disease
2 CD I-NP I-Disease
regions NNS I-NP O
at IN B-PP O
11q13 CD B-NP O
and CC I-NP O
10q11 CD I-NP O
. . O O

The DT B-NP O
disease NN I-NP O
in IN B-PP O
these DT B-NP O
two CD I-NP O
kindreds NNS I-NP O
was VBD B-VP O
linked VBN I-VP O
to TO B-PP O
five CD B-NP O
markers NNS I-NP O
in IN B-PP O
the DT B-NP O
1q21 NN I-NP O
- HYPH O O
q32 NN B-NP O
region NN I-NP O
( ( O O
logarithm NN B-NP O
- HYPH O O
of IN B-PP O
- HYPH B-NP O
odds VBZ B-VP O
scores NNS B-NP O
3 CD B-NP O
. . I-NP O

2 CD I-NP O
- : O O
4 CD B-NP O
2 CD I-NP O
- : O O
4 CD B-NP O
. . I-NP O

2 CD I-NP O
) ) O O
, , O O
whereas IN O O
linkage NN B-NP O
to TO B-PP O
the DT B-NP O
MEN1 NN I-NP B-Disease
and CC I-NP O
MEN2 NN I-NP B-Disease
regions NNS I-NP O
was VBD B-VP O
excluded VBN I-VP O
. . O O

Meiotic JJ B-NP O
recombinations NNS I-NP O
detected VBN B-VP O
in IN B-PP O
affected VBN B-NP O
individuals NNS I-NP O
placed VBD B-VP O
the DT B-NP O
locus NN I-NP O
telomeric NN I-NP O
of IN B-PP O
D1S215 NN B-NP O
, , O O
thus RB B-ADVP O
narrowing VBG B-VP O
the DT B-NP O
HRPT2 NN I-NP O
region NN I-NP O
from IN B-PP O
> SYM B-NP O
60 CD I-NP O
to TO B-PP O
approximately RB B-NP O
34 CD I-NP O
centimorgans NNS I-NP O
. . O O

Loss NN B-NP O
of IN B-PP O
heterozygosity NN B-NP O
was VBD B-VP O
studied VBN I-VP O
in IN B-PP O
seven CD B-NP O
renal JJ I-NP B-Disease
hamartomas NNS I-NP I-Disease
from IN B-PP O
two CD B-NP O
affected VBN I-NP O
individuals NNS I-NP O
in IN B-PP O
the DT B-NP O
first JJ I-NP O
family NN I-NP O
, , O O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
in IN B-PP O
a DT B-NP O
jaw JJ I-NP B-Disease
tumor NN I-NP I-Disease
and CC O O
a DT B-NP O
parathyroid JJ I-NP B-Disease
tumor NN I-NP I-Disease
from IN B-PP O
the DT B-NP O
second JJ I-NP O
family NN I-NP O
. . O O

All DT B-NP O
renal JJ I-NP B-Disease
hamartomas NNS I-NP I-Disease
showed VBD B-VP O
loss NN B-NP O
of IN B-PP O
heterozygosity NN B-NP O
at IN B-PP O
the DT B-NP O
1q21 NN I-NP O
- HYPH B-NP O
q32 NN I-NP O
region NN I-NP O
. . O O

The DT B-NP O
losses NNS I-NP O
invariably RB B-ADVP O
involved VBD B-VP O
the DT B-NP O
wild JJ I-NP O
type NN I-NP O
allele NN I-NP O
derived VBN B-VP O
from IN B-PP O
the DT B-NP O
unaffected JJ I-NP O
parent NN I-NP O
, , O O
suggesting VBG B-VP O
the DT B-NP O
inactivation NN I-NP O
of IN B-PP O
a DT B-NP O
tumor NN I-NP B-Disease
suppressor NN I-NP O
gene NN I-NP O
in IN B-PP O
this DT B-NP O
region NN I-NP O
Independent JJ B-NP O
origin NN I-NP O
of IN B-PP O
single JJ B-NP O
and CC I-NP O
double JJ I-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
human JJ I-NP O
glucose NN I-NP O
6 CD I-NP O
- HYPH I-NP O
phosphate NN I-NP O
dehydrogenase NN I-NP O
gene NN I-NP O
. . O O

The DT B-NP O
vast JJ I-NP O
majority NN I-NP O
of IN B-PP O
both CC B-NP O
polymorphic JJ I-NP O
and CC I-NP O
sporadic JJ I-NP O
G6PD NN I-NP O
variants NNS I-NP O
are VBP B-VP O
due JJ B-ADJP O
to TO B-PP O
single JJ B-NP O
missense JJ I-NP O
mutations NNS I-NP O
. . O O

In IN B-PP O
the DT B-NP O
four CD I-NP O
polymorphic JJ I-NP O
variants NNS I-NP O
that WDT B-NP O
have VBP B-VP O
two CD B-NP O
point NN I-NP O
mutations NNS I-NP O
, , O O
one CD B-NP O
of IN B-PP O
the DT B-NP O
mutations NNS I-NP O
is VBZ B-VP O
always RB B-ADVP O
376 CD B-NP O
A NN I-NP O
- SYM O O
- HYPH O O
> SYM O O
G NN B-NP O
( ( O O
126 CD B-NP O
Asn NN I-NP O
- SYM B-NP O
- HYPH B-NP O
> SYM I-NP O
Asp NN I-NP O
) ) O O
, , O O
which WDT B-NP O
on IN B-PP O
its PRP$ B-NP O
own JJ I-NP O
gives NNS I-NP O
rise NN I-NP O
to TO B-PP O
the DT B-NP O
nondeficient JJ I-NP O
polymorphic JJ I-NP O
variant NN I-NP O
, , O O
G6PD NN B-NP O
A NN I-NP O
. . O O

In IN B-PP O
a DT B-NP O
study NN I-NP O
of IN B-PP O
G6PD NN B-NP B-Disease
deficient JJ I-NP I-Disease
patients NNS I-NP O
who WP B-NP O
presented VBD B-VP O
with IN B-PP O
clinical JJ B-NP O
favism NN I-NP B-Disease
in IN B-PP O
Spain NNP B-NP O
, , O O
we PRP B-NP O
have VBP B-VP O
found VBN I-VP O
a DT B-NP O
new JJ I-NP O
polymorphic JJ I-NP O
variant NN I-NP O
that IN B-NP O
we PRP B-NP O
have VBP B-VP O
called VBN I-VP O
G6PD NNP B-NP O
Malaga NNP I-NP O
, , O O
whose WP$ B-NP O
only RB I-NP O
abnormality NN I-NP O
is VBZ B-VP O
a DT B-NP O
542 CD I-NP O
A NN I-NP O
- SYM O O
- HYPH O O
> SYM O O
T NN B-NP O
( ( O O
181 CD B-NP O
Asp NN I-NP O
- SYM B-NP O
- HYPH B-NP O
> SYM I-NP O
Val NN I-NP O
) ) O O
mutation NN B-NP O
. . O O

This DT B-NP O
is VBZ B-VP O
the DT B-NP O
same JJ I-NP O
mutation NN I-NP O
as IN B-SBAR O
previously RB B-ADVP O
found VBN B-VP O
in IN B-PP O
association NN B-NP O
with IN B-PP O
the DT B-NP O
mutation NN I-NP O
of IN B-PP O
G6PD NN B-NP O
A NN I-NP O
in IN B-PP O
the DT B-NP O
double JJ I-NP O
mutant NN I-NP O
, , O O
G6PD NN B-NP O
Santamaria NNP I-NP O
. . O O

G6PD NN B-NP O
Malaga NNP I-NP O
is VBZ B-VP O
associated VBN I-VP O
with IN B-PP O
enzyme NN B-NP B-Disease
deficiency NN I-NP I-Disease
( ( O O
class NN B-NP O
III CD I-NP O
) ) O O
, , O O
and CC O O
the DT B-NP O
enzymic JJ I-NP O
properties NNS I-NP O
of IN B-PP O
G6PD NN B-NP O
Malaga NN I-NP O
and CC O O
G6PD NN B-NP O
Santamaria NNP I-NP O
are VBP B-VP O
quite RB B-ADJP O
similar JJ I-ADJP O
, , O O
indicating VBG B-VP O
that IN B-SBAR O
in IN B-PP O
this DT B-NP O
case NN I-NP O
the DT B-NP O
effects NNS I-NP O
of IN B-PP O
the DT B-NP O
two CD I-NP O
mutations NNS I-NP O
are VBP B-VP O
additive JJ B-ADJP O
rather RB B-PP O
than IN I-PP O
synergistic JJ B-ADJP O
. . O O

G6PD NN B-NP O
Santamaria NNP I-NP O
might MD B-VP O
have VB I-VP O
been VBN I-VP O
produced VBN I-VP O
by IN B-PP O
recombination NN B-NP O
between IN B-PP O
G6PD NN B-NP O
A NN I-NP O
and CC O O
G6PD NN B-NP O
Malaga NNP I-NP O
; : O O
however RB B-NP O
haplotype NN I-NP O
analysis NN I-NP O
, , O O
including VBG B-PP O
the DT B-NP O
use NN I-NP O
of IN B-PP O
a DT B-NP O
new JJ I-NP O
silent JJ I-NP O
polymorphism NN I-NP O
, , O O
suggests VBZ B-VP O
that IN B-SBAR O
the DT B-NP O
same JJ I-NP O
542 CD I-NP O
A NN I-NP O
- SYM B-NP O
- HYPH I-NP O
> SYM I-NP O
T NN I-NP O
mutation NN I-NP O
has VBZ B-VP O
taken VBN I-VP O
place NN B-NP O
independently RB B-ADVP O
in IN B-PP O
a DT B-NP O
G6PD NN I-NP O
B NN I-NP O
gene NN I-NP O
to TO B-VP O
give VB I-VP O
G6PD NN B-NP O
Malaga NNP I-NP O
and CC B-PP O
in IN B-PP O
a DT B-NP O
G6PD NN I-NP O
A NN I-NP O
gene NN I-NP O
to TO B-VP O
give VB I-VP O
G6PD NN B-NP O
Santamaria NNP B-NP O
. . O O

These DT B-NP O
findings NNS I-NP O
help VBP B-VP O
to TO I-VP O
outline VB I-VP O
the DT B-NP O
relationship NN I-NP O
and CC I-NP O
evolution NN I-NP O
of IN B-PP O
mutations NNS B-NP O
in IN B-PP O
the DT B-NP O
human JJ I-NP O
G6PD NN I-NP O
locus NN I-NP O
. . O O

. . O O

BRCA1 NN B-NP O
R841W NN I-NP O
: : O O
a DT B-NP O
strong JJ I-NP O
candidate NN I-NP O
for IN B-PP O
a DT B-NP O
common JJ I-NP O
mutation NN I-NP O
with IN B-PP O
moderate JJ B-NP O
phenotype NN I-NP O
. . O O

BRCA1 NN B-NP O
mutations NNS I-NP O
cause VBP B-VP O
increased VBN B-NP O
risk NN I-NP O
for IN B-PP O
breast NN B-NP B-Disease
and CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
, , O O
frequently RB B-ADVP O
of IN B-PP O
early JJ B-NP O
onset NN I-NP O
. . O O

Many JJ B-NP O
different JJ I-NP O
mutations NNS I-NP O
occur VBP B-VP O
in IN B-PP O
BRCA1 NN B-NP O
, , O O
including VBG B-PP O
several JJ B-NP O
examples NNS I-NP O
of IN B-PP O
recurrent JJ B-NP O
mutations NNS I-NP O
, , O O
each DT B-NP O
of IN B-PP O
which WDT B-NP O
accounts VBZ B-VP O
for IN B-PP O
a DT B-NP O
significant JJ I-NP O
number NN I-NP O
of IN B-PP O
families NNS B-NP O
with IN B-PP O
heritable JJ B-NP O
cancer NN I-NP B-Disease
predisposition NN I-NP O
. . O O

These DT B-NP O
common JJ I-NP O
mutations NNS I-NP O
have VBP B-VP O
an DT B-NP O
etiological JJ I-NP O
role NN I-NP O
in IN B-PP O
many JJ B-NP O
breast NN I-NP B-Disease
and CC I-NP I-Disease
ovarian JJ I-NP I-Disease
cancer NN I-NP I-Disease
cases NNS I-NP O
and CC O O
provide VBP B-VP O
the DT B-NP O
opportunity NN I-NP O
to TO B-VP O
examine VB I-VP O
genotype NN B-NP O
- HYPH B-NP O
phenotype NN I-NP O
correlations NNS I-NP O
and CC O O
genotype NN B-NP O
- HYPH I-NP O
environment NN I-NP O
interactions NNS I-NP O
in IN B-PP O
individuals NNS B-NP O
with IN B-PP O
the DT B-NP O
identical JJ I-NP O
BRCA1 NN I-NP O
lesion NN I-NP O
. . O O

We PRP B-NP O
report VBP B-VP O
a DT B-NP O
novel JJ I-NP O
missense JJ I-NP O
change NN I-NP O
in IN B-PP O
BRCA1 NN B-NP O
, , O O
2640 CD B-NP O
C JJ I-NP O
- SYM O O
- HYPH O O
> SYM O O
T NN B-NP O
( ( O O
R841W NN B-NP O
) ) O O
, , O O
found VBN B-VP O
in IN B-PP O
3 CD B-NP O
cases NNS I-NP O
from IN B-PP O
a DT B-NP O
subject JJ I-NP O
group NN I-NP O
of IN B-PP O
305 CD B-NP O
breast NN I-NP B-Disease
and CC O I-Disease
79 CD B-NP I-Disease
ovarian JJ I-NP I-Disease
cancer NN I-NP I-Disease
cases NNS I-NP O
from IN B-PP O
Orange NNP B-NP O
County NNP I-NP O
, , O O
CA NNP B-NP O
. . O O

These DT B-NP O
are VBP B-VP O
consecutive JJ B-ADJP O
, , O O
population NN B-NP O
- HYPH B-NP O
based VBN I-NP O
cases NNS I-NP O
not RB B-VP O
selected VBN I-VP O
for IN B-PP O
age NN B-NP O
or CC I-NP O
family NN I-NP O
history NN I-NP O
. . O O

In IN B-PP O
all DT B-NP O
three CD I-NP O
cases NNS I-NP O
, , O O
there EX B-NP O
is VBZ B-VP O
a DT B-NP O
strong JJ I-NP O
family NN I-NP O
history NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
, , O I-Disease
ovarian JJ B-ADJP I-Disease
, , O I-Disease
or CC O I-Disease
other JJ B-NP I-Disease
cancers NNS I-NP I-Disease
possibly RB B-ADJP O
related JJ I-ADJP O
to TO B-PP O
a DT B-NP O
BRCA1 NN I-NP O
defect NN I-NP O
and CC I-NP O
family NN I-NP O
members NNS I-NP O
showed VBD B-VP O
a DT B-NP O
high JJ I-NP O
concordance NN I-NP O
of IN B-PP O
cancer NN B-NP B-Disease
incidence NN I-NP O
with IN B-PP O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
R841W NN B-NP O
. . O O

The DT B-NP O
age NN I-NP O
of IN B-PP O
cancer NN B-NP B-Disease
onset NN I-NP O
was VBD B-VP O
not RB O O
always RB B-ADVP O
distinct JJ B-ADJP O
from IN B-PP O
typical JJ B-NP O
sporadic JJ I-NP O
cases NNS I-NP O
. . O O

Testing NN B-NP O
of IN B-PP O
a DT B-NP O
sample NN I-NP O
of IN B-PP O
413 CD B-NP O
unrelated JJ I-NP O
individuals NNS I-NP O
to TO B-VP O
examine VB I-VP O
the DT B-NP O
hypothesis NN I-NP O
that IN B-SBAR O
R841W NN B-NP O
might MD B-VP O
be VB I-VP O
a DT B-NP O
rare JJ I-NP O
polymorphism NN I-NP O
detected VBD B-VP O
one CD B-NP O
additional JJ I-NP O
instance NN I-NP O
in IN B-PP O
a DT B-NP O
woman NN I-NP O
with IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
diagnosed VBN B-VP O
at IN B-PP O
age NN B-NP O
77 CD B-NP O
years NNS I-NP O
, , O O
and CC O O
cancer NN B-NP B-Disease
in IN B-PP O
one CD B-NP O
parent NN I-NP O
. . O O

R841W NN B-NP O
is VBZ B-VP O
likely JJ B-ADJP O
to TO B-VP O
be VB I-VP O
an DT B-NP O
etiologically RB I-NP O
significant JJ I-NP O
lesion NN I-NP O
with IN B-PP O
involvement NN B-NP O
in IN B-PP O
close JJ B-NP O
to TO I-NP O
1 CD I-NP O
% NN I-NP O
( ( O O
95 CD B-NP O
% NN I-NP O
confidence NN I-NP O
interval NN I-NP O
of IN B-PP O
0 CD B-NP O
- HYPH I-NP O
1 CD I-NP O
. . O O

7 CD B-NP O
% NN I-NP O
) ) O O
of IN B-PP O
all DT B-NP O
breast NN I-NP B-Disease
and CC I-NP I-Disease
ovarian JJ I-NP I-Disease
cancers NNS I-NP I-Disease
in IN B-PP O
this DT B-NP O
population NN I-NP O
. . O O

Ataxia NN B-NP B-Disease
- HYPH I-NP I-Disease
telangiectasia NN I-NP I-Disease
: : O O
founder NN B-NP O
effect NN I-NP O
among IN B-PP O
north JJ B-NP O
African JJ I-NP O
Jews NNS I-NP O
. . O O

The DT B-NP O
ATM NN I-NP O
gene NN I-NP O
is VBZ B-VP O
responsible JJ B-ADJP O
for IN B-PP O
the DT B-NP O
autosomal JJ I-NP B-Disease
recessive JJ I-NP I-Disease
disorder NN I-NP I-Disease
ataxia NN I-NP B-Disease
- HYPH B-NP I-Disease
telangiectasia NN I-NP I-Disease
( ( O O
A NN B-NP B-Disease
- HYPH O I-Disease
T NN B-NP I-Disease
) ) O O
, , O O
characterized VBN B-VP O
by IN B-PP O
cerebellar JJ B-NP B-Disease
degeneration NN I-NP I-Disease
, , O O
immunodeficiency NN B-NP B-Disease
and CC O O
cancer NN B-NP B-Disease
predisposition NN I-NP I-Disease
. . O O

A DT B-NP B-Disease
- HYPH I-NP I-Disease
T NN I-NP I-Disease
carriers NNS I-NP O
were VBD B-VP O
reported VBN I-VP O
to TO I-VP O
be VB I-VP O
moderately RB B-NP O
cancer NN I-NP B-Disease
- HYPH O I-Disease
prone NN B-NP I-Disease
. . O O

A DT B-NP O
wide JJ I-NP O
variety NN I-NP O
of IN B-PP O
A NN B-NP B-Disease
- HYPH I-NP I-Disease
T NN I-NP I-Disease
mutations NNS I-NP O
, , O O
most JJS B-NP O
of IN B-PP O
which WDT B-NP O
are VBP B-VP O
unique JJ B-ADJP O
to TO B-PP O
single JJ B-NP O
families NNS I-NP O
, , O O
were VBD B-VP O
identified VBN I-VP O
in IN B-PP O
various JJ B-NP O
ethnic JJ I-NP O
groups NNS I-NP O
, , O O
precluding VBG B-VP O
carrier NN B-NP O
screening NN I-NP O
with IN B-PP O
mutation NN B-NP O
- HYPH B-NP O
specific JJ I-NP O
assays NNS I-NP O
. . O O

However RB B-ADVP O
, , O O
a DT B-NP O
single JJ I-NP O
mutation NN I-NP O
was VBD B-VP O
observed VBN I-VP O
in IN B-PP O
32 CD B-NP O
/ SYM O O
33 CD B-NP O
defective JJ I-NP O
ATM NN I-NP O
alleles NNS I-NP O
in IN B-PP O
Jewish JJ B-NP O
A NN I-NP B-Disease
- HYPH I-NP I-Disease
T NN I-NP I-Disease
families NNS I-NP O
of IN B-PP O
North JJ B-NP O
African JJ I-NP O
origin NN I-NP O
, , O O
coming VBG B-VP O
from IN B-PP O
various JJ B-NP O
regions NNS I-NP O
of IN B-PP O
Morocco NNP B-NP O
and CC I-NP O
Tunisia NNP I-NP O
. . O O

This DT B-NP O
mutation NN I-NP O
, , O O
103C NN B-NP O
- HYPH O O
- HYPH O O
> SYM O O
T NNP B-NP O
, , O O
results VBZ B-VP O
in IN B-PP O
a DT B-NP O
stop NN I-NP O
codon NN I-NP O
at IN B-PP O
position NN B-NP O
35 CD I-NP O
of IN B-PP O
the DT B-NP O
ATM NN I-NP O
protein NN I-NP O
. . O O

In IN B-PP O
keeping VBG B-NP O
with IN B-PP O
the DT B-NP O
nature NN I-NP O
of IN B-PP O
this DT B-NP O
mutation NN I-NP O
, , O O
various JJ B-NP O
antibodies NNS I-NP O
directed VBN B-VP O
against IN B-PP O
the DT B-NP O
ATM NN I-NP O
protein NN I-NP O
failed VBD B-VP O
to TO I-VP O
defect VB I-VP O
this DT B-NP O
protein NN I-NP O
in IN B-PP O
patient NN B-NP O
cells NNS I-NP O
. . O O

A DT B-NP O
rapid JJ I-NP O
carrier NN I-NP O
detection NN I-NP O
assay NN I-NP O
detected VBD B-VP O
this DT B-NP O
mutation NN I-NP O
in IN B-PP O
three CD B-NP O
out IN I-NP O
of IN I-NP O
488 CD I-NP O
ATM NN I-NP O
alleles NNS I-NP O
of IN B-PP O
Jewish JJ B-NP O
Moroccan NN I-NP O
or CC O O
Tunisian JJ B-NP O
origin NN I-NP O
. . O O

This DT B-NP O
founder NN I-NP O
effect NN I-NP O
provides VBZ B-VP O
a DT B-NP O
unique JJ I-NP O
opportunity NN I-NP O
for IN B-PP O
population NN B-NP O
- HYPH O O
based VBN B-NP O
screening NN I-NP O
for IN B-PP O
A NN B-NP B-Disease
- HYPH I-NP I-Disease
T NN I-NP I-Disease
carriers NNS I-NP O
in IN B-PP O
a DT B-NP O
large JJ I-NP O
Jewish JJ I-NP O
community NN I-NP O
. . O O

. . O O

Mutation NN B-NP O
analysis NN I-NP O
of IN B-PP O
BRCA1 NN B-NP O
and CC I-NP O
BRCA2 NN I-NP O
in IN B-PP O
a DT B-NP O
male JJ I-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
population NN I-NP O
. . O O

A DT B-NP O
population NN I-NP O
- HYPH B-VP O
based VBN I-VP O
series NN B-NP O
of IN B-PP O
54 CD B-NP O
male JJ I-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
cases NNS I-NP O
from IN B-PP O
Southern NNP B-NP O
California NNP I-NP O
were VBD B-VP O
analyzed VBN I-VP O
for IN B-PP O
germ NN B-NP O
- HYPH I-NP O
line NN I-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
inherited VBN I-NP B-Disease
breast NN I-NP I-Disease
/ SYM B-NP I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
genes NNS I-NP O
, , O O
BRCA1 NN B-NP O
and CC O O
BRCA2 NN B-NP O
. . O O

Nine CD B-NP O
( ( O O
17 CD B-NP O
% NN I-NP O
) ) O O
of IN B-PP O
the DT B-NP O
patients NNS I-NP O
had VBD B-VP O
a DT B-NP O
family NN I-NP O
history NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
and CC O I-Disease
/ SYM B-NP I-Disease
or CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
in IN B-PP O
at IN B-NP O
least JJS I-NP O
one CD I-NP O
first JJ I-NP O
- HYPH I-NP O
degree NN I-NP O
relative JJ B-ADJP O
. . O O

A DT B-NP O
further JJ I-NP O
seven CD I-NP O
( ( O O
13 CD B-NP O
% NN I-NP O
) ) O O
of IN B-PP O
the DT B-NP O
patients NNS I-NP O
reported VBD B-VP O
breast NN B-NP B-Disease
/ SYM B-NP I-Disease
ovarian JJ I-NP I-Disease
cancer NN I-NP I-Disease
in IN B-PP O
at IN B-NP O
least JJS I-NP O
one CD I-NP O
second JJ I-NP O
- HYPH I-NP O
degree NN I-NP O
relative JJ B-ADJP O
and CC O O
in IN B-PP O
no DT B-NP O
first JJ I-NP O
- HYPH I-NP O
degree NN I-NP O
relatives NNS I-NP O
. . O O

No DT B-NP O
germ NN I-NP O
- HYPH B-NP O
line NN I-NP O
BRCA1 NN I-NP O
mutations NNS I-NP O
were VBD B-VP O
found VBN I-VP O
. . O O

Two CD B-NP O
male JJ I-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
patients NNS I-NP O
( ( O O
4 CD B-NP O
% NN I-NP O
of IN B-PP O
the DT B-NP O
total NN I-NP O
) ) O O
were VBD B-VP O
found VBN I-VP O
to TO I-VP O
carry VB I-VP O
novel JJ B-NP O
truncating VBG I-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
BRCA2 NN I-NP O
gene NN I-NP O
. . O O

Only RB B-NP O
one CD I-NP O
of IN B-PP O
the DT B-NP O
two CD I-NP O
male JJ I-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
patients NNS I-NP O
carrying VBG B-VP O
a DT B-NP O
BRCA2 NN I-NP O
mutation NN I-NP O
had VBD B-VP O
a DT B-NP O
family NN I-NP O
history NN I-NP O
of IN B-PP O
cancer NN B-NP B-Disease
, , O O
with IN B-PP O
one CD B-NP O
case NN I-NP O
of IN B-PP O
ovarian JJ B-NP B-Disease
cancer NN I-NP I-Disease
in IN B-PP O
a DT B-NP O
first JJ I-NP O
- HYPH I-NP O
degree NN I-NP O
relative JJ B-ADJP O
. . O O

The DT B-NP O
remaining VBG I-NP O
eight CD I-NP O
cases NNS I-NP O
( ( O O
89 CD B-NP O
% NN I-NP O
) ) O O
of IN B-PP O
male JJ B-NP B-Disease
breast NN I-NP I-Disease
cancer NN I-NP I-Disease
with IN B-PP O
a DT B-NP O
family NN I-NP O
history NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
/ SYM B-NP I-Disease
ovarian JJ I-NP I-Disease
cancer NN I-NP I-Disease
in IN B-PP O
first JJ B-NP O
- HYPH I-NP O
degree NN I-NP O
relatives NNS I-NP O
remain VBP B-VP O
unaccounted JJ B-ADJP O
for IN B-PP O
by IN B-PP O
mutations NNS B-NP O
in IN B-PP O
either CC O O
the DT B-NP O
BRCA1 NN I-NP O
gene NN I-NP O
or CC O O
the DT B-NP O
BRCA2 NN I-NP O
gene NN I-NP O
. . O O

. . O O

Molecular JJ B-NP O
basis NN I-NP O
for IN B-PP O
Duarte NNP B-NP B-Disease
and CC I-NP I-Disease
Los NNP I-NP I-Disease
Angeles NNP I-NP I-Disease
variant JJ I-NP I-Disease
galactosemia NN I-NP I-Disease
. . O O

Human JJ B-NP O
orythrocytes NNS I-NP O
that WDT B-NP O
are VBP B-VP O
homozygous JJ B-ADJP O
for IN B-PP O
the DT B-NP O
Duarte JJ I-NP B-Disease
enzyme NN I-NP I-Disease
variant NN I-NP I-Disease
of IN B-PP I-Disease
galactosemia NN B-NP I-Disease
( ( O O
D NN B-NP O
/ SYM B-NP O
D NN I-NP O
) ) O O
have VBP B-VP O
a DT B-NP O
characteristic JJ I-NP O
isoform NN I-NP O
on IN B-PP O
isoelectric JJ B-NP O
focusing NN I-NP O
and CC O O
50 CD B-NP O
% NN I-NP O
reduction NN I-NP O
in IN B-PP O
galactose NN B-NP O
- HYPH B-NP O
1 CD I-NP O
- HYPH I-NP O
phosphate NN I-NP O
uridyltransferase NN I-NP O
( ( O O
GALT NN B-NP O
) ) O O
enzyme NN B-NP O
activity NN I-NP O
. . O O

The DT B-NP O
Duarte NNP I-NP O
biochemical JJ I-NP O
phenotype NN I-NP O
has VBZ B-VP O
a DT B-NP O
molecular JJ I-NP O
genotype NN I-NP O
of IN B-PP O
N314D NN B-NP O
/ SYM B-NP O
N314D NN I-NP O
. . O O

The DT B-NP O
characteristic JJ I-NP O
Duarte NNP I-NP O
isoform NN I-NP O
is VBZ B-VP O
also RB I-VP O
associated VBN I-VP O
with IN B-PP O
a DT B-NP O
variant JJ I-NP O
called VBN B-VP O
the DT B-NP O
Los NNP I-NP O
Angeles NNP I-NP O
( ( O O
LA NN B-NP O
) ) O O
phenotype NN B-NP O
, , O O
which WDT B-NP O
has VBZ B-VP O
increased VBN I-VP O
GALT NN B-NP O
enzyme NN I-NP O
activity NN I-NP O
. . O O

We PRP B-NP O
evaluated VBD B-VP O
GALT NN B-NP O
enzyme NN I-NP O
activity NN I-NP O
and CC O O
screened VBD B-VP O
the DT B-NP O
GALT NN I-NP O
genes NNS I-NP O
of IN B-PP O
145 CD B-NP O
patients NNS I-NP O
with IN B-PP O
one CD B-NP O
or CC I-NP O
more JJR I-NP O
N314D NN I-NP O
- HYPH O O
containing VBG B-VP O
alleles NNS B-NP O
. . O O

We PRP B-NP O
found VBD B-VP O
seven CD B-NP O
with IN B-PP O
the DT B-NP O
LA NN I-NP O
biochemical JJ I-NP O
phenotype NN I-NP O
, , O O
and CC O O
all DT B-NP O
had VBD B-VP O
a DT B-NP O
1721C NN I-NP O
- SYM B-NP O
- SYM B-NP O
> SYM I-NP O
T NN I-NP O
transition NN I-NP O
in IN B-PP O
exon NN B-NP O
7 CD I-NP O
in IN B-PP O
cis NN B-NP O
with IN B-PP O
the DT B-NP O
N314D NN I-NP O
missense JJ I-NP O
mutation NN I-NP O
. . O O

The DT B-NP O
1721C NN I-NP O
- SYM B-VP O
- SYM B-NP O
> SYM I-NP O
T NN I-NP O
transition NN I-NP O
is VBZ B-VP O
a DT B-NP O
neutral JJ I-NP O
polymorphism NN I-NP O
for IN B-PP O
leucine NN B-NP O
at IN B-PP O
amino NN B-NP O
acid NN I-NP O
218 CD I-NP O
( ( O O
L218L NN B-NP O
) ) O O
. . O O

In IN B-PP O
pedigree NN B-NP O
analyses NNS I-NP O
, , O O
this DT B-NP O
1721C NN I-NP O
- SYM B-NP O
- SYM B-NP O
> SYM I-NP O
T NN I-NP O
transition NN I-NP O
segregated VBD B-VP O
with IN B-PP O
the DT B-NP O
LA NN I-NP O
phenotype NN I-NP O
of IN B-PP O
increased VBN B-NP O
GALT NN I-NP O
activity NN I-NP O
in IN B-PP O
three CD B-NP O
different JJ I-NP O
biochemical JJ I-NP O
phenotypes NNS I-NP O
( ( O O
LA NN B-NP O
/ SYM O O
N NN B-NP O
, , O O
LA NN B-NP O
/ SYM I-NP O
G NN I-NP O
, , O O
and CC O O
LA NN B-NP O
/ SYM B-NP O
D NN I-NP O
) ) O O
. . O O

To TO B-VP O
determine VB I-VP O
the DT B-NP O
mechanism NN I-NP O
for IN B-PP O
increased VBN B-NP O
activity NN I-NP O
of IN B-PP O
the DT B-NP O
LA NN I-NP O
variant NN I-NP O
, , O O
we PRP B-NP O
compared VBD B-VP O
GALT NN B-NP O
mRNA NN I-NP O
, , O O
protein NN B-NP O
abundance NN I-NP O
, , O O
and CC O O
enzyme NN B-NP O
thermal JJ I-NP O
stability NN I-NP O
in IN B-PP O
lymphoblast NN B-NP O
cell NN I-NP O
lines NNS I-NP O
of IN B-PP O
D NN B-NP O
and CC I-NP O
LA NN I-NP O
phenotypes NNS I-NP O
with IN B-PP O
comparable JJ B-NP O
genotypes NNS I-NP O
. . O O

GALT NN B-NP O
protein NN I-NP O
abundance NN I-NP O
was VBD B-VP O
increased VBN I-VP O
in IN B-PP O
LA NN B-NP O
compared VBN B-VP O
to TO B-PP O
D NN B-NP O
alleles NNS I-NP O
, , O O
but CC O O
mRNA NN B-NP O
was VBD B-VP O
similar JJ B-ADJP O
among IN B-PP O
all DT B-NP O
genotypes NNS I-NP O
. . O O

When WRB B-ADVP O
LA NN B-NP O
/ SYM B-NP O
D NN I-NP O
and CC I-NP O
D NN I-NP O
/ SYM B-NP O
D NN I-NP O
GALT NN I-NP O
biochemical JJ I-NP O
phenotypes NNS I-NP O
were VBD B-VP O
compared VBN I-VP O
to TO B-PP O
N NN B-NP O
/ SYM B-NP O
N NN I-NP O
GALT NN I-NP O
phenotypes NNS I-NP O
, , O O
both DT B-NP O
had VBD B-VP O
50 CD B-NP O
% NN I-NP O
, , O O
as IN B-SBAR O
compared VBN B-VP O
to TO B-PP O
21 CD B-NP O
% NN I-NP O
, , O O
reduction NN B-NP O
in IN B-PP O
GALT NN B-NP O
activity NN I-NP O
in IN B-PP O
the DT B-NP O
wild JJ I-NP O
type NN I-NP O
( ( O O
N NN B-NP O
/ SYM B-NP O
N NN I-NP O
) ) O O
after IN B-PP O
exposure NN B-NP O
at IN B-PP O
identical JJ B-NP O
initial JJ I-NP O
enzyme NN I-NP O
activity NN I-NP O
to TO B-PP O
50 CD B-NP O
degrees NNS I-NP O
C JJ B-ADJP O
for IN B-PP O
15 CD B-NP O
min NN I-NP O
. . O O

We PRP B-NP O
conclude VBP B-VP O
that IN B-SBAR O
the DT B-NP O
codon NN I-NP O
change NN I-NP O
N314D NN I-NP O
in IN B-PP O
cis NN B-NP O
with IN B-PP O
the DT B-NP O
base NN I-NP O
- HYPH I-NP O
pair NN I-NP O
transition NN I-NP O
1721C NN I-NP O
- SYM O O
- HYPH O O
> SYM O O
T NN B-NP O
produces VBZ B-VP O
the DT B-NP O
LA NN I-NP B-Disease
variant NN I-NP I-Disease
of IN B-PP I-Disease
galactosemia NN B-NP I-Disease
and CC O O
that IN B-SBAR O
this DT B-NP O
nucleotide NN I-NP O
change NN I-NP O
increases VBZ B-VP O
GALT NN B-NP O
activity NN I-NP O
by IN B-PP O
increasing VBG B-VP O
GALT NN B-NP O
protein NN I-NP O
abundance NN I-NP O
without IN B-PP O
increasing VBG B-VP O
transcription NN B-NP O
or CC O O
decreasing VBG B-VP O
thermal JJ B-NP O
lability NN I-NP O
. . O O

A DT B-NP O
favorable JJ I-NP O
codon NN I-NP O
bias NN I-NP O
for IN B-PP O
the DT B-NP O
mutated VBN I-NP O
codon NN I-NP O
with IN B-PP O
consequently RB B-NP O
increased VBN I-NP O
translation NN I-NP O
rates NNS I-NP O
is VBZ B-VP O
postulated VBN I-VP O
as IN B-PP O
the DT B-NP O
mechanism NN I-NP O
. . O O

. . O O

The DT B-NP O
TSG101 NN I-NP O
tumor NN I-NP B-Disease
susceptibility NN I-NP O
gene NN I-NP O
is VBZ B-VP O
located JJ B-ADJP O
in IN B-PP O
chromosome NN B-NP O
11 CD I-NP O
band NN I-NP O
p15 NN I-NP O
and CC O O
is VBZ B-VP O
mutated VBN I-VP O
in IN B-PP O
human JJ B-NP O
breast NN I-NP B-Disease
cancer NN I-NP I-Disease
. . O O

Recent JJ B-NP O
work NN I-NP O
has VBZ B-VP O
identified VBN I-VP O
a DT B-NP O
mouse NN I-NP O
gene NN I-NP O
( ( O O
tsg101 NN B-NP O
) ) O O
whose WP$ B-NP O
inactivation NN I-NP O
in IN B-PP O
fibroblasts NNS B-NP O
results VBZ B-VP O
in IN B-PP O
cellular JJ B-NP O
transformation NN I-NP O
and CC O O
the DT B-NP O
ability NN I-NP O
to TO B-VP O
produce VB I-VP O
metastatic JJ B-NP B-Disease
tumors NNS I-NP I-Disease
in IN B-PP O
nude JJ B-NP O
mice NNS I-NP O
. . O O

Here RB B-ADVP O
, , O O
we PRP B-NP O
report VBP B-VP O
that IN B-SBAR O
the DT B-NP O
human JJ I-NP O
homolog NN I-NP O
, , O O
TSG101 NN B-NP O
, , O O
which WDT B-NP O
we PRP B-NP O
isolated VBD B-VP O
and CC O O
mapped VBD B-VP O
to TO B-PP O
chromosome NN B-NP O
11 CD I-NP O
, , O O
bands NNS B-NP O
15 CD B-NP O
. . O O

1 CD B-NP O
- HYPH I-NP O
15 CD B-NP O
1 CD I-NP O
- HYPH I-NP O
15 CD I-NP O
. . O O

2 CD B-NP O
, , O O
a DT B-NP O
region NN I-NP O
proposed VBN B-VP O
to TO I-VP O
contain VB I-VP O
tumor NN B-NP B-Disease
suppressor NN I-NP O
gene NN I-NP O
( ( I-NP O
s NNS I-NP O
) ) O O
, , O O
is VBZ B-VP O
mutated VBN I-VP O
at IN B-PP O
high JJ B-NP O
frequency NN I-NP O
in IN B-PP O
human JJ B-NP O
breast NN I-NP B-Disease
cancer NN I-NP I-Disease
. . O O

In IN B-PP O
7 CD B-NP O
of IN B-PP O
15 CD B-NP O
uncultured JJ I-NP O
primary JJ I-NP O
human JJ I-NP O
breast NN I-NP B-Disease
carcinomas NNS I-NP I-Disease
, , O O
intragenic JJ B-NP O
deletions NNS I-NP O
were VBD B-VP O
shown VBN I-VP O
in IN B-PP O
TSG101 NN B-NP O
genomic JJ I-NP O
DNA NN I-NP O
and CC O O
transcripts NNS B-NP O
by IN B-PP O
gel NN B-NP O
and CC O O
sequence NN B-NP O
analysis NN I-NP O
, , O O
and CC O O
mutations NNS B-NP O
affecting VBG B-VP O
two CD B-NP O
TSG101 NN I-NP O
alleles NNS I-NP O
were VBD B-VP O
identified VBN I-VP O
in IN B-PP O
four CD B-NP O
of IN B-PP O
these DT B-NP O
cancers NNS I-NP B-Disease
. . O O

No DT B-NP O
TSG101 NN I-NP O
defects NNS I-NP O
were VBD B-VP O
found VBN I-VP O
in IN B-PP O
matched VBN B-NP O
normal JJ I-NP O
breast NN I-NP O
tissue NN I-NP O
from IN B-PP O
the DT B-NP O
breast NN I-NP B-Disease
cancer NN I-NP I-Disease
patients NNS I-NP O
. . O O

These DT B-NP O
findings NNS I-NP O
strongly RB B-VP O
implicate VBP I-VP O
TSG101 NN B-NP O
mutations NNS I-NP O
in IN B-PP O
human JJ B-NP O
breast NN I-NP B-Disease
cancer NN I-NP I-Disease
Moderate JJ B-NP O
intergenerational JJ I-NP O
and CC I-NP O
somatic JJ I-NP O
instability NN I-NP O
of IN B-PP O
a DT B-NP O
55 CD I-NP O
- HYPH I-NP O
CTG NN I-NP O
repeat NN I-NP O
in IN B-PP O
transgenic JJ B-NP O
mice NNS I-NP O
. . O O

Myotonic JJ B-NP B-Disease
dystrophy NN I-NP I-Disease
( ( O O
DM NN B-NP B-Disease
) ) O O
is VBZ B-VP O
associated VBN I-VP O
with IN B-PP O
the DT B-NP O
expansion NN I-NP O
of IN B-PP O
a DT B-NP O
( ( O O
CTG NN O O
) ) O O
n NN B-NP O
trinucleotide NN I-NP O
repeat NN I-NP O
in IN B-PP O
the DT B-NP O
3 CD I-NP O
untranslated JJ I-NP O
region NN I-NP O
( ( O O
UTR NN B-NP O
) ) O O
of IN B-PP O
the DT B-NP O
DM NN I-NP B-Disease
protein NN I-NP O
kinase NN I-NP O
gene NN I-NP O
( ( O O
DMPK NN B-NP O
) ) O O
. . O O

The DT B-NP O
( ( O O
CTG NN O O
) ) O O
n NN B-NP O
repeat NN I-NP O
is VBZ B-VP O
polymorphic JJ B-ADJP O
and CC O O
varies VBZ B-VP O
in IN B-PP O
size NN B-NP O
between IN B-PP O
5 CD B-NP O
and CC I-NP O
37 CD I-NP O
repeats NNS I-NP O
in IN B-PP O
unaffected JJ B-NP O
individuals NNS I-NP O
whereas IN B-ADVP O
in IN B-PP O
affected VBN B-NP O
patients NNS I-NP O
there RB B-ADVP O
are VBP B-VP O
between IN B-PP O
50 CD B-NP O
and CC I-NP O
4 CD I-NP O
, , I-NP O
000 CD I-NP O
CTGs NNS I-NP O
. . O O

The DT B-NP O
size NN I-NP O
of IN B-PP O
the DT B-NP O
( ( O O
CTG NN O O
) ) O O
n NN B-NP O
repeat NN I-NP O
, , O O
which WDT B-NP O
increases VBZ B-VP O
through IN B-PP O
generations NNS B-NP O
, , O O
generally RB B-ADVP O
correlates VBZ B-VP O
with IN B-PP O
clinical JJ B-NP O
severity NN I-NP O
and CC I-NP O
age NN I-NP O
of IN B-PP O
onset NN B-NP O
. . O O

The DT B-NP O
instability NN I-NP O
of IN B-PP O
the DT B-NP O
CTG NN I-NP O
repeat NN I-NP O
appears VBZ B-VP O
to TO I-VP O
depend VB I-VP O
on IN B-PP O
its PRP$ B-NP O
size NN I-NP O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
on IN B-PP O
the DT B-NP O
sex NN I-NP O
of IN B-PP O
the DT B-NP O
transmitting JJ I-NP O
parent NN I-NP O
. . O O

Moreover RB B-ADVP O
, , O O
mitotic JJ B-NP O
instability NN I-NP O
analysis NN I-NP O
of IN B-PP O
different JJ B-NP O
human JJ I-NP O
DM NN I-NP B-Disease
tissues NNS I-NP O
shows VBZ B-VP O
length NN B-NP O
mosaicism NN I-NP O
between IN B-PP O
different JJ B-NP O
cell NN I-NP O
lineages NNS I-NP O
. . O O

The DT B-NP O
molecular JJ I-NP O
mechanisms NNS I-NP O
of IN B-PP O
triplet JJ B-NP O
instability NN I-NP O
remain VBP B-VP O
elusive JJ B-ADJP O
. . O O

To TO B-VP O
investigate VB I-VP O
the DT B-NP O
role NN I-NP O
of IN B-PP O
genomic JJ B-NP O
sequences NNS I-NP O
in IN B-PP O
instability NN B-NP O
, , O O
we PRP B-NP O
produced VBD B-VP O
transgenic JJ B-NP O
mice NNS I-NP O
containing VBG B-VP O
a DT B-NP O
45 CD I-NP O
- HYPH I-NP O
kb NN I-NP O
genomic JJ I-NP O
segment NN I-NP O
with IN B-PP O
a DT B-NP O
55 CD I-NP O
- HYPH I-NP O
CTG NN I-NP O
repeat NN I-NP O
cloned VBN B-VP O
from IN B-PP O
a DT B-NP O
mildly RB I-NP O
affected VBN I-NP O
patient NN I-NP O
. . O O

In IN B-PP O
contrast NN B-NP O
to TO B-PP O
other JJ B-NP O
mouse NN I-NP O
models NNS I-NP O
containing VBG B-VP O
CAG NN B-NP O
repeats NNS I-NP O
within IN B-PP O
cDNAs NNS B-NP O
, , O O
these DT B-NP O
mice NNS I-NP O
showed VBD B-VP O
both CC O O
intergenerational JJ B-NP O
and CC I-NP O
somatic JJ I-NP O
repeat NN I-NP O
instability NN I-NP O
. . O O

. . O O

Missense JJ B-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
Fas NN I-NP O
gene NN I-NP O
resulting VBG B-VP O
in IN B-PP O
autoimmune JJ B-NP B-Disease
lymphoproliferative JJ I-NP I-Disease
syndrome NN I-NP I-Disease
: : O O
a DT B-NP O
molecular JJ I-NP O
and CC I-NP O
immunological JJ I-NP O
analysis NN I-NP O
. . O O

Programmed VBN B-NP O
cell NN I-NP O
death NN I-NP O
( ( O O
or CC O O
apoptosis NN B-NP O
) ) O O
is VBZ B-VP O
a DT B-NP O
physiological JJ I-NP O
process NN I-NP O
essential JJ B-ADJP O
to TO B-PP O
the DT B-NP O
normal JJ I-NP O
development NN I-NP O
and CC O O
homeostatic JJ B-NP O
maintenance NN I-NP O
of IN B-PP O
the DT B-NP O
immune JJ I-NP O
system NN I-NP O
. . O O

The DT B-NP O
Fas NN I-NP O
/ SYM B-NP O
Apo NN I-NP O
- HYPH B-NP O
1 CD I-NP O
receptor NN I-NP O
plays VBZ B-VP O
a DT B-NP O
crucial JJ I-NP O
role NN I-NP O
in IN B-PP O
the DT B-NP O
regulation NN I-NP O
of IN B-PP O
apoptosis NN B-NP O
, , O O
as IN B-SBAR O
demonstrated VBN B-VP O
by IN B-PP O
lymphoproliferation NN B-NP O
in IN B-PP O
MRL NN B-NP O
- HYPH B-NP O
lpr NN I-NP O
/ SYM B-NP O
lpr NN I-NP O
mice NNS I-NP O
and CC B-PP O
by IN B-PP O
the DT B-NP O
recently RB I-NP O
described VBN I-NP O
autoimmune JJ I-NP B-Disease
lymphoproliferative JJ I-NP I-Disease
syndrome NN I-NP I-Disease
( ( O O
ALPS NN B-NP B-Disease
) ) O O
in IN B-PP O
humans NNS B-NP O
, , O O
both DT B-NP O
of IN B-PP O
which WDT B-NP O
are VBP B-VP O
due JJ B-ADJP O
to TO B-PP O
mutations NNS B-NP O
in IN B-PP O
the DT B-NP O
Fas NN I-NP O
gene NN I-NP O
. . O O

We PRP B-NP O
describe VBP B-VP O
a DT B-NP O
novel JJ I-NP O
family NN I-NP O
with IN B-PP O
ALPS NN B-NP B-Disease
in IN B-PP O
which WDT B-NP O
three CD B-NP O
affected VBN I-NP O
siblings NNS I-NP O
carry VBP B-VP O
two CD B-NP O
distinct JJ I-NP O
missense JJ I-NP O
mutations NNS I-NP O
on IN B-PP O
both CC O O
the DT B-NP O
Fas NN I-NP O
gene NN I-NP O
alleles NNS I-NP O
and CC O O
show VBP B-VP O
lack NN B-NP O
of IN B-PP O
Fas NN B-NP O
- HYPH B-NP O
induced VBN I-NP O
apoptosis NN I-NP O
. . O O

The DT B-NP O
children NNS I-NP O
share VBP B-VP O
common JJ B-NP O
clinical JJ I-NP O
features NNS I-NP O
including VBG B-PP O
splenomegaly NN B-NP B-Disease
and CC I-NP O
lymphadenopathy NN I-NP B-Disease
, , O O
but CC O O
only RB B-NP O
one CD I-NP O
developed VBD B-VP O
severe JJ B-NP O
autoimmune JJ I-NP B-Disease
manifestations NNS I-NP I-Disease
. . O O

In IN B-PP O
all DT B-NP O
three CD I-NP O
siblings NNS I-NP O
, , O O
we PRP B-NP O
demonstrated VBD B-VP O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
anergic JJ B-NP O
CD3 NN I-NP O
+ SYM B-NP O
CD4 NN I-NP O
- SYM B-NP O
CD8 NN I-NP O
- SYM B-NP O
( ( O O
double RB B-ADJP O
negative JJ I-ADJP O
, , O O
[ ( O O
DN NNP B-NP O
] ) O O
) ) O O
T NN B-NP O
cells NNS I-NP O
; : O O
moreover RB B-ADVP O
, , O O
a DT B-NP O
chronic JJ I-NP O
lymphocyte NN I-NP O
activation NN I-NP O
was VBD B-VP O
found VBN I-VP O
, , O O
as IN B-SBAR O
demonstrated VBN B-VP O
by IN B-PP O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
high JJ B-NP O
levels NNS I-NP O
of IN B-PP O
HLA NN B-NP O
- HYPH B-NP O
DR NN I-NP O
expression NN I-NP O
on IN B-PP O
peripheral JJ B-NP O
CD3 NN I-NP O
+ SYM B-NP O
cells NNS I-NP O
and CC B-PP O
by IN B-PP O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
high JJ B-NP O
levels NNS I-NP O
of IN B-PP O
serum NN B-NP O
activation NN I-NP O
markers NNS I-NP O
such JJ B-PP O
as IN I-PP O
soluble JJ B-NP O
interleukin NN I-NP O
- HYPH O O
2 CD B-NP O
receptor NN I-NP O
( ( O O
slL NN B-NP O
- HYPH B-NP O
2R NN I-NP O
) ) O O
and CC O O
soluble JJ B-NP O
CD30 NN I-NP O
( ( O O
sCD30 NN B-NP O
) ) O O
. . O O

. . O O

The DT B-NP O
ataxia NN I-NP B-Disease
- HYPH I-NP I-Disease
telangiectasia NN I-NP I-Disease
gene NN I-NP O
product NN I-NP O
, , O O
a DT B-NP O
constitutively RB I-NP O
expressed VBN I-NP O
nuclear JJ I-NP O
protein NN I-NP O
that WDT B-NP O
is VBZ B-VP O
not RB O O
up RB B-ADVP O
- HYPH B-NP O
regulated VBN B-VP O
following VBG B-PP O
genome NN B-NP O
damage NN I-NP O
. . O O

The DT B-NP O
product NN I-NP O
of IN B-PP O
the DT B-NP O
ataxia NN I-NP B-Disease
- HYPH B-NP I-Disease
telangiectasia NN I-NP I-Disease
gene NN I-NP O
( ( O O
ATM NN B-NP O
) ) O O
was VBD B-VP O
identified VBN I-VP O
by IN B-PP O
using VBG B-VP O
an DT B-NP O
antiserum NN I-NP O
developed VBN B-VP O
to TO B-PP O
a DT B-NP O
peptide NN I-NP O
corresponding VBG B-VP O
to TO B-PP O
the DT B-NP O
deduced VBN I-NP O
amino JJ I-NP O
acid NN I-NP O
sequence NN I-NP O
. . O O

The DT B-NP O
ATM NN I-NP O
protein NN I-NP O
is VBZ B-VP O
a DT B-NP O
single JJ I-NP O
, , I-NP O
high JJ I-NP O
- HYPH I-NP O
molecular JJ I-NP O
weight NN I-NP O
protein NN I-NP O
predominantly RB B-VP O
confined VBN I-VP O
to TO B-PP O
the DT B-NP O
nucleus NN I-NP O
of IN B-PP O
human JJ B-NP O
fibroblasts NNS I-NP O
, , O O
but CC O O
is VBZ B-VP O
present JJ B-ADJP O
in IN B-PP O
both CC B-NP O
nuclear JJ I-NP O
and CC I-NP O
microsomal JJ I-NP O
fractions NNS I-NP O
from IN B-PP O
human JJ B-NP O
lymphoblast NN I-NP O
cells NNS I-NP O
and CC O O
peripheral JJ B-NP O
blood NN I-NP O
lymphocytes NNS I-NP O
. . O O

ATM NN B-NP O
protein NN I-NP O
levels NNS I-NP O
and CC O O
localization NN B-NP O
remain VBP B-VP O
constant JJ B-ADJP O
throughout IN B-PP O
all DT B-NP O
stages NNS I-NP O
of IN B-PP O
the DT B-NP O
cell NN I-NP O
cycle NN I-NP O
. . O O

Truncated VBN B-NP O
ATM NN I-NP O
protein NN I-NP O
was VBD B-VP O
not RB I-VP O
detected VBN I-VP O
in IN B-PP O
lymphoblasts NNS B-NP O
from IN B-PP O
ataxia NN B-NP B-Disease
- HYPH B-PP I-Disease
telangiectasia NN B-NP I-Disease
patients NNS I-NP O
homozygous JJ B-ADJP O
for IN B-PP O
mutations NNS B-NP O
leading VBG B-VP O
to TO B-PP O
premature JJ B-NP O
protein NN I-NP O
termination NN I-NP O
. . O O

Exposure NN B-NP O
of IN B-PP O
normal JJ B-NP O
human JJ I-NP O
cells NNS I-NP O
to TO B-PP O
gamma SYM B-NP O
- HYPH B-NP O
irradiation NN I-NP O
and CC O O
the DT B-NP O
radiomimetic JJ I-NP O
drug NN I-NP O
neocarzinostatin NN I-NP O
had VBD B-VP O
no DT B-NP O
effect NN I-NP O
on IN B-PP O
ATM NN B-NP O
protein NN I-NP O
levels NNS I-NP O
, , O O
in IN B-PP O
contrast NN B-NP O
to TO B-PP O
a DT B-NP O
noted VBN I-NP O
rise NN I-NP O
in IN B-PP O
p53 NN B-NP O
levels NNS I-NP O
over IN B-PP O
the DT B-NP O
same JJ I-NP O
time NN I-NP O
interval NN I-NP O
. . O O

These DT B-NP O
findings NNS I-NP O
are VBP B-VP O
consistent JJ B-ADJP O
with IN B-PP O
a DT B-NP O
role NN I-NP O
for IN B-PP O
the DT B-NP O
ATM NN I-NP O
protein NN I-NP O
in IN B-PP O
ensuring VBG B-VP O
the DT B-NP O
fidelity NN I-NP O
of IN B-PP O
DNA NN B-NP O
repair NN I-NP O
and CC O O
cell NN B-NP O
cycle NN I-NP O
regulation NN I-NP O
following VBG B-PP O
genome NN B-NP O
damage NN I-NP O
. . O O

. . O O

Type NN B-NP O
III CD I-NP O
collagen NN I-NP O
is VBZ B-VP O
crucial JJ B-ADJP O
for IN B-PP O
collagen NN B-NP O
I CD I-NP O
fibrillogenesis NN I-NP O
and CC B-PP O
for IN B-PP O
normal JJ B-NP O
cardiovascular JJ I-NP O
development NN I-NP O
. . O O

Type NN B-NP O
III CD I-NP O
collagen NN I-NP O
is VBZ B-VP O
a DT B-NP O
fibrillar JJ I-NP O
forming VBG I-NP O
collagen NN I-NP O
comprising VBG B-VP O
three CD B-NP O
alpha1 NN I-NP O
( ( O O
III CD B-NP O
) ) O O
chains NNS B-NP O
and CC O O
is VBZ B-VP O
expressed VBN I-VP O
in IN B-PP O
early JJ B-NP O
embryos NNS I-NP O
and CC B-PP O
throughout IN B-PP O
embryogenesis NN B-NP O
. . O O

In IN B-PP O
the DT B-NP O
adult NN I-NP O
, , O O
type NN B-NP O
III CD I-NP O
collagen NN I-NP O
is VBZ B-VP O
a DT B-NP O
major JJ I-NP O
component NN I-NP O
of IN B-PP O
the DT B-NP O
extracellular JJ I-NP O
matrix NN I-NP O
in IN B-PP O
a DT B-NP O
variety NN I-NP O
of IN B-PP O
internal JJ B-NP O
organs NNS I-NP O
and CC I-NP O
skin NN I-NP O
. . O O

Mutations NNS B-NP O
in IN B-PP O
the DT B-NP O
COL3A1 NN I-NP O
gene NN I-NP O
have VBP B-VP O
been VBN I-VP O
implicated VBN I-VP O
as IN B-PP O
a DT B-NP O
cause NN I-NP O
of IN B-PP O
type NN B-NP B-Disease
IV CD I-NP I-Disease
Ehlers NNP I-NP I-Disease
- HYPH I-NP I-Disease
Danlos NNP I-NP I-Disease
syndrome NN I-NP I-Disease
, , O O
a DT B-NP O
disease NN I-NP O
leading VBG B-VP O
to TO B-PP O
aortic JJ B-NP B-Disease
rupture NN I-NP I-Disease
in IN B-PP O
early JJ B-NP O
adult JJ I-NP O
life NN I-NP O
. . O O

To TO B-VP O
directly RB I-VP O
study VB I-VP O
the DT B-NP O
role NN I-NP O
of IN B-PP O
Col3a1 NN B-NP O
in IN B-PP O
development NN B-NP O
and CC I-NP O
disease NN I-NP O
, , O O
we PRP B-NP O
have VBP B-VP O
inactivated VBN I-VP O
the DT B-NP O
Col3a1 NN I-NP O
gene NN I-NP O
in IN B-PP O
embryonic JJ B-NP O
stem NN I-NP O
cells NNS I-NP O
by IN B-PP O
homologous JJ B-NP O
recombination NN I-NP O
. . O O

The DT B-NP O
mutated VBN I-NP O
allele NN I-NP O
was VBD B-VP O
transmitted VBN I-VP O
through IN B-PP O
the DT B-NP O
mouse NN I-NP O
germ NN I-NP O
line NN I-NP O
and CC O O
homozygous JJ B-NP O
mutant JJ I-NP O
animals NNS I-NP O
were VBD B-VP O
derived VBN I-VP O
from IN B-PP O
heterozygous JJ B-NP O
intercrosses NNS I-NP O
. . O O

About IN B-NP O
10 CD I-NP O
% NN I-NP O
of IN B-PP O
the DT B-NP O
homozygous JJ I-NP O
mutant JJ I-NP O
animals NNS I-NP O
survived VBD B-VP O
to TO B-PP O
adulthood NN B-NP O
but CC O O
have VBP B-VP O
a DT B-NP O
much RB I-NP O
shorter JJR I-NP O
life NN I-NP O
span NN I-NP O
compared VBN B-PP O
with IN B-PP O
wild JJ B-NP O
- HYPH I-NP O
type NN I-NP O
mice NNS I-NP O
. . O O

The DT B-NP O
major JJ I-NP O
cause NN I-NP O
of IN B-PP O
death NN B-NP O
of IN B-PP O
mutant JJ B-NP O
mice NNS I-NP O
was VBD B-VP O
rupture NN B-NP O
of IN B-PP O
the DT B-NP O
major JJ I-NP O
blood NN I-NP O
vessels NNS I-NP O
, , O O
similar JJ B-ADJP O
to TO B-PP O
patients NNS B-NP O
with IN B-PP O
type NN B-NP B-Disease
IV CD I-NP I-Disease
Ehlers NNP I-NP I-Disease
- HYPH I-NP I-Disease
Danlos NNP I-NP I-Disease
syndrome NN I-NP I-Disease
. . O O

Ultrastructural JJ B-NP O
analysis NN I-NP O
of IN B-PP O
tissues NNS B-NP O
from IN B-PP O
mutant JJ B-NP O
mice NNS I-NP O
revealed VBD B-VP O
that IN B-SBAR O
type NN B-NP O
III CD I-NP O
collagen NN I-NP O
is VBZ B-VP O
essential JJ B-ADJP O
for IN B-PP O
normal JJ B-NP O
collagen NN I-NP O
I CD I-NP O
fibrillogenesis NN I-NP O
in IN B-PP O
the DT B-NP O
cardiovascular JJ I-NP O
system NN I-NP O
and CC O O
other JJ B-NP O
organs NNS I-NP O
. . O O

. . O O

Nonsense NN B-NP O
mutation NN I-NP O
in IN B-PP O
exon NN B-NP O
3 CD I-NP O
of IN B-PP O
the DT B-NP O
proteolipid NN I-NP O
protein NN I-NP O
gene NN I-NP O
( ( O O
PLP NN B-NP O
) ) O O
in IN B-PP O
a DT B-NP O
family NN I-NP O
with IN B-PP O
an DT B-NP O
unusual JJ I-NP O
form NN I-NP O
of IN B-PP O
Pelizaeus NNP B-NP B-Disease
- HYPH I-NP I-Disease
Merzbacher NNP I-NP I-Disease
disease NN I-NP I-Disease
. . O O

We PRP B-NP O
report VBP B-VP O
a DT B-NP O
G NN I-NP O
- SYM B-NP O
- HYPH B-NP O
> SYM I-NP O
A NN I-NP O
transition NN I-NP O
at IN B-PP O
nucleotide NN B-NP O
431 CD I-NP O
of IN B-PP O
the DT B-NP O
proteolipid NN I-NP O
protein NN I-NP O
gene NN I-NP O
( ( O O
PLP NN B-NP O
) ) O O
results VBZ B-VP O
in IN B-PP O
a DT B-NP O
nonsense JJ I-NP O
codon NN I-NP O
in IN B-PP O
a DT B-NP O
family NN I-NP O
with IN B-PP O
an DT B-NP O
unusual JJ I-NP O
form NN I-NP O
of IN B-PP O
Pelizaeus NNP B-NP B-Disease
- HYPH I-NP I-Disease
Merzbacher NNP I-NP I-Disease
disease NN I-NP I-Disease
( ( O O
PMD NN B-NP B-Disease
) ) O O
. . O O

The DT B-NP O
mutation NN I-NP O
, , O O
which WDT B-NP O
creates VBZ B-VP O
a DT B-NP O
second JJ I-NP O
AluI NN I-NP O
restriction NN I-NP O
site NN I-NP O
, , O O
results VBZ B-VP O
in IN B-PP O
a DT B-NP O
nonsense JJ I-NP O
mutation NN I-NP O
in IN B-PP O
PLP NN B-NP O
. . O O

The DT B-NP O
clinical JJ I-NP O
picture NN I-NP O
resembles VBZ B-VP O
somewhat RB B-NP O
that DT I-NP O
of IN B-PP O
X NN B-NP B-Disease
- HYPH O I-Disease
linked VBN B-VP I-Disease
spastic JJ B-NP I-Disease
paraplegia NN I-NP I-Disease
( ( O O
SPG NN B-NP B-Disease
) ) O O
. . O O

It PRP B-NP O
differs VBZ B-VP O
from IN B-PP O
this DT B-NP O
and CC O O
both CC O O
the DT B-NP O
classical JJ I-NP O
and CC I-NP O
connatal JJ I-NP O
forms NNS I-NP O
of IN B-PP O
PMD NN B-NP B-Disease
in IN B-PP O
that IN B-NP O
it PRP B-NP O
is VBZ B-VP O
relatively RB B-ADJP O
mild JJ I-ADJP O
in IN B-PP O
form NN B-NP O
, , O O
onset NN B-NP O
is VBZ B-VP O
delayed VBN I-VP O
beyond IN B-PP O
age NN B-NP O
2 CD B-NP O
years NNS I-NP O
, , O O
nystagmus NN B-NP B-Disease
is VBZ B-VP O
absent JJ B-ADJP O
, , O O
tremors NNS B-NP B-Disease
are VBP B-VP O
prominent JJ B-NP O
, , I-NP O
mental JJ I-NP B-Disease
retardation NN I-NP I-Disease
is VBZ B-VP O
not RB O O
severe JJ B-ADJP O
, , O O
some DT B-NP O
patients NNS I-NP O
show VBP B-VP O
dementia NN B-NP B-Disease
or CC I-NP O
personality NN I-NP B-Disease
disorders NNS I-NP I-Disease
, , O O
the DT B-NP O
disease NN I-NP O
is VBZ B-VP O
progressive JJ B-ADJP O
rather RB B-PP O
than IN I-PP O
static JJ B-ADJP O
in IN B-PP O
some DT B-NP O
, , O O
and CC O O
several JJ B-NP O
females NNS I-NP O
show VBP B-VP O
signs NNS B-NP O
of IN B-PP O
disease NN B-NP O
. . O O

The DT B-NP O
nonsense JJ I-NP O
mutation NN I-NP O
, , O O
which WDT B-NP O
is VBZ B-VP O
in IN B-PP O
exon NN B-NP O
3B NN I-NP O
, , O O
should MD B-VP O
block VB I-VP O
the DT B-NP O
synthesis NN I-NP O
of IN B-PP O
normal JJ B-NP O
PLP NN I-NP O
but CC O O
spare JJ B-NP O
DM20 NN I-NP O
, , O O
the DT B-NP O
isoform NN I-NP O
whose WP$ B-NP O
persistence NN I-NP O
has VBZ B-VP O
been VBN I-VP O
associated VBN I-VP O
with IN B-PP O
mild JJ B-NP O
forms NNS I-NP O
of IN B-PP O
PLP NN B-NP B-Disease
- HYPH B-NP I-Disease
associated VBN I-NP I-Disease
disease NN I-NP I-Disease
in IN B-PP O
both CC B-NP O
humans NNS I-NP O
and CC I-NP O
mice NNS I-NP O
. . O O

. . O O

Common JJ B-NP O
BRCA1 NN I-NP O
variants NNS I-NP O
and CC O O
susceptibility NN B-NP O
to TO B-PP O
breast NN B-NP B-Disease
and CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
in IN B-PP O
the DT B-NP O
general JJ I-NP O
population NN I-NP O
. . O O

Most RBS B-NP O
multiple JJ I-NP O
case NN I-NP O
families NNS I-NP O
of IN B-PP O
young JJ B-NP O
onset NN I-NP O
breast NN I-NP B-Disease
cancer NN I-NP I-Disease
and CC O O
ovarian JJ B-NP B-Disease
cancer NN I-NP I-Disease
are VBP B-VP O
thought VBN I-VP O
to TO I-VP O
be VB I-VP O
due IN B-PP O
to TO B-PP O
highly RB B-NP O
penetrant JJ I-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
predisposing VBG I-NP O
genes NNS I-NP O
BRCA1 NN I-NP O
and CC I-NP O
BRCA2 NN I-NP O
. . O O

However RB B-ADVP O
, , O O
these DT B-NP O
mutations NNS I-NP O
are VBP B-VP O
uncommon JJ B-ADJP O
in IN B-PP O
the DT B-NP O
population NN I-NP O
and CC O O
they PRP B-NP O
probably RB B-ADVP O
account VBP B-VP O
for IN B-PP O
only RB B-NP O
a DT I-NP O
few JJ I-NP O
percent NN I-NP O
of IN B-PP O
all DT B-NP O
breast NN I-NP B-Disease
cancer NN I-NP I-Disease
incidence NN I-NP O
. . O O

A DT B-NP O
much RB I-NP O
larger JJR I-NP O
fraction NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
might MD B-VP O
, , O O
in IN B-PP O
principle NN B-NP O
, , O O
be VB B-VP O
due JJ B-PP O
to TO B-PP O
common JJ B-NP O
variants NNS I-NP O
which WDT B-NP O
confer VBP B-VP O
more RBR B-NP O
modest JJ I-NP O
individual JJ I-NP O
risks NNS I-NP O
. . O O

There EX B-NP O
are VBP B-VP O
several JJ B-NP O
common JJ I-NP O
polymorphisms NNS I-NP O
in IN B-PP O
the DT B-NP O
BRCA1 NN I-NP O
gene NN I-NP O
which WDT B-NP O
generate VBP B-VP O
amino JJ B-NP O
acid NN I-NP O
substitutions NNS I-NP O
. . O O

We PRP B-NP O
have VBP B-VP O
examined VBN I-VP O
the DT B-NP O
frequency NN I-NP O
of IN B-PP O
four CD B-NP O
of IN B-PP O
these DT B-NP O
polymorphisms NNS I-NP O
Gln356Arg NN I-NP O
, , O O
Pro871Leu NN B-NP O
, , O O
Glu1038Gly NN B-NP O
and CC I-NP O
Ser1613Gly NN I-NP O
in IN B-PP O
large JJ B-NP O
series NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
and CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
cases NNS I-NP O
and CC O O
matched JJ B-NP O
controls NNS I-NP O
. . O O

Due JJ B-PP O
to TO B-PP O
strong JJ B-NP O
linkage NN I-NP O
disequilibrium NN I-NP O
, , O O
these DT B-NP O
four CD I-NP O
sites NNS I-NP O
generate VBP B-VP O
only RB B-NP O
three CD I-NP O
haplotypes NNS I-NP O
with IN B-PP O
a DT B-NP O
frequency NN I-NP O
> JJR B-NP O
1 CD I-NP O
. . O O

3 CD B-NP O
% NN I-NP O
. . O O

The DT B-NP O
most RBS I-NP O
common JJ I-NP O
haplotypes NNS I-NP O
, , O O
defined VBN B-VP O
by IN B-PP O
the DT B-NP O
alleles NNS I-NP O
Gln356Pro871Glu1038Ser1613 NN I-NP O
and CC I-NP O
Gln356Leu871Gly1038Gly1613 NN I-NP O
, , O O
have VBP B-VP O
frequencies NNS B-NP O
of IN B-PP O
0 CD B-NP O
. . O O

57 CD B-NP O
and CC I-NP O
0 CD I-NP O
. . O O

32 CD B-NP O
respectively RB I-NP O
, , O O
and CC O O
these DT B-NP O
frequencies NNS I-NP O
do VBP B-VP O
not RB I-VP O
differ VB I-VP O
significantly RB B-ADVP O
between IN B-PP O
patient NN B-NP O
and CC I-NP O
control NN I-NP O
groups NNS I-NP O
. . O O

Thus RB B-ADVP O
the DT B-NP O
most RBS I-NP O
common JJ I-NP O
polymorphisms NNS I-NP O
of IN B-PP O
the DT B-NP O
BRCA1 NN I-NP O
gene NN I-NP O
do VBP B-VP O
not RB I-VP O
make VB I-VP O
a DT B-NP O
significant JJ I-NP O
contribution NN I-NP O
to TO B-PP O
breast NN B-NP B-Disease
or CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
risk NN I-NP O
. . O O

However RB B-ADVP O
, , O O
our PRP$ B-NP O
data NNS I-NP O
suggest VBP B-VP O
that IN B-SBAR O
the DT B-NP O
Arg356 NN I-NP O
allele NN I-NP O
may MD B-VP O
have VB I-VP O
a DT B-NP O
different JJ I-NP O
genotype NN I-NP O
distribution NN I-NP O
in IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
patients NNS I-NP O
from IN B-PP O
that DT B-NP O
in IN B-PP O
controls NNS B-NP O
( ( O O
Arg356 NN B-NP O
homozygotes NNS I-NP O
are VBP B-VP O
more RBR B-ADJP O
frequent JJ I-ADJP O
in IN B-PP O
the DT B-NP O
control NN I-NP O
groups NNS I-NP O
, , O O
P NN B-NP O
= SYM B-VP O
0 CD B-NP O
. SYM I-NP O

01 CD I-NP O
) ) O O
, , O O
indicating VBG B-VP O
that IN B-SBAR O
it PRP B-NP O
may MD B-VP O
be VB I-VP O
protective JJ B-ADJP O
against IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
. . O O

If IN B-SBAR O
this DT B-NP O
finding NN I-NP O
can MD B-VP O
be VB I-VP O
confirmed VBN I-VP O
, , O O
it PRP B-NP O
may MD B-VP O
provide VB I-VP O
an DT B-NP O
insight NN I-NP O
into IN B-PP O
the DT B-NP O
structural JJ I-NP O
features NNS I-NP O
of IN B-PP O
the DT B-NP O
BRCA1 NN I-NP O
protein NN I-NP O
that WDT B-NP O
are VBP B-VP O
important JJ B-ADJP O
for IN B-PP O
its PRP$ B-NP O
function NN I-NP O
. . O O

Kniest JJS B-NP B-Disease
dysplasia NN I-NP I-Disease
: : O O
Dr NNP B-NP O
. . I-NP O

W NNP I-NP O
. . O O

Kniest JJS B-ADVP O
, , O O
his PRP$ B-NP O
patient NN I-NP O
, , O O
the DT B-NP O
molecular JJ I-NP O
defect NN I-NP O
. . O O

Kniest JJS B-NP B-Disease
dysplasia NN I-NP I-Disease
is VBZ B-VP O
a DT B-NP O
severe JJ I-NP O
chondrodysplasia NN I-NP B-Disease
caused VBN B-VP O
by IN B-PP O
the DT B-NP O
defective JJ I-NP B-Disease
formation NN I-NP I-Disease
of IN B-PP I-Disease
type NN B-NP I-Disease
II CD I-NP I-Disease
collagen NN I-NP I-Disease
. . O O

We PRP B-NP O
report VBP B-VP O
about IN B-PP O
Dr NNP B-NP O
. . I-NP O

Kniest NNP I-NP O
, , O O
who WP B-NP O
first RB B-ADVP O
described VBD B-VP O
the DT B-NP O
condition NN I-NP O
in IN B-PP O
1952 CD B-NP O
, , O O
and CC O O
his PRP$ B-NP O
patient NN I-NP O
, , O O
who WP B-NP O
, , O O
at IN B-PP O
the DT B-NP O
age NN I-NP O
of IN B-PP O
50 CD B-NP O
years NNS I-NP O
is VBZ B-VP O
severely RB I-VP B-Disease
handicapped VBN I-VP I-Disease
with IN B-PP O
short JJ B-NP B-Disease
stature NN I-NP I-Disease
, , O O
restricted JJ B-NP B-Disease
joint JJ I-NP I-Disease
mobility NN I-NP I-Disease
, , O O
and CC O O
blindness NN B-NP B-Disease
but CC O O
is VBZ B-VP O
mentally RB B-ADJP O
alert JJ I-ADJP O
and CC O O
leads VBZ B-VP O
an DT B-NP O
active JJ I-NP O
life NN I-NP O
. . O O

Molecular JJ B-NP O
analysis NN I-NP O
of IN B-PP O
the DT B-NP O
patients NNS I-NP O
DNA NN I-NP O
showed VBD B-VP O
a DT B-NP O
single JJ I-NP O
base NN I-NP O
( ( O O
G NN B-NP O
) ) O O
deletion NN B-NP O
involving VBG B-VP O
the DT B-NP O
GT NN I-NP O
dinucleotide NN I-NP O
at IN B-PP O
the DT B-NP O
start NN I-NP O
of IN B-PP O
intron NN B-NP O
18 CD I-NP O
destroying VBG B-VP O
a DT B-NP O
splice NN I-NP O
site NN I-NP O
of IN B-PP O
the DT B-NP O
COL2A1 NN I-NP O
gene NN I-NP O
. . O O

This DT B-NP O
is VBZ B-VP O
in IN B-PP O
accordance NN B-NP O
with IN B-PP O
molecular JJ B-NP O
findings NNS I-NP O
in IN B-PP O
other JJ B-NP O
patients NNS I-NP O
with IN B-PP O
Kniest JJS B-NP B-Disease
dysplasia NN I-NP I-Disease
and CC I-NP O
confirms NNS I-NP O
, , O O
in IN B-PP O
the DT B-NP O
original JJ I-NP O
patient NN I-NP O
, , O O
that IN B-SBAR O
the DT B-NP O
disorder NN I-NP O
is VBZ B-VP O
caused VBN I-VP O
by IN B-PP O
small JJ B-NP O
inframe NN I-NP O
deletions NNS I-NP O
often RB B-ADVP O
due JJ B-ADJP O
to TO B-PP O
exon NN B-NP O
skipping NN I-NP O
as IN B-PP O
a DT B-NP O
result NN I-NP O
of IN B-PP O
COL2A1 NN B-NP O
splice NN I-NP O
site NN I-NP O
mutations NNS I-NP O
. . O O

. . O O

Cloning NN B-NP O
of IN B-PP O
the DT B-NP O
homogentisate NN I-NP O
1 CD I-NP O
, , I-NP O
2 CD I-NP O
- HYPH I-NP O
dioxygenase NN I-NP O
gene NN I-NP O
, , O O
the DT B-NP O
key JJ I-NP O
enzyme NN I-NP O
of IN B-PP O
alkaptonuria NN B-NP B-Disease
in IN B-PP O
mouse NN B-NP O
. . O O

We PRP B-NP O
determined VBD B-VP O
48 CD B-NP O
amino NN I-NP O
acid NN I-NP O
residues NNS I-NP O
from IN B-PP O
five CD B-NP O
peptides NNS I-NP O
from IN B-PP O
the DT B-NP O
homogeneous JJ I-NP O
monomer NN I-NP O
of IN B-PP O
homogentisate NN B-NP O
1 CD I-NP O
, , I-NP O
2 CD I-NP O
- HYPH I-NP O
dioxygenase NN B-NP O
( ( O O
HGO NN B-NP O
; : O O
E NN B-NP O
. . O O

C NN B-NP O
. . O O

1 CD B-NP O
. . I-NP O

13 CD I-NP O
. . O O

11 CD B-NP O
. . I-NP O

15 CD I-NP O
) ) O O
of IN B-PP O
mouse NN B-NP O
liver NN I-NP O
. . O O

After IN B-PP O
digestion NN B-NP O
with IN B-PP O
trypsin NN B-NP O
, , O O
peptides NNS B-NP O
were VBD B-VP O
separated VBN I-VP O
by IN B-PP O
reversed VBN B-NP O
phase NN I-NP O
chromatography NN I-NP O
and CC O O
amino NN B-NP O
acid NN I-NP O
sequenced VBN B-VP O
. . O O

The DT B-NP O
deduced VBN I-NP O
codon NN I-NP O
sequence NN I-NP O
of IN B-PP O
three CD B-NP O
peptides NNS I-NP O
was VBD B-VP O
used VBN I-VP O
to TO B-VP O
derive VB I-VP O
degenerated JJ B-NP O
oligomeres NNS I-NP O
. . O O

By IN B-PP O
combining VBG B-VP O
these DT B-NP O
oligos NNS I-NP O
, , O O
we PRP B-NP O
were VBD B-VP O
able JJ B-ADJP O
to TO B-VP O
amplify VB I-VP O
fragments NNS B-NP O
from IN B-PP O
100 CD B-NP O
to TO I-NP O
300 CD I-NP O
bases NNS I-NP O
( ( O O
b NN B-NP O
) ) O O
from IN B-PP O
mouse NN B-NP O
liver NN I-NP O
cDNA NN I-NP O
by IN B-PP O
polymerase NN B-NP O
chain NN I-NP O
reaction NN I-NP O
after IN B-PP O
reverse JJ B-NP O
transcription NN I-NP O
( ( O O
RT NN B-NP O
- HYPH B-NP O
PCR NN I-NP O
) ) O O
. . O O

A DT B-NP O
fragment NN I-NP O
of IN B-PP O
200 CD B-NP O
b NN I-NP O
was VBD B-VP O
cloned VBN I-VP O
and CC O O
used VBN B-VP O
as IN B-PP O
a DT B-NP O
probe NN I-NP O
to TO B-VP O
screen VB I-VP O
a DT B-NP O
mouse NN I-NP O
liver NN I-NP O
cDNA NN I-NP O
library NN I-NP O
. . O O

One CD B-NP O
clone NN I-NP O
from IN B-PP O
this DT B-NP O
library NN I-NP O
contained VBD B-VP O
the DT B-NP O
complete JJ I-NP O
cDNA NN I-NP O
- HYPH B-NP O
insert NN I-NP O
for IN B-PP O
HGO NN B-NP O
as IN B-SBAR O
determined VBN B-VP O
by IN B-PP O
sequencing NN B-NP O
. . O O

The DT B-NP O
cDNA NN I-NP O
encodes VBZ B-VP O
for IN B-PP O
a DT B-NP O
protein NN I-NP O
of IN B-PP O
50 CD B-NP O
kDa NN I-NP O
, , O O
as IN B-SBAR O
predicted VBN B-VP O
. . O O

The DT B-NP O
cDNA NN I-NP O
of IN B-PP O
mouse NN B-NP O
HGO NN I-NP O
has VBZ B-VP O
an DT B-NP O
overall JJ I-NP O
identity NN I-NP O
of IN B-PP O
41 CD B-NP O
% NN I-NP O
to TO B-PP O
the DT B-NP O
corresponding VBG I-NP O
gene NN I-NP O
hmgA NN I-NP O
from IN B-PP O
Aspergillus NN B-NP O
. . O O

Sequence NN B-NP O
similarities NNS I-NP O
to TO B-PP O
human JJ B-NP O
expressed VBN I-NP O
sequence NN I-NP O
tags NNS I-NP O
( ( O O
EST NN B-NP O
) ) O O
clones NNS B-NP O
ranged VBD B-VP O
from IN B-PP O
70 CD B-NP O
% NN I-NP O
to TO I-NP O
20 CD I-NP O
% NN I-NP O
. . O O

The DT B-NP O
positions NNS I-NP O
of IN B-PP O
122 CD B-NP O
conserved VBN B-VP O
amino JJ B-NP O
acids NNS I-NP O
could MD B-VP O
be VB I-VP O
determined VBN I-VP O
by IN B-PP O
multiple JJ B-NP O
sequence NN I-NP O
alignment NN I-NP O
. . O O

We PRP B-NP O
identified VBD B-VP O
one CD B-NP O
first JJ I-NP O
intron NN I-NP O
of IN B-PP O
928 CD B-NP O
b NN I-NP O
in IN B-PP O
the DT B-NP O
mouse NN I-NP O
gene NN I-NP O
. . O O

The DT B-NP O
gene NN I-NP O
for IN B-PP O
HGO NN B-NP O
seems VBZ B-VP O
to TO I-VP O
be VB I-VP O
expressed VBN I-VP O
in IN B-PP O
various JJ B-NP O
tissues NNS I-NP O
, , O O
as IN B-SBAR O
shown VBN B-VP O
by IN B-PP O
RT NN B-NP O
- HYPH B-NP O
PCR NN I-NP O
on IN B-PP O
different JJ B-NP O
cDNAs NNS I-NP O
. . O O

FISH NN B-NP O
experiments NNS I-NP O
with IN B-PP O
the DT B-NP O
whole JJ I-NP O
murine JJ I-NP O
cDNA NN I-NP O
as IN B-PP O
probe NN B-NP O
clearly RB B-ADVP O
revealed VBD B-VP O
signals NNS B-NP O
at IN B-PP O
the DT B-NP O
human JJ I-NP O
chromosomal JJ I-NP O
band NN I-NP O
3q13 NN I-NP O
. . O O

3 CD B-NP O
- HYPH I-NP O
q21 NN I-NP O
. . O O

This DT B-NP O
corresponds VBZ B-VP O
well RB B-ADVP O
to TO B-PP O
the DT B-NP O
previous JJ I-NP O
assignment NN I-NP O
of IN B-PP O
the DT B-NP O
locus NN I-NP O
for IN B-PP O
the DT B-NP O
human JJ I-NP O
alkaptonuria NN I-NP B-Disease
gene NN I-NP O
( ( O O
AKU NN B-NP O
) ) O O
to TO B-PP O
the DT B-NP O
same JJ I-NP O
chromosomal JJ I-NP O
region NN I-NP O
by IN B-PP O
multipoint JJ B-NP O
linkage NN I-NP O
analysis NN I-NP O
. . O O

We PRP B-NP O
therefore RB B-ADVP O
conclude VBP B-VP O
that IN B-SBAR O
the DT B-NP O
HGO NN I-NP O
cDNA NN I-NP O
encodes VBZ B-VP O
the DT B-NP O
gene NN I-NP O
responsible JJ B-ADJP O
for IN B-PP O
alkaptonuria NN B-NP B-Disease
. . O O

PTEN NN B-NP O
, , O O
a DT B-NP O
putative JJ I-NP O
protein NN I-NP O
tyrosine NN I-NP O
phosphatase NN I-NP O
gene NN I-NP O
mutated VBN B-VP O
in IN B-PP O
human JJ B-NP O
brain NN I-NP B-Disease
, , O I-Disease
breast NN B-NP I-Disease
, , O I-Disease
and CC O I-Disease
prostate NN B-NP I-Disease
cancer NN I-NP I-Disease
. . O O

Mapping NN B-NP O
of IN B-PP O
homozygous JJ B-NP O
deletions NNS I-NP O
on IN B-PP O
human JJ B-NP O
chromosome NN I-NP O
10q23 CD I-NP O
has VBZ B-VP O
led VBN I-VP O
to TO B-PP O
the DT B-NP O
isolation NN I-NP O
of IN B-PP O
a DT B-NP O
candidate NN I-NP O
tumor NN I-NP B-Disease
suppressor NN I-NP O
gene NN I-NP O
, , O O
PTEN NN B-NP O
, , O O
that WDT B-NP O
appears VBZ B-VP O
to TO I-VP O
be VB I-VP O
mutated VBN I-VP O
at IN B-PP O
considerable JJ B-NP O
frequency NN I-NP O
in IN B-PP O
human JJ B-NP O
cancers NNS I-NP B-Disease
. . O O

In IN B-PP O
preliminary JJ B-NP O
screens NNS I-NP O
, , O O
mutations NNS B-NP O
of IN B-PP O
PTEN NN B-NP O
were VBD B-VP O
detected VBN I-VP O
in IN B-PP O
31 CD B-NP O
% NN I-NP O
( ( O O
13 CD B-NP O
/ SYM O O
42 CD B-NP O
) ) O O
of IN B-PP O
glioblastoma NN B-NP B-Disease
cell NN I-NP O
lines NNS I-NP O
and CC O O
xenografts NNS B-NP O
, , O O
100 CD B-NP O
% NN I-NP O
( ( O O
4 CD B-NP O
/ SYM I-NP O
4 CD I-NP O
) ) O O
of IN B-PP O
prostate NN B-NP B-Disease
cancer NN I-NP I-Disease
cell NN I-NP O
lines NNS I-NP O
, , O O
6 CD B-NP O
% NN I-NP O
( ( O O
4 CD B-NP O
/ SYM O O
65 CD B-NP O
) ) O O
of IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
cell NN I-NP O
lines NNS I-NP O
and CC O O
xenografts NNS B-NP O
, , O O
and CC O O
17 CD B-NP O
% NN I-NP O
( ( O O
3 CD B-NP O
/ SYM O O
18 CD B-NP O
) ) O O
of IN B-PP O
primary JJ B-NP B-Disease
glioblastomas NNS I-NP I-Disease
. . O O

The DT B-NP O
predicted VBN I-NP O
PTEN NN I-NP O
product NN I-NP O
has VBZ B-VP O
a DT B-NP O
protein NN I-NP O
tyrosine NN I-NP O
phosphatase NN I-NP O
domain NN I-NP O
and CC O O
extensive JJ B-NP O
homology NN I-NP O
to TO B-PP O
tensin NN B-NP O
, , O O
a DT B-NP O
protein NN I-NP O
that WDT B-NP O
interacts VBZ B-VP O
with IN B-PP O
actin NN B-NP O
filaments NNS I-NP O
at IN B-PP O
focal JJ B-NP O
adhesions NNS I-NP O
. . O O

These DT B-NP O
homologies NNS I-NP O
suggest VBP B-VP O
that IN B-SBAR O
PTEN NN B-NP O
may MD B-VP O
suppress VB I-VP O
tumor NN B-NP B-Disease
cell NN I-NP O
growth NN I-NP O
by IN B-PP O
antagonizing VBG B-VP O
protein NN B-NP O
tyrosine NN I-NP O
kinases NNS I-NP O
and CC O O
may MD B-VP O
regulate VB I-VP O
tumor NN B-NP B-Disease
cell NN I-NP O
invasion NN I-NP O
and CC O O
metastasis NN B-NP B-Disease
through IN B-PP O
interactions NNS B-NP O
at IN B-PP O
focal JJ B-NP O
adhesions NNS I-NP O
. . O O

. . O O

Heterogeneity NN B-NP O
in IN B-PP O
Schwartz NNP B-NP B-Disease
- HYPH B-NP I-Disease
Jampel NNP I-NP I-Disease
chondrodystrophic JJ I-NP I-Disease
myotonia NN I-NP I-Disease
. . O O

The DT B-NP O
Schwartz NNP I-NP B-Disease
- HYPH I-NP I-Disease
Jampel NNP I-NP I-Disease
syndrome NN I-NP I-Disease
( ( O O
SJS NN B-NP B-Disease
; : O O
chondrodystrophic JJ B-NP B-Disease
myotonia NN I-NP I-Disease
; : O O
McK NN B-NP O
255 CD I-NP O
, , I-NP O
800 CD I-NP O
) ) O O
is VBZ B-VP O
a DT B-NP O
recessively RB I-NP B-Disease
inherited VBN I-NP I-Disease
condition NN I-NP I-Disease
defined VBN B-VP O
by IN B-PP O
myotonia NN B-NP B-Disease
, , O O
short JJ B-NP B-Disease
stature NN I-NP I-Disease
, , O O
and CC O O
bone NN B-NP B-Disease
dysplasia NN I-NP I-Disease
. . O O

Genetic JJ B-NP O
linkage NN I-NP O
between IN B-PP O
SJS NN B-NP B-Disease
and CC O O
chromosomal JJ B-NP O
region NN I-NP O
1q36 CD I-NP O
- HYPH B-NP O
34 CD I-NP O
has VBZ B-VP O
been VBN I-VP O
observed VBN I-VP O
in IN B-PP O
several JJ B-NP O
families NNS I-NP O
, , O O
but CC O O
the DT B-NP O
gene NN I-NP O
has VBZ B-VP O
not RB I-VP O
yet RB I-VP O
been VBN I-VP O
identified VBN I-VP O
. . O O

We PRP B-NP O
studied VBD B-VP O
the DT B-NP O
clinical JJ I-NP O
and CC I-NP O
radiological JJ I-NP O
features NNS I-NP O
in IN B-PP O
81 CD B-NP O
patients NNS I-NP O
from IN B-PP O
the DT B-NP O
literature NN I-NP O
and CC O O
5 CD B-NP O
own JJ I-NP O
patients NNS I-NP O
trying VBG B-VP O
to TO I-VP O
identify VB I-VP O
distinct JJ B-NP O
subgroups NNS I-NP O
. . O O

In IN B-PP O
addition NN B-NP O
, , O O
we PRP B-NP O
tested VBD B-VP O
genetic JJ B-NP O
linkage NN I-NP O
to TO B-PP O
the DT B-NP O
SJS NN I-NP B-Disease
locus NN I-NP O
on IN B-PP O
chromosome NN B-NP O
1 CD I-NP O
in IN B-PP O
one CD B-NP O
family NN I-NP O
with IN B-PP O
two CD B-NP O
affected VBN I-NP O
sibs NNS I-NP O
. . O O

We PRP B-NP O
found VBD B-VP O
that IN B-SBAR O
a DT B-NP O
group NN I-NP O
of IN B-PP O
patients NNS B-NP O
have VBP B-VP O
mild JJ B-NP O
skeletal JJ I-NP O
changes NNS I-NP O
which WDT B-NP O
may MD B-VP O
be VB I-VP O
secondary JJ B-NP O
consequences NNS I-NP O
of IN B-PP O
myotonia NN B-NP B-Disease
, , O O
while IN B-SBAR O
another DT B-NP O
group NN I-NP O
of IN B-PP O
patients NNS B-NP O
appear VBP B-VP O
to TO I-VP O
have VB I-VP O
primary JJ B-NP O
bone NN I-NP B-Disease
dysplasia NN I-NP I-Disease
with IN B-PP O
myotonia NN B-NP B-Disease
. . O O

Within IN B-PP O
this DT B-NP O
latter JJ I-NP O
group NN I-NP O
, , O O
there EX B-NP O
are VBP B-VP O
differences NNS B-NP O
in IN B-PP O
age NN B-NP O
of IN B-PP O
manifestation NN B-NP O
, , O O
clinical JJ B-NP O
course NN I-NP O
and CC I-NP O
pattern NN I-NP O
of IN B-PP O
bone NN B-NP O
changes NNS I-NP O
. . O O

We PRP B-NP O
tentatively RB B-ADVP O
isolate VBP B-VP O
three CD B-NP O
different JJ I-NP O
types NNS I-NP O
of IN B-PP O
SJS NN B-NP B-Disease
type NN I-NP I-Disease
1A NN I-NP I-Disease
, , O O
usually RB B-VP O
recognized VBN I-VP O
in IN B-PP O
childhood NN B-NP O
, , O O
with IN B-PP O
moderate JJ B-NP O
bone NN I-NP B-Disease
dysplasia NN I-NP I-Disease
, , O O
corresponding VBG B-VP O
to TO B-PP O
the DT B-NP O
original JJ I-NP O
descriptions NNS I-NP O
of IN B-PP O
Schwartz NNP B-NP O
, , I-NP O
Jampel NNP I-NP O
and CC I-NP O
Aberfeld NNP I-NP O
; : O O
type NN B-NP O
1B NN I-NP O
, , O O
similar JJ B-ADJP O
to TO B-PP O
type NN B-NP O
1A NN I-NP O
but CC O O
recognizable JJ B-ADJP O
at IN B-PP O
birth NN B-NP O
, , O O
with IN B-PP O
more RBR B-NP O
pronounced JJ I-NP O
bone NN I-NP B-Disease
dysplasia NN I-NP I-Disease
resembling VBG B-VP O
Kniest JJS B-NP B-Disease
dysplasia NN I-NP I-Disease
; : O O
and CC O O
type NN B-NP O
2 CD I-NP O
, , O O
manifest JJS B-ADVP O
at IN B-PP O
birth NN B-NP O
, , O O
with IN B-PP O
increased VBN B-NP O
mortality NN I-NP O
and CC I-NP O
bone NN I-NP B-Disease
dysplasia NN I-NP I-Disease
resembling VBG B-VP O
Pyle NN B-NP B-Disease
disease NN I-NP I-Disease
. . O O

Genetic JJ B-NP O
analysis NN I-NP O
of IN B-PP O
the DT B-NP O
family NN I-NP O
with IN B-PP O
two CD B-NP O
sibs NNS I-NP O
affected VBN B-VP O
by IN B-PP O
SJS NN B-NP B-Disease
type NN I-NP I-Disease
2 CD I-NP I-Disease
showed VBD B-VP O
evidence NN B-NP O
against IN B-PP O
linkage NN B-NP O
to TO B-PP O
chromosome NN B-NP O
1p36 NN I-NP O
- HYPH B-NP O
34 CD I-NP O
. . O O

CONCLUSIONS NNS B-NP O
SJS NN I-NP B-Disease
is VBZ B-VP O
clinically RB B-ADVP O
and CC O O
radiologically RB B-ADJP O
heterogeneous JJ I-ADJP O
. . O O

The DT B-NP O
causes NNS I-NP O
of IN B-PP O
heterogeneity NN B-NP O
are VBP B-VP O
not RB I-VP O
known VBN I-VP O
yet RB B-ADVP O
but CC O O
are VBP B-VP O
likely JJ B-ADJP O
to TO B-VP O
include VB I-VP O
both CC O O
different JJ B-NP O
mutations NNS I-NP O
at IN B-PP O
the DT B-NP O
SJS NN I-NP B-Disease
locus NN I-NP O
on IN B-PP O
chromosome NN B-NP O
1 CD I-NP O
and CC O O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
a DT B-NP O
second JJ I-NP O
SJS NN I-NP B-Disease
locus NN I-NP O
. . O O

A DT B-NP O
tentative JJ I-NP O
clinico AFX I-NP O
- HYPH I-NP O
radiological JJ I-NP O
classification NN I-NP O
can MD B-VP O
be VB I-VP O
useful JJ B-ADJP O
for IN B-PP O
the DT B-NP O
characterization NN I-NP O
of IN B-PP O
patients NNS B-NP O
and CC O O
the DT B-NP O
development NN I-NP O
of IN B-PP O
genotype NN B-NP O
- HYPH B-NP O
phenotype NN I-NP O
correlations NNS I-NP O
. . O O

. . O O

A DT B-NP O
clinical JJ I-NP O
overview NN I-NP O
of IN B-PP O
WT1 NN B-NP O
gene NN I-NP O
mutations NNS I-NP O
. . O O

Mutations NNS B-NP O
in IN B-PP O
the DT B-NP O
WT1 NN I-NP O
gene NN I-NP O
were VBD B-VP O
anticipated VBN I-VP O
to TO B-VP O
explain VB I-VP O
the DT B-NP O
genetic JJ I-NP O
basis NN I-NP O
of IN B-PP O
the DT B-NP O
childhood NN I-NP O
kidney NN I-NP B-Disease
cancer NN I-NP I-Disease
, , O O
Wilms NNP B-NP B-Disease
tumour NN I-NP I-Disease
( ( O O
WT NN B-NP B-Disease
) ) O O
. . O O

Six CD B-NP O
years NNS I-NP O
on IN B-ADVP O
, , O O
we PRP B-NP O
review VBP B-VP O
100 CD B-NP O
reports NNS I-NP O
of IN B-PP O
intragenic JJ B-NP O
WT1 NN I-NP O
mutations NNS I-NP O
and CC O O
examine VB B-VP O
the DT B-NP O
accompanying VBG I-NP O
clinical JJ I-NP O
phenotypes NNS I-NP O
. . O O

While IN B-SBAR O
only RB B-NP O
5 CD I-NP O
% NN I-NP O
of IN B-PP O
sporadic JJ B-NP B-Disease
Wilms NNP I-NP I-Disease
tumours NNS I-NP I-Disease
have VBP B-VP O
intragenic JJ B-NP O
WT1 NN I-NP O
mutations NNS I-NP O
, , O O
> SYM B-NP O
90 CD B-NP O
% NN I-NP O
of IN B-PP O
patients NNS B-NP O
with IN B-PP O
the DT B-NP O
Denys NNPS I-NP B-Disease
- HYPH I-NP I-Disease
Drash NN I-NP I-Disease
syndrome NN I-NP I-Disease
( ( O O
renal JJ B-NP B-Disease
nephropathy NN I-NP I-Disease
, , O O
gonadal JJ B-ADJP B-Disease
anomaly RB B-ADVP I-Disease
, , O O
predisposition NN B-NP B-Disease
to TO B-PP I-Disease
WT NN B-NP I-Disease
) ) O O
carry VBP B-VP O
constitutional JJ B-NP O
intragenic JJ I-NP O
WT1 NN I-NP O
mutations NNS I-NP O
. . O O

WT1 NN B-NP O
mutations NNS I-NP O
have VBP B-VP O
also RB I-VP O
been VBN I-VP O
reported VBN I-VP O
in IN B-PP O
juvenile JJ B-NP B-Disease
granulosa NN I-NP I-Disease
cell NN I-NP I-Disease
tumour NN I-NP I-Disease
, , O O
non AFX B-NP B-Disease
- HYPH I-NP I-Disease
asbestos NN I-NP I-Disease
related VBN I-NP I-Disease
mesothelioma NN I-NP I-Disease
, , O O
desmoplastic JJ B-NP B-Disease
small JJ I-NP I-Disease
round JJ I-NP I-Disease
cell NN I-NP I-Disease
tumour NN I-NP I-Disease
and CC O O
, , O O
most RBS B-ADVP O
recently RB I-ADVP O
, , O O
acute JJ B-NP B-Disease
myeloid JJ I-NP I-Disease
leukemia NN I-NP I-Disease
. . O O

. . O O

A DT B-NP O
mutation NN I-NP O
in IN B-PP O
autosomal JJ B-NP B-Disease
dominant JJ I-NP I-Disease
myotonia NN I-NP I-Disease
congenita NN I-NP I-Disease
affects VBZ B-VP O
pore NN B-NP O
properties NNS I-NP O
of IN B-PP O
the DT B-NP O
muscle NN I-NP O
chloride NN I-NP O
channel NN I-NP O
. . O O

Autosomal JJ B-NP B-Disease
dominant JJ I-NP I-Disease
myotonia NN I-NP I-Disease
congenita NN I-NP I-Disease
is VBZ B-VP O
an DT B-NP O
inherited VBN I-NP B-Disease
disorder NN I-NP I-Disease
of IN B-PP I-Disease
skeletal JJ B-NP I-Disease
muscle NN I-NP I-Disease
caused VBN B-VP O
by IN B-PP O
mutations NNS B-NP O
in IN B-PP O
a DT B-NP O
voltage NN I-NP O
- HYPH O O
gated VBN B-NP O
Cl NN I-NP O
- HYPH B-NP O
channel NN I-NP O
gene NN I-NP O
( ( O O
CLCN1 NN B-NP O
, , O O
7q35 CD B-NP O
) ) O O
. . O O

Here RB B-ADVP O
, , O O
we PRP B-NP O
report VBP B-VP O
that IN B-SBAR O
a DT B-NP O
mutation NN I-NP O
predicting VBG B-VP O
the DT B-NP O
substitution NN I-NP O
of IN B-PP O
Gly NN B-NP O
230 CD I-NP O
by IN B-PP O
glutamic JJ B-NP O
acid NN I-NP O
( ( O O
G230E NN B-NP O
) ) O O
between IN B-PP O
segments NNS B-NP O
D3 NN I-NP O
and CC I-NP O
D4 NN I-NP O
dramatically RB B-ADVP O
alters VBZ B-VP O
the DT B-NP O
pore NN I-NP O
properties NNS I-NP O
of IN B-PP O
a DT B-NP O
recombinant JJ I-NP O
human JJ I-NP O
muscle NN I-NP O
Cl NN I-NP O
- HYPH B-NP O
channel NN I-NP O
( ( O O
hCIC NN B-NP O
- HYPH B-NP O
1 CD I-NP O
) ) O O
expressed VBN B-VP O
in IN B-PP O
a DT B-NP O
mammalian JJ I-NP O
cell NN I-NP O
line NN I-NP O
( ( O O
tsA201 NN B-NP O
) ) O O
. . O O

The DT B-NP O
G230E NN I-NP O
mutation NN I-NP O
causes VBZ B-VP O
substantial JJ B-NP O
changes NNS I-NP O
in IN B-PP O
anion NN B-NP O
and CC I-NP O
cation NN I-NP O
selectivity NN I-NP O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
a DT B-NP O
fundamental JJ I-NP O
change NN I-NP O
in IN B-PP O
rectification NN B-NP O
of IN B-PP O
the DT B-NP O
current JJ I-NP O
- HYPH I-NP O
voltage NN I-NP O
relationship NN I-NP O
. . O O

Whereas IN B-PP O
wild JJ B-NP O
- HYPH I-NP O
type NN I-NP O
channels NNS I-NP O
are VBP B-VP O
characterized VBN I-VP O
by IN B-PP O
pronounced JJ B-NP O
inward JJ I-NP O
rectification NN I-NP O
and CC O O
a DT B-NP O
Cl NN I-NP O
> SYM B-NP O
thiocyanate NN I-NP O
> SYM I-NP O
Br NN I-NP O
> SYM B-NP O
NO NN I-NP O
( ( O O
3 CD B-NP O
) ) O O
> SYM B-NP O
I NN I-NP O
> SYM B-NP O
CH NN I-NP O
( ( B-LST O
3 LS I-LST O
) ) O O
SO NN B-NP O
( ( O O
3 CD B-NP O
) ) O O
selectivity NN B-NP O
, , O O
G230E NN B-NP O
exhibits VBZ B-VP O
outward JJ B-NP O
rectification NN I-NP O
at IN B-PP O
positive JJ B-NP O
potentials NNS I-NP O
and CC O O
a DT B-NP O
thiocyanate NN I-NP O
> SYM O O
NO NN B-NP O
( ( O O
3 CD B-NP O
) ) O O
> SYM B-NP O
I NN I-NP O
> SYM B-NP O
Br NN I-NP O
> SYM I-NP O
Cl NN I-NP O
> SYM B-NP O
CH NN I-NP O
( ( O O
3 CD B-NP O
) ) O O
SO NN B-NP O
( ( O O
3 CD B-NP O
) ) O O
selectivity NN B-NP O
. . O O

Furthermore RB B-ADVP O
, , O O
the DT B-NP O
cation NN I-NP O
- HYPH B-ADJP O
to TO B-PP O
- HYPH B-NP O
anion NN I-NP O
permeability NN I-NP O
ratio NN I-NP O
of IN B-PP O
the DT B-NP O
mutant NN I-NP O
is VBZ B-VP O
much RB B-ADJP O
greater JJR I-ADJP O
than IN B-PP O
that DT B-NP O
of IN B-PP O
the DT B-NP O
wild JJ I-NP O
- HYPH I-NP O
type NN I-NP O
channel NN I-NP O
. . O O

Voltage NN B-NP O
- HYPH I-NP O
dependent JJ I-NP O
blocks NNS I-NP O
by IN B-PP O
intracellular JJ B-NP O
and CC I-NP O
extracellular JJ I-NP O
iodide NN I-NP O
help NN I-NP O
to TO B-VP O
distinguish VB I-VP O
two CD B-NP O
distinct JJ I-NP O
ion NN I-NP O
binding NN I-NP O
sites NNS I-NP O
within IN B-PP O
the DT B-NP O
hClC NN I-NP O
- HYPH B-NP O
1 CD I-NP O
conduction NN I-NP O
pathway NN I-NP O
. . O O

Both DT B-NP O
binding NN I-NP O
sites NNS I-NP O
are VBP B-VP O
preserved VBN I-VP O
in IN B-PP O
the DT B-NP O
mutant NN I-NP O
but CC O O
have VBP B-VP O
decreased VBN I-VP O
affinities NNS B-NP O
for IN B-PP O
iodide NN B-NP O
. . O O

These DT B-NP O
findings NNS I-NP O
suggest VBP B-VP O
that IN B-SBAR O
Gly NN B-NP O
230 CD I-NP O
is VBZ B-VP O
critical JJ B-ADJP O
for IN B-PP O
normal JJ B-NP O
ion NN I-NP O
conductance NN I-NP O
in IN B-PP O
hClC NN B-NP O
- HYPH B-NP O
1 CD I-NP O
and CC O O
that IN B-SBAR O
this DT B-NP O
residue NN I-NP O
resides VBZ B-VP O
within IN B-PP O
the DT B-NP O
channel NN I-NP O
pore NN I-NP O
. . O O

. . O O

The DT B-NP O
incidence NN I-NP O
of IN B-PP O
PAX6 NN B-NP O
mutation NN I-NP O
in IN B-PP O
patients NNS B-NP O
with IN B-PP O
simple JJ B-NP O
aniridia NN I-NP B-Disease
: : O O
an DT B-NP O
evaluation NN I-NP O
of IN B-PP O
mutation NN B-NP O
detection NN I-NP O
in IN B-PP O
12 CD B-NP O
cases NNS I-NP O
. . O O

Twelve CD B-NP O
aniridia NN I-NP B-Disease
patients NNS I-NP O
, , O O
five CD B-NP O
with IN B-PP O
a DT B-NP O
family NN I-NP O
history NN I-NP O
and CC O O
seven CD B-NP O
presumed VBN B-VP O
to TO I-VP O
be VB I-VP O
sporadic JJ B-ADJP O
, , O O
were VBD B-VP O
exhaustively RB I-VP O
screened VBN I-VP O
in IN B-SBAR O
order NN O O
to TO B-VP O
test VB I-VP O
what WP B-NP O
proportion NN I-NP O
of IN B-PP O
people NNS B-NP O
with IN B-PP O
aniridia NN B-NP B-Disease
, , O O
uncomplicated VBN B-VP O
by IN B-PP O
associated VBN B-NP O
anomalies NNS I-NP O
, , O O
carry VBP B-VP O
mutations NNS B-NP O
in IN B-PP O
the DT B-NP O
human JJ I-NP O
PAX6 NN I-NP O
gene NN I-NP O
. . O O

Mutations NNS B-NP O
were VBD B-VP O
detected VBN I-VP O
in IN B-PP O
90 CD B-NP O
% NN I-NP O
of IN B-PP O
the DT B-NP O
cases NNS I-NP O
. . O O

Three CD B-NP O
mutation NN I-NP O
detection NN I-NP O
techniques NNS I-NP O
were VBD B-VP O
used VBN I-VP O
to TO B-VP O
determine VB I-VP O
if IN B-SBAR O
one CD B-NP O
method NN I-NP O
was VBD B-VP O
superior JJ B-ADJP O
for IN B-PP O
this DT B-NP O
gene NN I-NP O
. . O O

The DT B-NP O
protein NN I-NP O
truncation NN I-NP O
test NN I-NP O
( ( O O
PTT NN B-NP O
) ) O O
was VBD B-VP O
used VBN I-VP O
on IN B-PP O
RT NN B-NP O
- HYPH I-NP O
PCR NN I-NP O
products NNS I-NP O
, , O O
SSCP NN B-NP O
on IN B-PP O
genomic JJ B-NP O
PCR NN I-NP O
amplifications NNS I-NP O
, , O O
and CC O O
chemical JJ B-NP O
cleavage NN I-NP O
of IN B-PP O
mismatch NN B-NP O
on IN B-PP O
both CC O O
RT NN B-NP O
- HYPH B-NP O
PCR NN I-NP O
and CC O O
genomic JJ B-NP O
amplifications NNS I-NP O
. . O O

For IN B-PP O
RT NN B-NP O
- HYPH B-NP O
PCR NN I-NP O
products NNS I-NP O
, , O O
only RB B-NP O
the DT I-NP O
translated VBN I-NP O
portion NN I-NP O
of IN B-PP O
the DT B-NP O
gene NN I-NP O
was VBD B-VP O
screened VBN I-VP O
. . O O

On IN B-PP O
genomic JJ B-NP O
products NNS I-NP O
exons NNS I-NP O
1 CD B-NP O
to TO B-PP O
13 CD B-NP O
( ( O O
including VBG B-PP O
740 CD B-NP O
bp NN I-NP O
of IN B-PP O
the DT B-NP O
3 CD I-NP O
untranslated JJ I-NP O
sequence NN I-NP O
and CC O O
all DT B-NP O
intron NN I-NP O
/ SYM B-VP O
exon NN B-NP O
boundaries NNS I-NP O
) ) O O
were VBD B-VP O
screened VBN I-VP O
, , O O
as IN B-SBAR O
was VBD B-VP O
a DT B-NP O
neuroretina NN I-NP O
specific JJ I-NP O
enhancer NN I-NP O
in IN B-PP O
intron NN B-NP O
4 CD I-NP O
. . O O

Ten CD B-NP O
of IN B-PP O
the DT B-NP O
possible JJ I-NP O
12 CD I-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
five CD I-NP O
familial JJ I-NP O
cases NNS I-NP O
and CC O O
five CD B-NP O
of IN B-PP O
the DT B-NP O
sporadic JJ I-NP O
patients NNS I-NP O
were VBD B-VP O
found VBN I-VP O
, , O O
all DT B-NP O
of IN B-PP O
which WDT B-NP O
conformed VBD B-VP O
to TO B-PP O
a DT B-NP O
functional JJ I-NP O
outcome NN I-NP O
of IN B-PP O
haploinsufficiency NN B-NP O
. . O O

Five CD B-NP O
were VBD B-VP O
splice NN B-NP O
site NN I-NP O
mutations NNS I-NP O
( ( O O
one CD B-NP O
in IN B-PP O
the DT B-NP O
donor NN I-NP O
site NN I-NP O
of IN B-PP O
intron NN B-NP O
4 CD I-NP O
, , I-NP O
two CD I-NP O
in IN B-PP O
the DT B-NP O
donor NN I-NP O
site NN I-NP O
of IN B-PP O
intron NN B-NP O
6 CD I-NP O
, , I-NP O
one CD I-NP O
in IN B-PP O
each DT B-NP O
of IN B-PP O
the DT B-NP O
acceptor NN I-NP O
sites NNS I-NP O
of IN B-PP O
introns NNS B-NP O
8 CD B-NP O
and CC I-NP O
9 CD I-NP O
) ) O O
and CC O O
five CD B-NP O
were VBD B-VP O
nonsense JJ B-NP O
mutations NNS I-NP O
in IN B-PP O
exons NNS B-NP O
8 CD I-NP O
, , I-NP O
9 CD I-NP O
, , I-NP O
10 CD I-NP O
, , I-NP O
11 CD I-NP O
, , O O
and CC O O
12 CD B-NP O
. . O O

SSCP NN B-NP O
analysis NN I-NP O
of IN B-PP O
individually RB B-NP O
amplified VBN I-NP O
exons NNS I-NP O
, , O O
with IN B-PP O
which WDT B-NP O
nine CD B-NP O
of IN B-PP O
the DT B-NP O
10 CD I-NP O
mutations NNS I-NP O
were VBD B-VP O
seen VBN I-VP O
, , O O
was VBD B-VP O
the DT B-NP O
most RBS I-NP O
useful JJ I-NP O
detection NN I-NP O
method NN I-NP O
for IN B-PP O
PAX6 NN B-NP O
. . O O

. . O O

Insulin NN B-NP O
gene NN I-NP O
region NN I-NP O
contributes VBZ B-VP O
to TO B-PP O
genetic JJ B-NP O
susceptibility NN I-NP O
to TO B-PP O
, , O O
but CC O O
may MD B-VP O
not RB O O
to TO B-PP O
low JJ B-NP O
incidence NN I-NP O
of IN B-PP O
, , O O
insulin NN B-NP B-Disease
- HYPH B-NP I-Disease
dependent JJ I-NP I-Disease
diabetes NN I-NP I-Disease
mellitus NN I-NP I-Disease
in IN B-PP O
Japanese NNPS B-NP O
. . O O

In IN B-PP O
the DT B-NP O
Caucasian JJ I-NP O
population NN I-NP O
, , O O
it PRP B-NP O
has VBZ B-VP O
been VBN I-VP O
demonstrated VBN I-VP O
that IN B-SBAR O
the DT B-NP O
insulin NN I-NP O
gene NN I-NP O
( ( O O
INS NN B-NP O
) ) O O
region NN B-NP O
contains VBZ B-VP O
the DT B-NP O
insulin NN I-NP B-Disease
- HYPH B-NP I-Disease
dependent JJ I-NP I-Disease
diabetes NN I-NP I-Disease
mellitus NN I-NP I-Disease
locus NN I-NP O
( ( O O
IDDM2 NN B-NP O
) ) O O
. . O O

In IN B-PP O
the DT B-NP O
Japanese JJ I-NP O
population NN I-NP O
, , O O
however RB B-ADVP O
, , O O
there EX B-NP O
has VBZ B-VP O
been VBN I-VP O
no DT B-NP O
report NN I-NP O
demonstrating VBG B-VP O
the DT B-NP O
contribution NN I-NP O
of IN B-PP O
IDDM2 NN B-NP O
to TO B-PP O
the DT B-NP O
pathogenesis NN I-NP O
of IN B-PP O
IDDM NN B-NP B-Disease
. . O O

We PRP B-NP O
conducted VBD B-VP O
an DT B-NP O
association NN I-NP O
study NN I-NP O
of IN B-PP O
IDDM NN B-NP B-Disease
in IN B-PP O
a DT B-NP O
large JJ I-NP O
number NN I-NP O
of IN B-PP O
Japanese JJ B-NP O
subjects NNS I-NP O
with IN B-PP O
multiple JJ B-NP O
polymorphisms NNS I-NP O
in IN B-PP O
INS NN B-NP O
region NN I-NP O
. . O O

We PRP B-NP O
found VBD B-VP O
a DT B-NP O
significant JJ I-NP O
association NN I-NP O
of IN B-PP O
the DT B-NP O
INS NN I-NP O
region NN I-NP O
with IN B-PP O
IDDM NN B-NP B-Disease
. . O O

Alleles NNS B-NP O
positively RB B-VP O
associated VBN I-VP O
with IN B-PP O
IDDM NN B-NP B-Disease
in IN B-PP O
INS NN B-NP O
region NN I-NP O
were VBD B-VP O
the DT B-NP O
same JJ I-NP O
as IN B-PP O
those DT B-NP O
positively RB B-NP O
- HYPH I-NP O
associated VBN B-VP O
with IN B-PP O
IDDM NN B-NP B-Disease
in IN B-PP O
Caucasian JJ B-NP O
population NN I-NP O
, , O O
although IN B-SBAR O
positively RB B-ADVP O
- HYPH O O
associated VBN B-NP O
alleles NNS I-NP O
are VBP B-VP O
very RB B-ADJP O
common JJ I-ADJP O
( ( O O
allele NN B-NP O
frequencies NNS I-NP O
> SYM B-VP O
0 CD B-NP O
. . I-NP O

9 CD I-NP O
) ) O O
in IN B-PP O
the DT B-NP O
Japanese JJ I-NP O
general JJ I-NP O
population NN I-NP O
. . O O

These DT B-NP O
data NNS I-NP O
suggest VBP B-VP O
that IN B-SBAR O
IDDM2 NN B-NP O
is VBZ B-VP O
involved VBN I-VP O
in IN B-PP O
the DT B-NP O
genetic JJ I-NP O
susceptibility NN I-NP O
to TO B-PP O
IDDM NN B-NP B-Disease
in IN B-PP O
Japanese NNPS B-NP O
. . O O

The DT B-NP O
high JJ I-NP O
frequencies NNS I-NP O
of IN B-PP O
disease NN B-NP O
- HYPH B-NP O
associated VBN I-NP O
alleles NNS I-NP O
in IN B-PP O
the DT B-NP O
general JJ I-NP O
population NN I-NP O
suggest VBP B-VP O
that IN B-SBAR O
IDDM2 NN B-NP O
locus NN I-NP O
is VBZ B-VP O
not RB O O
responsible JJ B-ADJP O
for IN B-PP O
the DT B-NP O
low JJ I-NP O
incidence NN I-NP O
of IN B-PP O
IDDM NN B-NP B-Disease
in IN B-PP O
Japanese NNPS B-NP O
. . O O

The DT B-NP O
human JJ I-NP O
complement NN I-NP O
C9 NN I-NP O
gene NN I-NP O
: : O O
identification NN B-NP O
of IN B-PP O
two CD B-NP O
mutations NNS I-NP O
causing VBG B-VP O
deficiency NN B-NP O
and CC I-NP O
revision NN I-NP O
of IN B-PP O
the DT B-NP O
gene NN I-NP O
structure NN I-NP O
. . O O

The DT B-NP O
ninth JJ I-NP O
component NN I-NP O
of IN B-PP O
human JJ B-NP O
complement NN I-NP O
( ( O O
C9 NN B-NP O
) ) O O
is VBZ B-VP O
the DT B-NP O
last JJ I-NP O
of IN B-PP O
the DT B-NP O
terminal JJ I-NP O
complement NN I-NP O
components NNS I-NP O
creating VBG B-VP O
the DT B-NP O
membrane NN I-NP O
attack NN I-NP O
complex NN I-NP O
. . O O

C9 NN B-NP O
is VBZ B-VP O
a DT B-NP O
single JJ I-NP O
- HYPH I-NP O
chain NN I-NP O
serum NN I-NP O
protein NN I-NP O
that WDT B-NP O
is VBZ B-VP O
encoded VBN I-VP O
by IN B-PP O
a DT B-NP O
gene NN I-NP O
located VBN B-VP O
on IN B-PP O
chromosome NN B-NP O
5p NN I-NP O
. . O O

Deficiency NN B-NP B-Disease
of IN B-PP I-Disease
terminal JJ B-NP I-Disease
complement NN I-NP I-Disease
components NNS I-NP I-Disease
is VBZ B-VP O
generally RB I-VP O
associated VBN I-VP O
with IN B-PP O
recurrent JJ B-NP O
neisseria NN I-NP B-Disease
infections NNS I-NP I-Disease
. . O O

We PRP B-NP O
studied VBD B-VP O
a DT B-NP O
previously RB I-NP O
described VBN I-NP O
Swiss JJ I-NP O
family NN I-NP O
with IN B-PP O
inherited VBN B-NP B-Disease
C9 NN I-NP I-Disease
deficiency NN I-NP I-Disease
. . O O

To TO B-VP O
identify VB I-VP O
the DT B-NP O
genetic JJ I-NP O
basis NN I-NP O
of IN B-PP O
C9 NN B-NP B-Disease
deficiency NN I-NP I-Disease
, , O O
we PRP B-NP O
developed VBD B-VP O
an DT B-NP O
approach NN I-NP O
using VBG B-VP O
exon NN B-NP O
- HYPH B-NP O
specific JJ I-NP O
PCR NN I-NP O
and CC O O
direct JJ B-NP O
DNA NN I-NP O
sequencing NN I-NP O
. . O O

As IN B-PP O
a DT B-NP O
cause NN I-NP O
of IN B-PP O
C9 NN B-NP B-Disease
deficiency NN I-NP I-Disease
, , O O
we PRP B-NP O
found VBD B-VP O
two CD B-NP O
different JJ I-NP O
point NN I-NP O
mutations NNS I-NP O
, , O O
both DT B-NP O
generating VBG I-NP O
TGA NN I-NP O
stop NN I-NP O
codons NNS I-NP O
in IN B-PP O
the DT B-NP O
coding VBG I-NP O
sequence NN I-NP O
. . O O

One CD B-NP O
mutation NN I-NP O
, , O O
a DT B-NP O
C NN I-NP O
to TO B-PP O
A NN B-NP O
exchange NN I-NP O
, , O O
was VBD B-VP O
detected VBN I-VP O
in IN B-PP O
exon NN B-NP O
2 CD I-NP O
at IN B-PP O
cDNA NN B-NP O
position NN I-NP O
166 CD I-NP O
, , O O
the DT B-NP O
other JJ I-NP O
, , O O
a DT B-NP O
C NN I-NP O
to TO B-PP O
T NN B-NP O
exchange NN I-NP O
, , O O
was VBD B-VP O
located VBN I-VP O
in IN B-PP O
exon NN B-NP O
4 CD I-NP O
( ( O O
cDNA NN B-NP O
position NN I-NP O
464 CD I-NP O
) ) O O
. . O O

In IN B-PP O
family NN B-NP O
studies NNS I-NP O
of IN B-PP O
three CD B-NP O
first JJ I-NP O
- HYPH I-NP O
degree NN I-NP O
relatives NNS I-NP O
with IN B-PP O
heterozygous JJ B-NP O
C9 NN I-NP B-Disease
deficiency NN I-NP I-Disease
, , O O
we PRP B-NP O
demonstrated VBD B-VP O
that IN B-SBAR O
the DT B-NP O
two CD I-NP O
mutations NNS I-NP O
are VBP B-VP O
segregating VBG I-VP O
independently RB B-ADVP O
. . O O

Therefore RB B-ADVP O
, , O O
these DT B-NP O
mutations NNS I-NP O
are VBP B-VP O
sufficient JJ B-ADJP O
to TO B-VP O
explain VB I-VP O
the DT B-NP O
complete JJ I-NP O
deficiency NN I-NP O
of IN B-PP O
both PDT O O
the DT B-NP O
probands NNS I-NP O
studied VBN B-VP O
. . O O

DNA NN B-NP O
sequencing NN I-NP O
of IN B-PP O
the DT B-NP O
exon NN I-NP O
- HYPH B-NP O
intron NN I-NP O
junctions NNS I-NP O
revealed VBD B-VP O
a DT B-NP O
number NN I-NP O
of IN B-PP O
revisions NNS B-NP O
regarding VBG B-VP O
the DT B-NP O
boundaries NNS I-NP O
between IN B-PP O
exons NNS B-NP O
4 CD I-NP O
, , I-NP O
5 CD I-NP O
, , O O
and CC O O
6 CD B-NP O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
between IN B-PP O
exons NNS B-NP O
10 CD B-NP O
and CC I-NP O
11 CD I-NP O
. . O O

No DT B-NP O
additional JJ I-NP O
introns NNS I-NP O
were VBD B-VP O
detected VBN I-VP O
in IN B-PP O
exons NNS B-NP O
6 CD B-NP O
and CC I-NP O
10 CD I-NP O
. . O O

Furthermore RB B-ADVP O
, , O O
DNA NN B-NP O
marker NN I-NP O
studies NNS I-NP O
were VBD B-VP O
conducted VBN I-VP O
using VBG B-VP O
known JJ B-NP O
polymorphisms NNS I-NP O
of IN B-PP O
the DT B-NP O
C6 NN I-NP O
, , O O
C7 NN B-NP O
, , O O
and CC O O
C9 NN B-NP O
genes NNS I-NP O
, , O O
confirming VBG B-VP O
the DT B-NP O
linkage NN I-NP O
of IN B-PP O
the DT B-NP O
observed VBN I-NP O
C9 NN I-NP O
mutations NNS I-NP O
with IN B-PP O
defined VBN B-NP O
haplotypes NNS I-NP O
. . O O

. . O O

BRCA1 NN B-NP O
mutations NNS I-NP O
in IN B-PP O
women NNS B-NP O
attending VBG B-VP O
clinics NNS B-NP O
that WDT B-NP O
evaluate VBP B-VP O
the DT B-NP O
risk NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
. . O O

BACKGROUND NN B-NP O
To TO B-VP O
define VB I-VP O
the DT B-NP O
incidence NN I-NP O
of IN B-PP O
BRCA1 NN B-NP O
mutations NNS I-NP O
among IN B-PP O
patients NNS B-NP O
seen VBN B-VP O
in IN B-PP O
clinics NNS B-NP O
that WDT B-NP O
evaluate VBP B-VP O
the DT B-NP O
risk NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
, , O O
we PRP B-NP O
analyzed VBD B-VP O
DNA NN B-NP O
samples NNS I-NP O
from IN B-PP O
women NNS B-NP O
seen VBN B-VP O
in IN B-PP O
this DT B-NP O
setting VBG I-NP O
and CC I-NP O
constructed VBN I-NP O
probability NN I-NP O
tables NNS I-NP O
to TO B-VP O
provide VB I-VP O
estimates NNS B-NP O
of IN B-PP O
the DT B-NP O
likelihood NN I-NP O
of IN B-PP O
finding VBG B-VP O
a DT B-NP O
BRCA1 NN I-NP O
mutation NN I-NP O
in IN B-PP O
individual JJ B-NP O
families NNS I-NP O
. . O O

METHODS NNS B-NP O
Clinical JJ I-NP O
information NN I-NP O
, , O O
family NN B-NP O
histories NNS I-NP O
, , O O
and CC O O
blood NN B-NP O
for IN B-PP O
DNA NN B-NP O
analysis NN I-NP O
were VBD B-VP O
obtained VBN I-VP O
from IN B-PP O
263 CD B-NP O
women NNS I-NP O
with IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
. . O O

Conformation NN B-NP O
- HYPH I-NP O
sensitive JJ I-NP O
gel NN I-NP O
electrophoresis NN I-NP O
and CC O O
DNA NN B-NP O
sequencing NN I-NP O
were VBD B-VP O
used VBN I-VP O
to TO B-VP O
identify VB I-VP O
BRCA1 NN B-NP O
mutations NNS I-NP O
. . O O

RESULTS NNS B-NP O
BRCA1 NN I-NP O
mutations NNS I-NP O
were VBD B-VP O
identified VBN I-VP O
in IN B-PP O
16 CD B-NP O
percent NN I-NP O
of IN B-PP O
women NNS B-NP O
with IN B-PP O
a DT B-NP O
family NN I-NP O
history NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
. . O O

Only RB B-NP O
7 CD I-NP O
percent NN I-NP O
of IN B-PP O
women NNS B-NP O
from IN B-PP O
families NNS B-NP O
with IN B-PP O
a DT B-NP O
history NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
but CC B-CONJP O
not RB I-CONJP O
ovarian JJ B-NP B-Disease
cancer NN I-NP I-Disease
had VBD B-VP O
BRCA1 NN B-NP O
mutations NNS I-NP O
. . O O

The DT B-NP O
rates NNS I-NP O
were VBD B-VP O
higher JJR B-ADJP O
among IN B-PP O
women NNS B-NP O
from IN B-PP O
families NNS B-NP O
with IN B-PP O
a DT B-NP O
history NN I-NP O
of IN B-PP O
both CC O O
breast NN B-NP B-Disease
and CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
. . O O

Among IN B-PP O
family NN B-NP O
members NNS I-NP O
, , O O
an DT B-NP O
average JJ I-NP O
age NN I-NP O
of IN B-PP O
less JJR B-NP O
than IN I-NP O
55 CD I-NP O
years NNS I-NP O
at IN B-PP O
the DT B-NP O
diagnosis NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
, , O O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
ovarian JJ B-NP B-Disease
cancer NN I-NP I-Disease
, , O O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
and CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
in IN B-PP O
the DT B-NP O
same JJ I-NP O
woman NN I-NP O
, , O O
and CC O O
Ashkenazi NNP B-NP O
Jewish JJ I-NP O
ancestry NN I-NP O
were VBD B-VP O
all DT O O
associated VBN B-VP O
with IN B-PP O
an DT B-NP O
increased VBN I-NP O
risk NN I-NP O
of IN B-PP O
detecting VBG B-VP O
a DT B-NP O
BRCA1 NN I-NP O
mutation NN I-NP O
. . O O

No DT B-NP O
association NN I-NP O
was VBD B-VP O
found VBN I-VP O
between IN B-PP O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
bilateral JJ B-NP O
breast NN I-NP B-Disease
cancer NN I-NP I-Disease
or CC O O
the DT B-NP O
number NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
cancers NNS I-NP I-Disease
in IN B-PP O
a DT B-NP O
family NN I-NP O
and CC O O
the DT B-NP O
detection NN I-NP O
of IN B-PP O
a DT B-NP O
BRCA1 NN I-NP O
mutation NN I-NP O
, , O O
or CC O O
between IN B-PP O
the DT B-NP O
position NN I-NP O
of IN B-PP O
the DT B-NP O
mutation NN I-NP O
in IN B-PP O
the DT B-NP O
BRCA1 NN I-NP O
gene NN I-NP O
and CC O O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
ovarian JJ B-NP B-Disease
cancer NN I-NP I-Disease
in IN B-PP O
a DT B-NP O
family NN I-NP O
. . O O

CONCLUSIONS NNS B-NP O
Among IN B-PP O
women NNS B-NP O
with IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
and CC O O
a DT B-NP O
family NN I-NP O
history NN I-NP O
of IN B-PP O
the DT B-NP O
disease NN I-NP O
, , O O
the DT B-NP O
percentage NN I-NP O
with IN B-PP O
BRCA1 NN B-NP O
coding NN I-NP O
- HYPH B-NP O
region NN I-NP O
mutations NNS I-NP O
is VBZ B-VP O
less JJR B-ADJP O
than IN B-PP O
the DT B-NP O
45 CD I-NP O
percent NN I-NP O
predicted VBN B-VP O
by IN B-PP O
genetic JJ B-NP O
- HYPH I-NP O
linkage NN I-NP O
analysis NN I-NP O
. . O O

These DT B-NP O
results NNS I-NP O
suggest VBP B-VP O
that IN B-SBAR O
even RB B-PP O
in IN I-PP O
a DT B-NP O
referral JJ I-NP O
clinic NN I-NP O
specializing VBG B-VP O
in IN B-PP O
screening VBG B-VP O
women NNS B-NP O
from IN B-PP O
high JJ B-NP O
- HYPH I-NP O
risk NN I-NP O
families NNS I-NP O
, , O O
the DT B-NP O
majority NN I-NP O
of IN B-PP O
tests NNS B-NP O
for IN B-PP O
BRCA1 NN B-NP O
mutations NNS I-NP O
will MD B-VP O
be VB I-VP O
negative JJ B-ADJP O
and CC O O
therefore RB B-ADJP O
uninformative JJ I-ADJP O
. . O O

. . O O

Mutations NNS B-NP O
in IN B-PP O
the DT B-NP O
arginine NN I-NP O
- HYPH B-NP O
rich JJ I-NP O
protein NN I-NP O
gene NN I-NP O
( ( O O
ARP NN B-NP O
) ) O O
in IN B-PP O
pancreatic JJ B-NP B-Disease
cancer NN I-NP I-Disease
. . O O

The DT B-NP O
ARP NN I-NP O
gene NN I-NP O
encodes VBZ B-VP O
a DT B-NP O
highly RB I-NP O
conserved VBN I-NP O
arginine NN I-NP O
- HYPH I-NP O
rich JJ I-NP O
protein NN I-NP O
from IN B-PP O
chromosomal JJ B-NP O
band NN I-NP O
3p21 NN I-NP O
. . O O

1 CD B-NP O
1 CD I-NP O
. . O O

At IN B-PP O
the DT B-NP O
cytogenetic JJ I-NP O
level NN I-NP O
this DT B-NP O
region NN I-NP O
is VBZ B-VP O
frequently RB I-VP O
deleted VBN I-VP O
in IN B-PP O
a DT B-NP O
variety NN I-NP O
of IN B-PP O
different JJ B-NP O
solid JJ I-NP B-Disease
tumors NNS I-NP I-Disease
, , O O
although IN B-SBAR O
not RB O O
in IN B-PP O
pancreatic JJ B-NP B-Disease
cancer NN I-NP I-Disease
. . O O

We PRP B-NP O
have VBP B-VP O
reported VBN I-VP O
the DT B-NP O
presence NN I-NP O
of IN B-PP O
a DT B-NP O
specific JJ I-NP O
mutation NN I-NP O
( ( O O
ATG50 NN B-NP O
- SYM O O
- HYPH B-NP O
> SYM I-NP O
AGG NN I-NP O
) ) O O
or CC O O
deletion NN B-NP O
of IN B-PP O
codon NN B-NP O
50 CD I-NP O
of IN B-PP O
the DT B-NP O
ARP NN I-NP O
gene NN I-NP O
in IN B-PP O
different JJ B-NP O
tumor NN I-NP B-Disease
types NNS I-NP I-Disease
( ( O O
Shridhar NNP B-NP O
et FW I-NP O
al FW I-NP O
. FW I-NP O

, , O O
1996 CD B-NP O
, , I-NP O
1996a CD I-NP O
) ) O O
. . O O

In IN B-PP O
the DT B-NP O
present JJ I-NP O
study NN I-NP O
, , O O
we PRP B-NP O
have VBP B-VP O
observed VBN I-VP O
mutations NNS B-NP O
involving VBG B-VP O
codon NN B-NP O
50 CD I-NP O
in IN B-PP O
11 CD B-NP O
of IN B-PP O
37 CD B-NP O
pancreatic JJ I-NP B-Disease
tumors NNS I-NP I-Disease
. . O O

The DT B-NP O
frequency NN I-NP O
of IN B-PP O
codon NN B-NP O
50 CD I-NP O
mutation NN I-NP O
is VBZ B-VP O
roughly RB B-NP O
the DT I-NP O
same JJ I-NP O
in IN B-PP O
pancreatic JJ B-NP B-Disease
tumors NNS I-NP I-Disease
as IN B-PP O
in IN B-PP O
the DT B-NP O
other JJ I-NP O
types NNS I-NP O
of IN B-PP O
tumors NNS B-NP B-Disease
previously RB B-VP O
examined VBN I-VP O
. . O O

In IN B-PP O
addition NN B-NP O
, , O O
we PRP B-NP O
have VBP B-VP O
detected VBN I-VP O
mutations NNS B-NP O
at IN B-PP O
codon NN B-NP O
51 CD I-NP O
in IN B-PP O
multiple JJ B-NP O
PCR NN I-NP O
subclones NNS I-NP O
in IN B-PP O
two CD B-NP O
other JJ I-NP O
pancreatic JJ I-NP B-Disease
tumors NNS I-NP I-Disease
. . O O

Mutations NNS B-NP O
in IN B-PP O
the DT B-NP O
ARP NN I-NP O
gene NN I-NP O
are VBP B-VP O
thus RB I-VP O
commonly RB I-VP O
observed VBN I-VP O
in IN B-PP O
pancreatic JJ B-NP B-Disease
cancer NN I-NP I-Disease
, , O O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
many JJ B-NP O
other JJ I-NP O
cancers NNS I-NP B-Disease
. . O O

Difficulties NNS B-NP O
in IN B-PP O
the DT B-NP O
ascertainment NN I-NP O
of IN B-PP O
C9 NN B-NP B-Disease
deficiency NN I-NP I-Disease
: : O O
lessons NNS B-NP O
to TO B-VP O
be VB I-VP O
drawn VBN I-VP O
from IN B-PP O
a DT B-NP O
compound NN I-NP O
heterozygote NN I-NP O
C9 NN I-NP B-Disease
- HYPH B-NP I-Disease
deficient JJ I-NP I-Disease
subject NN I-NP O
. . O O

A DT B-NP O
group NN I-NP O
of IN B-PP O
patients NNS B-NP O
with IN B-PP O
long RB B-ADVP O
- HYPH O O
surviving VBG B-VP O
mismatched VBN B-NP O
kidney NN I-NP O
allografts NNS I-NP O
were VBD B-VP O
investigated VBN I-VP O
for IN B-PP O
complement NN B-NP O
function NN I-NP O
using VBG B-VP O
haemolytic JJ B-NP O
assays NNS I-NP O
in IN B-PP O
agarose NN B-NP O
gels NNS I-NP O
. . O O

One CD B-NP O
patient NN I-NP O
was VBD B-VP O
found VBN I-VP O
to TO I-VP O
have VB I-VP O
no DT B-NP O
alternative JJ I-NP O
pathway NN I-NP O
activity NN I-NP O
but CC O O
a DT B-NP O
low JJ I-NP O
normal JJ I-NP O
classical JJ I-NP O
pathway NN I-NP O
. . O O

Surprisingly RB B-ADVP O
, , O O
investigation NN B-NP O
revealed VBD B-VP O
that IN B-SBAR O
the DT B-NP O
patients NNS I-NP O
complement NN I-NP O
was VBD B-VP O
normal JJ B-ADJP O
for IN B-PP O
all DT B-NP O
components NNS I-NP O
except IN B-PP O
C9 NN B-NP O
, , O O
which WDT B-NP O
was VBD B-VP O
functionally RB B-ADJP O
absent JJ I-ADJP O
. . O O

The DT B-NP O
patient NN I-NP O
was VBD B-VP O
shown VBN I-VP O
to TO I-VP O
be VB I-VP O
heterozygous JJ B-ADJP O
for IN B-PP O
DNA NN B-NP O
markers NNS I-NP O
in IN B-PP O
the DT B-NP O
C6 NN I-NP O
, , I-NP O
C7 NN I-NP O
and CC I-NP O
C9 NN I-NP O
region NN I-NP O
of IN B-PP O
chromosome NN B-NP O
5 CD I-NP O
and CC O O
therefore RB B-VP O
appears VBZ I-VP O
to TO I-VP O
be VB I-VP O
a DT B-NP O
compound NN I-NP O
heterozygote NN I-NP O
for IN B-PP O
two CD B-NP O
uncharacterized JJ I-NP O
C9 NN I-NP B-Disease
deficiency NN I-NP I-Disease
genes NNS I-NP O
. . O O

Serological JJ B-NP O
analysis NN I-NP O
by IN B-PP O
ELISA NN B-NP O
revealed VBD B-VP O
that IN B-SBAR O
he PRP B-NP O
has VBZ B-VP O
trace NN B-NP O
concentrations NNS I-NP O
of IN B-PP O
a DT B-NP O
non AFX I-NP O
- HYPH I-NP O
functional JJ I-NP O
C9 NN I-NP O
molecule NN I-NP O
. . O O

Western NN B-NP O
blot NN I-NP O
analysis NN I-NP O
was VBD B-VP O
not RB O O
sufficiently RB B-ADJP O
sensitive JJ I-ADJP O
to TO B-VP O
permit VB I-VP O
detection NN B-NP O
of IN B-PP O
this DT B-NP O
molecule NN I-NP O
. . O O

We PRP B-NP O
hypothesize VBP B-VP O
that IN B-SBAR O
the DT B-NP O
patient NN I-NP O
is VBZ B-VP O
heterozygous JJ B-ADJP O
for IN B-PP O
a DT B-NP O
complete JJ I-NP B-Disease
deficiency NN I-NP I-Disease
of IN B-PP I-Disease
C9 NN B-NP I-Disease
and CC B-PP O
for IN B-PP O
a DT B-NP O
gene NN I-NP O
directing VBG B-VP O
hyposynthesis NN B-NP O
of IN B-PP O
a DT B-NP O
defective JJ I-NP O
C9 NN I-NP O
. . O O

We PRP B-NP O
also RB B-ADVP O
suggest VBP B-VP O
that IN B-SBAR O
C9 NN B-NP B-Disease
deficiency NN I-NP I-Disease
may MD B-VP O
be VB I-VP O
more RBR B-ADJP O
common JJ I-ADJP O
among IN B-PP O
Caucasians NNPS B-NP O
than IN B-SBAR O
has VBZ B-VP O
been VBN I-VP O
reported VBN I-VP O
. . O O

. . O O

Screening NN B-NP O
for IN B-PP O
ESR NN B-NP O
mutations NNS I-NP O
in IN B-PP O
breast NN B-NP B-Disease
and CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
patients NNS I-NP O
. . O O

In IN B-PP O
the DT B-NP O
present JJ I-NP O
study NN I-NP O
, , O O
leukocyte NN B-NP O
DNA NN I-NP O
from IN B-PP O
143 CD B-NP O
patients NNS I-NP O
with IN B-PP O
familial JJ B-NP O
clustering NN I-NP O
of IN B-PP O
breast NN B-NP B-Disease
and CC O I-Disease
/ SYM B-NP I-Disease
or CC O I-Disease
ovarian JJ B-NP I-Disease
cancer NN I-NP I-Disease
and CC O O
tumour NN B-NP B-Disease
DNA NN I-NP O
from IN B-PP O
96 CD B-NP O
breast NN I-NP B-Disease
carcinomas NNS I-NP I-Disease
were VBD B-VP O
screened VBN I-VP O
for IN B-PP O
base NN B-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
estrogen NN I-NP O
receptor NN I-NP O
gene NN I-NP O
( ( O O
ESR NN B-NP O
) ) O O
. . O O

Three CD B-NP O
patients NNS I-NP O
with IN B-PP O
a DT B-NP O
family NN I-NP O
history NN I-NP O
of IN B-PP O
cancer NN B-NP B-Disease
were VBD B-VP O
carrying VBG I-VP O
a DT B-NP O
Gly160Cys NN I-NP O
germline NN I-NP O
substitution NN I-NP O
. . O O

This DT B-NP O
alteration NN I-NP O
was VBD B-VP O
also RB I-VP O
detected VBN I-VP O
in IN B-PP O
eight CD B-NP O
( ( O O
four CD B-NP O
females NNS I-NP O
and CC O O
four CD B-NP O
males NNS I-NP O
) ) O O
of IN B-PP O
729 CD B-NP O
controls NNS I-NP O
( ( O O
366 CD B-NP O
female JJ I-NP O
, , O O
363 CD B-NP O
males NNS I-NP O
) ) O O
, , O O
indicating VBG B-VP O
that IN B-SBAR O
the DT B-NP O
substitution NN I-NP O
probably RB B-ADVP O
represents VBZ B-VP O
a DT B-NP O
polymorphism NN I-NP O
. . O O

However RB B-ADVP O
, , O O
in IN B-PP O
the DT B-NP O
229 CD I-NP O
female JJ I-NP O
controls NNS I-NP O
in IN B-PP O
whom WP B-NP O
family NN B-NP O
history NN I-NP O
of IN B-PP O
cancer NN B-NP B-Disease
was VBD B-VP O
known VBN I-VP O
, , O O
one CD B-NP O
of IN B-PP O
two CD B-NP O
who WP B-NP O
had VBD B-VP O
a DT B-NP O
sister NN I-NP O
with IN B-PP O
breast NN B-NP B-Disease
cancer NN I-NP I-Disease
was VBD B-VP O
carrying VBG I-VP O
the DT B-NP O
variant JJ I-NP O
allele NN I-NP O
. . O O

Hence RB B-ADVP O
, , O O
a DT B-NP O
possible JJ I-NP O
clinical JJ I-NP O
significance NN I-NP O
of IN B-PP O
the DT B-NP O
glycine NN I-NP O
into IN B-PP O
cysteine NN B-NP O
cannot MD B-VP O
be VB I-VP O
completely RB I-VP O
ruled VBN I-VP O
out RP B-PRT O
and CC O O
should MD B-VP O
be VB I-VP O
further RBR B-ADJP O
investigated VBN I-ADJP O
. . O O

Somatic JJ B-NP O
mutations NNS I-NP O
were VBD B-VP O
not RB I-VP O
detected VBN I-VP O
in IN B-PP O
any DT B-NP O
of IN B-PP O
the DT B-NP O
tumours NNS I-NP B-Disease
studied VBN B-VP O
, , O O
and CC O O
the DT B-NP O
present JJ I-NP O
data NNS I-NP O
do VBP B-VP O
not RB I-VP O
provide VB I-VP O
support NN B-NP O
for IN B-PP O
somatic JJ B-NP O
ESR NN I-NP O
base NN I-NP O
mutations NNS I-NP O
as IN B-PP O
an DT B-NP O
important JJ I-NP O
mechanism NN I-NP O
for IN B-PP O
hormonal JJ B-NP O
therapy NN I-NP O
resistance NN I-NP O
in IN B-PP O
estrogen NN B-NP B-Disease
receptor NN I-NP I-Disease
- HYPH B-NP I-Disease
positive JJ I-NP I-Disease
breast NN I-NP I-Disease
carcinomas NNS I-NP I-Disease
. . O O

. . O O

Molecular JJ B-NP O
bases NNS I-NP O
of IN B-PP O
C7 NN B-NP B-Disease
deficiency NN I-NP I-Disease
: : O O
three CD B-NP O
different JJ I-NP O
defects NNS I-NP O
. . O O

The DT B-NP O
molecular JJ I-NP O
basis NN I-NP O
of IN B-PP O
C7 NN B-NP B-Disease
deficiency NN I-NP I-Disease
has VBZ B-VP O
been VBN I-VP O
investigated VBN I-VP O
in IN B-PP O
two CD B-NP O
Irish JJ I-NP O
families NNS I-NP O
and CC O O
a DT B-NP O
number NN I-NP O
of IN B-PP O
Israeli JJ B-NP O
families NNS I-NP O
of IN B-PP O
Moroccan NNP B-NP O
Sephardic NNP I-NP O
Jewish NNP I-NP O
origin NN I-NP O
. . O O

Exon NN B-NP O
PCR NN I-NP O
and CC I-NP O
sequencing NN I-NP O
revealed VBD B-VP O
a DT B-NP O
heterozygous JJ I-NP O
point NN I-NP O
mutation NN I-NP O
at IN B-PP O
the DT B-NP O
3 CD I-NP O
splice NN I-NP O
acceptor NN I-NP O
site NN I-NP O
of IN B-PP O
intron NN B-NP O
1 CD I-NP O
in IN B-PP O
one CD B-NP O
Irish JJ I-NP O
family NN I-NP O
. . O O

In IN B-PP O
the DT B-NP O
other JJ I-NP O
Irish JJ I-NP O
family NN I-NP O
, , O O
exons NNS B-NP O
7 CD B-NP O
and CC I-NP O
8 CD I-NP O
failed VBD B-VP O
to TO I-VP O
amplify VB I-VP O
and CC O O
they PRP B-NP O
were VBD B-VP O
shown VBN I-VP O
to TO I-VP O
be VB I-VP O
deleted VBN I-VP O
. . O O

Marker NN B-NP O
haplotype NN I-NP O
studies NNS I-NP O
of IN B-PP O
the DT B-NP O
C6 NN I-NP O
and CC I-NP O
C7 NN I-NP O
gene NN I-NP O
region NN I-NP O
and CC O O
Southern JJ B-NP O
blots NNS I-NP O
show VBP B-VP O
that IN B-SBAR O
the DT B-NP O
Irish JJ I-NP O
family NN I-NP O
with IN B-PP O
the DT B-NP O
splice NN I-NP O
defect NN I-NP O
also RB B-ADVP O
segregate VBP B-VP O
for IN B-PP O
the DT B-NP O
deletion NN I-NP O
, , O O
which WDT B-NP O
is VBZ B-VP O
not RB I-VP O
easily RB I-VP O
detected VBN I-VP O
in IN B-PP O
heterozygotes NNS B-NP O
. . O O

The DT B-NP O
Israeli JJ I-NP O
C7 NN I-NP B-Disease
- HYPH O I-Disease
deficient JJ B-NP I-Disease
cases NNS I-NP O
all DT B-ADVP O
share VBP B-VP O
a DT B-NP O
C7 NN I-NP O
haplotype NN I-NP O
and CC O O
are VBP B-VP O
homozygous JJ B-ADJP O
for IN B-PP O
a DT B-NP O
mis AFX I-NP O
- HYPH I-NP O
sense NN I-NP O
mutation NN I-NP O
in IN B-PP O
exon NN B-NP O
9 CD I-NP O
. . O O

However RB B-ADVP O
, , O O
one CD B-NP O
individual NN I-NP O
is VBZ B-VP O
heterozygous JJ B-ADJP O
for IN B-PP O
markers NNS B-NP O
at IN B-PP O
adjacent JJ B-NP O
C6 NN I-NP O
loci NNS I-NP O
, , O O
showing VBG B-VP O
that IN B-SBAR O
there EX B-NP O
has VBZ B-VP O
been VBN I-VP O
an DT B-NP O
intergenic JJ I-NP O
recombination NN I-NP O
and CC O O
suggesting VBG B-VP O
that IN B-SBAR O
the DT B-NP O
deficiency NN I-NP O
mutation NN I-NP O
is VBZ B-VP O
of IN B-PP O
appreciable JJ B-NP O
antiquity NN I-NP O
. . O O

. . O O

Molecular JJ B-NP O
heterogeneity NN I-NP O
of IN B-PP O
classical JJ B-NP B-Disease
and CC I-NP I-Disease
Duarte JJ I-NP I-Disease
galactosemia NN I-NP I-Disease
: : O O
mutation NN B-NP O
analysis NN I-NP O
by IN B-PP O
denaturing VBG B-VP O
gradient NN B-NP O
gel NN I-NP O
electrophoresis NN I-NP O
. . O O

Classical JJ B-NP B-Disease
galactosemia NN I-NP I-Disease
is VBZ B-VP O
caused VBN I-VP O
by IN B-PP O
one CD B-NP O
common JJ I-NP O
missense JJ I-NP O
mutation NN I-NP O
( ( O O
Q188R NN B-NP O
) ) O O
and CC O O
by IN B-PP O
several JJ B-NP O
rare JJ I-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
galactose NN I-NP O
- HYPH B-NP O
1 CD I-NP O
- HYPH I-NP O
phosphate NN I-NP O
uridyltransferase NN I-NP O
( ( O O
GALT NN B-NP O
) ) O O
gene NN B-NP O
. . O O

The DT B-NP O
most RBS I-NP O
common JJ I-NP O
variant NN I-NP O
of IN B-PP O
GALT NN B-NP O
, , O O
the DT B-NP O
Duarte NNP I-NP O
variant NN I-NP O
, , O O
occurs VBZ B-VP O
as IN B-PP O
two CD B-NP O
types NNS I-NP O
, , O O
Duarte NNP B-NP O
- HYPH B-NP O
1 CD I-NP O
( ( O O
D NN B-NP O
- HYPH B-NP O
1 CD I-NP O
) ) O O
and CC O O
Duarte NN B-NP O
- HYPH O O
2 CD B-NP O
( ( O O
D NN B-NP O
- HYPH O O
2 CD B-NP O
) ) O O
, , O O
both DT B-NP O
of IN B-PP O
which WDT B-NP O
carry VBP B-VP O
the DT B-NP O
sequence NN I-NP O
change NN I-NP O
N314D NN I-NP O
. . O O

D NN B-NP O
- HYPH B-NP O
1 CD I-NP O
increases NNS I-NP O
, , O O
whereas IN O O
D NN B-NP O
- HYPH O O
2 CD B-NP O
decreases VBZ B-VP O
GALT NN B-NP O
activity NN I-NP O
. . O O

To TO B-VP O
study VB I-VP O
the DT B-NP O
molecular JJ I-NP O
genetics NNS I-NP O
of IN B-PP O
classical JJ B-NP B-Disease
and CC I-NP I-Disease
Duarte JJ I-NP I-Disease
galactosemia NN I-NP I-Disease
, , O O
we PRP B-NP O
analyzed VBD B-VP O
the DT B-NP O
GALT NN I-NP O
mutations NNS I-NP O
in IN B-PP O
30 CD B-NP O
families NNS I-NP O
with IN B-PP O
classical JJ B-NP B-Disease
galactosemia NN I-NP I-Disease
, , O O
in IN B-PP O
10 CD B-NP O
families NNS I-NP O
with IN B-PP O
the DT B-NP O
D NN I-NP O
- HYPH O O
2 CD B-NP O
variant NN I-NP O
and CC O O
in IN B-PP O
3 CD B-NP O
individuals NNS I-NP O
carrying VBG B-VP O
the DT B-NP O
D NN I-NP O
- HYPH B-NP O
1 CD I-NP O
allele NN I-NP O
by IN B-PP O
denaturing VBG B-VP O
gradient NN B-NP O
gel NN I-NP O
electrophoresis NN I-NP O
( ( O O
DGGE NN B-NP O
) ) O O
. . O O

DGGE NN B-NP O
detected VBD B-VP O
59 CD B-NP O
of IN B-PP O
the DT B-NP O
60 CD I-NP O
classical JJ I-NP O
galactosemia NN I-NP B-Disease
alleles NNS I-NP O
. . O O

Q188R NN B-NP O
accounted VBD B-VP O
for IN B-PP O
60 CD B-NP O
% NN I-NP O
, , O O
K285N NN B-NP O
accounted VBD B-VP O
for IN B-PP O
28 CD B-NP O
% NN I-NP O
of IN B-PP O
these DT B-NP O
alleles NNS I-NP O
. . O O

Eight CD B-NP O
novel JJ I-NP O
candidate NN I-NP O
galactosemia NN I-NP B-Disease
mutations NNS I-NP O
were VBD B-VP O
found VBN I-VP O
. . O O

On IN B-PP O
all DT B-NP O
D NN I-NP O
- HYPH B-NP O
2 CD I-NP O
alleles NNS I-NP O
N314D NN I-NP O
occurred VBD B-VP O
in IN B-PP O
cis NN B-NP O
with IN B-PP O
two CD B-NP O
intronic JJ I-NP O
sequence NN I-NP O
changes NNS I-NP O
, , O O
on IN B-PP O
the DT B-NP O
D NN I-NP O
- HYPH B-NP O
1 CD I-NP O
alleles NNS I-NP O
in IN B-PP O
cis NN B-NP O
with IN B-PP O
a DT B-NP O
neutral JJ I-NP O
mutation NN I-NP O
in IN B-PP O
exon NN B-NP O
7 CD I-NP O
. . O O

We PRP B-NP O
conclude VBP B-VP O
that IN B-SBAR O
the DT B-NP O
mutations NNS I-NP O
causing VBG B-VP O
galactosemia NN B-NP B-Disease
are VBP B-VP O
highly RB B-ADJP O
heterogeneous JJ I-ADJP O
and CC O O
that IN B-SBAR O
K285N NN B-NP O
is VBZ B-VP O
a DT B-NP O
second JJ I-NP O
common JJ I-NP O
galactosemia NN I-NP B-Disease
mutation NN I-NP O
in IN B-PP O
our PRP$ B-NP O
population NN I-NP O
. . O O

. . O O

Isolation NN B-NP O
of IN B-PP O
full JJ B-NP O
- HYPH I-NP O
length NN I-NP O
ATM NN I-NP O
cDNA NN I-NP O
and CC I-NP O
correction NN I-NP O
of IN B-PP O
the DT B-NP O
ataxia NN I-NP B-Disease
- HYPH B-NP I-Disease
telangiectasia NN I-NP I-Disease
cellular JJ I-NP O
phenotype NN I-NP O
. . O O

A DT B-NP O
gene NN I-NP O
mutated VBN B-VP O
in IN B-PP O
the DT B-NP O
human JJ I-NP O
genetic JJ I-NP B-Disease
disorder NN I-NP I-Disease
ataxia NN I-NP B-Disease
- HYPH B-NP I-Disease
telangiectasia NN I-NP I-Disease
( ( O O
A NN B-NP B-Disease
- HYPH I-NP I-Disease
T NN I-NP I-Disease
) ) O O
, , O O
ATM NN B-NP O
, , O O
was VBD B-VP O
recently RB I-VP O
identified VBN I-VP O
by IN B-PP O
positional JJ B-NP O
cloning NN I-NP O
. . O O

ATM NN B-NP O
is VBZ B-VP O
a DT B-NP O
member NN I-NP O
of IN B-PP O
the DT B-NP O
phosphatidylinositol NN I-NP O
- HYPH B-NP O
3 CD I-NP O
- HYPH I-NP O
kinase NN I-NP O
superfamily NN I-NP O
, , O O
some DT B-NP O
of IN B-PP O
which WDT B-NP O
are VBP B-VP O
protein NN B-NP O
kinases NNS I-NP O
and CC O O
appear VBP B-VP O
to TO I-VP O
have VB I-VP O
important JJ B-NP O
roles NNS I-NP O
in IN B-PP O
cell NN B-NP O
cycle NN I-NP O
control NN I-NP O
and CC O O
radiation NN B-NP O
signal NN I-NP O
transduction NN I-NP O
. . O O

We PRP B-NP O
describe VBP B-VP O
herein RB B-ADVP O
, , O O
to TO B-PP O
our PRP$ B-NP O
knowledge NN I-NP O
, , O O
for IN B-PP O
the DT B-NP O
first JJ I-NP O
time NN I-NP O
, , O O
the DT B-NP O
cloning NN I-NP O
of IN B-PP O
a DT B-NP O
full JJ I-NP O
- HYPH I-NP O
length NN I-NP O
cDNA NN I-NP O
for IN B-PP O
ATM NN B-NP O
and CC I-NP O
correction NN I-NP O
of IN B-PP O
multiple JJ B-NP O
aspects NNS I-NP O
of IN B-PP O
the DT B-NP O
radio AFX I-NP O
- HYPH I-NP O
sensitive JJ I-NP O
phenotype NN I-NP O
of IN B-PP O
A NN B-NP B-Disease
- HYPH I-NP I-Disease
T NN I-NP I-Disease
cells NNS I-NP O
by IN B-PP O
transfection NN B-NP O
with IN B-PP O
this DT B-NP O
cDNA NN I-NP O
. . O O

Overexpression NN B-NP O
of IN B-PP O
ATM NN B-NP O
cDNA NN I-NP O
in IN B-PP O
A NN B-NP B-Disease
- HYPH I-NP I-Disease
T NN I-NP I-Disease
cells NNS I-NP O
enhanced VBD B-VP O
the DT B-NP O
survival NN I-NP O
of IN B-PP O
these DT B-NP O
cells NNS I-NP O
in IN B-PP O
response NN I-PP O
to TO I-PP O
radiation NN B-NP O
exposure NN I-NP O
, , O O
decreased VBD B-VP O
radiation NN B-NP O
- HYPH B-NP O
induced VBN I-NP O
chromosome NN I-NP O
aberrations NNS I-NP O
, , O O
reduced VBD B-VP O
radio AFX B-NP O
- HYPH B-NP O
resistant JJ I-NP O
DNA NN I-NP O
synthesis NN I-NP O
, , O O
and CC O O
partially RB B-VP O
corrected VBN I-VP O
defective JJ B-NP O
cell NN I-NP O
cycle NN I-NP O
checkpoints NNS I-NP O
and CC O O
induction NN B-NP O
of IN B-PP O
stress NN B-NP O
- HYPH B-NP O
activated VBN I-NP O
protein NN I-NP O
kinase NN I-NP O
. . O O

This DT B-NP O
correction NN I-NP O
of IN B-PP O
the DT B-NP O
defects NNS I-NP O
in IN B-PP O
A NN B-NP B-Disease
- HYPH I-NP I-Disease
T NN I-NP I-Disease
cells NNS I-NP O
provides VBZ B-VP O
further JJR B-NP O
evidence NN I-NP O
of IN B-PP O
the DT B-NP O
multiplicity NN I-NP O
of IN B-PP O
effector NN B-NP O
functions NNS I-NP O
of IN B-PP O
the DT B-NP O
ATM NN I-NP O
protein NN I-NP O
and CC O O
suggests VBZ B-VP O
possible JJ B-NP O
approaches NNS I-NP O
to TO B-PP O
gene NN B-NP O
therapy NN I-NP O
. . O O

. . O O

Fusion NN B-NP O
genes NNS I-NP O
resulting VBG B-VP O
from IN B-PP O
alternative JJ B-NP O
chromosomal JJ I-NP O
translocations NNS I-NP O
are VBP B-VP O
overexpressed VBN I-VP O
by IN B-PP O
gene NN B-NP O
- HYPH B-NP O
specific JJ I-NP O
mechanisms NNS I-NP O
in IN B-PP O
alveolar JJ B-NP B-Disease
rhabdomyosarcoma NN I-NP I-Disease
. . O O

Chromosomal JJ B-NP O
translocations NNS I-NP O
identified VBN B-VP O
in IN B-PP O
hematopoietic JJ B-NP B-Disease
and CC I-NP I-Disease
solid JJ I-NP I-Disease
tumors NNS I-NP I-Disease
result VBP B-VP O
in IN B-PP O
deregulated VBN B-NP O
expression NN I-NP O
of IN B-PP O
protooncogenes NNS B-NP O
or CC O O
creation NN B-NP O
of IN B-PP O
chimeric JJ B-NP O
proteins NNS I-NP O
with IN B-PP O
tumorigenic JJ B-NP O
potential NN I-NP O
. . O O

In IN B-PP O
the DT B-NP O
pediatric JJ I-NP O
solid JJ I-NP B-Disease
tumor NN I-NP I-Disease
alveolar JJ I-NP B-Disease
rhabdomyosarcoma NN I-NP I-Disease
, , O O
a DT B-NP O
consistent JJ I-NP O
t NN I-NP O
( ( O O
2 CD B-NP O
; : O O
13 CD B-NP O
) ) O O
( ( O O
q35 NN B-NP O
; : O O
q14 NN B-NP O
) ) O O
or CC O O
variant JJ B-NP O
t NN I-NP O
( ( O O
1 CD B-NP O
; : O O
13 CD B-NP O
) ) O O
( ( O O
p36 NN B-NP O
; : O O
q14 NN B-NP O
) ) O O
translocation NN B-NP O
generates VBZ B-VP O
PAX3 NN B-NP O
- HYPH I-NP O
FKHR NN I-NP O
or CC I-NP O
PAX7 NN I-NP O
- HYPH B-NP O
FKHR NN I-NP O
fusion NN I-NP O
proteins NNS I-NP O
, , O O
respectively RB B-ADVP O
. . O O

In IN B-PP O
this DT B-NP O
report NN I-NP O
, , O O
we PRP B-NP O
demonstrate VBP B-VP O
that IN B-SBAR O
in IN B-PP O
addition NN B-NP O
to TO B-PP O
functional JJ B-NP O
alterations NNS I-NP O
these DT B-NP O
translocations NNS I-NP O
are VBP B-VP O
associated VBN I-VP O
with IN B-PP O
fusion NN B-NP O
product NN I-NP O
overexpression NN I-NP O
. . O O

Furthermore RB B-ADVP O
, , O O
PAX3 NN B-NP O
- HYPH I-NP O
FKHR NN I-NP O
and CC I-NP O
PAX7 NN I-NP O
- HYPH B-NP O
FKHR NN I-NP O
overexpression NN I-NP O
occurs VBZ B-VP O
by IN B-PP O
distinct JJ B-NP O
mechanisms NNS I-NP O
. . O O

Transcription NN B-NP O
of IN B-PP O
PAX3 NN B-NP O
- HYPH B-NP O
FKHR NN I-NP O
is VBZ B-VP O
increased VBN I-VP O
relative JJ B-ADVP O
to TO B-PP O
wild JJ B-NP O
- HYPH I-NP O
type NN I-NP O
PAX3 NN I-NP O
by IN B-PP O
a DT B-NP O
copy NN I-NP O
number NN I-NP O
- HYPH B-NP O
independent JJ I-NP O
process NN I-NP O
. . O O

In IN B-PP O
contrast NN B-NP O
, , O O
PAX7 NN B-NP O
- HYPH I-NP O
FKHR NN I-NP O
overexpression NN I-NP O
results VBZ B-VP O
from IN B-PP O
fusion NN B-NP O
gene NN I-NP O
amplification NN I-NP O
. . O O

Thus RB B-ADVP O
, , O O
gene NN B-NP O
- HYPH B-NP O
specific JJ I-NP O
mechanisms NNS I-NP O
were VBD B-VP O
selected VBN I-VP O
to TO I-VP O
overexpress VB I-VP O
PAX3 NN B-NP O
- HYPH B-NP O
FKHR NN I-NP O
and CC I-NP O
PAX7 NN I-NP O
- HYPH B-NP O
FKHR NN I-NP O
in IN B-PP O
alveolar JJ B-NP B-Disease
rhabdomyosarcoma NN I-NP I-Disease
, , O O
presumably RB B-ADJP O
due JJ I-ADJP O
to TO B-PP O
differences NNS B-NP O
in IN B-PP O
regulation NN B-NP O
between IN B-PP O
the DT B-NP O
wild JJ I-NP O
- HYPH I-NP O
type NN I-NP O
loci NNS I-NP O
. . O O

We PRP B-NP O
postulate VBP B-VP O
that IN B-SBAR O
these DT B-NP O
overexpression NN I-NP O
mechanisms NNS I-NP O
ensure VBP B-VP O
a DT B-NP O
critical JJ I-NP O
level NN I-NP O
of IN B-PP O
gene NN B-NP O
product NN I-NP O
for IN B-PP O
the DT B-NP O
oncogenic JJ I-NP O
effects NNS I-NP O
of IN B-PP O
these DT B-NP O
fusions NNS I-NP O
. . O O

. . O O

atm NN B-NP O
and CC I-NP O
p53 NN I-NP O
cooperate VBP B-VP O
in IN B-PP O
apoptosis NN B-NP O
and CC I-NP O
suppression NN I-NP O
of IN B-PP O
tumorigenesis NN B-NP O
, , B-PP O
but CC I-PP O
not RB B-PP O
in IN I-PP O
resistance NN B-NP O
to TO B-PP O
acute JJ B-NP B-Disease
radiation NN I-NP I-Disease
toxicity NN I-NP I-Disease
. . O O

Mutations NNS B-NP O
in IN B-PP O
atm NN B-NP O
and CC I-NP O
p53 NN I-NP O
cause VBP B-VP O
the DT B-NP O
human JJ I-NP O
cancer NN I-NP B-Disease
- HYPH B-NP I-Disease
associated VBN I-NP I-Disease
diseases NNS I-NP I-Disease
ataxia NN I-NP B-Disease
- HYPH B-NP I-Disease
telangiectasia NN I-NP I-Disease
and CC O O
Li NNP B-NP B-Disease
- HYPH I-NP I-Disease
Fraumeni NNP I-NP I-Disease
syndrome NN I-NP I-Disease
, , O O
respectively RB B-ADVP O
. . O O

The DT B-NP O
two CD I-NP O
genes NNS I-NP O
are VBP B-VP O
believed VBN I-VP O
to TO I-VP O
interact VB I-VP O
in IN B-PP O
a DT B-NP O
number NN I-NP O
of IN B-PP O
pathways NNS B-NP O
, , O O
including VBG B-PP O
regulation NN B-NP O
of IN B-PP O
DNA NN B-NP O
damage NN I-NP O
- HYPH B-VP O
induced VBN B-NP O
cell NN I-NP O
- HYPH B-NP O
cycle NN I-NP O
checkpoints NNS I-NP O
, , O O
apoptosis NN B-NP O
and CC I-NP O
radiation NN I-NP O
sensitivity NN I-NP O
, , O O
and CC O O
cellular JJ B-NP O
proliferation NN I-NP O
. . O O

Atm NN B-NP O
- HYPH I-NP O
mice NNS I-NP O
, , O O
as RB B-CONJP O
well RB I-CONJP O
as IN I-CONJP O
those DT B-NP O
for IN B-PP O
p53 NN B-NP O
, , O O
develop VBP B-VP O
mainly RB B-ADVP O
T NN B-NP B-Disease
- HYPH B-NP I-Disease
cell NN I-NP I-Disease
lymphomas NNS I-NP I-Disease
, , O O
supporting VBG B-VP O
the DT B-NP O
view NN I-NP O
that IN B-SBAR O
these DT B-NP O
genes NNS I-NP O
have VBP B-VP O
similar JJ B-NP O
roles NNS I-NP O
in IN B-PP O
thymocyte NN B-NP O
development NN I-NP O
. . O O

To TO B-VP O
study VB I-VP O
the DT B-NP O
interactions NNS I-NP O
of IN B-PP O
these DT B-NP O
two CD I-NP O
genes NNS I-NP O
on IN B-PP O
an DT B-NP O
organismal JJ I-NP O
level NN I-NP O
, , O O
we PRP B-NP O
bred VBD B-VP O
mice NNS B-NP O
heterozygous JJ B-ADJP O
for IN B-PP O
alleles NNS I-NP O
of IN B-PP O
both CC O O
atm NN B-NP O
and CC O O
p53 NN B-NP O
to TO B-VP O
produce VB I-VP O
all DT B-NP O
genotypic JJ I-NP O
combinations NNS I-NP O
. . O O

Mice NNS B-NP O
doubly RB B-ADJP O
for IN B-PP O
atm NN B-NP O
and CC I-NP O
p53 NN I-NP O
exhibited VBD B-VP O
a DT B-NP O
dramatic JJ I-NP O
acceleration NN I-NP O
of IN B-PP O
tumour NN B-NP B-Disease
formation NN I-NP O
relative JJ B-ADVP O
to TO B-PP O
singly RB B-NP O
mice NNS I-NP O
, , O O
indicating VBG B-VP O
that IN B-SBAR O
both DT B-NP O
genes NNS I-NP O
collaborate VBP B-VP O
in IN B-PP O
a DT B-NP O
significant JJ I-NP O
manner NN I-NP O
to TO B-VP O
prevent VB I-VP O
tumorigenesis NN B-NP O
. . O O

With IN B-PP O
respect NN B-NP O
to TO B-PP O
their PRP$ B-NP O
roles NNS I-NP O
in IN B-PP O
apoptosis NN B-NP O
, , O O
loss NN B-NP O
of IN B-PP O
atm NN B-NP O
rendered JJ I-NP O
thymocytes NNS I-NP O
only RB B-ADJP O
partly RB I-ADJP O
resistant JJ I-ADJP O
to TO B-PP O
irradiation NN B-NP O
- HYPH B-NP O
induced VBN I-NP O
apoptosis NN I-NP O
, , O O
whereas IN O O
additional JJ B-NP O
loss NN I-NP O
of IN B-PP O
p53 NN B-NP O
engendered VBD B-VP O
complete JJ B-NP O
resistance NN I-NP O
. . O O

This DT B-NP O
implies VBZ B-VP O
that IN B-SBAR O
the DT B-NP O
irradiation NN I-NP O
- HYPH B-NP O
induced VBN I-NP O
atm NN I-NP O
and CC I-NP O
p53 NN I-NP O
apoptotic JJ I-NP O
pathways NNS I-NP O
are VBP B-VP O
not RB O O
completely RB B-ADJP O
congruent JJ I-ADJP O
. . O O

Finally RB B-ADVP O
- HYPH B-ADJP O
and CC O O
in IN B-PP O
contrast NN B-NP O
to TO B-PP O
prior JJ B-NP O
predictions NNS I-NP O
- HYPH B-NP O
atm NN I-NP O
and CC I-NP O
p53 NN I-NP O
do VBP B-VP O
not RB I-VP O
appear VB I-VP O
to TO I-VP O
interact VB I-VP O
in IN B-PP O
acute JJ B-NP B-Disease
radiation NN I-NP I-Disease
toxicity NN I-NP I-Disease
, , O O
suggesting VBG B-VP O
a DT B-NP O
separate JJ I-NP O
atm NN I-NP O
effector NN I-NP O
pathway NN I-NP O
for IN B-PP O
this DT B-NP O
DNA NN I-NP O
damage NN I-NP O
response NN I-NP O
and CC O O
having VBG B-VP O
implications NNS B-NP O
for IN B-PP O
the DT B-NP O
prognosis NN I-NP O
and CC I-NP O
treatment NN I-NP O
of IN B-PP O
human JJ B-NP O
tumours NNS I-NP B-Disease
. . O O

. . O O

Trinucleotide NN B-NP O
repeat NN I-NP O
expansion NN I-NP O
at IN B-PP O
the DT B-NP O
myotonic JJ I-NP B-Disease
dystrophy NN I-NP I-Disease
locus NN I-NP O
reduces VBZ B-VP O
expression NN B-NP O
of IN B-PP O
DMAHP NN B-NP O
. . O O

Myotonic JJ B-NP B-Disease
dystrophy NN I-NP I-Disease
, , O O
or CC O O
dystrophia NN B-NP B-Disease
myotonica NN I-NP I-Disease
( ( O O
DM NN B-NP B-Disease
) ) O O
, , O O
is VBZ B-VP O
an DT B-NP O
autosomal JJ I-NP B-Disease
dominant JJ I-NP I-Disease
multisystem NN I-NP I-Disease
disorder NN I-NP I-Disease
caused VBN B-VP O
by IN B-PP O
the DT B-NP O
expansion NN I-NP O
of IN B-PP O
a DT B-NP O
CTG NN I-NP O
trinucleotide NN I-NP O
repeat NN I-NP O
in IN B-PP O
the DT B-NP O
3 CD I-NP O
untranslated JJ I-NP O
region NN I-NP O
of IN B-PP O
the DT B-NP O
DMPK NN I-NP O
protein NN I-NP O
kinase NN I-NP O
gene NN I-NP O
on IN B-PP O
chromosome NN B-NP O
19q13 CD I-NP O
. . O O

3 CD B-NP O
( ( O O
refs NNS B-NP O
1 CD I-NP O
- HYPH I-NP O
3 CD I-NP O
) ) O O
. . O O

Although IN B-SBAR O
the DT B-NP O
DM NN I-NP B-Disease
mutation NN I-NP O
was VBD B-VP O
identified VBN I-VP O
more JJR B-NP O
than IN I-NP O
five CD I-NP O
years NNS I-NP O
ago RB B-ADVP O
, , O O
the DT B-NP O
pathogenic JJ I-NP O
mechanisms NNS I-NP O
underlying VBG B-VP O
this DT B-NP O
most RBS I-NP O
prevalent JJ I-NP O
form NN I-NP O
of IN B-PP O
hereditary JJ B-NP O
adult JJ I-NP O
neuromuscular JJ I-NP B-Disease
disease NN I-NP I-Disease
remain VBP B-VP O
elusive JJ B-ADJP O
. . O O

Previous JJ B-NP O
work NN I-NP O
from IN B-PP O
our PRP$ B-NP O
laboratory NN I-NP O
demonstrated VBD B-VP O
that IN B-SBAR O
a DT B-NP O
DNase NN I-NP O
l NN I-NP O
- HYPH B-NP O
hypersensitive JJ I-NP O
site NN I-NP O
located JJ I-NP O
adjacent JJ B-ADJP O
to TO B-PP O
the DT B-NP O
repeats NNS I-NP O
on IN B-PP O
the DT B-NP O
wild JJ I-NP O
- HYPH I-NP O
type NN I-NP O
allele NN I-NP O
is VBZ B-VP O
eliminated VBN I-VP O
by IN B-PP O
repeat NN B-NP O
expansion NN I-NP O
, , O O
indicating VBG B-VP O
that IN B-SBAR O
large JJ B-NP O
CTG NN I-NP O
- HYPH B-NP O
repeat NN I-NP O
arrays NNS I-NP O
may MD B-VP O
be VB I-VP O
associated VBN I-VP O
with IN B-PP O
a DT B-NP O
local JJ I-NP O
chromatin NN I-NP O
environment NN I-NP O
that WDT B-NP O
represses VBZ B-VP O
gene NN B-NP O
expression NN I-NP O
. . O O

Here RB B-ADVP O
we PRP B-NP O
report VBP B-VP O
that IN B-SBAR O
the DT B-NP O
hypersensitive JJ I-NP O
site NN I-NP O
contains VBZ B-VP O
an DT B-NP O
enhancer NN I-NP O
element NN I-NP O
that WDT B-NP O
regulates VBZ B-VP O
transcription NN B-NP O
of IN B-PP O
the DT B-NP O
adjacent JJ I-NP O
DMAHP NN I-NP O
homeobox NN I-NP O
gene NN I-NP O
. . O O

Analysis NN B-NP O
of IN B-PP O
DMAHP NN B-NP O
expression NN I-NP O
in IN B-PP O
the DT B-NP O
cells NNS I-NP O
of IN B-PP O
DM NN B-NP B-Disease
patients NNS I-NP O
with IN B-PP O
loss NN B-NP O
of IN B-PP O
the DT B-NP O
hypersensitive JJ I-NP O
site NN I-NP O
revealed VBD B-VP O
a DT B-NP O
two CD I-NP O
- HYPH B-ADVP O
to TO B-PP O
fourfold JJ B-NP O
reduction NN I-NP O
in IN B-PP O
steady JJ B-NP O
- HYPH I-NP O
state NN I-NP O
DMAHP NN I-NP O
transcript NN I-NP O
levels NNS I-NP O
relative JJ B-ADJP O
to TO B-PP O
wild JJ B-NP O
- HYPH I-NP O
type NN I-NP O
controls NNS I-NP O
. . O O

Allele NN B-NP O
- HYPH I-NP O
specific JJ I-NP O
analysis NN I-NP O
of IN B-PP O
DMAHP NN B-NP O
expression NN I-NP O
showed VBD B-VP O
that IN B-SBAR O
steady JJ B-NP O
- HYPH I-NP O
state NN I-NP O
transcript NN I-NP O
levels NNS I-NP O
from IN B-PP O
the DT B-NP O
expanded VBN I-NP O
allele NN I-NP O
were VBD B-VP O
greatly RB I-VP O
reduced VBN I-VP O
in IN B-PP O
comparison NN B-NP O
to TO B-PP O
those DT B-NP O
from IN B-PP O
the DT B-NP O
wild JJ I-NP O
- HYPH I-NP O
type NN I-NP O
allele NN I-NP O
. . O O

Together RB B-ADVP O
, , O O
these DT B-NP O
results NNS I-NP O
demonstrate VBP B-VP O
that IN B-SBAR O
CTG NN B-NP O
- HYPH B-NP O
repeat NN I-NP O
expansions NNS I-NP O
can MD B-VP O
suppress VB I-VP O
local JJ B-NP O
gene NN I-NP O
expression NN I-NP O
and CC O O
implicate VBP B-VP O
DMAHP NN B-NP O
in IN B-PP O
DM NN B-NP B-Disease
pathogenesis NN I-NP O
. . O O

Constitutively RB B-NP O
methylated VBN I-NP O
CpG NN I-NP O
dinucleotides NNS I-NP O
as IN B-PP O
mutation NN B-NP O
hot JJ I-NP O
spots NNS I-NP O
in IN B-PP O
the DT B-NP O
retinoblastoma NN I-NP B-Disease
gene NN I-NP O
( ( O O
RB1 NN B-NP O
) ) O O
. . O O

A DT B-NP O
wide JJ I-NP O
spectrum NN I-NP O
of IN B-PP O
mutations NNS B-NP O
, , O O
ranging VBG B-VP O
from IN B-PP O
point NN B-NP O
mutations NNS I-NP O
to TO B-PP O
large JJ B-NP O
deletions NNS I-NP O
, , O O
have VBP B-VP O
been VBN I-VP O
described VBN I-VP O
in IN B-PP O
the DT B-NP O
retinoblastoma NN I-NP B-Disease
gene NN I-NP O
( ( O O
RB1 NN B-NP O
) ) O O
. . O O

Mutations NNS B-NP O
have VBP B-VP O
been VBN I-VP O
found VBN I-VP O
throughout IN B-PP O
the DT B-NP O
gene NN I-NP O
; : O O
however RB B-ADVP O
, , O O
these DT B-NP O
genetic JJ I-NP O
alterations NNS I-NP O
do VBP B-VP O
not RB I-VP O
appear VB I-VP O
to TO I-VP O
be VB I-VP O
homogeneously RB I-VP O
distributed VBN I-VP O
. . O O

In IN B-PP O
particular JJ B-NP O
, , O O
a DT B-NP O
significant JJ I-NP O
proportion NN I-NP O
of IN B-PP O
disease NN B-NP O
- HYPH O O
causing VBG B-VP O
mutations NNS B-NP O
results VBZ B-VP O
in IN B-PP O
the DT B-NP O
premature JJ I-NP O
termination NN I-NP O
of IN B-PP O
protein NN B-NP O
synthesis NN I-NP O
, , O O
and CC O O
the DT B-NP O
majority NN I-NP O
of IN B-PP O
these DT B-NP O
mutations NNS I-NP O
occur VBP B-VP O
as IN B-PP O
C NN B-NP O
- HYPH O O
- SYM B-NP O
> SYM I-NP O
T NN I-NP O
transitions NNS I-NP O
at IN B-PP O
CpG NN B-NP O
dinucleotides NNS I-NP O
( ( O O
CpGs NNS B-NP O
) ) O O
. . O O

Such JJ B-NP O
recurrent JJ I-NP O
CpG NN I-NP O
mutations NNS I-NP O
, , O O
including VBG B-PP O
those DT B-NP O
found VBN B-VP O
in IN B-PP O
RB1 NN B-NP O
, , O O
are VBP B-VP O
likely JJ B-ADJP O
the DT B-NP O
result NN I-NP O
of IN B-PP O
the DT B-NP O
deamination NN I-NP O
of IN B-PP O
5 CD B-NP O
- HYPH I-NP O
methylcytosine NN I-NP O
within IN B-PP O
these DT B-NP O
CpGs NNS I-NP O
. . O O

In IN B-PP O
the DT B-NP O
present JJ I-NP O
study NN I-NP O
, , O O
we PRP B-NP O
used VBD B-VP O
the DT B-NP O
sodiumbisulfite JJ I-NP O
conversion NN I-NP O
method NN I-NP O
to TO B-VP O
detect VB I-VP O
cytosine NN B-NP O
methylation NN I-NP O
in IN B-PP O
representative JJ B-NP O
exons NNS I-NP O
of IN B-PP O
RB1 NN B-NP O
. . O O

We PRP B-NP O
analyzed VBD B-VP O
DNA NN B-NP O
from IN B-PP O
a DT B-NP O
variety NN I-NP O
of IN B-PP O
tissues NNS B-NP O
and CC O O
specifically RB B-NP O
targeted VBN I-NP O
CGA NN I-NP O
codons NNS I-NP O
in IN B-PP O
RB1 NN B-NP O
, , O O
where WRB B-ADVP O
recurrent JJ B-NP O
premature JJ I-NP O
termination NN I-NP O
mutations NNS I-NP O
have VBP B-VP O
been VBN I-VP O
reported VBN I-VP O
. . O O

We PRP B-NP O
found VBD B-VP O
that IN B-SBAR O
DNA NN B-NP O
methylation NN I-NP O
within IN B-PP O
RB1 NN B-NP O
exons NNS I-NP O
8 CD B-NP O
, , I-NP O
14 CD I-NP O
, , I-NP O
25 CD I-NP O
, , O O
and CC O O
27 CD B-NP O
appeared VBD B-VP O
to TO I-VP O
be VB I-VP O
restricted VBN I-VP O
to TO B-PP O
CpGs NNS B-NP O
, , O O
including VBG B-PP O
six CD B-NP O
CGA NN I-NP O
codons NNS I-NP O
. . O O

Other JJ B-NP O
codons NNS I-NP O
containing VBG B-VP O
methylated VBN B-NP O
cytosines NNS I-NP O
have VBP B-VP O
not RB I-VP O
been VBN I-VP O
reported VBN I-VP O
to TO I-VP O
be VB I-VP O
mutated VBN I-VP O
. . O O

Therefore RB B-ADVP O
, , O O
disease NN B-NP O
- HYPH O O
causing VBG B-VP O
mutations NNS B-NP O
at IN B-PP O
CpGs NNS B-NP O
in IN B-PP O
RB1 NN B-NP O
appear VBP B-VP O
to TO I-VP O
be VB I-VP O
determined VBN I-VP O
by IN B-PP O
several JJ B-NP O
factors NNS I-NP O
, , O O
including VBG B-PP O
the DT B-NP O
constitutive JJ I-NP O
presence NN I-NP O
of IN B-PP O
DNA NN B-NP O
methylation NN I-NP O
at IN B-PP O
cytosines NNS B-NP O
within IN B-PP O
CpGs NNS B-NP O
, , O O
the DT B-NP O
specific JJ I-NP O
codon NN I-NP O
within IN B-PP O
which WDT B-NP O
the DT B-NP O
methylated VBN I-NP O
cytosine NN I-NP O
is VBZ B-VP O
located JJ B-ADJP O
, , O O
and CC O O
the DT B-NP O
particular JJ I-NP O
region NN I-NP O
of IN B-PP O
the DT B-NP O
gene NN I-NP O
within IN B-PP O
which WDT B-NP O
that DT B-NP O
codon NN I-NP O
resides VBZ B-VP O
. . O O

. . O O

The DT B-NP O
von NNP I-NP B-Disease
Hippel NNP I-NP I-Disease
- HYPH I-NP I-Disease
Lindau NNP I-NP I-Disease
tumor NN I-NP I-Disease
suppressor NN I-NP O
gene NN I-NP O
product NN I-NP O
interacts VBZ B-VP O
with IN B-PP O
Sp1 NN B-NP O
to TO B-VP O
repress VB I-VP O
vascular JJ B-NP O
endothelial JJ I-NP O
growth NN I-NP O
factor NN I-NP O
promoter NN I-NP O
activity NN I-NP O
. . O O

The DT B-NP O
von NNP I-NP B-Disease
Hippel NNP I-NP I-Disease
- HYPH I-NP I-Disease
Lindau NNP I-NP I-Disease
tumor NN I-NP I-Disease
suppressor NN I-NP O
gene NN I-NP O
( ( O O
VHL NN B-NP O
) ) O O
has VBZ B-VP O
a DT B-NP O
critical JJ I-NP O
role NN I-NP O
in IN B-PP O
the DT B-NP O
pathogenesis NN I-NP O
of IN B-PP O
clear JJ B-NP B-Disease
- HYPH I-NP I-Disease
cell NN I-NP I-Disease
renal JJ I-NP I-Disease
cell NN I-NP I-Disease
carcinoma NN I-NP I-Disease
( ( O O
RCC NN B-NP B-Disease
) ) O O
, , O O
as IN B-SBAR O
VHL NN B-NP O
mutations NNS I-NP O
have VBP B-VP O
been VBN I-VP O
found VBN I-VP O
in IN B-PP O
both DT B-NP O
von NNP B-NP B-Disease
Hippel NNP I-NP I-Disease
- HYPH B-NP I-Disease
Lindau NNP I-NP I-Disease
disease NN I-NP I-Disease
- HYPH B-VP I-Disease
associated VBN B-NP I-Disease
and CC I-NP I-Disease
sporadic JJ I-NP I-Disease
RCCs NNS I-NP I-Disease
. . O O

Recent JJ B-NP O
studies NNS I-NP O
suggest VBP B-VP O
that IN B-SBAR O
vascular JJ B-NP O
endothelial JJ I-NP O
growth NN I-NP O
factor NN I-NP O
( ( O O
VEGF NN B-NP O
) ) O O
mRNA NN B-NP O
is VBZ B-VP O
upregulated VBN I-VP O
in IN B-PP O
RCC NN B-NP B-Disease
- HYPH O I-Disease
and CC O I-Disease
von NNP B-NP I-Disease
Hippel NNP I-NP I-Disease
- HYPH B-NP I-Disease
Lindau NNP I-NP I-Disease
disease NN I-NP I-Disease
- HYPH B-NP I-Disease
associated VBN I-NP I-Disease
tumors NNS I-NP I-Disease
. . O O

We PRP B-NP O
have VBP B-VP O
therefore RB I-VP O
assessed VBN I-VP O
the DT B-NP O
effect NN I-NP O
of IN B-PP O
the DT B-NP O
VHL NN I-NP O
gene NN I-NP O
product NN I-NP O
on IN B-PP O
VEGF NN B-NP O
expression NN I-NP O
. . O O

VEGF NN B-NP O
promoter NN I-NP O
- HYPH B-NP O
luciferase NN I-NP O
constructs NNS I-NP O
were VBD B-VP O
transiently RB I-VP O
cotransfected VBN I-VP O
with IN B-PP O
a DT B-NP O
wild JJ I-NP O
- HYPH I-NP O
type NN I-NP O
VHL NN I-NP O
( ( O O
wt NN B-NP O
- HYPH B-NP O
VHL NN I-NP O
) ) O O
vector NN B-NP O
in IN B-PP O
several JJ B-NP O
cell NN I-NP O
lines NNS I-NP O
, , O O
including VBG B-PP O
293 CD B-NP O
embryonic JJ I-NP O
kidney NN I-NP O
and CC I-NP O
RCC NN I-NP B-Disease
cell NN I-NP O
lines NNS I-NP O
. . O O

wt AFX B-NP O
- HYPH I-NP O
VHL NN I-NP O
protein NN I-NP O
inhibited VBD B-VP O
VEGF NN B-NP O
promoter NN I-NP O
activity NN I-NP O
in IN B-PP O
a DT B-NP O
dose NN I-NP O
- HYPH B-NP O
dependent JJ I-NP O
manner NN I-NP O
up IN B-NP O
to TO I-NP O
5 CD I-NP O
- HYPH I-NP O
to TO B-PP O
10 CD B-NP O
- HYPH O O
fold RB B-ADVP O
. . O O

Deletion NN B-NP O
analysis NN I-NP O
defined VBD B-VP O
a DT B-NP O
144 CD I-NP O
- HYPH I-NP O
bp NN I-NP O
region NN I-NP O
of IN B-PP O
the DT B-NP O
VEGF NN I-NP O
promoter NN I-NP O
necessary JJ B-ADJP O
for IN B-PP O
VHL NN B-NP O
repression NN I-NP O
. . O O

This DT B-NP O
VHL NN I-NP O
- HYPH B-NP O
responsive JJ I-NP O
element NN I-NP O
is VBZ B-VP O
GC NN B-NP O
rich JJ B-ADJP O
and CC O O
specifically RB B-VP O
binds VBZ I-VP O
the DT B-NP O
transcription NN I-NP O
factor NN I-NP O
Sp1 NN I-NP O
in IN B-PP O
crude JJ B-NP O
nuclear JJ I-NP O
extracts NNS I-NP O
. . O O

In IN B-PP O
Drosophila NN B-NP O
cells NNS I-NP O
, , O O
cotransfected VBN B-NP O
VHL NN I-NP O
represses VBZ B-VP O
Sp1 NN B-NP O
- HYPH O O
mediated VBN B-NP O
activation NN I-NP O
but CC B-CONJP O
not RB I-CONJP O
basal JJ B-NP O
activity NN I-NP O
of IN B-PP O
the DT B-NP O
VEGF NN I-NP O
promoter NN I-NP O
. . O O

We PRP B-NP O
next RB B-ADVP O
demonstrated VBD B-VP O
in IN B-PP O
coimmunoprecipitates NNS B-NP O
that IN B-SBAR O
VHL NN B-NP O
and CC I-NP O
Sp1 NN I-NP O
were VBD B-VP O
part NN B-NP O
of IN B-PP O
the DT B-NP O
same JJ I-NP O
complex NN I-NP O
and CC O O
, , O O
by IN B-PP O
using VBG B-VP O
a DT B-NP O
glutathione NN I-NP O
- HYPH I-NP O
S NN I-NP O
- HYPH I-NP O
transferase NN I-NP O
- HYPH I-NP O
VHL NN I-NP O
fusion NN I-NP O
protein NN I-NP O
and CC O O
purified VBN B-NP O
Sp1 NN I-NP O
, , O O
that IN B-SBAR O
VHL NN B-NP O
and CC I-NP O
Sp1 NN I-NP O
directly RB B-ADVP O
interact VBP B-VP O
. . O O

Furthermore RB B-ADVP O
, , O O
endogenous JJ B-NP O
VEGF NN I-NP O
mRNA NN I-NP O
levels NNS I-NP O
were VBD B-VP O
suppressed VBN I-VP O
in IN B-PP O
permanent JJ B-NP O
RCC NN I-NP B-Disease
cell NN I-NP O
lines NNS I-NP O
expressing VBG B-VP O
wt NN B-NP O
- HYPH B-NP O
VHL NN I-NP O
, , O O
and CC O O
nuclear JJ B-NP O
run NN I-NP O
- HYPH B-ADVP O
on IN B-PP O
studies NNS B-NP O
indicated VBD B-VP O
that IN B-SBAR O
VHL NN B-NP O
regulation NN I-NP O
of IN B-PP O
VEGF NN B-NP O
occurs VBZ B-VP O
at IN B-ADVP O
least JJS I-ADVP O
partly RB B-ADVP O
at IN B-PP O
the DT B-NP O
transcriptional JJ I-NP O
level NN I-NP O
. . O O

These DT B-NP O
observations NNS I-NP O
support VBP B-VP O
a DT B-NP O
new JJ I-NP O
mechanism NN I-NP O
for IN B-PP O
VHL NN B-NP O
- HYPH O O
mediated VBN B-VP O
transcriptional JJ B-NP O
repression NN I-NP O
via IN B-PP O
a DT B-NP O
direct JJ I-NP O
inhibitory JJ I-NP O
action NN I-NP O
on IN B-PP O
Sp1 NN B-NP O
and CC O O
suggest VBP B-VP O
that IN B-SBAR O
loss NN B-NP O
of IN B-PP O
Sp1 NN B-NP O
inhibition NN I-NP O
may MD B-VP O
be VB I-VP O
important JJ B-ADJP O
in IN B-PP O
the DT B-NP O
pathogenesis NN I-NP O
of IN B-PP O
von NNP B-NP B-Disease
Hippel NNP I-NP I-Disease
- HYPH B-NP I-Disease
Lindau NNP I-NP I-Disease
disease NN I-NP I-Disease
and CC I-NP O
RCC NN I-NP B-Disease
. . O O

. . O O

Adult JJ B-NP B-Disease
onset NN I-NP I-Disease
globoid JJ I-NP I-Disease
cell NN I-NP I-Disease
leukodystrophy NN I-NP I-Disease
( ( O O
Krabbe NNP B-NP B-Disease
disease NN I-NP I-Disease
) ) O O
: : O O
analysis NN B-NP O
of IN B-PP O
galactosylceramidase NN B-NP O
cDNA NN I-NP O
from IN B-PP O
four CD B-NP O
Japanese JJ I-NP O
patients NNS I-NP O
. . O O

We PRP B-NP O
examined VBD B-VP O
galactosylceramidase NN B-NP O
( ( O O
GALC NN B-NP O
) ) O O
cDNA NN B-NP O
in IN B-PP O
four CD B-NP O
Japanese JJ I-NP O
patients NNS I-NP O
with IN B-PP O
adult JJ B-NP B-Disease
onset NN I-NP I-Disease
globoid JJ I-NP I-Disease
cell NN I-NP I-Disease
leukodystrophy NN I-NP I-Disease
( ( O O
Krabbe NNP B-NP B-Disease
disease NN I-NP I-Disease
; : O O
AO NN B-NP B-Disease
- HYPH I-NP I-Disease
GLD NN I-NP I-Disease
) ) O O
by IN B-PP O
polymerase NN B-NP O
chain NN I-NP O
reaction NN I-NP O
/ SYM B-NP O
single JJ I-NP O
- HYPH I-NP O
strand NN I-NP O
conformation NN I-NP O
polymorphism NN I-NP O
( ( O O
PCR NN B-NP O
- HYPH B-NP O
SSCP NN I-NP O
) ) O O
analysis NN B-NP O
, , O O
subsequent JJ B-NP O
sequence NN I-NP O
determination NN I-NP O
, , O O
and CC O O
restriction NN B-NP O
enzyme NN I-NP O
digestion NN I-NP O
of IN B-PP O
PCR NN B-NP O
products NNS I-NP O
, , O O
initial JJ B-NP O
symptoms NNS I-NP O
were VBD B-VP O
the DT B-NP O
onset NN I-NP O
of IN B-PP O
slowly RB B-NP O
progressive JJ I-NP O
spastic JJ I-NP B-Disease
paraplegia NN I-NP I-Disease
from IN B-PP O
the DT B-NP O
middle NN I-NP O
of IN B-PP O
the DT B-NP O
second JJ I-NP O
decade NN I-NP O
, , O O
and CC O O
all DT B-NP O
patients NNS I-NP O
had VBD B-VP O
diminished VBN I-VP B-Disease
GALC NN B-NP I-Disease
activity NN I-NP I-Disease
in IN B-PP O
their PRP$ B-NP O
leukocytes NNS I-NP O
. . O O

We PRP B-NP O
identified VBD B-VP O
three CD B-NP O
missense JJ I-NP O
mutations NNS I-NP O
( ( O O
I66M NN B-NP O
, , O O
G270D NN B-NP O
, , O O
L618S NN B-NP O
) ) O O
and CC O O
one CD B-NP O
exon NN I-NP O
- HYPH O O
6 CD B-NP O
skipping NN I-NP O
( ( O O
535 CD B-NP O
- HYPH I-NP O
573del NN I-NP O
) ) O O
. . O O

Two CD B-NP O
of IN B-PP O
the DT B-NP O
patients NNS I-NP O
had VBD B-VP O
only RB B-NP O
the DT I-NP O
I66M NN I-NP O
mutant NN I-NP O
mRNA NN I-NP O
, , O O
and CC O O
one CD B-NP O
only RB I-NP O
the DT I-NP O
G27OD NN I-NP O
mutant NN I-NP O
mRNA NN I-NP O
. . O O

The DT B-NP O
fourth JJ I-NP O
patient NN I-NP O
carried VBD B-VP O
a DT B-NP O
compound NN I-NP O
heterozygous JJ I-NP O
mutation NN I-NP O
of IN B-PP O
535 CD B-NP O
- HYPH I-NP O
573del NN I-NP O
and CC I-NP O
L618S NN I-NP O
. . O O

To TO B-VP O
determine VB I-VP O
the DT B-NP O
enzymatic JJ I-NP O
activities NNS I-NP O
produced VBN B-VP O
by IN B-PP O
these DT B-NP O
mutations NNS I-NP O
, , O O
we PRP B-NP O
constructed VBD B-VP O
mutated VBN I-VP O
GALC NN B-NP O
cDNAs NNS I-NP O
and CC O O
expressed VBD B-VP O
them PRP B-NP O
in IN B-PP O
COS NN B-NP O
- HYPH B-NP O
1 CD I-NP O
cells NNS I-NP O
. . O O

Three CD B-NP O
mutations NNS I-NP O
, , O O
viz NN B-NP O
. NN I-NP O

, , O O
G270D NN B-NP O
, , O O
L618S NN B-NP O
, , O O
and CC O O
exon NN B-NP O
- HYPH O O
6 CD B-NP O
skipping NN I-NP O
( ( O O
535 CD B-NP O
- HYPH I-NP O
573del NN I-NP O
) ) O O
, , O O
produced VBD B-VP O
diminished VBN I-VP B-Disease
GALC NN B-NP I-Disease
activity NN I-NP I-Disease
as IN B-SBAR O
expected VBN B-VP O
. . O O

The DT B-NP O
I66M NN I-NP O
mutation NN I-NP O
in IN B-PP O
the DT B-NP O
wild JJ I-NP O
- HYPH I-NP O
type NN I-NP O
GALC NN I-NP O
cDNA NN I-NP O
( ( O O
I289 NN B-NP O
) ) O O
had VBD B-VP O
normal JJ B-NP O
activity NN I-NP O
, , O O
but CC O O
when WRB B-ADVP O
this DT B-NP O
mutation NN I-NP O
and CC O O
the DT B-NP O
V289 NN I-NP O
polymorphism NN I-NP O
were VBD B-VP O
introduced VBN I-VP O
into IN B-PP O
the DT B-NP O
same JJ I-NP O
allele NN I-NP O
, , O O
it PRP B-NP O
had VBD B-VP O
decreased VBN I-VP O
activity NN B-NP O
. . O O

Thus RB B-ADVP O
, , O O
the DT B-NP O
combination NN I-NP O
of IN B-PP O
a DT B-NP O
unique JJ I-NP O
mutation NN I-NP O
and CC I-NP O
polymorphism NN I-NP O
causes VBZ B-VP O
conformational JJ B-NP O
change NN I-NP O
in IN B-PP O
the DT B-NP O
GALC NN I-NP O
enzyme NN I-NP O
, , O O
resulting VBG B-VP O
in IN B-PP O
low JJ B-NP O
enzymatic JJ I-NP O
activity NN I-NP O
. . O O

AO NN B-NP B-Disease
- HYPH I-NP I-Disease
GLD NN I-NP I-Disease
mutations NNS I-NP O
, , O O
including VBG B-PP O
those DT B-NP O
found VBN B-VP O
here RB B-ADVP O
, , O O
are VBP B-VP O
located JJ B-ADJP O
in IN B-PP O
the DT B-NP O
N NN I-NP O
- HYPH O O
terminus NN B-NP O
( ( O O
I66M NN B-NP O
, , O O
G270D NN B-NP O
, , O O
535 CD B-NP O
- HYPH I-NP O
573del NN I-NP O
) ) O O
or CC O O
C NN B-NP O
- HYPH O O
terminus NN B-NP O
( ( O O
L618S NN B-NP O
) ) O O
of IN B-PP O
the DT B-NP O
GALC NN I-NP O
enzyme NN I-NP O
, , O O
whereas IN O O
the DT B-NP O
reported VBN I-NP O
mutations NNS I-NP O
in IN B-PP O
the DT B-NP O
infantile JJ I-NP O
form NN I-NP O
( ( O O
IF NN B-NP B-Disease
- HYPH B-NP I-Disease
GLD NN I-NP I-Disease
) ) O O
are VBP B-VP O
in IN B-PP O
the DT B-NP O
central JJ I-NP O
domain NN I-NP O
. . O O

This DT B-NP O
difference NN I-NP O
in IN B-PP O
mutation NN B-NP O
sites NNS I-NP O
may MD B-VP O
affect VB I-VP O
the DT B-NP O
clinical JJ I-NP O
features NNS I-NP O
of IN B-PP O
GLD NN B-NP B-Disease
. . O O

